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Abstract 
This dissertation presents a framework for assessing equity and efficiency in health and health 
care for ill V -positive adults in South 
data on and consequences 
care system. 
which is tested in the extensive of empirical 
laltlernaWte illV -treatment Smlle!!~leS in the public health 
I 
I 
I 
" ! 
The framework is built through three key Que:sti<ms. The first - what is the good 
(value or benefit) of health care - con~iders what ought to be in the evaluative space of 
distributive justice in relation to this "'''''I't~tl{\'' and in health economics more generally. The 
second question might constitute claims on this good, including 
personal responsibility, the contlextas wen as the impact good on 
the health of society and the social fabric. The final question - how should the good be distributed 
pv<.rn1np" alternative social choice rules for 
that I ...... it .. ·.... 
the good and develops an approach 
the choice of one rule over another. 
apply this framework, patient and population-level costs and consequences associated with 
I . 
"]t, ....... ,,,th, .. illV -treatment interventions are in Markov models. These are extensively 
l 
validated uncertainty is assessed $rough probabilistic and sensitivity analyses. 
Results of these analyses are inputs into mathematical programming algorithms that allow an 
; 
assessment ofthe implications of choqsing one social choice rule over another in terms of gains 
in the good and the proportion that can be met through one or more treatment Stnlltell'Y 
across a range of budgets. 
In Ul::'\,;U1.:Sll.l!':. and concluding, these empirical results are reintegrated into the conceptual 
framework where the notion of claims on the good and a decision-making approach grounded in 
procedural justice is further developed. It is argued that the proper implementation of this 
framework will result in allocations of the good that are fair even if this is at a level ofless than 
universal access to the most effective treatment strategy. 
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Index of key terms 
First-line ART: A treatment strategy for HIV that includes first-line antiretrovirals only and the 
VHI';Vll.'F. treatment and prophylaxis of opportunistic and HIV -related infections events. 
First and second-line ART: A treatment HIV that first and se(:onO-lme 
antiretrovirals and the ongoing treatment and prophylaxis of opportunistic and liN-related 
UU""I.IUll» and events. 
DIV-treatment: treatment in dissertation it includes No-ART 
below), first-line ART and first and second-line ART. 
Independent programmes and mutually exclusive interventions: An programme 
such as HIV -treatment consists of a set of mutually interventions which in this case 
includes No-ART (see below), first-line ART and and second-line ART. Because these are 
exclusive, a can receive one of these treatment "tr<,t",~,i",,, at a time. 
Markov model: A state transition model that is particularly appropriate for 
UlSI~C::S A Markov model consists of a number of Markov states. The probability of moving 
between these states over "time" is detennined by transition probabilities. The model is run over 
time until all are collected in an absorbing state. If this state then the 
model estimates life expectancy. 
Monte Carlo simulation: First-order Monte Carlo simulation is a way of solving a Markov 
model. Each "patient" is sent the model one at a time. Because different can take 
different (a number of transitions are possible from each Markov state) one is able to build 
up a profile of potential outcomes and to assess the variability in results .. u", "'"""". second-order 
Monte Carlo simulation, uncertainty in underlying data can also be assessed. If a range is attached 
to each transition instead of a one is to any data "n,,,p.~+.,int,, 
in the final outcomes. 
No-ART: Treatment and prophylaxis of opportunistic and HIV -related infections and events 
without ARVs. 
Probabilistic sensitivity analysis: First and second-order Monte Carlo simulation 
v 
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Chapter 1: Introduction 
South Africa's mY-epidemic is one of the worst in the world. A population 
COUIPle:Q with high prevalence has meant that South Africa has only "","".,.ntllu been 
India as the country with the highest number ofmV -infected people. According to ASSA2003 
projections!, the country has experienced a rapidly growing mv epidemic since the mid 1980s, 
with a 
million 
in incidence at 781,000 new infections in 1998. In 2005, there were ppn)Xillrlately 6 
-mtec'tedpeople and over 400,000 deaths. At least 1.8 million 
have died of HI V-related causes during the twenty years since the start of the epidemic. Because 
of this, lttt:~-e;li[pe.ctaJllcy has declined from a high of 62.9 years in 1989 to 49.2 years in 2005 and 
HIV -related deaths currently "''''''''''"'u deaths from all other single causes. 
Antiretroviral treatment (ART) has been shown to be effective in reducing morbidity and 
mortality in pallents infected with mv in developing countries (ART -LINC and ART -CC 2006) 
and the feasibility of providing access to this treatment has been demonstrated in pilot n"i'1,'PI't" 
Hildebrand et at 2004). However, in South access to ART is "'n,.,."'~,tl" 
constrained, particularly for those dependent on the public health system. The challenge over the 
next ten years will be to increase coverage rapidly in order ultimately to provide treatment 
opportunities to all oftoday's 6 million mY-infected !"'"'VI,"'''' 
Providing treatment for HIV I AIDS is a classic example of resource allocation in the face of 
scarcity. Although dealing with scarcity is the key rationale for the existence of the economics 
the allocation of resources to HI V-treatment is particularly charged for a number of 
reasons. Firstly, without treatment HIV -positive people will a premature death. If no ptt,"l'tn,p 
treatment were these deaths would be a tragedy, but because effective treatment is 
feasible, mv -related deaths have been to be a moral 2004). 
Secondly, HIV/AIDS is a new and complex disease. Because infection is associated with immune 
.... """UA"', HIV-treatment is not restricted to controlling the spread of the virus in the body, but also 
requjn~s knowledge and capacity in the treatment of opportunistic and HIV -related infections and 
I The Actuarial Society of South Africa (ASSA) is the pre-eminent body undertaking demographic 
modelling of the South African mY-epidemic. The data in this thesis have been extracted 
from the most recent version ofthe ASSA suite the ASSA2003lite AIDS and Demographic 
Model (release 24 November as downloaded in December 2005 from www.assa.org.za. 
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events, many of which were previously rare. IfHIV affects it can be 
expected to have a significant impact on demand for health care in these age groups and for 
the country in total (Over 2004). Without a commensurate increase in health care supply, 
providing HIV -treatment can be expected to crowd out health care interventions. The 
allocation of resources to HIV -treatment is therefore not about the scale at which the 
HIV -treatment programme is but about the creation of a new health care programme 
with associated of health investments in infrastructure and medical equipment 
and development of drug procurement and delivery systems. Thirdly, treatment as currently 
proposed is relatively costly and the cost is associated with recurrent eXl)enOlt1llfe 
on medlc:mc::s that need to be taken for the duration of a n",1·, .. r,1"" '" lifetime. Although not a cure, 
treatment can be particularly effective and it is conceivable that patients could be maintained in 
care for years if not decades; if scale-up is successful, millions of South Africans will be enrolled 
in HIV-treatment programmes in the near future. 
In recent years, the previous dearth of developing country health economics .... "', .. "'I"£"h into HIV-
treatment has been replaced by a growing number of analyses of treatment resource needs 
Hp.11'n7'71 Gutierrez et al. 2004; Gutierrez, Johns et at 2004) and the cost-effectiveness or 
alternative (Yazdanpanah, Losina et al. Bachman 2006; et at 2006; 
Mcintyre et at 2006; et al. 2006). While these developments are to 
be welcomed, national strl!lte:gic planning around HIV -treatment is not "" • .,. .... 11"1., undertaken 
an economics approach. If economic input is taken into account, this is normally the ex post 
consideration of the costs of scaling up the proposed strategy. While these costing studies are 
useful in ass;isting with the setting of annual treatment budgets, they provide no insight into the 
relative efficiency of alternative courses of action. On the other while cost-effectiveness 
analyses can theoretically assist in the choice of efficient str.!lteli;ie:s, as normally they 
no insight into the costs 
are also concerned with aUordaol 
up are .... I'.1'." .. lv unhelpful to policymakers who 
There have also been a growing number published in the 
distribution of health and health care to people (Daniels 2004; Macklin 2004; 
Rosen, Sanne et aL 2004; WHO and UNAIDS 2004; Bennett and Chanfreau 2005; Rosen, Sanne 
et at 2005). While some ofthese have proposed a framework for equitable resource allocation, 
none have provided a method that enables the consideration of efficiency, equity or the costs of 
2 Defined as those 15 to 49. 
2 
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scaling up. Whitehead (1992) argues that health inequity relates to differences in health status that 
are avoidable unfair. definition of avoidable here must be a function of the availability 
of resources. 
The contribution of this thesis is to bring an explicitly economics perspective to concerns about 
the distribution of health and health care to HIV -positive South adults on the 
public care system. This is done through the creation of a framework that considers 
what "the good" of health care could be to HIV -positive people, where the good could be defined 
in terms of utility within a welfarist health within an extra-welfarist perspective or 
functionings, following Sen (1992). debated and defmed this objective 
function, the framework secondly what claims HIV -positive people might have on this 
good. The concept of a claim is based on Broome (1991) who argues that claims are the object of 
fairness. If an HfV -positive person has a claim on health care, this is than a or 
desire because a claim includes the notion of there a duty on the to ",,,,,,,vul,,, 
this care. In considering these claims, the thesis broadens its scope from a focus on health care 
resources and health outcomes to consider the social context of the majority ofHN -positive 
South Africans; the impact ofHIV-treatment on the macro-economy, households and social 
Ivp.'ne:,,<;:.· and the of ART on the health of society which involves a of the 
potential positive and negative treatment externalities. 
The third section of the framework asks how the good be distributed. A of 
social choice rules are those that aim to maximize the the 
or to trade-off between maximization and The impact one of these 
over another is illustrated through the introduction of a mathematical programming approach 
which allows the simultaneous consideration of efficiency, equity and the total costs of scaling up 
a variety of HIV -treatment interventions. Given however that a judgment of equity or fairness in 
the distribution of health and health care is subjective, this thesis refrains from promoting the 
"...,,"' ........ views author about the of one or other social rule and 
instead argues that the proposed framework has the potential to enhance in decision-
on from it is that jf this framework were to 
be used to elicit the distributive of South African citizens with to distributions 
of the good, the consequences of this process would be fair. 
3 
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The remainder ofthis thesis has the fonowing structure. Chapter 2 descrihes South African HIV-
treatment policy and current clinical """, ... ",.,u,-,,,. While a full analysis of policy development 
processes is heyond the scope ofthe background intnrnnMinn is to 
concepts that will he discussed in later chapters. 
In ..... U<"jJ~"" 3, theoretical and pm" ....... ",1 litemture is reviewed with a view to v .... ,uu.uE> the 
foundations of the decision-making framework. Chapter 4 reviews methodologicallitemture and 
"''''~'''''H",",'' the approach that will he used in the data. 
Chapters 5-7 contain empirical results. Chapter 5 reviews and coUates unit cost data from primary 
sources and grey and litemture. 6 data on the 
costs and outcomes mY-treatment and Because 
HIV -treatment can be a long-tenn health care intervention, Markov modelling has been used to 
calculate results. Models have extensively justified and validated to reduce errors and 
enhance has included an of similar analyses in 
the empiricallitemture. Uncertainty has heen through second order Monte 
Carlo simulation (probabilistic sensitivity analysis) and simple sensitivity analyses. 
7 a mathematical approach to a:s:st::s:smg tecnmcru '"'U""''''U'''J 
equity, the equity/efficiency tmde-offand the costs of scaling-up HIV-treatment. This technique 
allows the decision-maker to consider the total health and the proportion of the population 
in need that can be treated within a range of HIV -treatment constmints. 
Chapter 8 reviews and discusses the that have been covered in earlier chapters 
and proposes the use of proceduml justice to assist in increasing legitimacy in mv -treatment 
allocations. Chapter 9 concludes. 
The new contributions of this thesis are ",mn""1,r.<>I analytical and C01]Ce:OUlal. 
contributions include a wide review ofunlt cost data and one of the pnmatry··C1ata driven cost-
effectiveness analyses to he conducted in the developing world. Analytical 
contributions the of Markov models, the use of probabilistic sensitivity 
analysis in solving these models and in assessing uncertainty, and the development of 
mathematical progmmming to assess technical efficiency, equity and the equity/efficiency trade-
off in HIV-treatment. The conceptual contribution relates to the franlework for 
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considering allocations of the good that has application to HlV-treatment and to health economics 
more generally_ It is that the use of this method will increase the ofHlV-
treatment which in itself will contribute to greater fairness in resource allocation. 
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Chapter 2: South African HIV/AIDS 
policy and treatment guidelines 
This chapter briefly outlines the policy and mY-treatment guidelines that were in 
place between 1994 and the end of2006. These include the 1994 National AIDS Plan, the 2000-
2005 National ~tr",t",oit' for the treatment of opportunistic and mv -related 
mtlectLons, the "Olpen:ltionaI Plan for Comprehensive HIV and AIDS Care", and antiretroviral 
treatment guidelines. At the time of writing, the government has also been in the process of 
finalizing a new National Strategic Plan that will set the framework for the implementation of 
mY-related interventions across multiple sectors between 2007 and 201 L Because this document 
has not it has not been in this The scope is limited to 
providing background information to allow for discussion of the economics of these policies and 
gUJlae.I1n<~s in later t'h""ntpl"<! 
Prior to 1994, South Africa was ruled by a minority white g01{eotUn,entunder the National 
From 1990, a series of discussions were held between the government and the African National 
Congress (ANC), which led to a nej;ot:lat~:d settlement and the first democratic elections 
(n~rreblanctle 2002). The ANC won the and Nelson Mandela became pre:Sloent ofthe 
country. As of the neg.oWllted settlement, of civil servants were protected the first 
five years of democratic rule, and a quasi-federal structure was established consisting of a 
national o""JPf"1nmprd and nine provincial g01vetnmem:s. The former is responsible for collecting 
and distributing revenue, broad Ui:1lIUO;:;'\,\,U]Il\.:). and norms and standards for 
~enllce delivery. The provincial are ''''':>I~vU''''lJ.'''' for .rn,,,I .. ,,,, ... ,,t,, .. .,., and 
t1 .. I""" .... no services (Schneider and Stein 2001). 
1994, the new ANC government adopted a National AIDS Plan for the country, which had 
been developed collaboratively between the ANC and the Department of Health prior to the 
elections. The plan embraced the sexual rights of women as a cross cutting theme and gave 
people living with AIDS a key role in AIDS policy development. It envisaged a coordinated 
network of AIDS policymakers at the national level and in the nine nr .... 'vtncP><: within a multi-
sectoral structure with iml'lelrneltltiflg units in the ministries of health, e0111C3.tlOn, w~lfare and 
defence (Schneider and Stein 2001). The was amDltlous, but 1998, AIDS policy 
implementation was to be characterised a slow and hesitant start which lacked 
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coherence and cOlltirmity (Schneider and 2001). Given the extent hi- ,"""j".-.,r·j, that was 
required in the post-apartheid period, it appears that the AIDS plan had overestimated the 
implementation In May 2000, the released the 
"HN/AIDS/STD Plan for South Africa 2000-2005" 
(Department of Health 2000a). Priority areas included prevention, treatment, legal and human 
rights and monitoring, research and evaluation. In order to improve treatment services provided 
public health the priorities were identified: 
• Developing guidelines for treatment and care 
• Ensuring an uninterrupted supply of appropriate 
and HIV -related mnlCtliOnS 
for the treatment of opportunistic 
• Building capacity of health professionals to provide HIV-related care 
• and treatment of tuberculosis (TB) and other nn,,,nT1"lu,,,,,t,f' 
infections 
An additional treatment-related objective was to """"'E."""" the use (ARVs) for 
nre:velrltic)fl of mother to child transmission (PMTCT) and to conduct research into the cost-
effectiveness of non-ART treatment (Department of Health 2000). At this time, 
there was no government policy with respect to the provision of ARV s for treatment of HIV. 
In October 2000, the Nationall)p""tTftn ... nt released its "Recommendations for the 
Prevention and Treatment of Opportunistic and mv Related Diseases in Adults" (Department of 
Health 2000b) which contains guidance for the management ofHlV -infected patients in public 
facilities. Services offered at the primary care level include HIV -testing, treatment and 
prophylaxis of opportunistic and HIV -related infections, STD treatment, palliative care, and TB 
treatment. Individuals who present with difficult clinical problems or who are seriously ill should 
be referred to hospitals. 
During the pre:siden<;y ofThabo Mbeki (1999 onwards) an"U'prnrnp1nt involvement in HIVI AIDS 
policy and debate became .n",.",,,,,,,n 
discourse about HIV/AIDS has 
fraught. It has been that the ltlclsatlon ofthe 
energy and attention away from the problems of policy 
de,relo'pm.ent and implementation (Van Niekerk 2001). Government has been criticised for its 
engagement with dissident scientists who argue that HIV does not cause AIDS; the perceived 
obstructive attitude of national government towards antiretroviral treatment and prevention of 
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",,,jen,,,,. to child transmission interventions has led to numerous clashes and court cases between 
government and treatment advocacy non governmental organisations (NGOs) such as the 
Treatment Action CaJrnp:aign. Given these events, a number cornmentators have PVf"f'p""",rl 
gm'ernment leadership with ,.".~.,,,,,,,t to mY/AIDS (Campbell and concern at the np.rr.p.l'vP.n lack 
MacPhail 2002; Cleary and Ross 2002; Benatar 2004; Nattrass 2004) where government 
leadership could be defined as personal public identification with the mY/AIDS cause by 
influential politicians, as well as a to and up implementation 
(Schneider and Stein 2001). 
Nevertheless, in July 2002, a Joint Health and Treasury Task Team was established to 
to the financing of an enhanced response to with a particular focus on 
antiretroviral treatment. the of the Task Team in 2003, Cabinet 
instructed the Department of Health to develop a detailed operational plan n ART (Department 
of Health 2003). 
This plan set a target of establishing at least one ART service point in every health district by the 
end of the first year of implementation. 2009, the aim was to deliver "equitable access" by 
providing service points within each local municipal area.. The of treatment was to be 
located within broader health care in an to avoid a vertical to 
ART. A vertical approach refers to the delivery of health services through 
programmes (Oliveira-Cruz, Kurowski et al. 2003). While a vertical approach might increase the 
of provision of ART this approach can divert resources from other public health 
services. It is hoped that if ART is located within the health other primary health 
care services might be and McCoy 2004; Stewart and 2005). 
"",,,,;1 .... ,, to the ART Operational 
following principles: 
Quality of care: 
the 
• Care should be of the H'6"~~' available 
of mY-treatment is to be by the 
proper dla,gnclsls, cmms1elling, 
treatment of opportunistic other preventive and ""' .... ,"""', .. d""'t"" .... ' such as 
nutritional advice and supplements, traditional and complementary and ARYs. 
• Attention should be to the proper use of ART in order to minimize toxicities, 
adverse events and the development of drug resistance. 
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• Care and treatment protocols will be based on international best pr~lctjce. Accreditation 
",,,,,",,,,PI1.,,.,,,,,, will help to ensure that facilities that are approved to ART are 
quality and observe the highest standards of care. Extensive training and certification of 
health professionals to deliver ART will be carried out. 
• A monitoring and evaluation system will be developed to allow the ongoing scrutiny of 
quality of care issues. 
ivp,..,,,,J,,J access to care and treatment: 
• The operational plan attempts to realize equitable implementation by achieving a balance 
between areas that can readily implement the programme and those that need additional 
investment to their health caJ:lacity 
Strengthening the national health system: 
• Upgrading smrIll1lg by improving HR ca(:taclty incentives to and health 
professionals in historically underserved areas 
• Upgrading facilities new facilities 
• patient health infonnation 
• Upgrading drug procurement and distribution systems 
• management systems 
• Consolidating the National Health Laboratory Service (NHLS) 
Providing a ""l>,mn,."t,,,n,,ivp "'.JI ......... UI of care and treatment: 
• This continuum includes ongoing medical services to provide treatment for HIV-related 
and opportunistic infections, antiretroviral treatment, an extensive nutrition intervention, 
traditional healing, counselling, adherence support groups, community mobilisation 
efforts to reduce and discriJnirlation, patient trail1Sp,ort home and cOlrnrrmnlity based 
care, and care. 
Sustainability: 
3 While the tenn "universal access" is used in HIV this is a misuse. Universal 
access to HIV -treatment means that the entire population would have access irrespective of whether they 
needed it. For the purposes of this it is assumed that universal access means access for HIV-
positive people who meet policy-prescribed medical criteria 
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,. Once people enter a "comprehensive treatment" programme, this must be sustained. The 
tests and human and physical infrastructure to sustain treatment are 
the potential financial burden of a programme of this nature, the majority 
finances will corne from the with lesser support from donor resources. 
In 2004, the National n",n",.'hnpnt of Health 1 "'l\;,a,,~iU the national ART guidelines (nf~nl'l1rtmp.nt of 
Health 2004) which "'''' ..... vu" .... , ... the following criteria for Inllru..rm ART in adults: 
Medical criteria: 
,. CD44 count <200 cells/I.ll ,.,.,.",...,.,.t"tiv,. of World Health Org;anil;ati<)D (WHO) 
appendix for details of the staging system (WHO 1993» 
OR 
,. WHO Stage IV (also known as AIDS) irrespective ofCD4 count 
l'S,rCnICl-s'ClcI:al C'Clmaa~:ral1orls (not criteria): 
,. Demonstrated reliability 
clinic) 
,. No active alcohol or substance abuse 
,. No untreated active l1 .. ru·p""'e,n 
attended three or more scheduled visits to an HIV 
,. Willingness to disclose HlV -status to at least one friend or family member or to join a 
support group 
• Acceptance ofHlV starus, understanding 
ART 
corls~~ue:nc€~s ofHlV status and the role of 
• Ability to attend services on a 
areas) 
basis (transport could be " .... "' .... ".,.11 for those in rural 
"',",',",UIUllJ,J".. to the Western "Antiretroviral Treatment Protocol" (provincial Government of 
the Western Cape 2004), if patients meet these clinical and psycho-social are 
referred from a service entry point (for example the local primary care clinic or TB clinic) to the 
4 The CD4 is a particular type of immune cell in the human body and the level of the CD4 an 
indication of the status ofthe immune system. A low CD4 count indicates that the immune system has 
decUned with the implication that the risk of the development of symptomatic disease and the risk of death 
is increased. 
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Figure 1: Management of a patient on Antiretroviral Treatment 
Prevention 
counselling 
Wellness clinic 
.. Nutrition and 
support 
.. Prevention of 
opportunistic 
infections 
Palliative care 
.. Prevention counselling 
.. and treatment ofTB 
and opportunistic infections 
.. for pregnancy 
.. Introduction to HIV services 
CD4 count test 
ART service point 
unless patient 
CD4<200 
cellslJ.ll 
.. Patient readiness assessment 
.. Treatment initiation 
Regimen 1: 
la:~~'n""n'~II~,~ivn,rtinpIF.t~'Jjn>n7 
1 b: sta,rudJineilarrlivuldineinleviloanine 
Continue 
reQ'lmtm 1 
CD4 decrease 
VL>400c/mm3 
Intensive 
adherence 
counselling 
Failure 
.. Home-based care 
.. Hospice 
.. support & 
social welfare 
Failure Regimen 2: 
zidovudine/didanosine/lopinavir/ritonavir 
Laboratory and clinical IH\J'llltV. 
Source: Department of Health, 2004 p. 25 
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To this chapter has outlined the current policy framework that guides the public 
sector response to HIV~treatment. March 2005, the bad succeeded in its of 
opening one ART site in each health district (Stewart and Loveday 2005) and by the end of2006, 
approximately 200,000 adults and children had been started on ART in the public sector (Mark 
Blecher, National communication). This treatment programme has therefore 
become one of the in the world within a short space LJ'v,;)LW''-' this success, later 
chapters will show that the of need that is being met is low. 
'-'W:llll:.o;o"" increasing access to ART will continue to dominate the health care landscape in South 
given that over 5 million 
country continues to grow. 
are currently infected and overall prevalence in the 
13 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
Chapter 3: Developing a framework for 
distributing health and health care 
1 Introduction 
This chapter proposes a framework social decision-making regarding the allocation ofthe 
oeIlenrs of health care, referred to as "the of health care, to adults in South 
Africa who are dependent on the public health care system. The problem concerns the allocation 
of these resources within an exogenously fixed government budget earmarked for HIV -treatment, 
and does not address the wider problem health care resources between HIV and 
other disease areas. This framework makes important to the 
economics -trl,atlneillt and health economics in a""''''''''''-' in that it del)atl~s and defines the 
good, considers the determinants of the claims that mY-positive people might have on this good, 
del)atl~s a number of social choice rules for argues that if 
de(;lSlOn-ma,laIlgtakes place within a procedurally just the distributions will 
be Three questions are posed in the development of this framework: 
.. What is the good that should be distributed? 
.. To whom should the be What are the "PT'"'''T''' "1" ... '.I"'1"P· ... 
the bases claims on the good? 
.. How (Le. on what basis and to what level or what 
distributed? 
should the good be 
that are 
Answering the question "what is the good" requires an identification of the value or of 
health care to HN -positive people, as discussed in Section 2. Section 3 considers how personal 
characteristics allow one to consider people to be equal or unequal in terms of their claims 
on the good. Section 4 examines a number of different social choice rules that could serve as the 
values or the principles on which distributions are based. However, that reasonable people 
could on the choice of such a rule as well as a number of issues the claims of 
people on the the section also outlines the concept of a procedurally just 
process in Section 5 summarises. 
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2 What is the good? 
At one level, the question posed in this section is ''what is the good (value or benefit) of health 
care"? But at another level, the question is Sen's (1982) more fundamental one about what ought 
to be in the evaluative space in distributive where are 
normative to allocate in limited supply relative to demand" (Lamont 
2003). In this view, the good is not health care per se - it would also be unusual to say that health 
care in itself has sufficient moral weight to it into the evaluative space of distributive 
justice. In the following or Dre:ierenc:es. "''''IJaU'HU''''''' and tunCtlCmlflgs, and health 
are each examined as potential candidates for the good. Am"',,,'" in order for any to bea 
coherent measure of the good for use in social choice, it is necessary for particular types of 
information to be available. 
2.1. Information about the good in social choice 
Arrow was the first to prove that it would be impossible to create a rule to distributive 
decisions for limited information was about the goodS. Put formally, 
Arrow showed that if it was desirable to have, for each logically possible configuration of 
individual pre~fel'ences over feasible social an ordering of social preferences that satisfied 
collective rationality and indlePl~ndeD(;e from irrelevant alternatives, then one would have to 
violate the weak Pareto principle or (Arrow 1973). 
Imagine an isolated individuaL His or her personal skins, qualities and the physical environment 
jointly limit the range of possible actions. Assume alternative actions are mutually exclusive. 
Thus the basic question for the individual is the choice of actions. The value system is the rule an 
individual uses to choose between mutually exclusive actions. This value is also assumed 
to have a .... " • .,.."'" The assumption that an 
exists over choices means that COllSI~r[erlCY assumlpti,ons are impm,ed on the value 
structure - n~tn"'liv derivable from an nT,'",.,.1n 
The first is completeness, which means that for a choice between two actions or 
one is "..."t ...... "'ti or there is indifference. The second assumption is that where for 
5 Arrow discussed his in terms or utility. In this is replaced by the 
term "the good" because this discussion is relevant to all candidates for the evaluative space that are 
considered in this cmlplt:r. 
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three altlernati'ves x, y and z, is or indifferent to y and y is preferred or to z 
then x is or indifferent to z. Finally, it is assumed that the choice is determined by the 
ordering - in other words, ifthere is an alternative that is to another, this one is chosen 
- this is known as the condition of reflexivity. To a transitive 
relation is called an order. The individual is also assumed to playa central role in social choice. 
As before, over social states can also be ordered. 
The choice is to find a rule for 
alternative social states. This process can conceptualised as one of forming a constitution - a 
social choice rule which associates a social function to each set of individual orderings. 
The is that a constitution or social choice 
where each rule must obey the following reasonable conditions: 
It rationality: for any set the social rule is derivable 
from an ordering. Others replaced this with the principle of unrestricted domain which 
means that the constitution or social choice rule must make social 
conceivable nrl',fp.rp.n{~ profile of society (Sen 1982; Roemer 1996). One 
for any 
is 
that one cannot assume that preferences will exclude sadistic preferences such as racism 
1992). 
It Pareto principle: if alternative x is ..... ",1-" .... ".1 to y every individual ::INymt1inlo to his 
It 
ordering, then the social ordering also ranks x above y. 
In<lep,enll1erlce of irrelevant alternatives: the social choice depends on the n .. £ll .... ina" 
of individuals with respect to the alternatives in that environment. For when 
choosing among candidates in a presidential election, the choice is only among 
candidates who are actually running for office - other non-running candidates are 
irrelevant alternatives. the social of x and y should not chlmll;e 
because some individuals who once y to z now z to y 1992). 
It Non-dictatorship: there is no individual whose preferences are automatically society's 
preferences without regard to the preferences of all other individuals. 
Consider the majority as a way between alternatives. the social 
choice rule states that any set cOIltaiiniflg the majority of voters is the one that cn(>os(~ the social 
state. there are three alternatives, x, yand z. One-third of the voters x andy to 
z, one-third y to z and z to x and one-third z to x and x to y. Then x will be ..... "'1-" .... ".1 
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toy by a to z a rn",i,\T';ro and z to x by a there can be no social 
choice rule simultaneously the conditions of collective rationality, the Pareto principle, 
independence of irrelevant alternatives and non-dictatorship unless 
about the good (Roemer 1996). 
is more infonnation 
Depending on the amount of infonnation that is available, infinitely many or only one potential 
function would be For ifthe function needs to the 
preienmcles on the then are a multitude of acceptable versions - namely 
aU transfonnations of the function as long as the transfonnations are strictly increasing. However, 
if the function must directly Tp.n,Tf'q,p.nt the pre:ter'en(~e "·rt1" .... ."" and if there is more infonnation 
about the states in that then only one function would be 
The level of infonnation by a LU"",."vu can be the number of acceptable 
transfonnations of the function that are allowable. If ordinal infonnation is "'VI"U<'U"~, one can 
only speak about the order of preferences on the good for x is preferred to y but one 
cannot about the of the To do one would need cardinal 
infonnation. Comparability allows one to compare the good between ~"'JIJ''''' 
• The good is cardinally rnp·",,,,,,,,,hlp and fully comparable if and only if the group of 
transfonnations is to the identity 
• The is ordinaUy measurable and noncomparable if the function can be transfonned 
by the group There are many of 
the function. 
• The good is cardinaHy measurable and noncomparable if the function can be transfonned 
by any affine tratlstclnnaticm 
• The is ordinally measurable and fully comparable if the function can be transfonned 
any increasing transfonnation. This is similar to ordinaUy measurable and 
noncom parable except that the functions of all people are transfonned in the same 
manner so as to preserve the jntl~rn'''T~I ... nl'l 
6 The identity transfonnation takes the fonn f = 1 
1 Affine are defined to be of the (a 1 + fJ i, .. " a fJ H) where are any real 
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To 
• The good is cardinally measurable and unit cOlnp:arable is mt:aIllflg.IUl to talk about 
differences between states for all citizens, but the absolute levels of the for 
individuals is 
properties. 
. In other words the good has interval but not ratio scale 
if information on the 
transformations is as as possible, but 
is ordinal and nOllc(J,mJ>aniblle, the set of 
information is U\,A,U"'U, the number of 
transformations becomes ""'''N-1l'o'f:At1 If fun , ... i-."1"J1".,t.",,, is available, only one re]:.re!.entation is 
possible. The type of information that is available about the good has implications for the types of 
social choice rules that can be used to make distributive judgements between states. To 
summarise: 
• As shown by Arrow, it is not possible to construct a social choice rule ifthere is only 
ordinal information about the 
• Similarly, there is no social choice rule if it is meaningful to talk about the intensity of the 
good (cardinal information) but not to compare between people (Sen 1982). 
• A social choice rule that seeks to maximise or equalise the good between is 
possible if the good is cardinally measurable and fully comparable. 
The key message from this section is that the less information there is about the good, the fewer 
coherent social choice rules are UV""JLllV. 
2.2. Utility 
A common approach in economics is to place utility or preferences in the evaluative space. Here 
it is assumed that people seek to maximise their utility, which is determined by the bundle of 
goods and ''''" .. "''''''',,. that they possess. To do so, their ideal bundle based on their 
taste for alternative and <:PI"'III"'''<1 on the of these alternatives and on budget 
constraint 2003). Under the revealed pn:fel'Cn1ccs approach (also known as ordinal non-
cOlnp:arable utility), a person is said to some bundle of goods x to another bundle y if she 
8 Transformations take the (a + p 1, •••• a + p H) where p H are any real numbers and a > O. Note 
that this set of transformations is therefore smaller than for affine transformations. 
9 Goods include tangible items such as medicines while services are intangible such as the treatment advice 
of a health professional (Lipsey, Courant et al. 1993). Thus health care inc1udes goods and services. 
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chooses x from a set of options which includes y. Utility is not a measure of any particular 
quality, but simply represents a choice (Sugden 1993), An advantage ofthis approach is that it 
does not reCIUlJ'e any un(lerstanding ofthe motivations for choice or the psyche ofthe individual. 
As a result however it is then not to attribute any value to the choice of x over y (Sugden 
1993) or to use utility as a measure of the good in distributive justice. 
The classical utilitarians viewed utility as a state that could be measured and cOlmp,art:d 
between people - it was to state that health care could confer utility happiness) 
on a person or that one person had a higher level of utility than another (Viner 1973). This 
allowed for the construction of coherent social choice rules. 
Howe'ver even with additional utility in the space in distributive 
justice has a number of shortcomings. One is that social welfare is a function of personal utilities 
- this is also known as This means that in making a choice between social no . 
infonnation is used other than the utility related to it does not matter 
what lies behind these choices 1982). An illustration from Sen (1982 p. 339-340) below is 
used to clarifY what this means. 
Consider a set of three social states x, y and z. These states have the following utility levels for 
persons 1 and 2: 
Person 1 's utility 
Person 2's utility 
Sum Total 
x 
4 
10 
14 
y 
7 
8 
15 
z 
7 
8 
15 
that the following 
as much as he 
infonnation is also in x person I is hungry and 2 
is Iny person 2 has given some food to 1. While 2 is worse off than in 
x, 1 has more utility and the sum total is higher. If one argues that the best social state is either 
one in which utility is maximised or utility is closest to being equal for persons 1 and 2, state y 
would be preferred to state x. Consider z - here 1 is as hungry as in x, and 2 is eating as much as 
he likes. However, person 1 is a sadist and is allowed to torture 2 2 suffers but his utility loss is 
less than the to 1. Welfarism would argue that if y is to x, then so too is z. Because 
welfarism encourages an exclusive focus on consequences, other considerations are irrelevant 
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unless they have an impact on personal utility (Richardson and McKie 2005). A related issue is 
that focusing on utility can discriminate people as person 2, the torture victim) who 
are but have to their in life and have to retain a 
of utility. desires are their happiness from small improvements in their 
situation may be disproportionate to the benefit judged from an alternative perspective (Sen 
1992). 
Sen (1999) also argues that placing utility into the evaluative space is problematic because this 
assumes that choice is motivated solely by self-interest While self-interest is an important 
motivation, it is also common for action to have a social that is beyond pure 
interest - it is Sen between sympathy and commitment. Feeling 
sympathy about the suffering of others involves self-interest. However, it might also be the case 
that one is wiHing to make utility-diminishing sacrifices for that go beyond sympathy. Sen 
argues that this is motivated by commitment. For example, if being concerned about the plight of 
AIDS orphans makes a person unhappy that he/she chooses to spend weekends 
volunteering in an AIDS orphanage, this is an example of sympathy, on self-interest. If 
however the presence of AIDS orphans leads to a determination to change a system that is to 
be (or more this determination is not fully explained by diminished personal 
utility) then this is an example of commitment. Thus committed behaviour involves self .. s:acriti(~ 
in a way that "AILi1~1-A .. """t""rl behaviour would not 10. 
2.3. Capabilities and functionings 
As an alternative to utility, Sen (1992) argues that "the good" should be viewed in terms of 
and which "reflect a to choose alternative 
lives" (Sen 1992 p. 83). Functionings are the valuable activities and states that make up a 
person's well-being, such as having a healthy body and having a good job. Capabilities are the 
alternative combinations of functionings that are achievable - while one may not pursue all 
possible functionings, the freedom to pursue alternative paths is also important. For example, an 
HIV-positive person can have the same level of health (functioning) as an HIV-negative person, 
but less freedom to pursue alternative paths. A benefit and capability approach 
as opposed to utility is that it a way that is not focussed on 
10 Committed behaviour should not be construed as solely positive certain committed behaviour can 
be harmful to the good in the same way that self-interested behaviour can be hannful. 
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the way in which people transfonn health care, for example, into utility and therefore does not 
penalise deprived people who can maintain their utility levels through small Sen's 
approach therefore focuses attention towards whether all people receive the same Uvll",'" 
(capability) from an of their capacity to benefit, ."",,."',,,,, a<;1mowledglIllg 
that some people would require additional inputs to reach a given capability level. 
2.4. Health 
While capabilities and tunlcticJnillgs could be defined more as the good in distributive 
justice, to do so risks having capabilities encompassing all human activity. When focusing on the 
distribution of health care resources, (2001) has for an "extra··weltar 
pelrspect,IVe which places health into the evaluative space. He argues that the distribution of health 
care is important because it serves a end the individual's health. Health is a 
constituent of functionings • good health provides people with the freedom to pursue the states 
and activities that they value while poor health can a freedom to 
choose between life paths (Culyer and 1993). The distribution of health care 
that postpones death or decreases disease and other influences on the quality of life is of 
significance if society has that all members should have the opportunity to flourish. 
Although health care provides other benefits, such as providing infonnation, reassurance and a 
of other services that are marginally connected with health, Culyer argues that health 
should be in the evaluative space as opposed to these other outputs of health care because "health • 
is important in ways that the other needs served by health care are not" (200 J p. The 
for HIV·positive in South Africa will therefore be argued to be health. 
2.4.1. Defining health 
OCtlSlnlg on health as the good for .T'lf',dtivp South Africans ,."" ... ,.,3" a definition of health 
that is appropriate to the topic and lends measurement. Unless one can measure health, 
one cannot assess the outcomes of alternative health care allocations. Evans and Stoddart (1994) 
argue that most activity in the health care reflects a view that health is an absence of 
disease or injury. Under this the appropriate response to ill-health is to provide 
health care only if effective care exists. An a01ValllUlg;e ofthis definition is that it lends itself to 
measurement and quantification for example through survival or death and incidence of 
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dlagnc)sable conditions. However, the World Health Or!~anjisation has ael:me~ health as "a state of 
complete physical, mental, and social well-being, and not merely the absence of disease or 
injury" (in Evans and Stoddart 1994 p. 28). This definition similar to the __ ~'aVJlH 
that health is affected all human activity. The determinants of health would 
therefore include a range of factors such as the targeted use of health care services, genetic 
endowments, environmental sanitation, adequacy and quality of nutrition, nOllsmg, 
<1,,,,,,,,.rl',"..., .. ""<1 of the social environment, sense adequacy 
control. While it is difficult to argue the validity World Health 
definition, the practicality of it for the purposes of health policy is problematic, especially if 
health has to be measured. 
Evans and Stoddart (1990) therefore propose an alternative framework. This differentiates 
between disease as labelled by the health care sector, health and function as experienced by the 
individual and World Health definition of health which they rename 
For two with a CD4 level 1 ceHsllJ,1 have the same 
disease and severity of disease as labelled by the health care system, but might experience 
slg:omcarmy uu,,,,.',,,.,, levels of health and Thus health in this thesis is defined narrowly 
but the perspecti\re individual as ''the absence or 
symptoms or impaired caf)acj:ty" and Stoddart 1994 p. 47). While the disease as labelled 
by the health care system will have a significant impact on the individual's perception of her 
health, the extent to which a disease will cause illness will differ from person to person. 
illness will have a impact on wellbeing, but will not be the only factor that is 
influential. 
2.4.2. Measuring health 
Following on the definition of health proposed above, this section outlines the theoretical and 
methodological approaches and challenges in measuring health. Such measurement is complex 
firstly because health is culturally determined - it is perceived differently by different people 
(Mooney 2002). Also, health is multidimensional it is not solely about but is also 
about the quality of that life) and in order to avoid results above) measurement 
must enable a to be made between people and a distinction to be made between 
different intensities of health a cardinal scale is Ifhealth is measured on an ordinal 
it is only to rank states as better to worse. An of an ordinal 
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for HIV is the WHO With this it is possible to say that WHO Stage III is better 
(Le. healthier) than WHO IV but it is not to say how much better. When a cardinal 
scale is it is to make If an interval scale is used (one of 
cardinal scale) it would be possible to say that the move from say WHO I to WHO Stage II 
was valued the same as the movement from WHO n to III, but it would not make sense to 
say that WHO Stage I was Tn .. ''''''_l"11' .... ''' better than WHO Stage m. However, if a ratio scale was 
used of cardinal such statements could be made validly. We have here an 
indication of the stringent infomlational requirements of ratio-scale cardinal health state 
measurement. 
In health one method for measuring health on a ratio scale is the Quality 
Life Year (QALY). The QALY model suggests that one year ofHfe in perfect health has a value 
of one while life years in less than health have values of less than one. "',,, ..... uuJ it is 
assumed 
worse than 
QALY t02 
death has a value of zero and that certain states that are C011Sl(leri~ to be 
have values. In with ratio scale moving from 1 
followed by death is the same as moving from 11 QALYs to 12 QALYs 
followed by death and 12 QAL Y s are six-times better than 2 QAL Y s. 
Constructing the quality component ofthe QAL Y "",n".",·" measurement of health-related 
quality oflife (HRQoL). This is often done b  administering a questionnaire to individuals in a 
health state of interest to the evaluation (unless the subjects are children, or emotionally or 
cognitively impaired individuals in which case proxy such as family members could 
be used and 1989)) or to the public. This includes questions about an 
individual's functioning in "domains" that are considered important in health 
including function, function, sensory function, 
function, pain, dexterity, and self care. and 1989 p. A 
person's perception of her level of functioning in each domain provides a subjective description 
of this person's health state. The measurement ofHRQoL therefore amounts to creating ordinal 
rankings over different domains that make up a health state. 
One shortcoming of using patients' to rank domains is that if patients have to 
their conditions and have a relatively optimistic view on their health they overstate 
their level of health and function. A similar point was made about using utility infomlation in the 
case of the deprived. If the public valued a health state from 
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!-,i:u.,<;;;u,-", might one be tempted to use their values instead? In this, one needs to bear in 
mind the nature of health state valuation - it is a matter opinion. 
a health state as over or under valued is given the multidimensional nature of 
health. It would therefore be difficult to justifY the use of non-patient responses to rank domains 
that patients have direct experience of the health state 
The next step in HRQoL measurement is to transform these ordinal rankings into a composite 
cardinal value for each health state. While ordinal ranking of domains is usually done by patients, 
the cardinal valuation of health states is often a process, and can be done the 
public, health care pro!tes;SIOI or patients and 1989). It is 
usually argued that it is most ~nr,rnrrri~'tp to use the values of the F.",L>" ..... public if the QAL Y data 
are being used in resource allocation decisions for society (Brazier and Fitzpatrick 2002; Dowie 
2002; 2002). 
There are three common methods of valuation: the time trade-off (TTO), the standard gamble 
(SG) and the visual analogue scale (VAS). The time trade-off method values health states by 
corlslderirlg the of life and quality this inherent to 
the QAL Y this value of a health state can be by assessmg 
the number person is indifferent between living in good health versus living for a 
longer period with a lower health-related quality of life (Torrance and Feeny 1989). A 
shortcoming of this method is that it assumes neutral time pre~ter'enc;e when it might be more 
likely that 
1993). 
value benefits that accrue sooner higher than accrue 
nWp.Vf~r others have that respOll0e:ms might build this discounting into their 
trade-offs with the implication that the 
(Martin, Glasziou et aI. 2000). 
resporldents is captured 
The standard gamble method is grounded in von Neumann Morgenstern (VNM) eXf)ec'ted utility 
theory (Torrance and Feeny 1989; Broome 1993). Proponents of this method often argue that it is 
a gold standard because it allows an assessment of health-related utility and 
1989). Although this thesis interprets the good as and not as health-related utility]], the 
ideas nnl1prliv.rm this <>"""""'l'h will nevertheless outlined. Von Neumann and M(1lrp'l',n"t~rn 
II In essence, this means that the QALY is viewed as an objective measure ofa person's health status, 
instead oca measure of the utility associated with that health state. 
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(1944) developed a theory of utility under uncertainty to describe how a rational person ought to 
behave when decisions under uncertain outcomes. Its axioms are: 
• Preferences exist and are transitive - for any pair of risky prospects, y is indifferent or 
nrp·ti>rr",rI to x and for any three x is 
indifferent or to z then y is md.lttl~relt1t to z. 
• - an individual should be IU"" .. U",,,' between a two-stage risky prospect 
and its probabilistically equivalent oml-su:w;e counterpart. 
• Continuity are outcomes such that x is "' .. ".i-...... "'rl to y which 
at which an individual is between 
outcome y with certainty and the prospect of outcome x with probability p 
and outcome z with probability 1 - p. 
The standard 0<1 .... 1"111", ITletrlOd is a direct apl:)lI(:atlIOn of the continuity nt',.,rf'·ti>l·",n,r'."''' axiom 
(Torrance and 1989). A paired comparison between two alternatives is described to the 
respondent Choice A is to accept the respondent's current health state while choice B involves a 
gamble on a treatment with a probability of death or of perfect health. The probability is varied 
until the respondent becomes indifferent between choices A and B. Following VNM axioms, the 
value of the state is to the probability and 1989}. A 
shortcoming of this method is that it assumes that an individual is risk neutral. If a person is risk-
averse or risk-loving, health state valuations will be biased (Torrance and Feeny 1989; Broome 
1993). 
According to Torrance and 
be equivalent to eXJ:lec
'
ted 
(1989) even if individuals were risk neutral, QAL Y s would not 
utility unless: 
• The two attributes of quality and quantity were mutually utility-independent (preferences 
for gambles on the one are independent of the amount of the other). 
• The trade-off of quantity for quality exhibited the constant proportional trade-off property 
(the proportion of remaining life that one would trade off for a specified quality 
improvement is independent of the amount ofremairring Hfe). 
• The single-attribute utility function for additional healthy life years were linear with time 
(for a fixed quality one's are directly proportional to . risk 
with to time). 
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Given that the above assumpti()ns are unlikely to hold, the QAL Y model does not hold under 
expect€~d utility (Broome 1993; Brouwer and Koopmanschap 2000). assertion has 
been validated in empirical tests (Doctor, Bleichrodt et al. 2004). However, QAL Y model 
might hold under utility theories - such as rank-dependent utility and prospect 
Rank-dependent utility deviates from ext)ected because it allows probability 
weighting and prospect theory deviates in that it allows probability weighting and loss aversion. 
In brief, probability weighting relaxes the assumption of risk neutrality, while loss aversion 
allows to than to Bleichrodt et al. (2004) an 
test of the model under utility, rank utility and prospect 
theory. Their findings suggest that subjects do not behave according to expected utility theory, 
but that the QAL Y model holds under either utility or The 
ImT)Uc:atlOtn is that probability aversion should be taken into account when 
valuing health states. However, to the best of the c:andidate's knowledge, this metl10d has to 
be used in large population surveys to establish health state valuations, which means that it is not 
available for use in p1'nnir1'(,<l1 research. 
The final method for valuing health states is the visual analogue scale (VAS). Here a respondent 
ranks a health state by drawing a line on a sc:ale such that the intervals between different health 
states to the respondent's for these states. There are two measurement 
biases associated with the V AS. Context b as reflects the fact that the V AS score for a state 
depends on how many better or worse states were evaluated by the respondent in the same sitting. 
The value of a state be if it is valued at the same time as a number of better 
states. End comes about because are reluctant to use the extreme cat:el!()rll~S 
on the sc:ale. On the other hand, V AS benefits in that it is generally to be easier to 
administer and easier for to understand et aL 2001). 
fmal assumption that is to operationalise the QAL Y in resource 
allocation is inter-personal comparability, which is normally interpreted as meaning that a QAL Y 
gained is of equal value to everyone (Williams 1996). When resource allocation concerns the 
entire range of diseases and interventions in the health sector, the of this assumption 
is questionable groups are each other solely 
in terms of their health However, the is more acceptable if the is 
restricted to adults who are on public health system, as is the case in 
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this thesis. It can also be that it is egalitarian to treat each mY-positive 
equally (Williams 1996). 
To summarize, the construction of a QAL Y requires a number of steps. In the first step, patients \l)I 
create ordinal on their current health state across a number of domains such as pain, 
usual activities and In a separate step, a population transfonns these ordinal 
rankings into a cardinal measure of each health state with ratio scale properties, using a time 
traICle-'OII. standard gamble or visual scale method. Resultant values are multiplied by 
the number of life years spent in each health state to calculate for the purposes 
of resource allocation it is usually that a QAL Y is of equal value to everyone. 
Before concluding, it is necessary to ask how good the QAL Y is as a measure of health - does it 
measure what it is supposed to measure, is it reliable and reproducible by people and can 
one relate it to some ofthe variables that are relevant to the policy question? 
In this (1""'''ff",t1t'", the QAL Y is inte:nd(~ to measure health as defined from the point of view of 
the mY-positive person as the abse:nce of illness or injury, symptoms or impaired 
capacity. This definition has a number of similarities to the health domains included in HRQoL 
such as pain and anxiety. In addition, these are answered by 
patIents in with the defmition of health from point of view individual. 
However, it should be borne in mind that is frequently assessed through Pf'!Tlf'!T'1IC 
questionnaires with specific domains that might not be appropriate to all settings and that 
different cultures have conceptualisations of health that may not be adt:quatelly 
reflected. In addition, while health is defined from the ofthe individual, the 
l"".",t""l"tinn of a measure on health state is done by a population SWiUpte. This is 
however defensible that the QAL Y is used in society level resource decisions. 
But what is less defensible are the assumptions that the QAL Y is a cardinal measure of health 
with ratio scale and that QAL Y model does not nonnally allow for or 
decreasing value of health This means that a gained in the context of 
limited health has the same marginal value as a QAL Y gained after greater health gains. 
t 
Figure I illustrates the potential relationship between the of a QAL Y and the quantity of 
QAL Y s for one individual. The assum:pttclfl used in the QAL Y model is that the value of 
a is constant, as lustrated by the au~.m-lmle. In other no matter how many 
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QAL Y s have been gained, additional has equal value. However, empirical tests 
suggested that this function be concave or become increasingly concave with increased 
survival time (Martin, Glasziou et al. 2000). However, it is hypothesised here that this function 
might be S-shaped. If this is the case, have a low but value at a low 
quantity. value continues until a certain level of QAL Ys is ... "LUU"'U, 
which point the curve inflects and becomes concave to indicate that each additional QAL Y has a 
value. This reflects what Gafni and Torrance (1984) have called the quantity 
effect, where the rp),;,th!p. diesil-abi for additional units of a would initially In ... 'rp",,~p but 
later decrease once a certain amount had achieved. 
Figure 2: The marginal value of a QALY - increasing. decreasing or constant 
ValueofaQALY 
Dec;rea:,ing marginal value 
Quantity of QAL Y s 
Is it possible to relate the to some of the variables that are relevant to the policy question? 
Dowie (2002) has posed a similar question in terms of decision validity - does the QAL Y 
measure what is necessary for the decision context? Does it embrace the fun range of outcomes 
that could result from all alternative treatment interventions under consideration? Here the answer 
is a tentative yes, are used QAL Y as in other is a 
simplification of reality that should be used in a way that encourages thought and draws .. tt."",T'h,., 
to areas of disagreement between the model and reality. the extent to which QAL Y health 
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state values are reproducible will be assessed in later sections by reviewing the empirical 
literature on HIV I AIDS health state values. 
3 To whom should the good be distributed? 
This section covers the von,",'" claims that HIV -positive people have on the good. The 
notion claim is based on Broome (I 991) who argues that claims (as opposed to other __ C'~U~ I 
are the object offaimess.lfan HIV-positive person has a claim to health care, this is stronger 
than merely a reason for Ulmntn"l," health care oecaus.e a claim includes the notion of there 
an obllig;<lti(].n on others to provide care. A number could be 
claims, including the social context in which most HIV-positive people live, whether or not 
people have personal responsibility in their need for health care, the impact ofHIV-
treatment on the broader health of society, and the of HI V / AIDS and treatment on the 
:3 
social fabric. These claims on the good are summarised in Figure&!, which has been adapted from 
Olsen, Richardson et al. (2003). claims will be discussed in the following sections. 
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, . . 
Figure 3:' A framework for considering to whom tile good should be distributed. SoUd 
arrows show the causes of illness knd consequences of health care. Dotted arrows show 
claims on the good. ! 
2:C!aim 
based on 
deprivation or 
disadvantage 
I ' 
'IIJI •• 
...... 
...... e. 6: Claim based on the impact of 
treatment on 
social fabric 
I , Individual health outcomes 
Impact on health of 
society:' . 
Positive externalities: 
Lower transmission of 
HIV' " 
resistant virus 
Higher transmission of 
HIV I 
I (QALY~) 
, Impact on ,the social 
fabric: 
Macro and microeconomic 
impact and without 
Creation of II 
so!idaristic soci7ty 
30 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
4.1. Consequentialist theories 
Theories are consequentialist if they recommend that IlUII\,i.O;) should be evaluated in 
tenns of their consequences. A number of theories are coIlseqUtmtJail:st in nature, mCludmg 
utilitarianism, which focuses on maximising outcomes, and egalitarian theories that propose 
equality in the space of outcomes. For example, Stinnott-Annstrong (2003) argues that Sen's 
of capabilities is consequentialist in the space although it should be noted 
capabilities also include procedural =il'~"'''> in that the focus is on access to 
opposed to what is done with the capability. 
4.1.1. Health maximisation and economic evaluation 
as 
U'''AU ... ", ... ~'n as a sodal choice is with the allocation of health care 
resources that maximises health. Conceptually, this approach is similar to classical utilitarianism. 
Utilitarians argue that society should seek to achieve the good for the greatest number 
(Viner Roemer 1996). There are many but they 
three features: consequentialism P01ICH~S are evaluated by 
(consequences are evaluated in tenns of the individual utility that they generate) and sum-
r::I'I1ilnTIO (the social rule maximises the sum total ofindividual utilities). As explained, 
ordinal utilitarianism differs from classical utilitarianism in that the sum ranking 
because it only allows ordinal non-comparable infonnation on whereas the latter 
allows preferences to be cardinal and interpersonally comparable (Rice 2003). 
While utilitarianism is traditionally associated with maximising utility, some health economists 
have argued for an extra-welfarist perspective which considers the non-utility aspects of welfare 
2003). In health these non-utility aspects are often to relate solely to 
health outcomes (Culyer and 1993). So, the extra-welfarist maintains 
elements lit""ri"ni"tn such as and cOllselqu~mtiaW;m, but 1\-,V"'"'.''' 
individual utility with individual health outcome. 
,Following Williams and Cookson (2000), health maximisation can be presented in tenns of an 
optimisation problem where a social choice rule is used to choose between options in an 
opportunity Set. The opportunity set can be presented as a health or QAL Y possibilities frontier, 
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which nrpc:pntc: the ~al:;.. .. ", .... t distributions of health between people. options on and within 
and are pOS'Stble the frontier are "",,,,,, ... ,,-, • .,1) ""...,11"11,,, (can be achieved with existent ","iIURl1V,;Y 
within budget Assume that the frontier is continuous, concave to the origin and 
monotonically decreasing from left to right. Consider two sets of people, A and B. The axes in 
,1x,rrespond to the QAL Ys A and B If we fix the QAL Ys of A at 
some ",,,,,,,tt"""'l the ofB will aep,ena on the value of A at that point, the supply of 
resources and the technical feasibility resources into QALYs. If the same process 
is followed for the QAL Y s a locus called the QAL Y possibility frontier can be mapped out 
as depicted by PP. This illustrates the maximum level ofQAL Ys any group can enjoy, the 
levels of other groups in other words it the interpersonal distribution of QAL Y s (De V 
Williams and 2000). 
Figure 4: Health possibilities frontier and health-related social welfare functions 
QALYsofB 
Welfare contour 
P / 
P 
Source: Williams and Cookson, 2000 p. 1874 
4 
of A 
In $, welfare contours are constructed at 450 to the origin to illustrate that QAL Ys are of 
equal social value to everyone the total amount is nt\T'1,,,nt These contours the 
locus of indifference between all pareto optimal states. A VIJ"'~"'" state is defined as a state 
where no-one can be made better off without H1U"'-li"6 someone else worse-off. At the point of 
tangency between the welfare contour and PP at QAL Y s are maximised for that budget (De V 
Graaff 1973; Williams and Cookson 2000). 
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The application of the health maximisation social choice rule in health ec(moml(~S is undertaken 
'lll'''UI'~U two types of economic evaluation - analysis and cost-utility 
analysis J3. These differ according to the way in which the benefits of health care are measured, 
but take a approach in their assessment The following include an 
explanation of the COllcelDt of cost that is appropriate in economic evaluation followed by a 
discussion of cost-effectiveness and cost-utility analysis. 
4.1.1.1. Cost 
The notion of cost used in economic evaluation is that of opportunity cost, which on 
the principles of and choice. Scarcity exists because societies do not have enl)ullil 
resources to fulfll every want, of the wealth of the society. Because of this, choices 
need to be made the activities that are undertaken and those that are not. Thus the cost of 
a programme in economic evaluation is defined as its opportunity cost, which is equivalent to the 
benefits from the best use of resources in an alternative h alth care programme 
(Donaldson 1990). It is also argued that if the benefit of a programme is expressed in terms of 
health outcomes such as life years or then only the opportunity cost of health care 
resources can be considered (Gerard Mooney I Posnett and Jan 1996; Mooney and Jan 
1991; Donaldson 1998; Currie, Donaldson et al. 1999). While some methodological texts 
recommend a societal perspective in costing (Luce, Manning et aL ] 996; Brouwer, Rutten et at. 
200 I), this would require the inclusion of non-health care resources (e.g. time costs associated 
with health Because these need to be with the potential or 
not only in health benefits but also in non-health benefits (e.g. diminished utility because of 
spending leisure time seeking health care), their inclusion in an economic evaluation that 
expresses outcomes in terms of health benefits would be inconsistent. 
4.1.1.2. (CEA) 
If it has been decided that a particular health care programme is to be delivered or a 
disease is to be the analysis tries to the best way of doing so 
(Donaldson 1990). To be more pre:ClSie, the "best" method is defined in terms of technical 
13 The other form of economic evaluation is the cost benefit analysis. This form of analysis a 
monetary value on health gains, so that both costs and outcomes are commensurate. owing to a 
number of difficulties in valuing health in these terms, the cost benefit is infrequently used in 
health economics. 
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efficiency: the production of a given quantity of output with the least cost combination of inputs 
(Birch and Gafni 1992). is therefore to be a method for 
determining the least cost way of achieving a output, whether the same level of output can 
be achieved with less of one input or the best way of spending a given budget for a group of 
patients (Donaldson, Currie et aI. 2002). 
CEA measures the outcomes of a health care programme in natural units, such as life years saved, 
viral or CD4 It follows that CEA can only compare between programmes that 
outcomes and Gafni 1992) and that CEA does not involve 
comparisons between patients with different diseases (Donaldson, Currie et at 2002). Moreover, 
because outcomes in CEA are unidimensional, if improvements in quality of life are an additional 
from a CEA that on improved life would 
understate the health-related of the 
The most common output from a CEA is an inc:rerneIltal cost-effectiveness ratio (ICER). This is 
calculated by dividing the additional costs of an intervention by the additional outcomes with the 
implication that lower ratios are preferable to higher ones. that the CEA only focuses on 
alternative approaches to achieve a given objective to treat a particular disease) the 
mcretloerltal costs and benefits relate to the introduction of a new treatment in COlmpamson 
to the status quo. In some unusual cases, a new treatment can be more effective and less costly 
than the status quo. In this case one could say that the new programme is technically efficient: in 
comparison to the status quo, the new intervention could produce a level of output with 
fewer resources. More frequently, however, the new treatment is both more effective and more 
costly than the status quo. In this case, on technical cannot be made If;-
and the analyst cannot comment on whether the new programme is cost-effective or not. To fund 
the new programme the same number would require diverting health care resources 
an alternative disease or health care programme (Birch and Gafui 1992; Donaldson, Currie 
et al. Sendi, Gafui et at 2002). Whether this is worth doing is a question 
efficiency, which will be discussed under the section on cost-utility analysis. 
Cost-Utility Analysis (CUA) 
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Theoretically, the cost_utility14 analysis is also able to assess technical efficiency, although the 
same caveats "",,,,,,,,r1in technical for programmes with costs and 
effects still "'''''''''''' as outlined above. The key difference between the CUA and CEA is that the 
CUA uses a broader outcome than the CEA. This is normally the QALY, but it is also possible to 
use the disability adjusted life year are aC(;el)'[ea as an measure of 
the benefit of health and iOt is accepted that they can suc:ce:,sTIlllljl combine length oflife 
and health-related quality of life in one index, one can argue that the CUA has advantages over 
the CEA 2003). This is because assessment can be made of treatment for a that 
has an impact on ofHfe and health-related ofHfe in COlnp:artl,On to an alternative. In 
this context, the CUA would be better placed to assess technical efficiency than the CEA because 
it provides a better measure of the health-related benefit of the intervention. 
""WPU"" it is also that the CUA can assess the efficiency of allocations between 
competing health care programmes (allocative efficiency). In this broader role, CUA aims to 
maximise health outcomes across programmes or interventions within the health care budget 
",'''''''''''CL'''' (Wagstaff 1991). The implication is that the CU A no r"'<l.ltri..-t<l. itself to 
evaluating goals that have already been defmed and that comparison is now made between 
different groups of patients, health care programmes and diseases. In this formulation of the 
it is once assumed that the QAL Y is an adequate measure of health 
care and that views a QAL Y as of equal value no matter who gains. It is also assumed that 
there are no other objectives in health care other than health maxir!1isation (Birch and Gafui 1992; 
M(Jlon~~v 2003). 
In pnlCilce, two different ,,,'\,,, ....... "'1',,,,.,, have been sul~gf:ste:d to assess allocative vu .• v"",v inCUA: 
the threshold ICER and QAL Y table. The threshold ICER reflects the maximum amount 
that society would be willing to pay to a QAL Y any intervention with an ICER below 
this level would be implemented and interventions with ICERs above this would not (Sendi, 
Gafui et aL 2002). This can be illustrated graphically in Figur/,1, through the use of the cost-
effectiveness plane (Briggs 1995; Briggs 2001). The plane is divided into four quadrnnts. The 
horizontal axis shows the difference in effect between two interventions (QAL Ys gained) while 
14 Although this thesis is interpreting the QAL Y as a measure of health and not health-related utility, the 
conventional term cost-utility has been maintained for reasons of clarity. 
15 Whether the or DALY is used does not alter the point made in this section, so the discussion will 
continue to focus on the 
16 For more details on the as a proxy for the good see section 2. 
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the vertical axis shows the incremental costs. If the of the show 
the in costs and effects in II or absolute dominance exists. In the case of 
II, the new treatment is more effective and less and should be In the 
case ofIV, the new treatment is more expensive but less effective, and should not be 
Iml[)lelnel!ltell. If results indicate quadrants I or a trade-off is In the case the 
new treatment is less costly, but is also less ",1"1""",1"."", and in the case the new treatment is 
more expensive and more effective. In this case, the "standard" eVA decision-making rule is to 
implement intervention as long as its leER is less than a maximum acceptable cost-
effectiveness as indicated the ofthe dotted line 1995; 2001). 
Figure 5: Tbe cost-effectiveness plane 
/ , 
Source: adapted from Briggs (1995) 
t; 
o 
U 
Maximum leER , 
/ 
I 
Outcome difference 
40 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
Despite the central role that is mcreasm:gly to the threshold value of the ICER in 
little attention has been given to determining the value of this threshold in practlc:e. 
the threshold ICER represents the opportunity cost of resources 
---~ 
which means that it is equal to the ICER of the last programme selected before the budget is 
exhausted. The implication is that a QAL Y table of all existing programmes needs to be 
produced in order to the threshold ICER and Birch 2006). 
In the QAL Y league table approach, the question that is addressed is "what additional 
can be bought by additional health service resources to the listed pyjdirlo 
l)fCIs;r:umrne:ST or to a new programme and Mooney 1993 p. The 1111,;"rhl1'"'' 
rationale is to produce each health care programme unti] the level of the ICER is the same across 
all interventions and the decision to introduce a new intervention therefore involves a comparison 
of the ICER of that intervention against other interventions. Note that this that 
one cannot assess whether ""U",UIl'J'. allJoc:atl;(}DS are 
A league table is constructed from a number of individual CUA studies. The validity of 
recommendations based on a table will be constrained by the availability 
,,.UV1'-'''. the quality of the research and whether have conducted in a that is 
appropriate to the decision context that the table seeks to address. Even if good quality 
studies are available, these will be context the ICER wiU depend on the cost structures 
and the epidemiology of the particular setting in which the study was conducted (Gerard and 
Mooney 1993). Given however the paucity of CUA studies, one danger is that analysts will make 
assumlpUons of constant returns to scale when the table (Birch and Gafui 
1992; Ubel, DeKay et aI. 1996; Nord, Pinto et al. 1999; Gafui et al. 2002). Consider 
(:, 
,,,,,,i1r,,nt I of the cost-effectiveness plane S. Ifthere are constant returns to 
scale, the ICER of intervention X would be OX j • HnwP'IJp.t' it is that intervention X 
would have a lower ICER at lower of scale (for if provision were through urban 
""HIT"''' as shown by OX2• As the intervention expands to rural areas, costs might increase, as 
exhibited by In other words, the ICER is dependent on the size ofthe intervention that is 
being considered and the context The implication is that each local or provincial government 
would require a league table for its specific context which would differ from league tables for 
other provinces or for the country as a whole. 
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Figure 6: Returns to scale on the cost-effectiveness plane 
... 
'" oU 
o 
Outcome difference 
Source: Sendi, Gafni et aL 2002 p. 25 
A further for the threshold leER or QAL Y table approach is that the leER 
should be calculated relative to the ..... ""."'.,. valued alternative use because the level of the leER is 
dependent on the cost to ratio of the comparator (Birch and Gafni 1992; Gerard and 
Mooney 1993; Ubel, DeKay et al. 1996; Nord, Pinto et al. 1999). For if the leER for 
ART were calculated to No-ART and No-ART had a high cost per QAL Y then the 
leER of ART would appear more favourable than otherwise. 
Given the many pitfalls of the QAL Y table or threshold leER approach, Birch and 
Donaldson (1987) argued that one theoretically correct approach to solving the health 
maximisation problem would be through the use of linear or integer programming. Following 
Stinnett and Paltiel (1996) the health maximisation problem could be structured as follows: 
Equation 1 
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Subject to: 
n L $;C 
i=l 
Where: 
C is the value of all health care resources over the planning period 
i is an index all mutually exclusive interventions available (i = 1, ... ,n) 
Cj is the "''''''"""nf value of the cost ...... '''''.r1'niCT intervention i over the p,auu:'''e period 
Ei is the present value of the QAL Y s of intervention i over the planning period 
Xi is a decision variable - if intervention i is not implemented, intervention i is 
The objective function in 1 seeks to maximise QALYs, subject to a number of 
constraints. The first set of constraints restricts each intervention's implementation level to be 
between 0 and 100 per cent. In other are to be divisible. The second 
constraint is on the budget in order to ensure that total costs do not exceed available resources. 
The final constraint ensures that the sum of the portions of mutually exclusive interventions 
implemented cannot exceed 100 per cent. 
linear programming to assess allocative across health care programmes in CUA 
would data on the costs and consequences of all mutually exclusive interventions within 
each independent health care programme. the approach can be used more in 
assessmg technical in the CUA when it has been decided that a particular treatment 
programme will be pursued and when a health care for this independent programme has 
been allocated. This approach to assessing technical efficiency has a number of strengths. Firstly, 
it solves the health maximisation problem within one independent programme in a theoretically 
correct manner a maximisation problem within a 
data on the full costs of each the costs 
Secondly, because it uses 
~~~"L"'''' up are also available for 
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consideration. Thirdly, it draws attention to the total health that can be achieved within 
alternative health care 
While this is an improvement on the standard decision rules of CEAlCUA, the shortcomings of 
...," .... 'uBE; constant returns to scale and divisibility are still problematic. Although the 
will be relaxed in the next data on or returns to scale are 
"'~'U"'V"". In addition, this approach is not able to quantifY the opportunity cost of the 
health care budget allocated to one independent programme over another; an assessment of 
allocative efficiency would costs and oerlenrs of aU independent programmes included in 
the total health care budget. However, clarity to the health associated with 
alternative bu<12ets within one programme should assist in setting evidence informed budgets for 
that programme. 
Equal health 
In contrast to the health maximisation an health proposes that a mir 
distribution ofHlV-treatment would be one that led to the for all HlV-positive 
people at a given level of need. and Wagstaff (1993) argue in favour of the equal health 
approach firstly because health is necessary for flourishing and fairness requires an equal 
opportunity to flourish. opportunity to flourish could be compatible with equal 
health or with equal access to health care. To move from opportunity to flourish to health, 
and Wagstaff (l 993) argue that differences in health that are unrelated to own free choice 
(such as and the socioeconomic are 11'1t>,nll.t"I-.II> 
Secondly, argue that differences in health that are related to n",¥'''''''''' n .. "' .... "',,,,,,,,,,.y are also 
inequitable. The principle health is however qualified by a side condition that Or.F'!Olt,>r 
equality cannot be achieved by reducing the health of some as a deliberate act of policy. In 
addition, they suggest that the apparent severity of health equality can be tempered through 
trading-off equal health against health maximisation. 
The health maximisation approach in can be rp"t!Olt~·tl to encompass equality 
the welfare contours convex to the origin and <:v.nrr>I>rr ..... ". around a 45° line. The 
making 
the 
curvature in the welfare contour, the to health over health 
maximisation. In the extreme case in the welfare contours would be L-
shaped implying a zero trade-off between maximisation and equalisation. This approach can be 
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operationalised for one programme HIV treatment) by replacing the linear 
programming approach from Equation 1 with an integer programming specification (Birch and 
Gafui 1992; Stinnett and Paltiel 1996): 
Equation 2 
"'"lhiA"t to: 
Xi = O •• .or··.xi .::::: 1 
sC 
i=l 
Where: 
C is the Drf~Se!1t value of all health care resources over the pla,nnmg period 
i is an index describing aU mutually exclusive interventions available (i = 1, .. ., n) 
Ci is the present value of the cost of providing intervention i over the planning period 
E; is the present value of the QAL Ys ofintervention i over the period 
Xi is a decision variable where intervention i is not implemented, intervention i is 
fully implemented 
Although the objective function in Equation 2 is the same as in Equation I, the value ofthis 
function is further restricted by an assumption of complete indivisibility as shown in the first set 
of constraints. What this means is that each intervention's implementation level can be either 0 or 
100 per cent. Because the programming approach 2 simply adds additional 
constraints to the linear approach of Equation 1, the optimal objective function 
value obtained from 2 is lower than Equation 1, although the difference would be 
"'''('<IIt,,,,,,,II,, related to the size of the budget. This difference shows the health benefit 
from an constraint (Stinnett and Paltiel 1996). 
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4.1.3. Trading off equality and maximisation 
The health maximisation social choice rule is often criticised for too little attention to who 
the QAL Y is. At the other equal health is criticised for too much 
attention to the worst off. According to Elster (1992), a "common alternative is to 
maximise total welfare subject to a floor constraint. In the tenninology of this thesis, this would 
imply maximising QAL Y s after providing a decent minimum level of QAL Y s to all. The 
in 0piera:tiollallisiI1lg this ''''''l v,,, .... u is to on the decent minimum, as will shown, 
this is function of the health care that is available to the HIV -treatment programme. At 
lower budgets, the decent minimum will be different from what would be possible at higher 
constraints. 
Empirical evidence supports this commonsense approach (Miller 1992). When with 
four alternative principles for distributing income (maximising the minimum, maximising the 
average, the average to a floor constraint and maxjI1llisJlng the average subject 
to a range constraint18) maxirnising sul)lec~t to a floor constraint was first choice for between two-
thirds and three-quarters of respondents. The second choice, by a large margin, was to maximise 
the average (i.e. QAL Y maximisation if the evaluation was in the space ofQAL Ys instead of 
incomes). Maximising the minimum which to an equal health approach was chosen 
by between zero and four per cent of respondents. 
The "decent minimum" can be operationalised through specifYing an intennediate position 
between Equation I and 2 in Equation 3. In this spe:CHlcatlon. QAL Y s are maximised subject to 
some fonn minimum" offered to an patients within an mdep(md.ent programme 
(i.e. HIV tre:atnlent) The sum of mutually ""v,,.llI",v,," interventions must be equal to one, but 
patIents do not have to receive the same fonn 
constraints relating to Equation 3. 
ftri~atrnel1lt, as indicated in the of 
17 Elster (1992) defines the commonsense conception of justice as the nri!lci"le" held by those 
who have to the matter but who are not philosophers. He argues that 
be held by economists and politicians. 
the gap between top and bottom incomes should not exceed a certain amount. 
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Equation 3 
Subject to: 
i=1 
1:1 
Where: 
C is the nr~~sel:1t value of all health care resources over the pla,nlllmg period 
i is an index describing aU possible mutually exclusive interventions available (i = 1, ... ,n) 
Cj is the value of the cost of providing intervention i over the planning period 
is the of the i over the Pl<'UUllU5 
Xj is a decision variable if intervention i is not intervention i is 
implemented 
4.2. Procedural justice 
Procedural justice focuses on the fairness of the process through which a distribution is achieved. 
In contrast to consequentiaHsm which judges fairness in terms of outcomes, non-
consequentialism judges fairness through the procedures that lead to the distribution of outcomes 
irrespective of the outcomes (Daniels 2004). Rawls (1971) has defined a number of different 
orC)cedul,3 justice. Perfect was defined with the of the 
division of a cake. If it is that the fairest outcome is for everyone to 
then one possible Of()Ce<1ulre would be that whoever cuts the cake 
after everyone else has chosen. The key constituent of this form of procedural 
of the same 
that remains 
is that there 
is an independent criterion for defining a fair division (i.e. equality) and a procedure that is 
guaranteed to lead to it. This differs from imperfect procedural justice. Here there is an 
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tnClepemlerlt criterion for the out,::ome, but there is no procedure that will lead to 
this outcome. For example, in the case of criminal trials, it might be agreed that the fair outcome 
is that those who are guilty are found and vice versa for those who are irmocent. 
problem is that the criminal justice is an carmot this 
outcome. contrast, in pure procedural justice there is no independent criterion for the right 
result (Daniels 2004). In the of this thesis, this means that reasonable will 
on which of the social choice rules should be used to guide distributions. 
4.2.1. Fair process 
Daniels (2004) argues that fair process allows legitimacy in selection when there is 
no clear about substantive principles that determine fair distributions. For eX~lmJ)le, 
some might argue that personal responsibility for HIV-status should limit claims on the good 
whilst others would argue that the social context ofHIV-infection implies an additional duty to 
provide and care for the poor. Some might a health social 
choice rule while others would be in favour of a decent minimum. 
While these "'OTltr{l,VP.1'<:1.1 might not be irresolvable, Daniels (2004) argues that 
"O'T""Plnplnt that could be solved through fair process. 
pose an area 
of substantial 
The central requirements of fair process are: 
.. Publicity: the process must be transparent and involve publicly available rationales for 
the priorities that are set This has the added benefit of encouraging governance. 
.. Relevance: who are by the decisions agree that rest on 
reasons, principles and evidence that they view as relevant to fair decisions about 
priorities. This has the added benefit of ensuring stakeholders that their voice has been 
heard. 
.. Revisability and "'P~""'""'" decisions can be """","tpl1 and revised in light of new evidence 
and This process protection to those who have leg.ititna1te 
reasons for an exception to adopted policies. 
.. Enforcement or 
conditions are met. 
a mechanism is in to ensure that the previous three 
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4.2.2. Communitarian claims 
An alternative approach to procedural justice, called communitarian claims, has been proposed by 
Mooney and (Mooney and Jan 1997; Mooney 1998; Mooney, Jan et al. 2002; M(Jiom~y 
2005). This rests in communitarianism which importance on the value of community and 
social relations. The aim is to create a good society with a balance between individual and 
It is also that individualistic notions of self discount the role that 
community plays in forming and " .... O' .... u.Hul;l; individuallaemll~les - traditional individualism with 
its rhetoric of personal liberty and rights tends to impede compromise, mutual understanding and 
the discovery of common ground. Although communitarians are of the individual, they 
are the on individuals and individual (Black and Mooney 
1:iU(~halflan(1989) argues that communitarians that a community is 
more than just an association of individuals. Members of a community have common ends, and 
these ends are conceived of and valued as common ends. "Each member thinks the 
cOlrnnmDlity's ends as a for us, not as a gain for happens to be accompanied by 
similar gains for other individuals constituting the group" (p. 857). 
""",,,,y,,,.... under this approach, claims are not just the claims of the community, but are 
communitarian claims, suggesting that there is an intrinsic value in community and that a duty is 
owed by the community to an individual by virtue of her being a member of that community. In 
addition, there is value to the community in over the process of criteria 
(Mooney 2005). approach also emphasises that the way in which distributions of the 
between mv -positive people is achieved might have an impact on the extent to which South 
Africa moves towards greater or lesser social solidarity. 
In order to opt~rattonalt!,e communitarian claims MCK)n~~y Joo et at. (2002) recommend dividing 
the population into groups which could determine the of claims. For "social 
.... A.',."'ll". health to benefit ... may be seen as forming bases for differential 
claims" (p. 1660). The second task is to establish the relative weights attributable to these ~''''''HJ. 
The establishment of the claims and also the differential weights would be done by the 
community. However, Mooney does not suggest that the community should replace the poHcy-
maker in considering the benefits and the costs of different technologies, but that the community 
should be consulted about the principles on which policy-makers should act. In other words, the 
community sets the value basis for in the health sector (Mooney 2005). 
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",,,,,·UP .. In".uU\OY (1998) concedes that the hOltnogelle11ty of the ""i',.p.h, and extent 
solidarity would be important in ensuring that claims are recognised. "An atomistic, 
individualistic society will be slow to recognise that the community does have a duty with res[)ect 
The more embedded individuals are in a community and the "r"!.t,,r 
embeddedness, the will be the strength of the communitarlan in 
that community" (p.1176). Although Mooney recognises that communitarianism is only good if 
the community on which it is based is good, he argues that the prospect for a good community 
seems when individuals are embedded in the ""llllUUHI.Y 
5. Summary 
The ultimate aim chapter has been to propose a framework for decision-making around 
allocations of health and health care to HIV-positive adults in South Africa. This thesis is 
therefore located within the field of distributive justice, where "principles of distributive justice 
are normative designed to allocate goods in limited supply relative to dernarld" 
(Lamont 2003). Distributive justice is a broad field, but of particular relevance in this thesis is 
consequentialism and procedural In consequentiaUsm, normative only deJ)en:d 
on consequences (Sinnott-Armstrong 2003). By contrast, focuses on the 
ULU"'''"., of the through which distribution is "'".,,""""'" 1971 ). 
In constructing this framework, three questions were posed. The first question what is the good 
- was partly about defining the outcomes of health care and about defining the 
space of distributive justice as applied to mv -treatment in South Africa. The good of health care 
was to be health, which was defined as an absence of illness from the point of view of the 
individuaL Placing in the evaluative space was defended because health is a fundamental 
constituent of capabilities - without good health a person is severely constrained in leading a life 
that she or he might have reason to value. 
Having defined health as the the next step is to a way health that is an 
accurate reflection of this definition, is able to some of the variables to the 
\.Iu~,,,,.n'H and is Given the multidimensional and culturally nature of 
health, even if defined from the point of view of the individual, it is obvious that there is 
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not a perfect match between the QAL Y and health. !-In'",p'"pr the use of the QAL Y is 
nevertheless defended in this thesis. Firstly, there is no comparison between 
HIV and other diseases, the interpersonal comparability assumptions are less restrictive than if the 
QAL Y were to be used to assess allocative across and interventions. 
Secondly, the QAL Y is preferred to a unidimensional outcome such as the life year because there 
is evidence to suggest that different HIV -treatment interventions can have an impact both in terms 
and quality of life. therefore capture more of the variables that are relevant to 
the policy than life years. 
The second section in this chapter C011si<ierc;:d a number of characteristics that could be used as the 
for constructing claims on the These included the personal characteristics of HI V -
nO"lTnlP people, the need for health care, and the impact ofHlV -treatment on the health of society 
and the social fabric. 
The third section examined a number of consequential social choice rules that could assist in 
distributive decisions. The three social choice rules were health maximisation, equal health and 
the decent minimum. While is not a list of all these been 
because they reflect a broad spectrum of the possible approaches that can be taken to distribution. 
In the literature, health maximisatio!!, is generally associated with allocative efficiency and 
pu., .. ",,", .. implementation normally involves a threshold leER or QAL Y table "'nr'rn,~{'h 
Neither <>n' ..... ,...<1"I ... "'" will be pursued their As an 
alternative, technical efficiency will be assessed as a health maximisation problem 
operationalised through programming across a number of different HIV -treatment 
The second social choice rule that was discussed and 
consequences associated with this approach in HIV-treatment will be ll;Ssessed 
final consequentialist rule decent minimu!,!! - proposes an 
'"'U""'''U''J trade-off where all in need receive HIV-treatment, but some receive 
less this will be assessed through programming as 
detailed in Equation 3. t r -It "'I ) 
While linear or programming is a useful approach to the costs and consequences 
forms ofHIV-treatment, an ultimate decision about which approach to be 
adopted is a que:sticm some people will health maximisation while others will 
insist on an opportunity for health for everyone in need. there is likely to be 
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Finally, because this thesis acknowledges that reasonable people will ....,0'0.;<,1",,, about the relevance 
of using one social choice rule over another, 8 on the Implememu'l.ti()fl 
of a fair process in HN -treatment 
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Chapter 4: Methodology 
1 Introduction 
This Ch~lPt(~r reviews relevant mf)th'xt()lOI~lcalliterature and describes methods for calculating the 
costs and outcomes of three mutually exclusive mv -treatment interventions: the treatment and 
prophylaxis of opportunistic infections and events (hereafter No-ART), the treatment and 
prophy laxis oPlporturlistic ulte1:tums and events with first-line antiretroviral 
ART) and the treatment and prophylaxis of opportunistic infections and events with first 
and second-line ARVs (hereafter first and second-line ART). Methods for establishing these costs 
and outcomes are described at the and at the population-level. In the costs 
and outcomes refer to those calculated over the while in the these 
are the fun costs and outcomes of scaling up each intervention to a defined population in need 
over a given planning period. The building blocks in these calculations include the utilisation of 
mv -related their associated full economic unit death, loss to fol1ow-up, treatment 
and health-related quality data. Because ARTis a long term intervention 
which final outcomes are unavailable from primary data, methods for extrapolating these building 
blocks, validating modelled results and for assessing uncertainty have been reviewed and 
developed. 
The building blocks in this analysis (utilisation of unit costs, health-related quality of 
and clinical outcomes) have been estimated in a cohort of patients enrolled in public sector 
HIV treatment pilots. The results from this setting will allow the calculation of a base case 
scenario. However, because these might not be generalizable to other settings, a generalized 
scenario will also be constructed by comparing the from the base case scenario to those in 
the empirical i+""..".'h, .. ", Where differences are found between Jusltme:nts will be made to 
unit costs, utilisation and outcomes. 
19 Death or survival, loss to and treatment failure will collectively be called clinical outcomes 
data to distinguish these from final health outcomes such as and life years. 
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2. Methodology for patient-level analyses 
2.1. Study population and setting 
Patients included in this study live in an area known as Khayelitsha which is located on the 
outskirts of Cape Town in the Western Cape Province of South Africa. Many live in 
made wood, cardboard and tin in unsanitary environments with access to toilet 
facilities, tapped water or electricity. The level of unemployment in the area is approximately 46 
per cent 2002). In 2000, three mv clinics were opened within Michael 
M,IJ)Ong;'wWla and Site B health centres in the area known as 
These clinics provided treatment and prophylaxis for HIV -related and opportunistic infections 
and events, counselling and support groups for HIV-positive people. Prophylactic agents included 
trimethoprim-sulphamethoxazole and influenza vaccines for all patients and fluconazole for 
patlents with cryptococcal Acute infections were at the clinics but 
severely ill patients were referred to secondary and tertiary hospitals. Patients suspected of having 
TB were referred to TB facilities. 
In May 2001, the service was extended to include ART for patients with CD41ess than 200 
cells/~I at any WHO or with WHO stage IV any CD4 leveL ART patients continued to 
receive treatment and prophylaxis for acute infections and appropriate referrals. Details 
clinical outcomes in this cohort are available from published sources (perspectives and Practice in 
rp,tnf'lvir'l'll Treatment 2003; Hildebrand et at. 2004; Louis et at 2004). 
This site was chosen for this research as it was the first public-sector based ART treatment pilot 
in South Africa and from this has informed the development of national ART 
gUlldellme:s. It access to the long-term prospective of a number of patients 
in a poor setting with a community mv that is high relative to other areas in the 
Western Cape. 
While utilisation, clinical outcomes and HRQoL data were prospectively measured on the 
cohort, in order to calculate costs that were widely cost data 
were combined with appropriate secondary data, either from or grey literature. For 
ART was undertaken at the three CHCs and the TC Newman 
district hospitaL The costs of No-ART services were also calculated in these LU .... ' .. "''''." and 
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additional was undertaken at ;ro!.sr()aas, 'U' .... J;, ... ,"'.,I.& and Browns Farm Wellington, 
Mbekweni and Phola Park clinics and the GF Jooste outpatient department (OPD). No-ART visit 
costs were also derived from secondary cost analyses undertaken in Guguletu CHC, Guguletu and 
Nomzamo clinics and Groote Schuur OPD McIntyre et at. 2000). For TB .. "'.'nn • ...,".., 
primary cos:tmg was undertal<en at and was supplemented with sec:ondruy 
data from Sinanovic, Floyd et al (2003). Nyanga TB clinic was chosen because its patients have 
the burden oflIlV -related tuberculosis in the health districeo (Soraya 
ElIoker, District Manager, communication). For level care, primary 
inpatient costing was undertaken at Tygerberg Academic Hospital and was supplemented with 
from Groote Schuur Hospital McIntyre et al. 2000). The cost of 
sec:onaaryICUstnct level care at GF Jooste and was 
derived from Haile (2000) and Smith De Scherif, Schoeman et al. (2005). Because of the 
additional lIlV -related burden of disease placed on the medicine wards at GF Jooste, the 
was in 2003. This additional care for medicine 
,",""'"'''''''' (many of whom are HN -positive) at a lower clinical """"U"'F. mten:slty 
Table 1 contains the fun list of facilities included in cost analyses, type of service, the source of 
or HlV-prevalence (according to the 2003 Western Cape antenatal 
clinic survey) and the area where the facility is located. 
20 Sixty-seven per cent ofNyanga TB patients are HIV-positive. 
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Table 1: Settings for calculation of unit costs ofBIV-related services 
Type of facility 
:CHllies 
Phola Pari< Cfinic 
Mbekweni Clinic 
Nomzamo Clinic 
CHCs 
Step-down facili 
Sources: 
§Govender, McIntyre et at (2000) 
*Sinanovic, Floyd et at (2000; 2003) 
± Haile (2000) 
of service (and data source) 
TB (*) 
Primary care (§) and TB (0) 
Primary care (primary data) 
t Smith De Scherif, Schoeman et aL (2005) 
Scope of costs 
Area 
11.6 Ca e Town central 
28.1 GuguletuINyanga 
10.1 Paar! 
10.1 Paar! 
10.1 Paar! 
9.3 South Peninsula 
28.1 
28.1 
28.1 
Western 
Costing takes a public health sector perspective in the context of scaling up a new health 
care programme over the long-run . ...,'"""..,,'" up this programme requires medlcmes, laboratory 
mv'esltlglitlC)llS and other variable resources as wen as l(\n:(}>_,'II" investments aimed at increasinll! 
the capacity health care in to provide care at the en'\II"'::Hn~ quantity while at 
the same time avoiding the crowding out of other priorities, The scope therefore includes 
both variable and fixed costs given that both have an opportunity cost in this context, Variable 
costs are defined as the value of goods, services and inputs that change as an intervention is 
implemented, for example medicines, imaging and laboratory investigations. It also makes sense 
to think of certain costs as semi-variable. While these do vary with the level of activity, this 
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happens in a non-continuous manner. An example is a salaried doctor on a short-term contract. 
While this doctor might be able to see up to thirty patients per day, he or she would still earn the 
same if the load were over the duration or her contract. HI1'Wf~ver_ 
on a short-term contract, the doctor can be reallocated to a with a higher 
patient load. On the other hand, a doctor on a long-term contract linked to a particular health 
facility could be as a fixed cost. Fixed costs are resources that are held at a constant 
independent level of production, such as equipment and buildings) 
and overheads (administration, security, cleaning and utilities) (Clewer and Perkins 1998). These 
are variable in the long-run. 
Costs are as total average costs and marginal costs of which are a function 
of the level of output. The total cost is the sum of the total fixed cost and the total variable cost. 
total cost, also known as the unit is obtained by dividing total cost by total output; 
it is also to between average variable cost and average fixed cost. At any 
level of output, cost is the increase in total cost that results from an increase in one unit 
of output. It relates to the rate of increase of the total cost curve if total cost is increasing rapidly 
(df:cn:~asilng returns to scale), marginal cost is high; if total cost is gradually 
returns to marginal cost is low; increase in total cost is constant unit 
output (constant returns to scale), marginal cost is also constant. definition, cost 
intersects the average total cost curve at its lowest point; if there were constant returns to 
U'--b'''-' and average costs would be across the entire schedule. In the short-run, the fixed 
cost does not vary with the level of production so the value of the cost curve is not 
affected by in the fixed cost. This in the when all costs are variable 
and Perkins 1998; Rice 2003). 
The marginal cost is the appropriate cost statistic to use in economic evaluation (Jacobs and 
Baladi 1996). However in practice it is difficult to estimate the marginal cost, with the 
implication that analysts assume that the average cost is a suitable proxy for the marginal cost. If 
the takes a short-run the average variable cost would be but taking a 
run pelrsplec1iive (as is the case in this /1"''''''T1";;,t,.nn means that the average total cost 
is taken as the proxy for ml'l-rp1Tll'l costs. This ....,~'w ... I'''.~u is only valid if the level of production 
coincides with the lowest point on the marginal cost curve or if there are constant returns to scale. 
While the marginal cost is the correct cost statistic to use, in the long run it is possible that the 
average total cost might be similar to the marginal cost. 
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Table 2 details categ()m:s of costs to be included in this evaluation. t'atlent-SJ)eCiIlC costs are 
those that are consumed by the patient, such as Ul,",Ul\#I11,",", laboratory estlgatlons and Imatgmg. 
Clinical staff costs relate to the time spent by medical officers and professional nurses providing 
illV -treatment. Overhead costs are costs that are shared by more than one programme, such as 
clinic administration, services and utilities such as 
P'1P"'Tr"~lTV and water. Capital costs include the equipment, vehicles and buildings that 
are required to increase access to HIV -treatment. Costs under the category of other related r' 
resources include support groups, direct observation ofTB treatment and nutrition. 
While these resources have a clear opportunity can this opportunity cost be related to health 
outcomes? While generally under the remit of social services, the opportunity cost of these 
resources can be related to health outcomes because these services are believed to contribute to 
patient retention and both of which are directly to the final health outcomes of 
the HIV -treatment programme. 
Table 2: Scope of costs to be included in the analyses 
Health care resources 
Patielnt-!:;DE~ciflC costs ",,,,,,nlr"""'''' including antiretrovirals, laboratory investigations, 
imaging) 
Clinical staff (medical officers and professional nurses) 
Overheads (non-clinical staff, running costs) 
Capital (equipment, furniture, vehicles, buildings) 
Other related resources 
Counselling and support groups 
observation of TB treatment 
Nutritional support 
The costs u"' ... u ..... u in Table 2 are normally referred to as direct which can be defined as "the 
value of all the goods, and other resources that are consumed in the provision of an 
intervention or in with the side effects or other current and future l'n,,,,p,nn~·n ... , .. "U 
Marming et al. 1996 p. 179). However, this is an inconclusive list. Direct costs also include the 
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inputs to care incurred patients and their families such as the transport costs associated with 
seeking care and the time associated with infonnal care that is provided by friends or family 
members. Although these resources have an opportunity the foregone benefit is much wider 
than health outcomes, therefore their opportunity cost cannot be to the outcome used in 
this thesis (Mooney and Jan 1997). Indirect costs - the secondary costs relating to paid and 
unpaid ..... "'rI"'''tnrt> activities (Donaldson 1990) - would also be excluded for reasons. 
These arise because of reduced productive activities while a patient is seeking treatment or is 
convalescing in hospital or at home. 
2.3. Health care utilisation 
The health care services associated with HIV -treatment have been catlel!olris~:d into inpl8bent care, 
TB treatment and clinic visits. Data on the utilisation services have been collected as part 
of the Khayelitsha HlV treatment pilot using a before and after study design to calculate 
utilisation in the ART and No-ART groups. This means that ART patients were as their own 
control the was to calculate No-ART utilisation and the POlst-t)aslellIle 
period was used to calculate ART utilisation. While a clinical trial comparing No-ART to ART 
would be the gold standard for measuring utilisation, obvious ethical limitations imply that the 
before and study is the only possible choice in this context. In a setting where access 
to ART is optimal, the before-and-after study could result in a Sel'eCljlOn 
patients with advanced disease who have not accessed ART do not adequately represent 
patients wbo never access ART. The delay between the launch of the service and the availability 
of ART witb the unmet demand for ART in this study ensured however that the 
was of patients who did not access ART at alL The is 
costs associated with death due to the survivor bias inherent in the No-ART do 
not die because in reality they are pre-ART patients. These costs will be addressed by the 
inclusion ot1trarlsltlon costs associated with death 
Utilisation of ART and No-ART clinic visits was established from 1,729 patients with 1,146 No-
ART patient years and 2,229 ART patient years of follow-up over a median No-ART and ART 
follow-up of 0.63 years (IQR max 4.35) and 1.03 years (IQR 0.68 1.70, max 4.08). 
While data on for inpatient and tuberculosis care were collected as part of the 
Khayelitsha pilot, this required validation. Although the collect data on patients referred 
for TB treatment or inpatient care, this data required substantial validation to ensure that events 
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were recorded. This validation was perfonned on a of 670 patients, with 50 I 
patient-years for No-ART (1,342 inpatient days and 159 TB episodes) and 693 patient-years for 
ART patients (with 840 days in hospital and 86 TB episodes). These data on inpatient utilisation 
excluded who had died. Instead, the utilisation services in the period to 
death was included by a "cost from a of 83 who 
had been using services in the mv clinics but had died before being able to start ART. These 
patients were followed up at hospitals to establish their utilisation of inpatient care in the 6-month 
death. The same was followed for the 81 ART who died. For 
ART this is a useful approach to ensure that costs around are not ere:stmlatl:ld when data 
are extrapolated. Further details are provided in section 2.5 on Markov modelling. 
2.4. Unit costs 
Unit costs of health services are defined as the (long run) average total cost per ART or No-ART 
visit, per inpatient day at and secondary/district facilities and per tuberculosis case 
treated. Unit costs were calculated the ingredients approach and the method in 
combination and Parker 1994; Brouwer, Rutten et al. 2001). Each methodology will be 
discussed in separate below. All costs were inflated to 2003 - the 
midpoint of the April 2003 - March 2004 financial year that is used in most public facilities. The 
consumer index excluding mortgage bonds was used to inflate recurrent costs and 
equipment capital costs. The Bureau of Economic Research Building Price Index was used to 
inflate building capital costs. Where necessary, doctor costs were increased to reflect the recent 
government scarce skills allowance of 15 per cent. These costs were converted to US$ an 
average 2003 rate Rands) Federal Reserve Board, 2005). 
2.4.1. Patient-specific costs and the ingredients method 
The ingredients approach, also called micro-costing (Luce, Manning et aL 1996), involves 
the resources concerned in a service - such as U'''''''''''''U''''''', 
laboratory "'''''''6''''"'''''''' and These are measured from actual utilisation of these 
resources by a SaInDlle of patients. These costs were estimated by ~'''-'''U''e. 
data on physical units resources quantities of different types 
laboratory investigations, imaging and Drc)cedm 
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At the three HIV clinics, ARV nrt::scIintions. nrnr,nvl" medicine n .. "·""_ •. "'.'r"t ... '£.'.'1_ (fluconazole 
~dmrn~l~opnml-rulphwml~ruoxazOI,e) are recorded in a database. 
I'rf'"",rin1t'nl~<l for curative medicines ~d multivitamins were extracted from the records of 60 
patients who had been on ART for at least one . This amounted to a swmple of757 visits for 
No~ART patients ~d visits for ART n"t'pnt" The ~d and 
monitoring laboratory tnvest!gaOotlS was based on nation:lI1 protocols in order to increase the 
generalizability of results. 
While the three Khayelitsha HIV clinics also provide care those who are not yet on 
most in South Africa would access wmbulatory No~ART care within general primary care 
services. A number of additional cost ~alyses at Wellington, Phola Park ~d Mbekweni clinics, 
Guguletu, and Browns Farm and TC Newman ~d Jooste OPDs were 
therefore undertaken. Because patients had not informed consent to be mc:lU(le<1 in a 
research project, ethical meant that record reviews were not possible. medical 
officers were hired to work in each facility ~d provide services to patients. At the end of each 
clinical consultation, the medical officer recorded pal:terlt-s:peClIiIC resources and the HIV -status of 
the patient. This was an ethically acceptable method because it kept of a patient's 
HIV ~status within the clinical relationship. Of the 810 patients treated medical officers across 
facilities, 121 (I5 per cent) had a confumed HIV-positive diagnosis and were included in the 
calculation of costs. 
The costs ofHIV-related TB care were established at the Nv<>"e,,, In this 
facility, the medical officer treated 47 patients, of whom 25 had an HIV-positive diagnosis. 
Utilisation of non-TB drugs and multivitamins was based on these 25 HIV -positive patients. 
Estimates of other patient-specific resources (TB drugs, X -rays, diagnostic tests) were based on 
South Afric~ national TB treatment (The South African Tuberculosis Control 
I'r..,,,,,,,,nnrnp· Practical Guidelines 2000) ~d were compared to a published TB cost 
S.n"nrm.(' Floyd et al. 2003). While the swmple size to calculate the cost ofnon-TB 
aIs:pelnse:a to HIV -positive patients was small, the overall of any over or underestimation 
of these costs is to be as they are a proportion costs. 
21 In South patient record reviews are only allowed if patients have given infonned consent to be 
included in research All in the pilot had provided such consent, enabling us 
to undertake this review. 
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At the tertiary hospital, clinical staff filled out resource-utilisation fonns for every mY-positive 
and HIV -suspected in the surgery, obstetrics, and """""""';::':1 
... n"" ..... ..,,,,, p:atle:nts with 243 inpatient were included in the analysis. A 
sec:ondary cost arJalysis from Groote Schuur tertiary hospital was also used (Govender, McIntyre 
et at 2000). 
At Jooste and secondary cost data were derived from the masters 
dissertation student in the Health Economics Unit (Haile 2000) and additional data were 
collected through a research collaboration (Smith De Scherif, Schoeman et 2005). there 
has been no vU,,,,,,;,,, in g01{entlm,ent policy with "P~'nP,,,t to the treatment of opportunistic and mv-
related uu,_"' .. ~ .. " at hospitals since 2000, the ofmV at Jooste has grown COflsidlerably 
over the last five years, implying that clinical practice might have changed because of resource 
constraints. """."", ... this might not be the case in other set1tmi~s so both sources of data on costs 
at Jooste have been included. 
South African "National Antiretroviral Treatment Guidelines" (Department of Health 2004) 
specify that on first-line ART receive a nucleoside reverse inhibitor 
backbone of stavudine and lamivudine in combination with a non-nucleoside reverse 
inhibitor (NNRTI), which can be either emvirenz or nevi rapine. The second-line regimen consists 
of an NR TI backbone of zidovudine and didanosine, in combination with lopinavir/ritonavir, a 
protease inhibitor. Prior to the publication ofthe national treatment guidelines, the first-line NRTI 
backbone in Khayelitsha consisted of lamivudine and 7,rlinvnrli,np but this was to be in 
line with national in 2004. To increase the the costs of the 
nationally recommended reg;lmens have been assumed. 
The opportunity cost of patient-specific resources was assumed to be equivalent to market values. 
The following market values have been used: 
• Medicine costs from provincial government tender 
• test costs from National Health Laboratory Services (NHLS) public sector 
The NHLS is the only provider of laboratory services to the public health 
• Imaging and procedure costs from the Unifonn Patient Fee Schedule - UPFS (2005) - a 
schedule used in public sector hospitals to detennine payments by private patients. The 
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....... "",,,<> UPFS scale was used because other are sul:1sidiseld, whereas the 
on costs. 
"ARV were obtained the the tender process, 
and are inclusive of VAT and delivery costs to the various provincial depots (Gray 2005). 
Mean patlent-slPecmc unit costs were calculated by multiplying nt"_"",,,,1 units of resources 
consumed with their market values. 
2.4.2. Overhead and capital costs using the step-down method 
Unit costs include resources that cannot be directly linked to patient utilisation. These "overhead 
costs" include utilities (water, non-cHnical and security 
personnel) and non-patient specific stores and livestock. The costs of pharmacists were also 
included under overhead costs. Capital costs, on the other hand, are defined to include the costs of 
medical equipment, and initial staff training. 
An overhead cost per visit in primary care clinics, CHCs and the HIV clinics was calculated using 
the method (Conteh and Walker 2004). Under the assumption that all a 
similar amount of overheads during each visit, the step-down method specifies that an overhead 
cost per visit would be calculated by establishing overhead expenditure from routine data over a 
period of time. This would be divided the total number of patient visits to the facility 
the same time frame. An period was chosen to any biases that from 
seasonal variations in visits and expenditure in facilities. The calculation is as 
Overhead cost per visit annual overhead expenditure/annual visits 
The methodology of calculating overhead costs for inpatients and hospital oU1tpatlellt n,f'n>'l,rlnlpnt.:: 
is similar. Because the hospitals in data collection did not have cost-centre accounting 
eve1"E>n", overhead was allocated to and an 
allocation factor based on the 
and Walker 2004). 
day (Barnum and Kutzin 1993; vUIH"ll 
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The PDE is calculated as foUows: 
PDEinp!l!ienis = (annual days) + outpatient x weigtltin.g 
PDEolltpatients (annual inpatient days x lIweighting + (annual outpatient visits) 
The factor was calculated as the average ratio of the cost per outpatient visit to the cost 
per day in the medicine and surgery departments at Groote Schuur hospital from April 
2002 to January 2003 where a cost-centre accounting system allows this calculation to be made. 
This calculation estimated that an outpatient visit cost approximately 0.265 times an inpatient 
The standard assumption in South is that an costs VLn,-UJLU 
inpatient day when there has been no attempt to calculate resources seJ)anltely 
which are normally higher per outpatient visit than per inpatient day. The use of 0.265 instead of 
0.33 is justified here because patient-specific resources have been calculated sef,anltely and this 
ratio is therefore only 
departments. 
used to allocate overhead costs between int::1ati1ent and ou1tpa1tlellt 
Th",,,,,.fn,·,,, in order to overhead costs between In}JlaUent and outpatient the 
following PDE was calculated: 
(annual inpatient days) + (annual outpatient x 0.265) 
(annual inpatient x 3.77) + (annual outpatient visits) 
This allowed the calculation of the overhead cost per inpatient day and outpatient visit as follows: 
Overhead cost per inpatient day = annual overhead eXIJen:OIture / 
Overhead cost per oultpatiellt overhead eXJ)endiullrel PDEoutpatients 
....... ap" .... costs are calculated cre:atlI1lg a list of aU establishing the rep,lacement 
value of each item, estimating the approximate working life of the item, and annuitizing a 
real interest rate to arrive at an annual cost (Walker and Kumaranayake 2002). This cost was 
allocated to inpatient days or clinic visits the step-down method. In South Africa, a real 
interest rate of 8 per cent is often which is the return on long teml o£",pn~m,;>nt bonds, in 
line with recommendations in the literature (Drummond and Jefferson 1996). This to 
"QJ."u,a"u~ capital costs is a feasible (although time consuming) approach for clinics but less so 
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hospitals. For this reason, many cost have not included costs in 
South Africa (Karstaedt, Lee et al. 1996; Govender, McIntyre et al. 2000). However, a relatively 
sophisticated capital _~~, .... ,., model has been developed by the nationaillf>n<lT1'rri,P ... t of Health 
(NDoH) to assist in for the of hospital facilities (Rod personal 
communication). This model calculates capital costs based on the foilowing inputs and 
assumptions: 
area per bed [I] 
Total number of beds [2] 
Total area of beds [IJ x 
Building cost per meter on quantity surveyor's estimates, to the 2004 
level, using the Bureau of Economic Research Building Cost Index, and including a mark-up for 
building fees) 
Equipment cost estimated at 30 """.,...,."t of the building cost for regIonal h/",n,t<l 
This model has been used to calculate capital costs in hospitals. However, it should be borne in 
mind that the equipment cost of 30 percent of building cost is a crude assum,pti<Dn. Recent work 
undertaken by staff at the Health Economics Unit that the costs in four 
district hospitals in Limpopo, KwaZulu-Natal and Mpumulanga varied between 10 per cent and 
41 per cent. Nevertheless this is unlikely to have 1"''''',nT'''' influenced the final restllts; as will 
be demonstrated capital costs account for a very small n"'T·I' .. ~,t"'~",· of the total costs of care. 
2.4.3. Counselling staff costs 
At the three Khayelitsha clinics and the TC Newman OPD, collllselliors are employed to assist 
with patient counselling and education about HIV and ART. These counsellors are managed by 
Non Governmental Organisations (NGOs) under contract to the provincial government. The full 
costs of counselling from the point of view of the provincial government included the 
counsellor's salaries and the ""T,nnn and administration costs incurred by the NGOs. In 
'nt,,,rv • .,.u",, with the coordinator revealed that counsellors spent 
approximately 50 per cent of their time cOlms,eHlng. The remainder was spent or 
.. ,,"" .... "6 between Xhosa and and dividing bulk-bought medicines 
visit dosages. Of the time, 80 per cent was spent with ART clients and the remainder 
with non-ART clients. The result was that 50 per cent ofthe fun counseUing cost was spread 
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equally across patient visits and that of the remaining cost, 80 per cent was across ART 
and 20 per cent across No-ART visits routine headcounts. At TC Newman, the 
COIJnSeHlmg costs were allocated directly to ART visits because this 
manage No-ART patients. 
2.4.4. CUnical staff costs 
does not routinely 
A final cost item of importance is the cost of clinical staff time. While the overall cost of clinical 
staffmay not be a cost (small in magnitude when to ARV costs) clinical 
o;,t<&ifT "]I-.£\ .. t<>O',,,,, are to be a constraint in equal access to HIV -related care for 
aU patients who are in need. At the HIV clinics, researchers used stopwatches to time clinical 
consultations for 54 ART visits and 94 No-ART and interviewed staff about their average 
wortarul hours. At all other OPDs and the TB the research doctor 
rec4[)r<1(~<1 the length of 147 clinical \AJII"U''''UIUU". 
This estimate of the time per clinical consultation was multiplied by the average clinical staff cost 
per minute in each to reflect hours annual days) to 
calculate the clinical staff cost per visit. 
The clinical staff cost per minute was based on the following inputs: 
• Data on employed clinical staff who are involved in n1't'l,vit1lnlY treatment to p""''''''''' in 
medical and pr(lte~isioinaI 
• Annual cost of employment (CoE) in 2003/04 for each cadre including pensions and 
other benefits and the recent policy medical officer scarce skills allowance (an 
additional 15 per cent on top of existing salary scales) 
An average annual CoE in different clinical categ()ric;:s was then calculated as follows: 
annual CoE \enr:lDl'OVf:(l staff of different cadres * relevant / number of clinical 
staff 
From this annual cost, a cost per minute was calculated. There are 220.25 working days per 
annum (on average, there are 365.2 days per year, 104 days fall on 22 days are annual 
67 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
holidays, 11 days are public holidays and it was assumed that there would be 8 of sick 
In during an 8-hour working only part of the day would spent seeing 
patients and the remainder would include various administrative and management tasks. If one is 
vi:1l'vU!"1LUj~ clinical by timing one to include a share 
administrative costs in cost per minute calculation. Interviews with clinic managers and 
medical officers indicated that clinical personnel spend approximately 6 out of 8 hours seeing 
.., .... , ... ,,'.., each Based on these inputs, the clinical staff cost per minute was calculated as 
follows: 
Clinical per minute annual CoE 1220.25/6 hours 160 minutes 
At the inpatient it was more difficult to calculate an mv -specific clinical staff cost owing 
to restrictions on researcher access to hospital wards. Therefore many HN -related inpatient cost 
have the method Lee et aI. 1996; 
Govender, et aJ. 2000; 2000; Chapman et al. 2000; Arthur et 
al. 2002). Clinical staff costs were estimated at Jooste and Carnation by establishing the number 
of full time doctors and nurses in each relevant ward and their average cost of 
employment. The resultant cost was split equally between in these wards. At 
Tygerberg, the annual expenditure on medical officers was established and allocated to inlltatilent 
days the PDE method. 
2.4.5. Measuring and valuing health related quality of life 
HRQoL is a multiclimensional cc)noept, 'nl'l11/1", many rliff"" ..... ntasplects of health such as 
functional status, physical and emotional status. It is argued that HRQoL should be 
included in an economic evaluation if it is conceptually relevant to the choice being made - in 
other words, HRQoL might be important if it differs between two alternative treatments (Dowie 
2002). In a related study ofHRQoL on a subset of patients from the Khayelitsha cohort, lelsma et 
at (2005) conclude that "HRQoL can be greatly improved by HAART [Highly Active 
Antiretroviral Therapy], and that the POSiSIDle side effects ofthe drugs seem to have a 
impact on the wellbeing of the (p. 1). Their indicate that it is important to 
consider ....,,,,r ..... ,,,, .. ,,,,n,1',, in HRQoL as an outcome associated with ART. 
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In HRQol, it is to use a or a condition-specific instrument. A (tPtlPMIr. 
instrument intends to cover the full range of health a COIldt1tlOfl-sr>eClItiC 
instrument attempts to pick up the range of outcomes associated with a particular condition 
(Dowie 2002). A review of different HRQoL descriptive or measurement techniques indicates 
while there are a number u",'",,_,n instruments that have been developed to measure 
HRQoL, only a number of these can be used to calculate QAL Y s in an economic 
evaluation (Brazier and Fitzpatrick 2002). The most common are the Quality of Well-Being 
(QWB) scale, the Rosser Classification of illness the Health Utilities (HUHIor 
HUI-III) and the on in each instrument, the number 
offeasible health states would differ. The QWB has 1,170, the Rosser has 29, HUI-II has 24,000, 
HUI-III has 972,000 and the has 243. The the number of health states, the longer 
the instrument takes to complete, and the more difficult with 
health states, the descriptive validity of the instrument might be lower. For instance, the EQ-5D, 
which has 243 health is to be less sensitive to in HRQoL than other 
instruments and 2002). it has benefits in terms 
research because it takes much less time to administer than instruments with more health states. 
For this Sec;()ndary HRQoL data have been used MacLean et at 2005). data 
were collected the at treatment 3, 6 and 12 on ART 
from patients enrolled in the Khayelitsha progranlIDe 98 and 83 respectively). No-
ART HRQoL was assumed to be the same as baseline HRQoL in ART patients. The EQ-5D 
consists of questions across five domains: mobility, usual pain or discomfort 
and or Patients can "no , "some or "severe 
Or(lbU~m~r- in each domain. The also has a VAS section (Euro VAS), allowing to 
value their current health state. The 243 health states generated from answers on domains 
been valued in a number TIO and V AS surveys 
While the use 
same cohort 
data is justifiable that they were collected from a sub-sample of the 
patlent:s, controversies remain how to transform these HRQoL 
.... ,~uu~,,, into a cardinal measure state. There is no in the as to 
which is between SG or VAS methods. A further difficulty is that no local 
population valuation has been undertaken in South Africa. 
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Table 3 n .. ",,,,,,nt,, the mean scores from Khayelitsha 
.... ,,'-'VLJ data three different valuations: 
United trade-off (Dolan, et 1995), Harare time rralae-,on 
Hansen et aL 2002) and Khayelitsha patients' own valuations using the Euro VAS. In general, the 
UK value set and Khayelitsha EuroVAS lower valuations of health states than the Harare 
value set. .... "'m"" .... (llth:mmcles would not matter because one is primarily 
interested the change in quality oflife between No-ART and ART. Here there is a""'!~1" ..... 
':'Uf'",,,,tn,,,,,t with the UK ITO values and the Euro V AS values both a similar per'Cerlta~~e 
increase of 14 per cent and 15 per cent while the Harare ITO values show a increase 
of 8 per cent. 
The fInal column in the table shows SF36 HRQoL from two Cape Town (O'Keefe 
and Wood 1996; Badri et at 2005) which have converted to values a United 
Kingdom standard gamble value set (Brazier, Roberts et at 2002). These results show the ar .. ,:,t",·ct 
per'ceIlta~~e increase from No-ART to ART out of presented data. 
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Table 3: Comparison ofHRQoL values 
Groote Schuur I 
Surwy setting Khayelitsha Khayelitsha Khayelitsha Guguletu 
Surwy instrument EO-50 EO-50 EuroVAS SF36 
lTO, Dolan et al lTO, Jelsma et al SG, Brazier et al 
Surwy valuation 1995 2002 Patients 2002 
Health states: 
ART 0-3 months 0.71 0.77 0.62 
ART 3-6 months 0.81 0.83 0.71 0.81 
ART 6-12 months 0.82 0.84 0.74 
ART >12 months 0.85 0.86 0.76 
No-ART 0.71 0.77 0.62 0.69 
Percentage increase: No-ART 
to 3-6 months on ART 14% 8% 15% 17% 
Sources: 
HRQoL measurement and EuroVAS: MacLean et al. (2005) 
Groote Schuur measurement SF36: O'Keefe and Wood (1996) 
Guguletu measurement using SF36: Pitt, Badri et al. (2005) 
TTO values: Dolan, Gudex et at (1995) 
TTO values: Jelsma, Hansen et al. (2002) 
SG values: Brazier, Roberts et at (2002) 
The second difficulty with HRQoL data is that no local valuation set is In this 
instance, the EuroQol group recommends the United tariff set which has 
derived from a general population survey (Dolan, Gudex et at 1995). This would imply assuming 
that people in different countries valued health states While this is unlikely to be the 
case, the important issue is ""n,F'Tn,'" it is acceptable to make this assumption. To illustrate 
potential Table 4 contains a comparison of the scores on 8 randomly selected 
health states that were valued using the TTO method in population samples in the United 
KiIlgdom and the United States and an urban from Zimbabwe. In the '-''V- .... '"'' 
health states correspond to five domains and three levels of domains. Thus a health state denoted 
12211 corresponds to "No problems walking about", "Some problems washing or dressing self', 
"Some problems with performing usual activities", "No pain or discomfort", and "Not anxious or 
rlpr\rp~:~p(1". This comparison shows that health state values were higher in the United States and 
Zimbabwe than in the United Kirlgd;om. 
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Table 4: Comparison of TTO valuations of 8 selected health states in the United Kingdom, 
United States of America and Zimbabwe 
Health state valuations !.Isin 
22121 
21232 
23321 
22331 
23232 
33333 
Sources: 
United 
Kingdom 
(UK) :t 
0.15 
-0.03 
-0.13 
-0.59 
United States of 
America (USA) 
± Dolan, Gudex et aI. (1995) 
t Shaw, Johnson et aL (2005) 
§ Hansen et al. (2002) 
Zimbabwe§ 
0.41 
0.31 
0.22 
-0.15 
Differences 
UK-
UK - USA Zimbabwe 
-0.03 
-0.06 
-0.06 
-0.36 
-0.23 -0.26 
-0.34 -0.34 
-0.33 -0.35 
-0.49 -0.44 
Some broad conclusions can be from this discussion: 
• While UK TIO valuations ofEQ5D bealth states were lower than the Harare and US 
values, these were most similar to the Khayelitsha EUROV AS values 
• The UK TIO values 
SF36 health states 
health states were similar to standard E>~uv"v values on 
One could from this that it would be appropriate to use either Euro VAS or UK TIO 
values. A further justification is that these were similar to SF36 data valued the standard 
E>a •. lIv., ... method. This is not to imply that the standard method is a standard, but 
rather that the use EUROV AS or UK TIO values on the EQ-5D health states seems 
that a tl;R~1"", .... t instrument a different valuation method (standard 
gamble) has produced highly comparable results. Primary data provide little guidance on whether 
it is more appropriate to use EUROVAS or UK TIO. The use of the latter will therefore be 
defended because nOll-Dawemvaluations is recommended for resource allocation decisions 
for (Torrance and 1989). 
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Markov modelling 
Because ART is a long-term for outcome data will be unavailable for 
the it is necessary to extrapolate from data to estimate Iife-
expectancy and costs. This extrapolation has been undertaken via Markov modelling, 
which is to modelling stochastic processes - random processes which evolve 
over time - is particularly appropriate to the of chronic diseases. A 
modelling approach also allows the synthesis of data from secondary sources and the 
extrapolation of primary data. A Markov model of a number of mutually and 
,p ... Tlv,,.lv exhaustive Markov states - each patient can only be in one state at a time (Kuntz and 
Weinstein 1997). At least one of these is an "absorbing state" from which no outgoing transitions 
are remain in each Markov state for an increment called a 
Markov cycle, before option to a state in the 
current state) as determined by a transition probability. States are distinguished from each other 
on the basis of different health characteristics (such as HRQoL) and different health care costs. 
While it seems to associate costs with a health these are kept separate in the 
calculation. For the costs with in an Markov state over a 
one-month period include health care resources required to treat this acute disease, while on the 
outcome one is assumed to accrue one month of life-expectancy which is by an 
appropriate HRQoL value. 
At the end of each Markov pat.",UL.:> move between states or in current state as 
determined by u..u", ... vu probabilities. As menw:me:Q Markov states are 
with different risks clinical events such as which are captured in the transition 
VI,-,vaVHHl~'i:>. Finally, when the model is run over a number long term costs and 
consequences of the disease under different interventions are calculated (Sonnenberg and Beck 
Briggs and Sculpher 1998). Sections 2.5.2 to 2.5.6 provide additional details about each 
element that is required to construct the Markov model. 
One sh()rt(~ornintg of a Markov model is that there is no memory -a 
patient's is at the end of each cycle, with the implication the probability of 
moving out of a state is independent of previous health states. This is known as the Markovian 
assumption. Because this is a limitation in certain circumstances, modellers make use of 
temporary tunnel so that cost adjustments can be made or t"'''nn' ... '''''' ... 
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different trrulSltIOn probabilities can be "'PIYU';;,U :sonlrlen and Beck 
1998). 
2.5.1. Markov cycle length 
There is no about the appropriate length for Markov models of HIV I AIDS in the 
literature - some use 1 month Scharf stein et al. 1998; Losina et al. 
Schackman, Goldie et at 2001; Richter, Hauber et aL 2002; Schackman, Freedberg et al. 2002; 
Badri, Cleary et al. 2006), some use 6 months (Sendi, Bucher et al. 1999) and others use 12 
months Sabin et aI. 2001 ; Henry et al. 2001). The methodological literature 
su~,ges:ts that the length needs to be appropriate for the of events in the disease or its 
life expectancy (Kuntz and Weinstein Shorter cycle lengths are required if events happen 
quickly for example in malaria, a patient can be infected, cured and re-infected within a one 
month which means that lengths would need to be shorter than this to these 
distinct health states and events in the model. On the other hand, in the time from 
initiating treatment to death can be many years. For this reason, a three-month cycle length has 
been chosen in this thesis because this is long enough to capture important changes in clinical 
outcomes (for "."'<lmnl". viral suppression). 
2.5.2. Markov states 
Markov mode1s for HIV/AIDS commonly base Markov states on three different "markers" of 
HIV disease progression: the CD4 count, HIV RNA level (Le. the number of copies of the virus 
in the body or viral load) and the WHO Stage (see Appendix A for details). Because CD4 cells 
are killed directly or indirectly by HIV, the number of these in the body is an important indicator 
of the progression oflllV. In addition, the CD4 cell count is used to qualify clinically for 
ART - in South Africa, are eligible for ART once their CD4 count is less than 200 
CD4 counts are also used to evaluate response to ART Satten et al. 1996). 
The viral load, on the other hand, is a more direct indicator ot1tre~ltment success - ifthe viral load 
is undetectable, the treatment is working, but if it becomes detectable above a certain limit, the 
patient is assUDrled to be "failing" treatment and could be switched to a different regimen. 
However, the viral load is only an indirect predictor of mortality; the CD4 is a better predictor of 
disease progression than viral load Chaisson et aI. 200 I). The WHO can also be 
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an important of mortality, in immune compromised patients. For a 
patient with CD4<50 and WHO Stage IV (Le. AIDS) would have a risk of death than a 
patient with the same CD4 level who has yet to AIDS. 
Published Markov models ofHIV/AIDS have used a wide combination of these markers and the 
of which to use is partly related to the modeUer's discretion and access to data, and partly 
related to the study question that is being examined. In of the of ART 
versus No-ART, it is fairly common to Markov states in tenns of the CD4 stratum and the 
WHO (Sendi, et 1999). is the cost-effectiveness of 
prophylaxis various opportunistic infections, then Markov states would also have to be 
created for these (Sendi, et al. 1999). Some studies that examine the cost-
effectiveness ART within different CD4 strata (for CD4>350 cells/J.11, CD4 
200-350 
(Tebas, 
et at. 2006). 
or CD4<200 have only used the viral load to define the Markov states 
et a1. 200 1) while others have used the CD4 level and WHO (Badri, Cleary 
A more complex model that uses all three markers has been used to examine the cost-
effectiveness of prophylaxis various opportunistic et al. 
1998), the of ART versus No-ART (Freedberg, Losinaet aL 2001) and the 
cost-effectiveness of different starting CD4 strata for ART Goldie et al. 2001; 
Schackman, Freedberg et al. 2002). This model classifies health states as acute, chronic or dead, 
and each state is by the CD4 count (0-50,51-100,101-200,201-300,301-500, >500) 
and the load (>30000,10 001-30 000,3001-10 000,501-3000 and ::::;500). For each 
combination and viral load stratum, have a risk an opportunistic 
infection (01) and the probability of dying is dependent on the outcome of each acute 01 event. 
caroB pneumonia (PCP), mycobacterium avium complex (MAC), 
disseminated int(~cUons and cytomegalovirus infection (CMV) are distinct OIs in the 
model; remaining OIs were captured as "other OJ". While a patient's history of opportunistic 
infections is an important detenninant of outcomes, data shortages often require many published 
studies to relate mortality, morbidity and costs to the CD4 count (Richter, Hauber et al. 2002). In 
addition, it is likely that this approach does not estimate costs accurately. This is because it is 
assumed that all non-ARV costs within a two-month window around each opportunistic 
infection are incurred in the state to that 01. This is highly unlikely to be the case 
- primary data from nn~,t,p"t C()stlIlg for this dissertation indicates that patients are hm'pi1:aIi:sed 
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with a number co-int€:ctIlons and it would be impossible to accurately allocate non patient-
specific costs such as hospital overheads to each infection. In addition, the sample from which 
costs and transition were would have to be very 
For this thesis, the patient-level Markov models for No-ART, first-line ART and first and second-
line ART have been developed in software (TreeAge Pro 2005 Suite, MA, USA). In 
"'''''''jJUJI1o'. with in the the CD4 count has been used to of death. This 
is operationalised by dividing the mod~l into CD4count strata of 50-199 cells/J.d, and <50 cells/J11 
because these categc)m:s have been shown to be assocllate:a different mortality rates in 
cohort analyses (Hogg, et at. 2001; May et at Further between 
patients was observed to be related to the amount of time the patient had been on ART mortality 
rates decreased steadily from until the end of the follow-up period of 48 months. 
Similarly, costs care are much higher in the fIrSt year because patients are relatively 
seriously ill and potentially inpatient care, are undergoing laboratory 
investigations as specified by South African ''National Antiretroviral Treatment Guidelines" 
(2004) and require more frequent visits to the 
To capture this heterogeneity adequately, it was necessary to divide the CD4-based Markov states 
into a number of temporary states, known as tunnel states. The use ofthese allowed the transition 
probabilities and costs to be varied as time on ART increased. the first 6 month 
t,,",nr.,.,..,v states were created for each Markov cycle and for each CD4 After 6 months 
on ART, there was no longer any significant difference in terms of costs and outcomes within 
CD4 strata, and these states were merged, However, differences in mortality rates and costs in 
relation to duration on ART were still significant, necessitating the on~~olflg use of tunnel states 
between 6 and 48 months on treatment. The Plan for comnren.emnve HIV and AIDS 
Management and Treatment for South Africa" (Operational Plan for HN 
and AIDS Care 2003) recommends first-line and second-line antiretroviral drug (ARV) 
After 6 months on both ART models a probability of the first-line 
regimen22 • For the first and second-line ART model, if first-line treatment was failed, the patient 
transitioned to the second-line regimen - the inclusion of separate states for the second-line 
regimen is essential because of the higher costs of these ARV s. In the first-line ART model, the 
transition probability of failing first-line was added to the probability of dying with the 
imt)]ic:atic'n that first-line increased the risk of death, See L 
22 No patients transitioned to second-Hne in the first six months. 
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There are a number of differences between the ART models in this thesis and the models in the 
literature. Most studies have modelled treatment via CD4 count cnam~jes 
if treatment is ",ft~."t"d'" p;aue:ms are moved into CD4 amd vice versa. 
data, on the other hamd, have suggested that the CD4 count is am in,.,,,,rl"p.{'t predictor of treatment 
success (Coetzee, Hildebrand et aL 2004). For this reason, overall has been based 
on a «1",,,,1<"'.'''' extrapolation of the risk of death over ",H;."ti"",~",,,,,, of ART 
is modelled as a risk of death according to time on treatment amd treatment failure is 
modelled as a risk of moving into a second-line state which is again dependent on overall time on 
treatment. A further difference between this ART model amd others in the literature is that it only 
considers patients who enter care with CD4<200 While it is not the case that patients 
with CD4>200 cell/Ill would never enter care, patients more frequently present for treatment amd 
Ola.~()SIS once are amd in terms of the policy, ART can be 
CD4<200 ceUS/1l1. In other the mV-related treatment burden relates 
to the late ofHIV disease. 
The No-ART model was also stratified into CD4-based Markov states ofCD4 50-199 ceUS/1l1 amd 
CD4 <50 cellS/ill, with death as the absorbing state. pr()grcesslon of disease was modelled as 
a risk oftramsitioning to a lower CD4-based state with a higher risk of death. Because the Hfe-
ex~)ectanc;y of No-ART patients is much shorter tham ART patients, mediam survival cam be 
established directly from data no extrapolation is 1'Pllni ... ·tl 
For all models, it is necessary to specify the point of entry into the model, which should be related 
to the aims amd objectives of the analysis. Although patients can start ART in South Africa once 
their CD4 count drops below 200 cellS/ill, in mamy start much later, and it is 
possible that this will partly in order to deal with the backlog of sick in the 
of the rollout, amd because patients nl'~'''''''U once are TP" .. nIP'" immune 
compromised. it is less effective and also less cost-effective to start ART 
later, it was nevertheless that would initiate one of the ART options in kee:pt11lg 
with the in Khayelitsha 63 per cent were assumed to enter each model 
with CD4 50-199 cellS/ill amd the remainder with CD4 counts < 50 ceHshll (see Figure I). The 
same starting distribution was modelled for the No-ART alternative so that each intervention is 
comparable in terms of the health states of patients at baseline. 
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2.5.3. Transition probabilities 
Transition probabilities in a Markov model are required to specify all possible movements 
between Markov states. In Markov transition probabilities are constant over time. If 
transition pr()ba,bU vary with time, the is called a Markov process 
(Sonnenberg and Beck 1993; Briggs and Sculpher 1998). 
In F,""''''''''', transition probabilities have been • ... "+'''m Meier product limit 
"".,u,uu,.",,, which give the ofthe cohort in a ",,,,.+,,,,"1 surviving or remaining 
on first-line) at a particular point in time. probabilities need to be calculated per three-month 
period, but at the Kaplan Meier was calculated over a time frame. For if 
one knew that the at 6 months and 24 months were 0.8 and 0.2 resnec:tivel 
then the probability of dying per three-month between months 6 and 24 would be: 
Therefore 
In(O.2/0.8)/(24-6) 
3 
] 
=0.76 
Where: 
is the proportion surviving at second time period 
KMJ is the proportion surviving at first time period 
t) is the value of second time period in months 
t1 is the value of first time period in months 
Equation 4 
cycle length is the Markov cycle for which transition probabilities are calculated 
In the ART model, transition probabilities were estimated from Kaplan Meier product limit 
estimates of survival for 1,729 patients ART in the first 48 months ofthe Khayelitsha 
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programme. There were 2,229 ART patient years over a median period of 1.03 years 
OQR 0.68 1.70, max 4.08). The probability of dying was from data 
and specified separately for each over the first 6 months on per 6-
month period for months 6-12 and per annual period in months 12-24,24-36 and 36-48. This 
allowed an accurate specification of the decline in mortality over four years on ART. Patients 
who were lost to follow-up were conservatively treated statistically as deaths. Because 
eX1Dec:taJlcy might be in pilot settings, the potential overestimate of mortality would 
increase the generalizability of results to routine services. Non HIV -related (all cause) mortality 
was captured from South African life tables (Koch 2003) corrected for socio-economic status, age 
and The probability oftransitioning to the second-line Markov states was from 
primary data for months 24-36 and 36-48. No switched to second-
line between months 0 and 6. 
Despite up to four years of follow-up data on ART, there are still a number of 
uncertainties about the long-term costs and effectiveness of this intervention. After TFw,r_",,"'''''' of 
follow-up, over 70 per cent of patients were alive and remaining in care. To extrapolate these data 
in order to calculate lifetime costs and outcomes, a number of assumptions were made. In all 
cases, were conservative. the after 48 months 
was assumed to be average probability between months 0 and 48. An "'I""U~'" 
would have been to calculate an average over months 36 to 48 for example, which would have 
resulted in much higher life the low rate of death once patients have been on 
ART for some time. Given many it was better potentially to 
underestimate Im:-eJi{pf~t:mcy. 
Secondly, the probability of switching to second-line was assumed to be the average probability 
as observed from primary data between months 0 and 48. Whether a patient is on first or second-
line in the model does not have an impact on life-expect:mcy, but does have importl'mt 
unpn,catlOl1lS for lifetime costs the second-line ARVs are more than twice as as the 
Thirdly, there is very information about whether will die 
whHe on treatment, or whether they will cease treatment after failure on the second-
line Given unavailability of these data in the near it has been assumed that aU 
patients would remain on treatment but that transitioning to death would incur an additional 
treatment cost in order to capture any inpatient care costs at the appropriate point in time. 
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No-ART outcomes were from Cape Town AIDS Cohort, a local natural history cohort 
of ART-naIve patients23 who presented at a specialised mV-clinic established at the New 
Somerset hospital in Town between 1992 and 2000 (post, Wood et al. 1996; 
Badri, Bekker et al. 2004). These mv clinics served largely who were referred 
from a wide range of public sector primary health care facilities (BOOri, Wilson et al. 2002). 
Patients were followed up 3 to 6 or when clinically (Badri, Bekker et at 2004). 
Given the likelihood that many patients in this cohort lived in similar circumstances to patients in 
Khayelitsha, the ethical limitations in following a matched No-ART cohort in Khayelitsha, and 
the lack of other No-ART cohorts, the use of these data to ,","U',",Ul,,"'" No-ART life-expectancy is 
''''''HI''". One data is that it is current No-
ART patients have worse progo()SIS than those in the Town AIDS Cohort. This is because 
access to care might have worsened owing to the far greater number of patients that are in need. 
potlentlal shortcoming is i:1UUlICiSiScuthr,Oull;h ,,.· ... ,,iti"'itv 
These secondary data sources provide estimates of the rate of death for patients with CD4<200 
cells/fJ.1 and CD4<50 cells/fJ.l, but do not rates of death for patients with CD4 50-199 
or the rate to lower CD4 50-199 to <50 ceUs/fJ.I). 
These probabilities have been calculated by using the hazard ratio for death for patients with 
CD4<50 in et 2004). The 
probability of dying in the CD4 50-199 was calculated by dividing the probability of 
dying in CD4<200 ceHslfJ.1 by 2.28. The probability of switching between CD4 50-199 cells/fJ.I 
and CD4<50 cells/fJ.1 was 
-~~;--~~ with CD4<200 
calculated to ensure overall ", .. ",n,<> matched survival for 
Sources of data for transition probabilities are summarised in Table 5. 
23 ART-naYve paul~mshave never received ART. 
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Table 5: Sources of data and assumptions used in calculating transition probabilities 
Input parameters Data source and assumptions 
Probabilities of transitioning to dead Markov states 
CD4<50 cellslml starting ART 
0-3 months Khayelitsha pilot 
3-6 months Khayelitsha !!ilot 
CD4 5(J..199 cellslml, starting ART 
0-3 months Khayelitsha pilot 
3-6 months Kha{elitsha pilot 
All ~ents on ART. Irrespective 
6-12 months Khayelitsha pilot 
12-24 months Khayelitsha pilot 
24-36 months Khayelitsha pilot 
36-48 months Khayelitsha pilot 
>48 months Average mortality rate in 0-48 months 
No ART. CD4 count <50 eellslml 
aU quarters Calculated from Cape Town AIDS Cohort 
No ART, CD4 5(J..199 eellslml 
all quarters Calculated from Cape Town AIDS Cohort 
Probabilities of transitioning between alive Markov states 
First-line regimen to second-line ''''!I''''''''' 
0-6 months NJA - no patients failed during this period 
6-48 months Khayelitsha pilot 
>48 months Average failure rate in 0-48 months 
No-ART, CD4 50-199 cellslml to CD4<50 eellslml 
Calculated from Cape Town AIDS Cohort using death hazard 
all quarters ratio from Khayelitsha pilot 
2.5.3.1. Non HIV-reJated mortality 
Transition probabilities should include an aU-cause risk that death from non-
mv related causes (Briggs and Sculpher 1998). Non HIV -related mortality was derived from pre-
mv era South Afiican life tables 2003) to avoid double-counting HIV-related deaths. 
~r"'rT1I1Icr with a hypothetical cohort of 100,000 people at age zero, these life tables show the 
proportion of the cohort that remains alive until age 100, when everyone is assumed to die. 
Mortality is expressed separately for men and women in six different socio-economic groups. In 
order to calculate non HIV -related mortality, it was therefore necessary to establish the average 
age, sex, and socio-economic status ofHN patients. 
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data were derived from a study people on ART in clinics in the Western 
located in Gugu]etu (Guguletu and GF Jooste Hospital), KhayeHtsha (Michael Mj:lnn",o"w<>n<> 
CHC), Hout Bay (Hout Bay clinic) and Paarl (TC Newman (pienaar, Myer et a1. 2006). 
Many patients are enrolled in routine care services, and it is likely that they are 
fairly representative of the mv population that is utilising care at this stage of the rollout in the 
Western but are unlikely to be representative ofthe country's HIV population in 
general, in particular in terms of socioeconomic status, for two reasons: 
.. The Western Cape is a relatively wealthy province. However, 72 per cent ofthe sample 
was born outside of the Western and 43 per cent was highly spending 
considerable time each year in other parts of the country. 
.. The was clinics located nnrnj:lri in urban areas so would not be 
representative of rum I HIV-ppsitive people. However, given that mY-prevalence is 
highest in poor urban areas, the sample might be representative of the majority of HIV-
positive South Africans24 
While this sample be overestimating the SOC:lO-leconOfOlc status ofmV-positive South 
Africans who are dependent on public health services, until a natiQnaUy representative sero-status 
linked household survey collects these data, these Western Cape data will continue to be the best 
available. 
In order to assess the socio-economic status of ART patients, an asset was cre::ltel1 
following a methodology developed by Filmer and Pritchett (2001) based on asset questions in 
the 1998 adult Demographic and Health Survey (DHS) dataset. This methodology has been 
applied to the South African 1998 DHS data and the resultant asset index was found to be an 
internaHy coherent and robust indicator in South Africa that compared well to 
mainstream poverty such as income and expenditure (Booysen 2001). The first step in 
this methodology is to recode asset variables into dichotomous variables, Ul;>UU!,Ul~'HUIO between 
nOllSellOl(lS that own the asset and those that do not (in other words, take the value of 
24 Data from a 2005 household survey for respondents aged 15-49 indicated prevalence in urban 
infomla] areas cent), followed by rural infomlal (17.3 per cent), and urban and rural fOmlal areas 
at 13.9 per cent Urban infomlal areas have infomlal or temporary housing made out oftin, cardboard 
and wood. Apartheid, squatters lived in these areas. 
83 
-------------------,- -,- --------'-- .. -----------------~ 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
Once the asset been calculated, six socio-economic groups were constructed in the 
DHS and tabulated in order to ascertain the range falling into each group. The 
next step was to map results onto the ART sample using the same means, standard 
and factor scores as had been calculated from the DHS This allows one to 
estimate the socio-economic strata of ART users in comparison to households from the DHS. Non 
mY-related rates were then calculated based on the proportions of men and women in 
the socio-economic groups and were transformed into month transition 
probabilities using Equation 4. 
2.5.4. Attaching weights to the Markov model 
Weights are attached to each Markov state in the model to represent the cost and health outcomes 
associated with each state. For instance, if one is modelling life-expectancy a three-month 
Markov a (representing three months in a would be attached to each 
state of the model in which the is alive and a of 0 would be attached to the dead 
state. If one were modelling QAL Y s, then the weight in each alive state would be multiplied by 
the appropriate HRQoL value. Similarly, the cost of being in each Markov state is computed for 
the length ofthe Markov cycle and is attached to the state. While it seems counterintuitive to 
attach costs to a health this is the that is used in the literature to 
the way in which costs can be ass.oCllatf~d with a ... " .... fro' .. state over the 
Markov cycle. When the model is run over a large number of cycles, each weight is summed 
across those cycles to give an estimate of lifetime QAL Y s and costs (Briggs and Sculpher 1998). 
2.5.5. Adjustments to costs and outcomes 
Since Markov models deal explicitly with time, they allow discounting of costs and outcomes at 
the point in time that these occur in the model. This is done by attaching a discount rate to each 
Markov state (Briggs and Sculpher 1998). This thesis follows common practice for developing 
countries in the literature, which is to use an annual rate of 3 per cent for both costs and effects 
(for see Coleman et at 1999). However, a zero rate is also in C!P11,,,jT,,,""V 
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Markov models assume that 
-" .... ,'"'' between health states occur between cycles, and 
the remain in their current state. In reality, patients move between of a 
disease constantly. The error associated with as opposed to continuous time can be 
corrected during first of the model one ofthree approaches. Ifno correction is 
performed, no rewards are accumulated during the first cycle of the model, thpl"f'h,v 
un1der'estiml:l.tulg both costs and correction is made, all patients receive full 
costs and effects the correction is made, all patients receive half the 
costs and half the effects. In choosing which correction to make, one should consider the 
proportion of patients who die the If the die, then no 
~nl'Tf"{~hl1,n is appropriate, if half die, then a half cycle correction is appropriate but if most "'"'U''''''' 
then a full cycle correction should be made. The last was chosen because 90 per cent of patients 
live through the first 3 months in both ART and No-ART groups. 
At times it is necessary to make adJustments to costs that are not by all patients in a 
Markov state. These can be modelled as transition costs which relate to specific transitions 
between states. In this a cost of dying was as a transition cost incurred by any 
died ofHIV-related . This approach ensures that the resources that are 
utilised at the time of death are not underestimated when primary data are extrapolated, which is 
particularly relevant for ART in this thesis given that data are only available for a maximum of 
;n1:'I"_"r",,,,,~ during which time less than 30 per cent of the sample died. An illustrates this 
Itn<.o'"'''' ClilCtIlatmg inpatient utilisation from 100 patients followed over 1 00 patlenlt-ye~rs 
During this time, 100 inpatient were accrued 10 who died resulting in an average 
inpatient utilisation of 1 per patient-year. However, if one were to apply these data to health states 
with higher rates of death, one would underestimate costs. A more robust approach would be to 
calculate separate costs for the patients who live, which would be attached to the alive Markov 
while the cost of dying would be associated with transitioning to the dead Markov state. 
2.5.6. Evaluating the model 
Two methods of evaluation are appropriate to Markov processes with nnle-Illet)en.oeltlt transition 
probabilities: cohort simulation and first-order Monte Carlo simulation. To understand the 
mechanics that a hypothetical cohort of 10,000 enters the 
25 Patients dying of nOD-HIV related causes do not incur this cost. 
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model at time zero and is distributed into CD4-defined Markov states. After each 
the cohort will distributed to different states as required by the transition probabilities 
attached to each state. When the model is run over sufficient 
are calculated. 
lifetime costs and outcomes 
First-order Monte Carlo simulation works differently in that it follows the same group of 
patients the model one at a Each takes a different through the model 
and when one considers the paths of a number of patients, one gains an overall profile of costs 
and outcomes. The cohort simulation method is more precise than Monte Carlo simulation 
because it gives an exact solution whereas Monte Carlo simulation will never 
the same result twice owing to the random nature ofthe simulation. The advantage of Monte 
Carlo simulation is that it gives an of the likely variance associated with the structure of 
the model. Both evaluation will be to calculate 
2.6. Model validation and sensitivity analysis 
2.6.1. Validating the model 
Because models are a simplified version of reality, it is important that they describe the real world 
to an level. Systematic validation of a model can help to achieve this goal. Sendi, 
Craig et (1999) propose four sequential levels of model validity: technical validity, predictive 
validity, face validity and modelling process validity. 
Technical validity involves identifYing and correcting for modelling bugs such as unexpected 
model behaviour, redundant variables, programming errors and typing errors (Sendi, Craig et aL 
1999). A useful method of debugging a model is to vary one or more over its entire 
range and to examine any anomalies in model outputs. process will be undertaken for the 
following transition Dt'(lbaiblH in the models: 
.. Probabilities of dying (ART and No-ART model) 
.. Probability of moving from CD4 50-199 to <50 cellshd (No-ART model) 
.. Probabilities oftransitioning to second-line (ART model) 
88 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
Predictive validity of a model can be tested by and final outcomes from 
the model outcomes from published or primary data sources (Sendi, Craig et aL 1999). 
This will be undertaken comparing the proportion ofthe cohort between 0 and 48 months that 
is in the ART model in comparison to real data at in A exercise 
will be undertaken for the No-ART 
Face validity assesses whether the model the output that one would (Sendi, Craig 
et al. 1999). For instance, one would expect that patients ART with CD4<50 
would have lower survival than patients starting with CD4 50-199 This assumption can 
be the predictions from the model. 
Modelling process validity is evaluated by the results and conclusions from different 
groups of researchers who have independently addressed the same results will 
differ between settings, the conclusions should be the same in terms of relative cm,t-e:ttectnreness 
(Sendi, et aL 1999). 
2.6.2. Accounting for uncertainty 
Briggs (1995) defines four broad types of uncertainty in economic evaluation, which to: 
• Data um~me:nts of the study 
• 
• Extrapolation of data 
• Choice of analytic method 
Uncertainty H.d':'UIJ'i". to data ,,.,.,.n"'"i1",, is mcreaiSlDlgly studied within the framework of the 
stochastic cost-effectiveness and this approach has been employed thesis. 
This data on resource use and health outcome. Usually the 
resource use is assumed to be stochastic, and deterministic unit costs are used as weights on the 
resource items 2001). Additional details are provided in section 2.6.2.3. 
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rn('"p.rtl~inltv relating to generalizability of results is concerned with the extent to which the results 
of this are applicable to other Generalizability has been assessed by COInplmtl 
ART clinical outcomes to other published cohorts in low income and 
ART-CC 2006; et at 2006) and No-ART outcomes toa review ofnarural history 
data (Schneider, Zwahlen et at 2004). Inpatient and visit utilisation data have been compared to a 
published South African (Badri, et aL 2006) and to national 
guidelines for follow-up oatlents on ART (National Antiretroviral Treatment Guidelines 2004). 
Unit costs have been constructed from a wide range 
generalizabiHty. Where this 
nn,ml'll"V and se<:OOlOaJt) sources to enhance 
and u~'''~ •.• ~~ data have been found, 
adjustments will be made with the use sensitivity analysis (see section 2.6.2.1). 
Uncertainty to extrapolation is an important problem in evaluation After 4 
years offoUow-up in over 70 per cent were alive and remaining in care, 
implying that the calculation of final outcomes requires data to be extrapolated over many cycles 
in the model. This uncertainty will be addressed with the aid of simple sensitivity analysis (see 
and by results under three different modelling time horizons: five 
years, ten years and simulation until 100 per cent of the cohort is On the other 
because life-expectancy is much shorter for No-ART patients (Post, Wood et aL 1996; 
Bekker et at 2004), for them no extrapolation is required to estimate final outcomes. 
The final source of uncertainty relates to " .... <"U,..£'<'" methods. These include methods for 
and HRQoL and methods for costs and benefits. This will '""-' •• ~u .. , .... 
uncertainty relating to HRQoL measurement and valuation by pre:serltJrlg outcomes as years 
and QAL Y s and uncertainty to the discount rate by the rates. 
Uncertainty can be assessed using sensitivity analysis. A number of different types are available -
each is discussed below. 
Simple sensitivity analysis 
Simple sensitivity analysis is the most common form of sensitivity analysis, and involves 
one or more over a plausible range, while other keep their base-case 
values. This allows analyst to the of variations in each on 
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the results (Briggs. Sculpher et al. 1994), which is useful for establishing the technical validity of 
the model (Sendi, et al. 1999) (see 2.6.1), and for uncovering the impact of analytical 
methods on results (Briggs 2001). 
A multi-way simple ",-"",nAY analysis involves varying two or more parameters at the same 
time. This can take the form of scenario analysis Sculpher et al. 1994). For in 
the case of ART, it to the of a scenario, where patients 
would be assumed to frequent laboratory monitoring and less expensive ARVs. This 
scenario would calculate the potential costs and outcomes of a less resource intensive version of 
as recommended by the World for resource poor settings (WHO 
2002). Current South African guidelines recommend a much more resource intensive approach 
(Operational Plan for mv and AIDS Care 2003; National Antiretroviral 
Treatment 2004). Multi-way can be used to enhance the 
generalizability of results. For Instance, while Khayelitsha patients are referred tertiary 
inpatient care, many people in South Africa would not have access to tertiary hospitals and 
different hospital costs should therefore be used to enhance generalizabiUty. Similarly, levels of 
retention and adherence be lower in routine adjustments will all be 
made through multi-way scenario 
Threshold analysis 
Threshold ",nolh,,,,,, is concerned with lOemllCYll11g the value above or below 
which would "Uu.UF." \~",",""~, , .. "" ..... 'u". et al. 1994). J:.Jnwp'vpr for interventions 
that are more effective and more costly (such as ART) this approach is only useful if one can 
compare the ICER to the maximum acceptable threshold, which is an approach that will not be 
used in this thesis for reasons outlined in Chapter 3. Alternatively, threshold analysis could be 
used to find the combinations of parameters that make ART cost saving (more or as effective but 
less costly) in relation to No-ART. it is highly unlikely that ART would be cost 
because once treatment has viral rebound and deterioration of the immune makes 
patients once susceptible to the HIV -related and opportunistic infections that characterise 
the No-ART "Y"";'YP(1r'U It is therefore most realistic to assume that patients will need the same 
inpatient and care that is typical of No-ART. Unless ARVs are less costly, and results 
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are discounted at a high 
will not be used. 
ART will not be cost saving. For these reasons, threshold analysis 
2.6.2.3. Probabilistic sensitivity analysis 
Probabilistic sensitivity analysis (PSA) is a that is able to summarize the uncertainty in 
a simulation as probability distributions for model outputs, such as incremental QAL Ys, 
incremental costs or the ICER 1995; O'Hagan, McCabe et aL 2005). To do this, 
palranlet1ers in a model are defined as distributions. In this dissertation, PSA was undertaken by 
specifYing distributions on all transition probabilities and utilisation estimates. The impact of 
paranleter uncertainty is propagated through the model means of Monte Carlo simulation-
this involves running the model many times using randomly selected values from input 
distributions in order to derive probability. This of Monte Carlo simulation is designed to 
CaJJtulre second-order uncertainty the variability in the of interest as to the 
variability in the population (this is first-order uncertainty - see section 
200 I; O'Hagan, McCabe et al. 2005). 
At this point, it is necessary to differentiate between and naves Ian interpretations of 
probability. The PSA approach is in nature 1999; 2001; 
O'Hagan and Luce 2003; \'I-I,,,,,,~,, .. McCabe et al. 2005). Under a rr~:lue:ntl:st approach, 
parameters are considered to have true values and not to vary. For a frequentist, only repeatable 
events have probabilities. when undertaking PSA, it is assumed that parameters are 
random variables, which can take a range defined by the chosen distribution. For a 
Bayesian, probability describes uncertainty, which can be owing to intrinsic unpredictability, 
random or because knowledge and Luce 2003). Bayesians also 
..... "UU5U,'''U I'Ipl'W~,pn prior distributions, likelihood distril)utioIllS and posterior distributions. The 
prior distribution is based on what is known about a problem to the new or current 
data. it is more helpful to think of the prior as summarising all external evidence about 
a quantity ofinterest Myles et at. 1999). Information from the prior distribution is 
then synthesised with the current data (as expressed in the likelihood distribution) to produce a 
posterior distribution (O'Hagan and Luce 2003). This synthesis is undertaken via Bayes' 
Theorem. lfthe prior information is less strong than the current information indicated by a 
higher variance) Bayes' theorem puts less weight on the prior than the likelihood distribution. 
92 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
When the current data are strong relative to prior information, then the prior is unlikely to make a 
big on the posterior, and it is common to a "non-informative" prior. In this 
circumstance, the likelihood distribution is the same as the posterior. A key benefit of the 
aPJ)rollch is its ability to make use of information in a manner, in order to 
produce stronger results. This is a distribution will be a more precise estimate 
with lower variance than the likeHhood distribution (O'Hagan and Luce 2003; O'Hagan, McCabe 
et al. 2005). in the case ofthis thesis, there is no source of South 
data on most of the parameters int(~res.t, which justifies the assunlptlon of a "non-informative" 
It is im' ....... ,-t£lflt to note that n£lf'£lm,ptp'N not be statistically moepemo,em, lmlr'llV:ln that it is 
necessary to think about correlation between paJranlet,ers in the model. In other 
probability distribution for all the parameter values is required. However, most analyses 
pragmatically assume McCabe et al. 2005), and this approach has been 
taken in this 
differences between Bayesian and frequentist approaches are summarized in Briggs (1999). 
He identifies three main Ba'vesian methods based on the approach to prior information. 
prior information on "1'I"vtr",,,IIV available statistical information. The use 
of this information can be related to the treqmlntlst approach to I'v,nu"F> available data. A second 
approach would come about if there were no prior information on the parameter of interest. This 
is the same as a frequentist approach when there are no data to pooL The final approach is called 
, which involves '"''''''''''''J;; information Py,,,prt" on the basis of their 
np,r"nn£ll beliefs. To clarify, assume that the p<u.au.,",,,~, ofinterest were the effectiveness of ART 
in South and that current data were derived from a cohort study_ Under an PTf1,nn,p", 
approach, these current data could be with information from a smaller pilot 
study of ART in South Africa. such pilot had been or if there were no 
published data, a nOl1-lIltolm~ltj prior could be assumed. Finally, a subjective approach 
would opinion as the prior. To the approach to PSA will be to 
assume an non-informative prior because data are derived from the first public sector pilot of 
ART in South Africa. 
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3. Methodology for population-level analyses 
This section nf'E',,!pnt"! methodology for establishing the need for HIV-treatment, population-level 
costs and outcomes associated with alternative HIV -treatment interventions, methods for using 
linear to solve for social choice rules and methods for the 
SOC:lo-leCOnOITIlC status of ART users in order to determine whether the servioe has potential to 
preferentially benefit the poor. The section also considers the impact of the programme size on 
the costs of scaling up. 
3.1.. Estimating need 
It has been that a patient is in need ofHIV-treatment when she or he develops AIDS 
(WHO IV). The number of adults developing AIDS each year has been estimated from 
demographic modelling of the South African HIV -epidemic. The key data used in these models 
are from antenatal clinics, where blood samples of pregnant women are anonymously tested for 
HIV. However, these data are not directly to the population as a whole because for 
example pregnallt women would not nec:essar be rep'res,entatnre of men, or of people who are 
not sexually active such as the youth and the elderly. On the other hand, there is evidence that 
HIV might affect the fertility of women, meaning that HIV-positive women are less likely to fall 
(UNAIDS and WHO 2005). Antenatal prevalenoe data therefore need to be adjusted to 
estimates for the h ... ",<lrt·· ... population tlmoujl:h <1iemcogr.apn modelling. In South Africa, a 
range of demographic models to achieve this have been the Actuarial of 
South Africa (ASSA). The latest model, ASSA2003, has been calibrated the 2003 
antenatal clinic surveys, as well as data from the 2002 Human Sciences Research Council 
(HSRC) national HIV survey (Smsana and Simbayi 2002) and the Reproductive Health Research 
Unit survey on the sexual behaviour and prevalence of HI V in youth in South Africa (Dorrington, 
Johnson et aI. 2004). 
It should be noted that it is neoessary to use estimates of new need (new AIDS as opposed 
to total AIDS cases in the modelling which means that need is underestimated within the 
first year of the projection, but underestimation should be negligible thereafter. While 
ASSA2003lite also provides estimates of total AIDS cases, using these data would be an 
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overestimate of need. For ex~unl)Ie, Im~lgU:le that in year I and year 2 there are 100 and 110 total 
AIDS cases respectively. Year 2 cases are comprised of new AIDS cases and any patients 
surviving from year 1. If one assumes that need is 100 in year 1 and I lOin year 2, one is counting 
a proportion of year I need twice. On the other hand, the clinical for ART initiation are 
CD4<200 ceIlsllJ1 at any WHO or an AIDS diagnosis at any CD4 level. The implication is 
that new AIDS cases as an estimate of need willlIDderestimate the number of people who 
clinically qualifY for ART because many patients with CD4<200 cells/lJl will be in other 
AIDS) WHO Despite these these data are the best available and their use is 
In an alternative scenrulO, need has based on the Operational Plan's (2003) of patients 
iniiri",tino ART. The does not ",.", •• u;""""" between adults and children. Because this thesis is 
focusing only on adult HIV -treatment, the patient targets have been adjusted to t>v<·lnrl", children 
by calculating the average proportion of new adult AIDS cases out of total new AIDS cases over 
the time frame from ASSA2003lite estimates. 
The plan initially envisaged starting approximately 53,000 adults and (49,290 adults) on 
ART by March 2004 and to reach 100 per cent of new AIDS cases by March 2009. This was 
runbitious that the rollout was only announced in October 2003, the Operational Plan was 
only finalized in November 2003, '''al,'vu«, Antiretroviral Treatment guidelines were only 
available in 2004 and had to be and had to be set 
up. In his State of the Nation Address delivered after the April 2004 general elections, President 
Mbeki stated that this initial patient target would be met by March 2005 (Mbeki 2004), which 
11n1'1II1"'" that the Operational Plan were to be one year. This alternative patient 
need will therefore assume that patient uptake is 49,290 adults by March 2005, that 1 00 
per cent of new adult AIDS cases are met by March 2010 and that 100 per cent of need continues 
to be met in suoiseCIUeltlt years, based on ASSA2003lite estimates. 
3.2. Population-level costs, QAL Y s and social choice rules 
While methods for Datlenl-le~Vel costs and outcomes focussed on the calculation oflifetime costs 
and individual health at the population-level one is concerned with calculating the total 
costs and outcomes up each intervention to a defined population in need over a 
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decision-making time frame. While the overall structure of the Markov models is the same as 
described at the patient-level, in order to estimate population-level new patIents in need of 
treatment are assumed to enter the Markov models during each of the planning period. 
Because the software (TreeAge Pro 2005 Suite, MA, USA) used in the patient-level 
models cannot accomplish this, population-level models have been developed in Microsoft® 
Office Excel 2003. By inputting need into the model each Markov cycle, one is able to 
calculate total and annual costs and total and annual from mutually exclusive 
mv -treatment intervention. 
total costs and total outcomes over a spe,cltied planning period are then inputted into the 
mathematical programming algorithms outlined in Chapter 3. This information allows one to 
calculate the health that can be achieved and the of patients that can be treated in 
total and in each treatment "n-",tpocv over a range social choice rule. 
3.3. Estimating the socioeconomic status of ART users 
As described in section the socioeconomic status of ART users has been on 749 
patients on ART in five clinics in the Western Cape (pienaar, Myer et al. 2006). The key 
difference in methods in this section as to above is that the SOC:IO('CO:normc status of the 
ART has been compared to the full DHS and to a DHS consisting of 
adults living in informal settlements around Johannesburg and Cape as constructed and 
described in Palmer et al. (2005). This allows one to compare the socioeconomic status of 
ART users to first the population of the country as a whole and second a sample representative of 
the communities from which they originate, in order to assess whether ART has the potential 
preferentially to benefit the poor within a particular ""' ..... " ..... 
3.4. Impact of programme size and implementation on costs 
According to Luce and Manning (1996) a increase or decrease in the level of an 
intervention can lead to economies or diseconomies economies based on !"',,· ..... "rlo_hv_ 
or returns to means that the 
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run average total cost de(~rea:"e" as scale i ........... "'" ... " are constant returns to 
output increases by the same proportion as the proportionate increase in an the and unit 
costs are unchanged; if there are diseconomies of scale (decreasing returns), output increases by a 
smaller proportion than the increase in inputs and Perkins 1998). hCl)nomu~s 
occur when the cost of joint production is less than the cost of producing several items 
separately (Clewer and Perkins 1998). Economies based on learning by doing refer to increased 
productivity as health for become more at a activity 
(Luce, et al. 
Economies of scale at the micro level within illV-treatment facilities could arise through 
spreading costs across larger n~bers It is assumed for the purposes of this 
thesis that these effects have been adequately reflected through the inclusion of a number of 
taciilitiles operating at different levels However that the "'_"""I!'> 
up ofillV -treatment might not be proportional to current configuration of " .. VllU .. '"" in South 
one-way sensitivity analysis will also be used to assess the costs of scaling up in clinics 
and health centres as opposed to hospital outpatient where overhead and 
are 
At the macro level, a number of costs could be affected the of the proposed illV-treatment 
programmes. For instance, the potentialfor the scale implementation 
of ART could lead to higher salaries being offered to health professionals in order to attract 
sufficient staff. Given the attention that has been given to the possibility of clinical personnel 
constraints (Kober and Van Damme 2004), the of professional nurses and medical 
"n."'"...., required to HIV-treatroent will calculated. there is a need 
massively to increase the capacity in the national laboratory services to meet laboratory testing 
requirements. It is unclear whether this increase incapacity would decrease or increase unit costs. 
On the other hand, antiretroviral drug costs appear to be related to the scale of 
programmes globally, the overall time since ... " ..... '''.0 to market, the level COlnpl;:tltlOn from 
ffP""' ... " manufacturers and and social pressures on multinational ph~mIlaC4~utiical 
factors lead to dramatic decreases in antiretrovirals that are 
currently prescribed in first-line regimens, but there has been less movement in the second-line 
drug prices (Luchini, Cisse et a1. 2003). Many would therefore anticipate that additional price 
reductions could be realised. However it is also that future ART guidelines will include 
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Chapter 5: Unit Costs ofHIV ... related 
III 
serVIces 
1 Introduction 
The aim of this chapter is to pool primary and secondary data from a variety sources to 
calculate generalizable unit costs ofHIV-related ... ,,"1"'''' .... ,''''' where unit costs can be defined as the 
full health care resources to a unit output. Cost analyses in this thesis 
have been conducted from a public health sector perspective and costs include direct health care 
resources and the resources of non-governmental organisations (NOOs) that are involved in 
""l', ... "rt.,.,,, .. HIV -treatment. All resources have been allocated to the following units of service 
output: 
III ART 'services at community health centres (CHCs) or hospital OUltpatlellt departments 
COPDs) (henceforward called ART visits) 
III Treatment of opportunistic and HIV -related infections and events at 
hospital OPDs (henceforward called No-ART visits) 
CHCs and 
III (TB) treatment for people 
III Inpatient care for HIV -positive people at secondary and tertiary level hospitals 
III ARV medicine and laboratory "''''''.l''.''''''VU costs per oatlent-mlonltn or per oal:tenlt-(]Ual 
on 
2 IT nit cost per visit 
The breakdown of the cost per ART and No-ART visit is in Table 7 and Table 8 and 
summarized in 9.ln each sample sizes for costing purposes have been prt:selrUe,G. 
LJ<UHIJ.'''' sizes for medicines, laboratory and to the number of visits 
that were used to calculate costs based on the ingredients method. The sample size for clinical 
to the number of clinical consultations that were timed. Overheads, capital and 
1 A patient-month is defmed as one month on treatment for one patient and a patient-quarter is defined as 
three months on treatment for one patient. 
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counselling sample sizes were based on the total visits to the facility. In the case of hospital 
OPDs, these sample sizes refer to the number and trauma and do not .",.,'.n£.1> 
Sample sizes provide information about the quantity of data that has been 
collected and the size of each facility and will be used to calculate weighted average costs in later 
sections. 
As shown in Table 7, costs at Jooste, TC Newman and Groote Schuur OPDs are higher than costs 
at clinics and CHCs. Within clinics and costs derived from McIntyre et aL 
(2000) are than those for . Costs oflaboratory 
and clinical staff were the main driver of these differences. A likely explanation of the differences 
is that since 2000, laboratory test costs have fallen for a number of key HIV-related investigations 
such as CD4 counts and viral load and current have a 
of nurses and junior doctors. Within primary data, the costs of visits at clinics are lower than costs 
at CHCs. The main difference relates to lower overhead costs in the former in comparison with 
the latter. 
2 These cost "lIla,lvo;:,~<: were conducted between 2003 and 2005. 
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Table7: Unit cost per No-ART visit across facilities (US$; 2004 prices) 
Khaye- Cross- Browns Guguletu Guguletu Welling- Mbe- Phola Guguletu Nom- Jooste TC New- Groote litsha roads kweni Schuur Farm CHC CHC CHC § ton clinic Park clinic clinic § zamo OPO man OPO CHCs CHC clinic clinic § OPO § 
Venue 
Sample sizes 
Medicines 757 11 18 16 30 4 25 8 30 30 4 23 30 
Laboratory and imaging 2,652 11 18 16 30 4 25 8 30 30 4 23 30 
Clinical staff 94 11 18 16 30 4 25 8 30 30 4 23 30 
Overheads and capital 18,546 49,044 35,703 194,660 194,660 56,009 66,990 31,850 49,420 49 ,420 24,503 198,192 459,374 
Counsellors 18,546 
I 
Costs 
Medicines 3.69 2.22 2.54 1.94 2.94 1.04 1.24 1.68 4.79 2.31 2.00 1.20 3.58 
Laboratory investigations 1.88 1.75 2.14 1.78 7.39 0.46 0.93 0.76 7.93 10.51 9.19 11.84 8.78 
Imaging 0.52 0.59 0.38 - 1.51 2.35 2.45 
elin ical staff 6.12 2.87 2.67 2.54 6.44 5.30 5.88 2.88 7.92 7.91 8.71 11 .21 9.88 
Counselling. staff 0.15 
Overheads 5.65 12.48 5.93 8.17 5.98 2.35 1.44 2.67 3.66 3.03 14.32 6.27 12 .18 
Buildings 1.00 0.39 0.24 0.29 2.61 0.31 0.31 0.31 2.79 0.77 4.51 0.69 1.33 
Equipment 0.42 0.05 0.09 0.06 0.56 0.05 0.01 0.02 0.30 0.22 3.82 0.13 0.43 
Staff training 0.03 
~tpervisit 18.92 19.77 14.14 ~61 __ 25.93 9.50 9.80 8.69 27.39 26.26 44.90 33.80 36.18 
--
Source: §Govender, Mclntyre et al. (2000) 
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Table 8: Unit cost per ART visit across facilities (US$; 2004 prices) 
Khayelitsha TC Newman 
CHCs OPO 
Venue 
Sample sizes 
Medicines 1,532 12 
Laboratory and imaging ART protocol ART protocol 
Clinical staff 54 12 
Overheads and capital 18,546 198,192 
Counsellors 18,546 3,419 
Costs 
Medicines 1.65 0.68 
Laboratory investigations N/A N/A 
Imaging -
Clinical staff 6.64 6.20 
Counselling staff 3.04 2.34 
Overheads 6.38 6.27 
Buildings 1.00 0.69 
Equipment 0.42 0.13 
Staff training 0.21 
Cost per visit 19.33 16.31 
Table 8 contains a comparison of ART visit costs at the three Khayelitsha CHCs and TC Newman 
OPO. ARV medicines and laboratory investigations have been calculated separately and are not 
included in ART visit costs (see section 5). The key cost differences between the two settings 
related to non-ARV medicines and capital. Overhead costs were similar despite TC Newman 
being a hospital OPO. 
Figure 9 contains a graphical breakdown of costs across facilities to aid comparison. It is clear 
from this figure that costs for clinics and CHCs from Govender, Mc1ntyre et al. (2000) are 
considerably higher. 
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Figure 9: Unit cost per ART and No-ART visit across facilities (US$; 2004 prices) 
50.00 
flfedicines 
40.00 
I AR!l No-ART 
30.00 
20.00 o Clinical staff 
10.00 • Counselling staff 
o Overheads 
....11 - LJ LJ LJ 
-
LJ CJ LJ 
-
1...1 I I 1....1 
-III 0 III U U U to? () () () to? to? 0 0 to? U a.. U I I I U 'c 'c 'c () () a.. a.. 0 
• Buildings I 0 I U U U I (3 (3 (3 :£ :£ 0 0 a.. U U C III E :::J U C 'c ~ (3 (3 Q) c 0 !1l !1l !1l -0 Q) :::J 0 en !1l ... 
.J::. ~ .J::. !1l !1l Q) !1l :::J 0 ~ :::J 'S Q) '5l ~ 0 III III e LL a.. Q) E 0 :::J ..... ..... Cl 'S .5 .!<: .J::. o Equipment J Q) Q) III III :::J Q) !1l 'S !1l -, () Z III C (9 Cl ~ .0 (5 Cl N Z >- >- e ~ :::J :::J E (/) !1l U !1l (9 ~ .J::. U .J::. .J::. U e a.. (9 0 Q) ~ I- ~ m z I- (5 e • Staff training (9 
Source: § Govender, Mclntyre et al. (2000) 
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2.1. Patient-specific cost per visit 
Patient-specific costs are defined as costs that can be directly related to usage by patients, 
including medicines, laboratory investigations and imaging. ART visit costs do not include ARVs 
and laboratory investigations as it is more accurate to calculate these per patient-quarter. A 
breakdown of patient-specific visit costs is presented in Figure 10. The average medicine cost per 
ART visit in the Khayelitsha CHCs was US$1.65, and US$0.68 at TC Newman OPD. For No-
ART services, there was a wide variation in medicine and laboratory investigation costs between 
facilities . Clinic and CHC patient-specific costs derived from Govender, McIntyre et al. (2000) 
were higher than primary data costs in similar facilities. Jfthese costs are excluded, costs are 
highest in the hospital OPDs. No-ART costs were lowest in the nurse-driven clinic services of 
Wellington, Mbekweni and Phola Park. 
Figure 10: Patient-specific cost per ART and No-ART visit across facilities (US$; 2004 
prices) 
18.00 
16.00 
14.00 
12 .00 
10.00 
8.00 
6.00 
4.00 
2.00 
~ ART~ 
1l--;:;-
I-- I--
0:: 0:: 
« « 
I 
'" U 0 a.. 
I 0 u c 
III III 
..c. E .~ ~ 
Cii Q) 
>- z 
I No-ART 
r-
I ~=.~. --a-~~-
I-- U U U <0'> .~ U U 0:: I I I U c £ :~ 4= u u U I U U U 0 :::> U c ~ 
'" § c Z '0 ]1 :::> 0 Q) III III III :::> ]1 C, ~ a.. 
'" 
e u.. c -" u Cl :::> III 
'" '" 
:::> Cl 
Q) a I 
'" 
c C> ~ .0 U e ~ :::> ~ ..c. C> u e a.. III 
..c. CD 
-
- - -
- - - -
-
- - -
-
-
-
-
-
1-
-
- -
.-
<0'> <0'> 0 I-- <0'> 
.~ .~ a.. 0:: 0 
c c 0 4= a.. 
U U 2 0 0 
'" 
z ~ 
:::> 0 :::> a; E 0 :::> 0 0 
'3 III -, ..c. o Medicines N a.. u Cl E 0 CI) :::> 
C> 0 Q) c 0 Z III 
E e Laboratory ~ ~ C> III in.es tigations 
..c. u Q) Q) 
::.:: I-- >- Z III U o Imaging 
..c. 
::.:: I--
Source: § Govender, McIntyre et al. (2000) 
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2.2. Clinical staff cost per visit 
Figure II shows the average time in minutes spent on clinical consultations across facilities and 
the resulting cost per visit. The time per visit ranged between 8 minutes at the Guguletu CHC to 
just over 46 minutes at the Jooste OPO. The cost per visit ranged between US$I.89 at the Browns 
Farm CHC to US$9.88 at the Groote Schuur OPO. The cost was not directly related to the time 
per visit because of different facility staff establishments - Wellington and Mbekweni had higher 
visit times, but their cost per visit was relatively low as these facilities are staffed only by nurses. 
Figure 11: Average time (in minutes) and cost (US$; 2004 prices) per visit across facilities 
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Source: § Govender, McIntyre et al. (2000) 
Table 9 presents a breakdown of clinical staff in selected facilities (these data were not available 
from secondary sources or from the Jooste OPO). Staff establishments differed widely between 
facilities. There were no medical officers at the clinics, and most facilities did not have a 
pharmacist. On average, the ratio of medical officers to professional nurses was 1.4 to 1 in ART 
services and 0.5 to 1 in No-ART services. ART services also had a much lower clinical staff to 
visit ratio, at 1 medical officer or professional nurse serving 2,450 patient visits versus 1 to 6,953 
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No-ART services. This indicates that services within ART clinics include 
some No-ART were more staff intensive than HIV services. 
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Table 9: Breakdown of clinical staff in selected facilities 
Khayelitsha TC Newman Average Crossroads Browns Guguletu Wellington Mbekweni Phola Park Average No 
CHCs OPO ART CHC Farm CHC CHC clinic clinic clinic ART 
Headcount 1B,546 3,419 49,044 35,703 194,660 56,009 66,990 31,B50 
Clinic manager Salary level 10 1.0 O.~ 
Senior medical officer Salary level 11 3.0 0.6 2.6 2.0 9.0 4.1 
Medical officer Salary level 10 1.0 1.3 1.0 2.0 0.5 
Salary level 9 1.0 1.0 0 .• 
Total medical officers 4.0 1.9 3.7 3.0 1.0 12.0 0.0 0.0 0.0 5.E 
Professional nurses Salary level 8 2.0 0.6 1.a 7.0 4.0 17.0 1.0 B .• 
Salary level 7 1.0 1.0 5.0 5.0 5.0 4.0 3.7 
Total professional nurses 3.0 0.6 2.6 8.0 4.0 22.0 5.0 6.0 4.0 12.0 
-
Nurses Salary level 6 3.0 1.0 11.0 4.5 
Salary level 5 5.0 2.0 16.0 2.0 3.0 3.0 B.C 
Salary level 4 0.6 0.1 1.0 0.1 
Salary level 3 1.0 1.0 O.f 
Salary level 2 2.0 4.0 I U 
Total other nurses 0.0 0.6 0.1 12.0 3.0 32.0 2.0 3.0 3.0 15.~ 
Pharmacist Salary level 9 0.6 0.1 2.0 O.~ 
-Total clinical personnel 7.0 3.7 6.f 23.0 8.0 68.0 7.0 9.0 7.0 33.~ 
-Ratio of medical officers to 
professional nurses 1.3 3.2 1.4 0.4 0.3 0.5 0.0 0.0 0.0 0.5 
~-
# visits per medical officer 4,637 1,799 4,195 16,348 35,703 16,222 - - - 11,331 
# visits per professional nurse 6,182 5,698 6,107 6,131 8,926 8,848 11 ,202 11 ,165 7,963 B,B6! 
# visits per medical officer + 
professional nurse 2,649 1,368 2,450 4,459 7,141 5,725 11 ,202 11 ,165 7,963 6,95; 
108 
University of Cape Town
2 . 3 .  O v e r h e a d  a n d  c a p i t a l  c o s t  p e r  v i s i t  
O v e r h e a d  c o s t s  i n c l u d e  a l l  r e s o u r c e s  t h a t  c a n n o t  b e  l i n k e d  t o  p a t i e n t - u t i l i z a t i o n  s u c h  a s  s e c u r i t y ,  
a d m i n i s t r a t i v e  a n d  c l e a n i n g  p e r s o n n e l ,  a n d  w a t e r  a n d  e l e c t r i c i t y .  C a p i t a l  c o s t s  i n c l u d e  b u i l d i n g s ,  
e q u i p m e n t  a n d  i n i t i a l  s t a f f  t r a i n i n g .  A  b r e a k d o w n  o f  o v e r h e a d  a n d  c a p i t a l  c o s t s  i s  p r e s e n t e d  i n  
F i g u r e  1 2 .  T h e s e  r a n g e d  b e t w e e n  U S $ 2 2 . 6 6  a t  t h e  J o o s t e  O P D  a n d  U S $ I . 7 6  a t  M b e k w e n i .  C o s t s  
a r e  g e n e r a l l y  h i g h e r  i n  t h e  O P D s  t h a n  i n  t h e  C H C s ,  w h i c h  i n  t u m  h a v e  h i g h e r  c o s t s  t h a n  t h e  
c l i n i c s .  
F i g u r e  1 2 :  O v e r b e a d  a D d  c a p i t a l  c o s t  p e r  A R T  a n d  N o - A R T  v i s i t  a c r o s s  f a c i l i t i e s  ( U S $ ;  
2 0 0 4  p r i c e s )  
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S o u r c e :  §  G o v e n d e r ,  M c I n t y r e  e t  a \ .  ( 2 0 0 0 )  
2 . 4 .  A v e r a g e  w e i g h t e d  u n i t  c o s t  p e r  A R T  a n d  N o - A R T  v i s i t  
T h e  u l t i m a t e  a i m  o f  t h i s  s e c t i o n  o n  v i s i t  c o s t s  i s  t o  c a l c u l a t e  a n d  j u s t i f y  a  r e p r e s e n t a t i v e  u n i t  c o s t  
f o r  A R T  a n d  N o - A R T  v i s i t s .  I t  h a s  b e e n  s h o w n  t h a t  l a b o r a t o r y  c o s t s  i n  C H C s  a n d  c l i n i c s  d e r i v e d  
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f r o m  G o v e n d e r ,  M c I n t y r e  e t  a l .  ( 2 0 0 0 )  a r e  h i g h e r  t h a n  c u r r e n t  c o s t s  b e c a u s e  t h e  c o s t s  o f  k e y  
l a b o r a t o r y  i n v e s t i g a t i o n s  f o r  i l l Y / A I D S  h a v e  f a l I e n  d r a m a t i c a l l y .  G i v e n  t h a t  t h e i r  i n c l u s i o n  m i g h t  
o v e r e s t i m a t e  t h e  u n i t  c o s t  p e r  v i s i t ,  t h e y  h a v e  b e e n  e x c l u d e d  f r o m  t h e  a v e r a g e  c o s t  c a l c u l a t i o n s .  
O n  t h e  o t h e r  h a n d ,  t h e  u n i t  c o s t  f r o m  t h e  G r o o t e  S c h u u r  ( t e r t i a r y )  O P D  i s  i n  l i n e  w i t h  c u r r e n t  
c a l c u l a t i o n s ,  a n d  g i v e n  t h a t  t h e  m i x  o f  s t a f f i n g  i n  t e r t i a r y  f a c i l i t i e s  h a s  n o t  c h a n g e d  d r a m a t i c a l I y  
o v e r  t i m e ,  t h i s  c o s t  i s  i n c l u d e d  i n  t h e  c a l c u l a t i o n .  
F o r  N o - A R T ,  t h e  c a l c u l a t i o n  o f  w e i g h t e d  a v e r a g e  c o s t s  h a s  b e e n  d o n e  i n  t h e  f o l l o w i n g  m a n n e r .  
F i r s t l y ,  t h e  c o s t s  o f  c l i n i c s  a n d  C H C s  h a v e  b e e n  g r o u p e d  s e p a r a t e l y  f r o m  O P D s .  S e c o n d l y ,  w i t h i n  
e a c h  g r o u p ,  t h e  f o l I o w i n g  m e t h o d s  h a v e  b e e n  u s e d  t o  c a l c u l a t e  w e i g h t e d  a v e r a g e  c l i n i c / C H C  a n d  
O P D  c o s t s :  
•  P a t i e n t - s p e c i f i c  c o s t s  ( m e d i c i n e s ,  i m a g i n g  a n d  l a b o r a t o r y  i n v e s t i g a t i o n s )  h a v e  b e e n  
w e i g h t e d  a c c o r d i n g  t o  t h e  c o s t i n g  s a m p l e  s i z e
3
.  
•  U s i n g  a  s i m i l a r  m e t h o d ,  c l i n i c a l  p e r s o n n e l  c o s t s  h a v e  b e e n  w e i g h t e d  a c c o r d i n g  t o  t h e  
n u m b e r  o f  v i s i t s  t h a t  w e r e  t i m e d  i n  e a c h  s e t t i n g .  
•  C a p i t a l  a n d  o v e r h e a d  c o s t s  h a v e  b e e n  w e i g h t e d  a c c o r d i n g  t o  t h e  p r o p o r t i o n  o f  a n n u a l  
v i s i t s  i n  x  f a c i l i t y  o u t  o f  t o t a l  a n n u a l  v i s i t s  f r o m  a l l  f a c i l i t i e s  i n c l u d e d  i n  d a t a  c o l l e c t i o n .  
O n c e  c l i n i c / C H C  a n d  O P D  a v e r a g e  c o s t s  h a v e  b e e n  e s t i m a t e d ,  t h e  t h i r d  s t e p  i s  t o  c a l c u l a t e  a  f i n a l  
a v e r a g e  w e i g h t e d  c o s t  a c r o s s  a l l  f a c i l i t y  t y p e s ,  b a s e d  o n  t h e  p r o p o r t i o n  o f  v i s i t s  t h a t  h a p p e n  a t  
c l i n i c s / C H C s  v e r s u s  O P D s  a c r o s s  t h e  c o u n t r y 4 .  D a t a  o n  t h e  n u m b e r  o f  h o s p i t a l  o u t p a t i e n t  
d e p a r t m e n t  v i s i t s  a n d  c l i n i c  a n d  C H C  v i s i t s  w e r e  e x t r a c t e d  f r o m  t h e  N a t i o n a l  D e p a r t m e n t  o f  
H e a l t h ' s  I H P F  m o d e l  w h i c h  w a s  u p d a t e d  t o  2 0 0 2 / 0 3
5
•  T h e s e  d a t a  i n d i c a t e d  t h a t  a c r o s s  t h e  
c o u n t r y  8 8  p e r  c e n t  o f  v i s i t s  w e r e  t o  c l i n i c s  a n d  C H C s  a n d  1 2  p e r  c e n t  t o  h o s p i t a l  O P D s .  T h i s  
p r o p o r t i o n  i s  s i m i l a r  t o  t h a t  f o u n d  i n  a n  a p p r a i s a l  o f 2 1  D i s t r i c t  H e a l t h  E x p e n d i t u r e  R e v i e w  
r e p o r t s ,  w h i c h  i n d i c a t e d  t h a t  1 6  p e r  c e n t  o f  v i s i t s  t o o k  p l a c e  a t  h o s p i t a l  O P D s  ( C l e a r y ,  O k o r a f o r  
e t  a l .  2 0 0 5 ) .  I t  i s  a s s u m e d  t h a t  a n y  e x p a n s i o n  i n  N o - A R T  s e r v i c e s  m a i n t a i n s  t h e  c u r r e n t  s e r v i c e  
c o n f i g u r a t i o n  i n  S o u t h  A f r i c a .  W h i l e  t h i s  i s  r e a s o n a b l e  i n  t h e  s h o r t - t e r m ,  i n  t h e  l o n g e r  r u n  i t  i s  
3  I f  t h e  t o t a l  s a m p l e  o f  v i s i t s  f o r  c a l c u l a t i n g  p a t i e n t - s p e c i f i c  c o s t s  w a s  1 0 0 ,  a n d  o n e  c l i n i c  c o n t r i b u t e d  8 0  
v i s i t s  t o  t h e  s a m p l e ,  t h e  a v e r a g e  p a t i e n t - s p e c i f i c  c o s t  f r o m  t h i s  s e t t i n g  w o u l d  b e  w e i g h t e d  a t  8 0 / 1 0 0 = 0 . 8 .  
4  T h i s  c a l c u l a t i o n  i n c l u d e s  a l l  d i s e a s e s  a n d  s e r v i c e s .  D a t a  a r e  n o t  r o u t i n e l y  c o l l e c t e d  f o r  N o - A R T  c a r e .  
5  A t t e m p t s  w e r e  u n s u c c e s s f u l  t o  a c c e s s  a  m o r e  r e c e n t  v e r s i o n  o f  t h e  m o d e l .  
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l i k e l y  t h a t  t h e  c o u n t r y ' s  s t o c k  o f  C H C  i n f r a s t r u c t u r e  w i l l  b e  u p g r a d e d  a n d  i n c r e a s e d  t o  m e e t  t h e  
b u r d e n  o f I D V - t r e a t m e n t  ( D e p a r t m e n t  o f  H e a l t h  2 0 0 7 ) .  A  s c e n a r i o  w i l l  t h e r e f o r e  b e  c o n s t r u c t e d  
w h e r e  i t  i s  a s s u m e d  t h a t  a l l  N o - A R T  v i s i t s  o c c u r  a t  c l i n i c s  a n d  C H C s .  
F i g u r e  1 3  p r e s e n t s  t h e  b r e a k d o w n  o f  c o s t s  a c r o s s  t h e  f a c i l i t i e s  t h a t  h a v e  b e e n  i n c l u d e d  i n  t h e  f i n a l  
N o - A R T  u n i t  c o s t  c a l c u l a t i o n s ,  a s  w e l l  a s  t h e  a v e r a g e  w e i g h t e d  u n i t  c o s t  a c r o s s  c l i n i c s  a n d  
C H C s ,  a n d  a c r o s s  O P D s .  
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Figure 13: Average weighted unit cost per No-ART visit (US$; 2004 prices) 
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University of Cape Town
F o r  A R T  s e r v i c e s ,  a v e r a g e  w e i g h t e d  c o s t s  h a v e  b e e n  c a l c u l a t e d  u s i n g  t h e  s a m e  m e t h o d s  a s  f o r  
N o - A R T  s e r v i c e s .  F i g u r e  1 4  s h o w s  t h e  f i n a l  u n i t  c o s t  p e r  A R T  v i s i t .  
F i g u r e  1 4 :  A v e r a g e  w e i g h t e d  u n i t  c o s t  p e r  A R T  v i s i t  ( U S $ ;  2 0 0 4  p r i c e s )  
3 0 . 0 0  
•  S t a f f  t r a i n i n g  
o  E q u i p m e n t  
2 0 . 0 0  
•  B u i l d i n g s  
o  Q \ e r h e a d s  
1 0 . 0 0  
o  C o u n s e l l i n g  s t a f f  
•  C l i n i c a l  s t a f f  
K h a y e l i t s h a  C H C s  
T C  N e w m a n  Q P D  U n i t  c o s t  A R T  
•  M e d i c i n e s  
1 1 3  
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T a b l e  1 0  c o m p a r e s  t h e  f i n a l  u n i t  c o s t  f o r  A R T  a n d  N o - A R T  v i s i t s .  C l i n i c a l  s t a f f ,  c o u n s e l l i n g  a n d  
c a p i t a l  c o s t s  a r e  h i g h e r  f o r  A R T  v i s i t s  w h i l e  m e d i c i n e  c o s t s  a r e  h i g h e r  f o r  N o - A R T .  B e a r  i n  m i n d  
t h a t  A R V  m e d i c i n e  a n d  l a b o r a t o r y  c o s t s  h a v e  b e e n  c a l c u l a t e d  s e p a r a t e l y  f o r  A R T  s e r v i c e s .  
T a b l e  J O :  C o m p a r i s o n  o f  u n i t  c o s t  p e r  A R T  a n d  N o - A R T  v i s i t  ( U S $ ;  2 0 0 4  p r i c e s )  
A R T  
%  
N o - A R T  %  
M e d i c i n e s  1 . 6 4  
8 . 6 %  
3 . 3 8  1 7 . 2 %  
L a b o r a t o r y  i n v e s t i g a t i o n s  
0 . 0 %  I  2 . 8 9  1 4 . 7 %  
I m a g i n g  0 . 0 %  0 . 1 5  
0 . 8 % '  
C l i n i c a l  s t a f f  
6 . 5 6  I  
3 4 . 5 %  
5 . 7 0  
2 9 . 0 %  
C o u n s e l l i n g  s t a f f  2 . 9 3  1 5 . 4 %  0 . 1 3  0 . 7 %  
O v e r h e a d s  6 . 3 6  3 3 . 4 %  6 . 7 9  3 4 . 6 %  
B u i l d i n g s  
0 . 9 5  5 . 0 %  
0 . 4 5  2 . 3 %  
E q u i p m e n t  0 . 3 7  2 . 0 %  
0 . 1 1  
0 . 6 %  
S t a f f  t r a i n i n g  0 . 2 1  1 . 1 %  0 . 0 2  
0 . 1 %  
C o s t  p e r  v i s i t  
1  
1 9 . 0 2  1  1 0 0 . 0 % 1  
1 9 .
6 2
1  
1 0 0 . 0 %  
3  U n i t  c o s t  o f  t u b e r c u l o s i s  t r e a t m e n t  
T u b e r c u l o s i s  ( T B )  i s  o n e  o f  t h e  l e a d i n g  c a u s e s  o f  d e a t h  f o r  H I V - p o s i t i v e  p a t i e n t s  ( B a d r i ,  W i l s o n  
e t  a l .  2 0 0 2 ) .  I n  S o u t h  A f r i c a ,  T B  t r e a t m e n t  i s  o f f e r e d  t h r o u g h  a  v e r t i c a l  s e r v i c e .  [ f a  p a t i e n t  i s  
s u s p e c t e d  o f  h a v i n g  T B ,  h e / s h e  i s  r e f e r r e d  f r o m  g e n e r a l  p r i m a r y  c a r e  s e r v i c e s  t o  T B  s e r v i c e s .  A t  
t h i s  p o i n t ,  T B  d i a g n o s i s  i s  c o n f i r m e d  a n d  t r e a t m e n t  i s  i n i t i a t e d .  T B  t r e a t m e n t  c o n s i s t s  o f  f o u r  o r  
f i v e  d o c t o r - b a s e d  c l i n i c  v i s i t s  f o r  t r e a t m e n t  i n i t i a t i o n  a n d  m o n i t o r i n g ,  a l o n g  w i t h  s t r u c t u r e d  
o n g o i n g  d i r e c t l y  o b s e r v e d  t r e a t m e n t  ( D O T )  s u p p o r t  a t  a  c l i n i c ,  b y  c o m m u n i t y  t r e a t m e n t  
s u p p o r t e r s  o r  a t  t h e  w o r k p l a c e .  T r e a t m e n t  h a s  t o  b e  s u s t a i n e d  f o r  6  m o n t h s  f o r  n e w  p a t i e n t s  a n d  7  
m o n t h s  f o r  r e t r e a t m e n t  p a t i e n t s .  S t a n d a r d  p r o t o c o l s  e x i s t  f o r  l a b o r a t o r y  i n v e s t i g a t i o n ,  i m a g i n g ,  
a n d  m e d i c i n e  r e g i m e n s  d e p e n d i n g  o n  w h e t h e r  t h e  p a t i e n t  i s  a  n e w  o r  r e t r e a t m e n t  c a s e  
( D e p a r t m e n t  o f  H e a l t h  2 0 0 0 c ) .  
1 1 4  
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T h e  c o s t i n g  o f T B  t r e a t m e n t  h a s  b e e n  b r o k e n  i n t o  t h r e e  c a t e g o r i e s :  c l i n i c  v i s i t s  f o r  t r e a t m e n t  
i n i t i a t i o n  a n d  m o n i t o r i n g ;  D O T S ;  a n d  p a t i e n t - s p e c i f i c  c o s t s  ( T B  m e d i c i n e s ,  l a b o r a t o r y  
i n v e s t i g a t i o n s ,  i m a g i n g  a n d  p r o c e d u r e s ) .  C o s t s  i n  t h e s e  c a t e g o r i e s  h a v e  b e e n  c a l c u l a t e d  s e p a r a t e l y  
f o r  n e w  a n d  r e t r e a t m e n t  c a s e s  ( s e e  T a b l e  I I ) .  T h e  c o s t s  o f  c l i n i c  v i s i t s  f o r  t r e a t m e n t  i n i t i a t i o n  a n d  
m o n i t o r i n g  h a v e  b e e n  b a s e d  o n  H I  V - p o s i t i v e  p a t i e n t s  a t  N y a n g a  c l i n i c  ( s e e  s e c o n d  c o l u m n  i n  
T a b l e  I I ) .  T h e  c o s t s  o f  c l i n i c  v i s i t s  f o r  i n i t i a t i o n  a n d  m o n i t o r i n g  h a v e  a l s o  b e e n  s o u r c e d  f r o m  
s e c o n d a r y  d a t a  f o r  p a t i e n t s  w h o  w e r e  n o t  n e c e s s a r i l y  H I V - p o s i t i v e  ( S i n a n o v i c ,  F l o y d  e t  a l .  2 0 0 0 ;  
S i n a n o v i c ,  F l o y d  e t  a l .  2 0 0 3 ) .  T h e  o v e r a l l  m a g n i t u d e  o f  c l i n i c  v i s i t  c o s t s  f r o m  s e c o n d a r y  d a t a  w a s  
s i m i l a r  t o  t h e  c o s t s  a t  N y a n g a ,  e s p e c i a l l y  i f  t h e  a d d i t i o n a l  m e d i c i n e s  ( m a i n l y  m u l t i v i t a m i n s  a n d  
c o t r i m o x a z o l e )  o f f e r e d  t o  H l V - p o s i t i v e  p a t i e n t s  w e r e  e x c l u d e d  f r o m  t h e  N y a n g a  v i s i t  c o s t .  F o r  
t h i s  r e a s o n ,  d e s p i t e  t h e  s a m p l e  s i z e  a t  N y a n g a  b e i n g  s m a l l ,  t h e  a v e r a g e  c o s t  p e r  c l i n i c  v i s i t  f o r  
i n i t i a t i o n  a n d  m o n i t o r i n g  w a s  b a s e d  o n  t h e s e  c o s t s  a n d  s e c o n d a r y  d a t a  w e r e  n o t  i n c l u d e d .  W h i l e  
D O T S  c o s t s  w e r e  a l s o  c a l c u l a t e d  f o r  N y a n g a ,  a  n w n b e r  o f  a l t e r n a t i v e  T B  s u p e r v i s i o n  m o d e l s  a r e  
e m p l o y e d  i n  t h e  h e a l t h  s y s t e m ,  w i t h  d i f f e r e n t  a s s o c i a t e d  c o s t s .  T o  c a p t u r e  t h e s e  d i f f e r e n c e s ,  
w e i g h t e d  a v e r a g e  c o s t s  f o r  T B  D O T S  i n c l u d e d  p r i m a r y  a n d  s e c o n d a r y  d a t a ,  a n d  c o s t s  w e r e  
w e i g h t e d  a c c o r d i n g  t o  t h e  t o t a l  p a t i e n t  s a m p l e  i n  e a c h  s e t t i n g .  P a t i e n t - s p e c i f i c  c o s t s ,  i n c l u d i n g  T B  
m e d i c i n e ,  l a b o r a t o r y  i n v e s t i g a t i o n  a n d  i m a g i n g ,  w e r e  b a s e d  o n  t h e  N a t i o n a l  P r o t o c o l .  S e c o n d a r y  
d a t a  w e r e  n o t  i n c l u d e d  i n  t h e  c a l c u l a t i o n ,  b u t  a r e  p r e s e n t e d  i n  T a b l e  I I  f o r  c o m p a r a t i v e  p u r p o s e s .  
T h e  w e i g h t e d  a v e r a g e  c o s t  p e r  p a t i e n t  t r e a t e d  w a s  U S $ 5 4 5  f o r  n e w  p a t i e n t s  a n d  U S $ 7 7 7  f o r  
r e t r e a t m e n t  p a t i e n t s .  
l I S  
University of Cape Town
T a b l e  1 1 :  U n i t  c o s t s  o f  T B  t r e a t m e n t  ( U S $ ;  2 0 0 4  p r i c e s )  
N y a n g a ;  N y a n g a ;  C h a p e l  S t ;  G u g u l e t u ;  
G u g u l e t u ;  
G u g u l e t u ;  
C o m -
V e n u e  C l i n i c  C l i n i c  C l i n i c  
C l i n i c  W o r k - p l a c e  
m u n i t y  
A l l e r a g e  
D O T S  D O T S '  D O T S '  
D O T S ·  
D O T S ·  
D O T S ·  
T o t a l  p a t i e n t  s a m p l e s  2 6  2 0 7  
1 3 5  6 1 4  
1 1  1 7 7  
1 1 7 0  
C o s t s  o f  T B  t r e a t m e n t  f o r  n e w  p a t i e n t s  
N e w  p a t i e n t  s a m p l e s  1 7  
1 3 6  9 3  
3 8 3  9  
1 4 5  7 8 3  
C o s t s  o f  4  c l i n i c  I I i  s i t s  f o r  i n i t i a t i o n  a n d  m o n i t o r i n g  
M e d i c i n e s  
5 . 6 7  
5 . 6 7  
C l i n i c a l  s t a f f  2 8 . 7 0  2 8 . 7 0  
O l l e r h e a d s  8 . 2 6  
8 . 2 6  
B u i l d i n g s  1 . 2 3  
1 . 2 3  
E q u i p m e n t  
0 . 2 3  
0 . 2 3  
T o t a l  
4 4 . 0 8  2 9 . 7 3  
3 2 . 8 6  2 7 . 3 4  2 8 . 0 4  2 8 . 0 2  4 4 . 0 8  
C o s t s  o f  o n g o i n g  D O T S  l I i s i t s  
O v e r h e a d s  2 6 8 . 4 3  
B u i l d i n g s  3 9 . 8 3  
E q u i p m e n t  7 . 3 2  
T o t a l  
3 1 5 . 5 7  5 0 8 . 5 0  
5 9 1 . 4 7  4 5 5 . 4 5  8 4 . 9 4  1 4 8 . 1 4  4 2 7 . 4 5  
P a t i e n t - s p e c i f i c  c o s t s  f o r  n e w  T B  c a s e  
T B  M e d i c i n e s  4 3 . 3 9  4 9 . 4 9  4 9 . 4 9  4 9 . 4 9  4 9 . 4 9  4 9 . 4 9  
4 3 . 3 9  
L a b o r a t o r y  i n v e s t i g a t i o n s  1 1 . 1 3  7 . 9 1  7 . 9 1  7 . 9 1  7 . 9 1  7 . 9 1  1 1 . 1 3  
I m a g i n g  &  p r o c e d u r e s  1 8 . 7 8  2 2 . 6 5  
2 2 . 6 5  
2 2 . 6 5  2 2 . 6 5  2 2 . 6 5  
1 8 . 7 8  
T o t a l  7 3 . 3 0  8 0 . 0 4  8 0 . 0 4  8 0 . 0 4  8 0 . 0 4  8 0 . 0 4  7 3 . 3 0  
T o t a l  c o s t  p e r  n e w  p a t i e n t  t r e a t e d  4 3 2 . 9 4  6 1 8 . 2 7  7 0 4 . 3 7  5 6 2 . 8 3  
1 9 3 . 0 2  2 6 6 . 2 1  6 4 4 . 8 2  
C o s t s  a t  T B  t r e a t m e n t  t o r  r e t r e a t m e n t  p a t i e n t s  
R e t r e a t m e n t  p a t i e n t  s a m p l e s  9  
7 1  
4 2  2 3 1  
2  
3 2  
3 8 7  
C o s t s  o f  5  c l i n i c  l I i s i t s  f o r  i n i t i a t i o n  a n d  m o n i t o r i n g  
M e d i c i n e s  7 . 0 8  7 . 0 8  
C l i n i c a l  s t a f f  3 5 . 8 7  
3 5 . 8 7  
O v e r h e a d s  1 0 . 3 2  1 0 . 3 2  
B u i l d i n g s  1 . 5 3  1 . 5 3  
E q u i p m e n t  
0 . 2 8  
0 . 2 8  
T o t a l  6 6 . 1 0  3 7 . 1 6  4 1 . 0 7  3 4 . 1 7  3 4 . 6 6  3 5 . 1 2  6 6 . 1 0  
C o s t s  o f  o n g o i n g  D O T S  l I i s i t s  
O v e r h e a d s  3 5 9 . 2 8  
B u i l d i n g s  
5 3 . 3 1  
I  
E q u i p m e n t  
9 . 7 9  
T o t a l  
4 2 2 . 3 8  6 8 0 . 6 1  7 9 1 . 6 6  6 0 9 . 4 4  2 0 3 . 9 4  2 7 0 . 3 1  6 8 3 . 7 8  
P a t i e n t - s p e c i f i c  c o s t s  f o r  r e t r e a t m e n t  T B  c a s e  
T B  M e d i c i n e s  8 4 . 3 9  1 0 4 . 6 9  1 0 4 . 6 9  1 0 4 . 6 9  1 0 4 . 6 9  1 0 4 . 6 9  8 4 . 3 9  
L a b o r a t o r y  i n l l e s t i g a t i o n s  3 4 . 7 1  2 3 . 8 2  2 3 . 8 2  2 3 . 8 2  2 3 . 8 2  2 3 . 8 2  
3 4 . 7 1  I  
I m a g i n g  &  p r o c e d u r e s  1 8 . 7 8  2 2 . 6 5  2 2 . 6 5  
2 2 . 6 5  2 2 . 6 5  
2 2 . 6 5  1 8 . 7 8  
T o t a l  
1 3 7 . 8 9  
1 6 1 . 1 5  1 6 1 . 1 6  
1 6 1 . 1 5  1 6 1 . 1 6  1 5 1 . 1 6  1 3 7 . 8 9  
T o t a l  c o s t  p e r  r e t r e a t m e n t  p a t i e n t  
t r e a t e d  
6 1 6 . 3 6  
8 6 8 . 9 2  
9 8 3 . 8 8  
7 9 4 . 7 6  
3 8 9 . 7 3  4 6 6 . 5 8  
7 7 6 . 7 7  
1 1 6  
University of Cape Town
T a b l e  1 2  s h o w s  t h e  f i n a l  a v e m g e  w e i g h t e d  c o s t  ( U S $ 6 2 2 )  t o  b e  u s e d  f o r  T B  s e r v i c e s .  T h i s  i s  a  
w e i g h t e d  a v e r a g e  o f  n e w  a n d  r e t r e a t r n e n t  c o s t s ,  w h e r e  t h e  w e i g h t i n g  i s  b a s e d  o n  t h e  p e r c e n t a g e  o f  
p a t i e n t s  i n  e a c h  c a t e g o r y .  O v e m l l ,  3 3  p e r  c e n t  o f  p a t i e n t s  w e r e  r e t r e a t m e n t  c a s e s .  T h i s  w a s  s i m i l a r  
t o  t h e  p e r c e n t a g e  o f  H I  V - p o s i t i v e  r e t r e a t m e n t  T B  p a t i e n t s  i n  N y a n g a  ( 3 5  p e r  c e n t ) .  T h e  c o s t s  o f  
D O T S  m o n i t o r i n g  c o m p r i s e d  7 8 . 1  p e r  c e n t  o f  t h e  c o s t  o f T B  t r e a t m e n t .  
T a b l e  1 2 :  C o m p a r i s o n  o f  c o s t s  o f  m a n a g i n g  n e w  a n d  r e t r e a t m e n t  T B  p a t i e n t s  ( U S $ ;  2 0 0 4  
p r i c e s )  
T y p e  o f  T B  t r e a t m e n t  
N e w  R e t r e a t m e n t  
A v e r a g e  
%  
p a t i e n t s  p a t i e n t s  
I  
, I  
P a t i e n t  s a m p l e s  
7 8 3  
3 8 7  1 1 7 0  
C o s t s  - c l i n i c  v i s i t s  
M e d i c i n e s  5 . 6 7  7 . 0 8  6 . 1 4  1 . 0 %  
C l i n i c a l  s t a f f  
2 8 . 7 0  3 5 . 8 7  
3 1 . 0 7  5 . 0 %  
O v e r h e a d s  
8 . 2 6  
1 0 . 3 2  
8 . 9 4  
1 . 4 %  
B u i l d i n g s  1 . 2 3  1 . 5 3  1 . 3 3  0 . 2 %  
E q u i p m e n t  0 . 2 3  0 . 2 8  0 . 2 4  0 . 0 %  
T o t a l  4 4 . 0 8  5 5 . 1 0  
4 7 . 7 2  
7 . 7 %  
C o s t s  - D O T S  v i s i t s  
T o t a l  
4 2 7 . 4 5  5 8 3 . 7 8  4 7 9 . 1 6  7 7 . 1 %  
P a t i e n t - s p e c i f i c  c o s t s  f o r  T B  
T B  M e d i c i n e s  
4 3 . 3 9  8 4 . 3 9  
5 6 . 9 5  9 . 2 %  
L a b o r a t o r y  i n v e s t i g a t i o n s  
1 1 . 1 3  3 4 . 7 1  
1 8 . 9 3  3 . 0 %  
I m a g i n g  &  p r o c e d u r e s  1 8 . 7 8  1 8 . 7 8  1 8 . 7 8  3 . 0 %  
T o t a l  7 3 . 3 0  1 3 7 . 8 9  9 4 . 6 6  
1 5 . 2 %  
T o t a l  c o s t s  o f  T B  t r e a t m e n t  5 4 4 . 8 2  7 7 6 . 7 7  6 2 1 . 5 4  
1 0 0 %  
4  U n i t  c o s t  p e r  i n p a t i e n t  d a y  
T h i s  s e c t i o n  d e s c r i b e s  a n d  s u m m a r i z e s  a  n u m b e r  o f  h o s p i t a l  c o s t  a n a l y s e s  t h a t  w i l l  b e  u s e d  t o  
i n f o r m  t h e  c o s t s  o f  i n p a t i e n t  c a r e  f o r  A R T  a n d  N o - A R T  p a t i e n t s .  T h e  s e c t i o n  i n c l u d e s  a  
d i s c u s s i o n  o f  p a t i e n t - s p e c i f i c  c o s t s ,  c l i n i c a l  p e r s o n n e l  c o s t s ,  o v e r h e a d  a n d  c a p i t a l  c o s t s  a n d  
c o n c l u d e s  w i t h  t h e  c a l c u l a t i o n  o f  a v e m g e  w e i g h t e d  u n i t  c o s t s  p e r  i n p a t i e n t  d a y .  
T a b l e  1 3  s u m m a r i z e s  t h e  p a t i e n t - s p e c i f i c  c o s t  p e r  i n p a t i e n t  d a y .  T h e  " s a m p l e  o f  i n p a t i e n t  d a y s "  
r e f e r s  t o  t h e  n u m b e r  o f  i n p a t i e n t  d a y s  t h a t  w a s  u s e d  t o  c a l c u l a t e  p a t i e n t - s p e c i f i c  c o s t s .  T h e  
" s a m p l e  o f  a d m i s s i o n s "  r e f e r s  t o  t h e  n u m b e r  o f  p a t i e n t s .  A t  t h e  s e c o n d a r y  l e v e l ,  o n e  o f  t h e  c o s t  
1 1 7  
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a n a l y s e s  c a l c u l a t e d  i n p a t i e n t  c o s t s  s e p a r a t e l y  f o r  A R T  a n d  N o - A R T  p a t i e n t s .  B e c a u s e  A R T -
s p e c i f i c  c o s t s  a r e  n o t  a v a i l a b l e  i n  o t h e r  f a c i l i t i e s ,  a n d  b e c a u s e  t h e  c o s t  w a s  s i m i l a r ,  t h e s e  d a t a  a r e  
m e r g e d .  I n  o t h e r  w o r d s ,  i t  i s  a s s u m e d  t h a t  t h e  c o s t  p e r  i n p a t i e n t  d a y  f o r  H I Y - p o s i t i v e  p a t i e n t s  i s  
t h e  s a m e  w h e t h e r  t h e  p a t i e n t  i s  o n  o r  o f f  A R T .  C o s t s  a t  J o o s t e  d e r i v e d  f r o m  S m i t h  D e  S c h e r i f ,  
S c h o e m a n  e t  a l .  ( 2 0 0 5 )  w e r e  f a r  l o w e r  t h a n  f r o m  H a i l e  ( 2 0 0 0 ) .  J o o s t e  h a d  b e e n  o p e n  f o r  o n e  y e a r  
a t  t h e  t i m e  o f  H a i l e ' s  s t u d y  a n d  h a d  p a t i e n t - s p e c i f i c  c o s t s  t h a t  w e r e  s i m i l a r  t o  t h o s e  a t  t e r t i a r y  
f a c i l i t i e s .  S i n c e  t h a t  t i m e ,  t h e  f a c i l i t y  h a s  e x p e r i e n c e d  a n  i n c r e a s i n g  H l Y - r e l a t e d  b u r d e n  i n  i t s  
m e d i c i n e  w a r d s  a n d  h a s  i n t r o d u c e d  s t e p - d o w n  c a r e  t o  c o p e  w i t h  t h i s  i n c r e a s e d  l o a d .  T h i s  i s  l i k e l y  
t o  b e  t h e  e x p l a n a t i o n  f o r  t h e  h i g h e r  p a t i e n t - s p e c i f i c  c o s t s  f r o m  t h e  H a i l e  s t u d y .  
A  w e i g h t e d  a v e r a g e  p a t i e n t - s p e c i f i c  c o s t  f o r  t e r t i a r y  a n d  s e c o n d a r y  h o s p i t a l s  h a s  b e e n  c a l c u l a t e d  
b a s e d  o n  t h e  p r o p o r t i o n  o f  t h e  s a m p l e  o f  i n p a t i e n t s  i n  f a c i l i t y  x  o u t  o f  t h e  t o t a l  i n p a t i e n t  s a m p l e  a t  
e a c h  l e v e l  o f  c a r e .  A s  b e f o r e ,  t h i s  c a l c u l a t i o n  m e t h o d  e n s u r e s  t h a t  l a r g e r  c o s t i n g  s a m p l e s  a r e  
g i v e n  r e l a t i v e l y  h i g h e r  w e i g h t  i n  a v e r a g e  c o s t  c a l c u l a t i o n s .  T h e  w e i g h t e d  a v e r a g e  p a t i e n t  s p e c i f i c  
c o s t  a t  t e r t i a r y  a n d  s e c o n d a r y  f a c i l i t i e s  w a s  U S $ 2 3 . 7 1  a n d  U S $ 1 5 . 2 1  r e s p e c t i v e l y .  
1 1 8  
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T a b l e  1 3 :  P a t i e n t - s p e c i f i c  c o s t  p e r  i n p a t i e n t  d a y  ( U S $ ;  2 0 0 4  p r i c e s )  
T y g e r b e r g  
N o - A R T  
o ·  
S a m p l e  o f  i n p a t i e n t  d a y s  2 4 3  
S a m p l e  o f  a d m i s s i o n s  6 1  
M e d i c i n e s  4 . 4 8  
L a b o r a t o r y  i n v e s t i g a t i o n s  6 . 4 0  
I m a g i n g  1 8 . 1 0  
C o n s u m a b l e s  
-
D i a g n o s t i c  a n d  t r e a t m e n t  p r o c e d u r e s  
-
I V  f l l i d s  a n d  b l o o d  
-
•  0  
. .  
T o t a l  p a t i e n t - s p e c i f i c  c o s t s  
I  
2 8 . 9 7 1  
S o u r c e s :  
§  G o v e n d e r ,  M c I n t y r e  e t  a l .  ( 2 0 0 0 )  
±  H a i l e  ( 2 0 0 0 )  
G r o o t e  
S c h u u r  §  
7 1 7  
1 0 0  
- 1  I  
5 . 6 7  
8 . 9 3  
3 . 2 2  
4 . 2 4  
-
-
-
2 2 . 0 6 1  
t  S m i t h  O e  S c h e r i f ,  S c h o e m a n  e t  a l .  ( 2 0 0 5 )  
A v e r a g e  
J o o s t e  &  
J o o s t e  ±  
C a r n a t i o n  
T e r t i a r y  
A R T t  
-
.  -
1 , 0 2 0  3 6 7  1 , 0 0 3  
1 6 1  
7 0  
. .  '  -
- ' " ' .  
.  
5 . 3 9  9 . 9 0  1 . 9 8  
8 . 3 2  1 2 . 9 7  
6 . 1 5  
6 . 7 6  4 . 1 6  3 . 7 4  
3 . 2 3  
- -
-
0 . 6 3  0 . 4 0  
-
-
3 , 0 4  
2 3 . 7 1  1  
2 7 . 6 6 1  1 2 . 2 6 1  
J o o s t e  &  
A v e r a g e  
C a m a t i o n  N o -
A R T t  
S e c o n d a r y  
6 5 4  
2 , 0 2 4  
6 0  
1 3 0  
1 . 9 0  
3 . 3 9  
6 . 2 7  
7 . 4 2  
4 . 4 3  
4 . 0 4  
-
-
0 . 1 3  0 . 3 5  
1 . 7 5  2 . 0 7  
-
1 2 . 7 4 1  
1 5 , 2 1  
T a b l e  1 4  c o n t a i n s  d e t a i l s  o f  o v e r h e a d ,  b u i l d i n g  a n d  e q u i p m e n t  c o s t s  p e r  i n p a t i e n t  d a y .  I n  a l l  
f a c i l i t i e s ,  o v e r h e a d  c o s t s  h a v e  b e e n  c a l c u l a t e d  f r o m  p r i m a r y  d a t a
6
,  a n d  c a p i t a l  c o s t s  a r e  b a s e d  o n  
t h e  N O o H  m o d e l .  T h e  t a b l e  a l s o  c o n t a i n s  i n f o r m a t i o n  o n  t h e  o v e r a l l  i n p a t i e n t  P O E  i n  e a c h  
f a c i l i t y ,  w h i c h  g i v e s  a  s e n s e  o f  t h e  s i z e  o f  e a c h  f a c i l i t y .  O v e r h e a d s  r a n g e d  b e t w e e n  U S $ 1 2 5 . 4 6  a t  
T y g e r b e r g  a n d  U S $ 4 5 . 9 5  a t  G r o o t e  S c h u u r .  T h e  l a t t e r  i s  s m a l l e r  b e c a u s e  c l i n i c a l  s t a f f  c o s t s  f o r  
n u r s e s  a n d  w a r d  s u p p o r t  s t a f f  h a v e  b e e n  c a l c u l a t e d  s e p a r a t e l y  ( s e e  T a b l e  1 5 ) .  
W e i g h t e d  a v e r a g e  o v e r h e a d  a n d  c a p i t a l  c o s t s  f o r  s e c o n d a r y  a n d  t e r t i a r y  f a c i l i t i e s  h a v e  b e e n  b a s e d  
o n  t h e  p r o p o r t i o n  o f  t h e  f a c i l i t y ' s  i n p a t i e n t  P O E  o u t  o f  t h e  t o t a l  i n p a t i e n t  P O E ,  i m p l y i n g  t h a t  t h e  
l a r g e r  f a c i l i t y  r e c e i v e d  g r e a t e r  e m p h a s i s  i n  a v e r a g e  c o s t  c a l c u l a t i o n s .  T h e  a v e r a g e  w e i g h t e d  
o v e r h e a d  c o s t  f o r  t e r t i a r y  f a c i l i t i e s  w a s  U S $ 8 5 . 5 7  a n d  U S $ 5 4 . 0 5  f o r  s e c o n d a r y  f a c i l i t i e s .  
E q u i p m e n t  a n d  b u i l d i n g  c o s t s  a r e  a l s o  h i g h e r  i n  t e r t i a r y  t h a n  s e c o n d a r y  h o s p i t a l s .  
6  W h i l e  p a t i e n t - s p e c i f i c  c o s t s  w e r e  d e r i v e d  f r o m  s e c o n d a r y  d a t a  i n  c e r t a i n  f a c i l i t i e s ,  a l l  o v e r h e a d s  h a v e  
b e e n  c a l c u l a t e d  u s i n g  m o r e  r e c e n t  r o u t i n e  f a c i l i t y  e x p e n d i t u r e  d a t a .  
I  
I  
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T a b l e  1 4 :  O v e r h e a d  a n d  c a p i t a l  c o s t s  p e r  i n p a t i e n t  d a y  ( U S $ ;  2 0 0 4  p r i c e s )  
T y g e r b e r g  
G r o o t e  S c h u u r  A v e r a g e  t e r t i a r y  J o o s t e i C a m a t i o n  
. . . •  
. -
. .  
. .  
-
-
O v e r h e a d  a n d  c a p i t a l  c o s t i n g  s a m p l e  ( P D E  
i n p a t i e n t s )  
5 1 6 , 4 7 3  4 2 4 , 9 4 2  9 3 , 7 2 0  
.  
- .  
O v e r h e a d  c o s t  p e r  i n p a t i e n t  d a y  1 2 5 . 4 6  4 5 . 9 5  
8 9 . 5 7  
5 4 . 0 5  
. -
. .  
- .  .  - - -
, .  
; -
B u i l d i n g  r e p l a c e m e n t  c o s t  
2 4 8 , 2 9 9 , 7 9 4 . 1 8  1 9 8 , 7 7 4 , 5 9 7 . 7 8  1 7 , 9 7 1 , 5 5 9 . 3 9  
E q u i p m e n t  r e p l a c e m e n t  c o s t  
1 2 4 , 1 4 9 , 8 9 7 . 0 9  9 9 , 3 8 7 , 2 9 8 . 8 9  
5 , 3 9 1 , 4 6 7 . 8 2  
B u i l d i n g  a n n u i t i z e d  c o s t  2 2 , 0 5 5 , 8 0 0 . 7 9  
1 7 , 6 5 6 , 6 1 1 . 2 2  1 , 5 9 6 , 3 6 5 . 1 3  
E q u i p m e n t  a n n u i t i z e d  c o s t  
3 1 , 0 9 4 , 2 2 1 , 2 3  
2 4 , 8 9 2 , 2 5 3 . 0 8  
1 , 3 5 0 , 3 3 1 . 3 1  
I  
B u i l d i n g  c o s t  p e r  i n p a t i e n t  d a y  
4 2 . 7 0  4 1 . 5 5  4 2 . 1 8  1 7 . 0 3  
E q u i p m e n t  c o s t  p e r  i n p a t i e n t  d a y  
- - I  
~020 I  
_ 5 8 5 8 1  
5 9 4 7 l  
- -
14~1 I  
S t a f f  c o s t s  w e r e  c a l c u l a t e d  f r o m  p r i m a r y  d a t a  a t  T y g e r b e r g  a n d  a t  J o o s t e  a n d  C a r n a t i o n ,  a n d  w e r e  
t a k e n  f r o m  s e c o n d a r y  d a t a  f o r  G r o o t e  S c h u u r .  S e p a r a t e  s t a f f  c o s t s  w e r e  c a l c u l a t e d  f o r  t h e  
C a r n a t i o n  w a r d  b e c a u s e  i t  h a s  s u b s t a n t i a l l y  l o w e r  c l i n i c a l  s t a f f  i n t e n s i t y  t h a n  t h e  J o o s t e  m e d i c i n e  
w a r d s .  J o o s t e  a n d  C a r n a t i o n  c o s t s  w e r e  c o m b i n e d  t o  c a l c u l a t e  a n  a v e r a g e  w e i g h t e d  c l i n i c a l  s t a f f  
c o s t  u s i n g  t h e  p r o p o r t i o n  o f  i n p a t i e n t  d a y s  s p e n t  i n  e a c h  f a c i l i t y  b y  p a t i e n t s  i n c l u d e d  i n  t h e  s t u d y  
b y  S m i t h  D e  C h e r i f ,  S c h o e m a n  e t  a l .  ( 2 0 0 5 )  a s  t h e  w e i g h t i n g  f a c t o r .  A s  m e n t i o n e d ,  G r o o t e  
S c h u u r  s t a f f  c o s t s  ( G o v e n d e r ,  M c I n t y r e  e t  a l .  2 0 0 0 )  c o v e r e d  a  w i d e r  r a n g e  o f  s t a f f  t h a n  i n  o t h e r  
f a c i l i t i e s ,  a n d  a r e  t h e r e f o r e  h i g h e r .  A t  T y g e r b e r g ,  i t  w a s  n o t  p o s s i b l e  t o  c a l c u l a t e  s e p a r a t e  n u r s i n g  
c o s t s  f o r  w a r d s  b e c a u s e  n u r s e s  w o r k  o n  a  f l e x i b l e  b a s i s  t h r o u g h o u t  t h e  f a c i l i t y .  A  w e i g h t e d  
a v e r a g e  s t a f f  c o s t  f o r  t e r t i a r y  f a c i l i t i e s  h a s  b e e n  b a s e d  o n  t h e  i n p a t i e n t  P D E ,  o n c e  a g a i n  g i v i n g  
g r e a t e r  w e i g h t  t o  s t a f f  c o s t s  f r o m  t h e  l a r g e r  f a c i l i t y .  
1 2 0  
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T a b l e  1 5 :  S t a f f  c o s t  p e r  i n p a t i e n t  d a y  ( U S $ ;  2 0 0 4  p r i c e s )  
A v e r a g e  
G r o o t e  
A v e r a g e  J o o s t e l  
T y g e r b e r g  
S c h u u r §  t e r t i a r y  
J o o s t e  
C a r n a t i o n  
C a r n a t i o n  
J  
M e d i c a l  o f f i c e r  
3 5 . 9 3  
2 8 . 4 1  3 2 . 5 3  1 4 . 2 8  1 . 4 5  
1 1 . 7 1  
P r o f e s s i o n a l  n u r s e  
4 2 . 0 4  1 8 . 9 7  6 . 3 3  5 . 4 5  
6 . 1 5  
W a r d  s u p p o r t  s t a f f  1 . 7 1  0 . 7 7  
- -
T o t a l  c l i n i c a l  s t a f f  c o s t s  
1  
3 5 . 9 3 1  7 2 . 1 6 1  5 2 . 2 8 1  2 0 . 6 0  I  6 . 9 0  I  
1 7 . 8 6  
S o u r c e :  § G o v e n d e r ,  M c I n t y r e  e t  a l .  ( 2 0 0 0 )  
T a b l e  1 6  s u m m a r i z e s  t h e  f i n a l  t e r t i a r y  a n d  s e c o n d a r y  l e v e l  i n p a t i e n t  u n i t  c o s t s  t h a t  w i l l  b e  u s e d  i n  
s u b s e q u e n t  c h a p t e r s .  T h e  a v e r a g e  w e i g h t e d  c o s t  p e r  i n p a t i e n t  d a y  i n  t e r t i a r y  c a r e  w a s  U S $ 2 6 7 . 2 1  
i n  c o m p a r i s o n  w i t h  U S $ 1 1 8 . S 6  f o r  s e c o n d a r y  l e v e l  c a r e .  I n  b o t h  i n s t a n c e s ,  t h e  b i g g e s t  c o s t  
d r i v e r s  w e r e  o v e r h e a d s  a n d  c a p i t a l .  P a t i e n t - s p e c i f i c  c o s t s  w e r e  8 . 9  p r  c e n t  a n d  1 2 . 8  p e r  c e n t  o f  
t h e  t o t a l  i n  t e r t i a r y  a n d  s e c o n d a r y  h o s p i t a l s  r e s p e c t i v e l y .  
T a b l e  1 6 :  A v e r a g e  w e i g h t e d  u n i t  c o s t  p e r  i n p a t i e n t  d a y  ( U S $ ;  2 0 0 4  p r i c e s )  
A v e r a g e  
%  
A v e r a g e  
%  
T e r t i a r y  S e c o n d a r y  
-
S a m p l e  s i z e s  
P a t i e n t - s p e c i f i c  c o s t i n g  s a m p l e  1 , 0 2 0  
2 , 0 2 4  
O v e r h e a d  a n d  c a p i t a l  c o s t i n g  s a m p l e  ( P O E  
i n p a t i e n t s )  
9 4 1 , 4 1 5  9 3 , 7 2 0  
- -
C o s t s  
P a t i e n t - s p e c i f i c  2 3 . 7 1  8 . 9 %  1 5 . 2 1  1 2 . 8 %  
C l i n i c a l  s t a f f  5 2 . 2 8  1 9 . 6 %  
1 7 . 8 6  
1 5 . 1 %  
O v e r h e a d  
8 9 . 5 7  3 3 . 5 %  
5 4 . 0 5  4 5 . 6 %  
B u i l d i n g s  
4 2 . 1 8  1 5 . 8 %  
1 7 . 0 3  1 4 . 4 %  
E q u i p m e n t  
5 9 . 4 7  2 2 . 3 %  
1 4 . 4 1  1 2 . 2 % ,  
I  
T o t a l  c o s t  p e r  I P O  
1  
2 6 7 . 2 1  1  1 0 0 . 0 % 1  1 1 8 . 5 6 1  1 0 0 . 0 % ,  
S o u r c e s :  
§  P a t i e n t  s p e c i f i c  c o s t s  f r o m  G o v e n d e r ,  M c I n t y r e  e t  a l .  ( 2 0 0 0 )  
* P a t i e n t  s p e c i f i c  c o s t s  f r o m  H a i l e  ( 2 0 0 0 )  a n d  S m i t h  D e  S c h e r i f ,  S c h o e m a n  e t  a l .  ( 2 0 0 5 )  
1 2 1  
University of Cape Town
5  A R V  a n d  l a b o r a t o r y  i n v e s t i g a t i o n  c o s t s  
S o u t h  A f r i c a  r e c e n t l y  a w a r d e d  t e n d e r s  f o r  t h e  s u p p l y  o f  A R V  d r u g s  t o  t h e  p u b l i c  s e c t o r ,  f o r  t h e  
p e r i o d  2 0 0 5  t o  2 0 0 8 .  A l t h o u g h  a l l  o t h e r  c o s t s  i n  t h i s  d i s s e r t a t i o n  h a v e  b e e n  e x p r e s s e d  i n  2 0 0 3 / 0 4  
p r i c e s ,  t h e  p r i c e s  o f  A R V s  r e f l e c t  t h o s e  i n  t h e  t e n d e r  a s  o f  O c t o b e r  2 0 0 5 .  T h i s  w a s  n e c e s s a r y  t o  
c a p t u r e  t h e  s u b s t a n t i a l  r e d u c t i o n s  i n  A R V  p r i c e s  t h a t  h a v e  o c c u r r e d  i n  r e c e n t  y e a r s  ( L u c h i n i ,  
C i s s e  e t  a l .  2 0 0 3 ) .  T h e  m a j o r i t y  o f  t h e  t e n d e r  h a s  b e e n  a w a r d e d  t o  S o u t h  A f r i c a n  g e n e r i c  f i r m  
A s p e n ,  w i t h  s m a l l e r  q u a n t i t i e s  t o  I n d i a n  g e n e r i c  m a n u f a c t u r e r  C i p l a  M e d p r o .  W i t h  t h e  e x c e p t i o n  
o f 2 0  p e r  c e n t  o f  t h e  l a m i v u d i n e  m a r k e t  s h a r e  t o  G l a x o S m i t h K l i n e ,  t h e  o r i g i n a t o r  m a n u f a c t u r e r s  
h a v e  o n l y  b e e n  s u c c e s s f u l  w h e n  n o  g e n e r i c  a l t e r n a t i v e  h a s  b e e n  a v a i l a b l e  ( a s  i s  t h e  c a s e  w i t h  
e f a v i r e n z  - m a n u f a c t u r e d  b y  M S D  - a n d  l o p i n a v i r l r i t o n a v i r  - m a n u f a c t u r e d  b y  A b b o t t ) .  I n  a l l  
c a s e s ,  t h e  t e n d e r i n g  f i r m  h a s  b e e n  i n  p o s s e s s i o n  o f  M e d i c i n e s  C o n t r o l  C o u n c i l  r e g i s t r a t i o n  a n d  
a p p r o p r i a t e  I n t e l l e c t u a l  P r o p e r t y  r i g h t s  ( p a t e n t s  i n  t h e  c a s e  o f  o r i g i n a t o r  m a n u f a c t u r e r s  a n d  
v o l u n t a r y  l i c e n s e s  i n  t h e  c a s e  o f  g e n e r i c s  - t h e r e  a r e  c u r r e n t l y  n o  c o m p u l s o r y  l i c e n s e s  f o r  A R V s  
i n  S o u t h  A f r i c a ) .  T a b l e  1 7  c o n t a i n s  a  s u m m a r y  o f  A R V  m e d i c i n e s  a n d  f o r m u l a t i o n s ,  t h e  
m a n u f a c t u r e r  ( a n d  s h a r e  o f  m a r k e t  w h e r e  a p p r o p r i a t e )  a n d  t h e  c o s t  p e r  u n i t .  
1 2 2  
University of Cape Town
T a b l e  1 7 :  A R V  m e d i c i n e s ,  f o r m u l a t i o n s ,  m a n u f a c t u r e r s  a n d  c o s t  ( U S $ ;  O c t o b e r  2 0 0 5  
p r i c e s )  
M e d i c i n e  n a m e ,  f o r m u l a t i o n  a n d  q u a n t i t y  M a n u f a c t u r e r  S h a r e  o f  t e n d e r  C o s t  p e r  u n i t  
F i r s t - l i n e  r e g i m e n  
S t a v u d i n e  C a p s u l e s  3 0 m g ;  6 0 ' S  A s p e n  7 0 %  2 . 6 7  
S t a v u d i n e  C a p s u l e s  3 0 m g ;  6 0 ' S  
C i p l a  M e d p r o  
3 0 %  
2 . 9 4  
S t a v u d i n e  C a p s u l e s  3 0 m g ;  6 0 s  - a v e r a g e  w e i g h t e d  c o s t  
2 . 7 5  
S t a v u d i n e  C a p s u l e s  4 0 m g ;  6 0 ' S  A s p e n  6 0 %  
2 . 9 7  
S t a v u d i n e  C a p s u l e s  4 0 m g ;  6 0 ' S  C i p l a  M e d p r o  
4 0 %  
3 . 2 0  
S t a v u d i n e  C a p s u l e s  4 0 m ! l ;  6 0 s  - a v e r a ! l e  w e i ! l h t e d  c o s t  
3 . 0 6  
L a m i v u d i n e  T a b l e t s  1 5 0 m g ;  6 0 ' S  G l a x o  2 0 %  5 . 5 8  
L a m i v u d i n e  T a b l e t s  1 5 0 m g ;  6 0 ' S  A s p e n  8 0 %  4 . 6 8  
L a m i v u d i n e  T a b l e t s  1 5 0 m g ;  6 0 ' S  - a v e r a g e  w e i g h t e d  c o s t  4 . 8 6  
E f a v i r e n z  T a b l e t s  6 0 0 m g ;  3 0 ' S  M S D  1 0 0 %  
2 8 . 7 1  
N e v i r a p i n e  T a b l e t s  2 0 0 m g ;  6 0 ' S  A s g e n  1 0 0 %  5 . 7 1  
S e c o n d - l i n e  r e g i m e n  
D i d a n o s i n e  T a b l e t s  2 5 m g ;  6 0 ' S  
A s p e n  
1 0 0 %  
9 . 3 8  
D i d a n o s i n e  T a b l e t s  1 0 0 m g ;  6 0 ' S  A s p e n  1 0 0 %  1 0 . 8 9  
Z i d o v u d i n e  T a b l e t s  3 0 0 m g ;  6 0 ' S  A s p e n  1 0 0 %  1 0 . 7 3 1  
L o p i n a v i r / R i t o n a v i r  C a p s u l e s  
4 7 6 0 1  
1 3 3 . 3 m g ; 3 3 . 3 m g ;  1 8 0 ' S  
A b b o t t  1 0 0 %  
A R T  i s  c o m p o s e d  o f a  c o m b i n a t i o n  o f  t h r e e  d i f f e r e n t  A R V  m e d i c i n e s ,  s o m e  o f w r u c h  n e e d  t o  b e  
t a k e n  i n  d i f f e r e n t  f o r m u l a t i o n s  b y  d i f f e r e n t  p a t i e n t s .  I n  t h e  f i r s t - l i n e  r e g i m e n ,  p a t i e n t s  c a n  t a k e  
e i t h e r  e f a v i r e n z  o r  n e v i r a p i n e  i n  c o m b i n a t i o n  w i t h  s t a v u d i n e  a n d  l a m i v u d i n e .  T h e  s h a r e  o f  
p a t i e n t s  o n  n e v i r a p i n e / e f a v i r e n z  h a s  b e e n  b a s e d  o n  p r i m a r y  d a t a  f r o m  t h e  K h a y e l i t s h a  p r o g r a m m e  
( s e e  C h a p t e r  6  f o r  d e t a i l s ) .  D o s a g e s  f o r  s t a v u d i n e  a n d  d i d a n o s i n e  d i f f e r  d e p e n d i n g  o n  w h e t h e r  t h e  
p a t i e n t  w e i g h s  m o r e  o r  l e s s  t h a n  6 0 k g .  I f  t h e  f o r m e r ,  t h e  p a t i e n t  r e c e i v e s  s t a v u d i n e  3 0 m g  b d  
( t w i c e  d a i l y )  I  d i d a n o s i n e  2 5 0 m g  o d  ( o n c e  d a i l y ) ;  i f  t h e  l a t t e r ,  t h e  p a t i e n t  r e c e i v e s  s t a v u d i n e  4 0 m g  
b d  I  d i d a n o s i n e  4 0 0 m g  o d .  I t  w a s  a s s u m e d  t h a t  5 0  p e r  c e n t  o f  p a t i e n t s  w o u l d  f a l l  i n t o  e a c h  g r o u p .  
T a b l e  1 8  p r e s e n t s  t h e  c o s t  p e r  t h r e e - m o n t h  p e r i o d  f o r  e a c h  A R V .  T h i s  A R V  u n i t  c o s t  i n f o r m a t i o n  
w i l l  b e  c o m b i n e d  w i t h  d a t a  o n  t h e  p r o p o r t i o n  o f  p a t i e n t s  o n  d i f f e r e n t  A R V s  i n  t h e  n e x t  c h a p t e r  t o  
c a l c u l a t e  c o s t s  p e r  M a r k o v  s t a t e .  
1 2 3  
University of Cape Town
T a b l e  1 8 :  C o s t  p e r  t h r e e - m o n t h  p e r i o d  f o r  e a c h  A R V  ( U S S ;  O c t o b e r  2 0 0 5  p r i c e s )  
M e d i c i n e  n a m e  a n d  f o r m u l a t i o n  
F i r s t - l i n e  
S t a v u d i n e  ( 3 0 m g )  
S t a v u d i n e  ( 4 0 m g )  
L a m i v u d i n e  ( 1 5 0 m g )  
E f a v i r e n z  ( 6 0 0 m g )  
N e v i r a p i n e  ( 2 0 0 m g l  
S e c o n d - l i n e  
Z i d o v u d i n e  ( 3 0 0 m g )  
D i d a n o s i n e  ( 1 0 0 m g + 2 5 m g )  
D i d a n o s i n e  ( 1  O O m g )  
L o p i n a v i r / r i t o n a v i r  ( 1 '  3 3 .  3 / 3 3 . 3 m . g )  
b d  =  t w i c e  d a i l y  
o d  =  o n c e  d a i l y  
U n w e i g h t e d  c o s t  
Dail~dose 
p e r  q u a r t e r  
3 0 m g  b d  8 . 2 5  
4 0 m g  b d  9 . 1 8  
1 5 0 m g  b d  1 4 . 5 8  
6 0 0 m 9 .  a t  n i g h t  
8 6 . 1 4  
2 0 0 m g b d  
1 7 . 1 2  
3 0 0 m g b d  3 2 . 1 9  
2 * 1  O O m g + 2 * 2 5 m g  o d  6 0 . 8 0  
4 * 1 0 0 m_g  o d  6 5 . 3 3  
3 * 1 3 3 . 3 / 3 3 . 3  m g  o d  
1 4 2 . 8 1 1  
T a b l e  1 9  s h o w s  t h e  s c h e d u l e  o f  l a b o r a t o r y  i n v e s t i g a t i o n s  f o r  p a t i e n t s  o n  A R T ,  a s  d e r i v e d  f r o m  t h e  
n a t i o n a l  g u i d e l i n e s  ( D e p a r t m e n t  o f  H e a l t h  2 0 0 4 ) .  V i r a l  l o a d  t e s t i n g  o c c u r s  a t  b a s e  c a s e  ( i . e .  
t r e a t m e n t  i n i t i a t i o n )  a n d  t h e n  6 - m o n t h l y  t h e r e a f t e r .  C D 4  c o u n t  t e s t i n g  o c c u r s  w h e n  a  p a t i e n t  i s  
s t a g e d  f o r  A R T  a n d  t h e n  6 - m o n t h l y  t h e r e a f t e r .  P a t i e n t s  o n  n e v i r a p i n e  r e q u i r e  A L T  t e s t i n g  a t  
w e e k s  2 ,  4 ,  8  a n d  6 - m o n t h l y  t h e r e a f t e r .  S e c o n d - l i n e  p a t i e n t s  r e q u i r e  a  f u l l  b l o o d  c o u n t  a n d  w h i t e  
c e l l  d i  f f  a t  b a s e  c a s e ,  w e e k s  4 ,  8 ,  1 2  a n d  6 - m o n t h l y  t h e r e a f t e r  a s  w e l l  a s  l e s s  f r e q u e n t  f a s t i n g  
c h o l e s t e r o l  a n d  g l u c o s e  t e s t s .  T e s t i n g  i s  i n t e n s i v e  d u r i n g  t h e  f i r s t  6  m o n t h s  o f  t r e a t m e n t  f o r  b o t h  
f i r s t  a n d  s e c o n d - l i n e  r e g i m e n s ,  a n d  d r o p s  o f f  t o  s i x - m o n t h l y  f o r  m o s t  t e s t s  f o r  t h e  r e m a i n i n g  t i m e  
o n  e a c h  r e g i m e n .  
1 2 4  
University of Cape Town
T a b l e  1 9 :  L a b o r a t o r y  i n v e s t i g a t i o n  s c h e d u l e  
S t a g i n g  
B a s e - W e e k  W e e k  W e e k  W e e k  
l i n e  
2  
4  
8  1 2  
R e g i m e n  1  
V i r a l  l o a d  X  
C D 4  c o u n t  X  
P a t i e n t s  o n  n e v i r a p i n e  
A L T  
X  
I  
X  X  
R e g i m e n  2  
V i r a l  l o a d  
C D 4  c o u n t  X  
F u l l  b l o o d  c o u n t  a n d  w h i t e  
X  X  
X  
X  
c e l l  d i f f  
F a s t i n g  c h o l e s t e r o l  a n d  
X  
t r i g l y c e r i d e  
F a s t i n g  g l u c o s e  
S t a g i n g  =  i n i t i a l  t e s t i n g  f o r  a l l  p a t i e n t s  w h e n  b e i n g  r e f e r r e d  f o r  A R T  
B a s e  c a s e  =  t e s t i n g  f o r  A R V  e l i g i b l e  p a t i e n t s ,  a t  i n i t i a t i o n  o f  A R T  
S o u r c e :  D e p a r t m e n t  o f  H e a l t h  ( 2 0 0 4 )  
W e e k  
6  
2 4  M o n t h l y  
X  
X  
X  
X  
X  
X  
X  
T a b l e  2 0  s h o w s  t h e  u n i t  c o s t  p e r  l a b o r a t o r y  t e s t .  C o s t s  a r e  h i g h e s t  f o r  v i r a l  l o a d s .  
T a b l e  2 0 :  U n i t  c o s t  p e r  l a b o r a t o r y  t e s t  ( U S $ ;  2 0 0 4  p r i c e s )  
T e s t  C o s t  p e r  t e s t  
V i r a l  l o a d  3 9 . 6 8  
C D 4  c o u n t  7 . 9 4  
A L T  3 . 3 6  
F u l l  b l o o d  c o u n t  a n d  w h i t e  c e l l  
d i f f  
6 . 3 5  
F a s t i n g  c h o l e s t e r o l  a n d  
t r i g l y c e r i d e  
2 . 6 5  
F a s t i n g  g l u c o s e  
2 . 1 8  
1 2  
M o n t h l y  
X  
X  
T a b l e  2 1  c o m b i n e s  d a t a  o n  q u a n t i t i e s  o f  l a b o r a t o r y  t e s t s  a n d  u n i t  c o s t s  t o  e s t i m a t e  l a b o r a t o r y  
c o s t s  p e r  p a t i e n t - q u a r t e r  o n  A R T .  F o r  t h e  f i r s t - l i n e  r e g i m e n ,  M a r k o v  t u n n e l  s t a t e s  a l l o w  s e p a r a t e  
c o s t s  t o  b e  c a l c u l a t e d  i n  m o n t h s  0 - 3 ,  3 - 6  a n d  6 - 1 2  t h e r e f o r e  s e p a r a t e  l a b o r a t o r y  c o s t s  h a v e  b e e n  
c a l c u l a t e d  i n  e a c h  p e r i o d .  A n  a v e r a g e  q u a r t e r l y  c o s t  i s  c a l c u l a t e d  f o r  p e r i o d s  b e y o n d  t h e  f i r s t  
y e a r .  B e c a u s e  o f  t h e  M a r k o v i a n  a s s u m p t i o n  ( n o  m e m o r y  o f  p r e v i o u s  c y c l e s )  i t  i s  n o t  p o s s i b l e  t o  
k e e p  t r a c k  o f  t h e  q u a r t e r s  f o r  t h e  s e c o n d - l i n e  r e g i m e n ,  a n d  a  w e i g h t e d  a v e r a g e  l a b o r a t o r y  t e s t  c o s t  
p e r  q u a r t e r  h a s  b e e n  c a l c u l a t e d  i n s t e a d .  
1 2 5  
University of Cape Town
C o s t s  a r e  h i g h e s t  d u r i n g  t h e  e a r l y  p e r i o d  o n  e a c h  r e g i m e n ,  b u t  f a l l  t o  U S $ 2 4 . 4 6  a n d  U S $ 2 8 . 1 9  p e r  
q u a r t e r  o n  f i r s t  a n d  s e c o n d - l i n e s  r e s p e c t i v e l y  a f t e r  t h e  f i r s t  y e a r .  
T a b l e  2 1 :  L a b o r a t o r y  c o s t s  p e r  p a t i e n t - q u a r t e r  
0 - 3  3 - 6  6 - 1 2  
Q u a r t e r l y  
m o n t h s  m o n t h s  m o n t h s  
F i r s t - l i n e  
V i r a l  l o a d  3 9 . 6 8  1 9 . 8 4  1 9 . 8 4  
C D 4  c o u n t  
7 . 9 4  3 . 9 7  3 . 9 7  
A L T  3 . 9 3  
-
0 . 6 5  
, T o t a l  p e r  p a t i e n t - q u a r t e r  
5 1 . 5 5  I  2 3 . 8 1  
2 4 . 4 6
1  
S e c o n d - l i n e  
V i r a l  l o a d  1 9 . 8 4  
C D 4  c o u n t  3 . 9 7  
F u l l  b l o o d  c o u n t  a n d  w h i t e  c e l l  d i f f  
3 . 1 7 1  
Fastin~ c h o l e s t e r o l  a n d  trigl~ceride 0 . 6 6  
F a s t i n g  g l u c o s e  
0 . 5 4  
T o t a l  p e r  p a t i e n t - q u a r t e r  
2 8 . 1 9  
6  S u m m a r y  
T h e s e  u n i t  c o s t s ,  w h i c h  h a v e  b e e n  c o m p i l e d  f r o m  p r i m a r y  a n d  s e c o n d a r y  d a t a  t o  a i d  i n  e n h a n c i n g  
g e n e r a l i z a b i l i t y ,  w i l l  b e  a  c o m p o n e n t  o f  t h e  m o d e l s  u s e d  t o  c a l c u l a t e  p a t i e n t - l e v e l  a n d  p o p u l a t i o n -
l e v e l  c o s t s  a n d  c o n s e q u e n c e s  i n  a l t e r n a t i v e  t r e a t m e n t  s t r a t e g i e s  i n  t h e  n e x t  3  c h a p t e r s  
1 2 6  
University of Cape Town
C h a p t e r  6 :  P a t i e n t - l e v e l  r e s u l t s  
1  I n t r o d u c t i o n  
T h i s  c h a p t e r  p r e s e n t s  p a t i e n t - l e v e l  l i f e t i m e  c o s t s  a n d  i n d i v i d u a l  l e v e l  h e a l t h  g a i n s  a s s o c i a t e d  w i t h  
a l t e r n a t i v e  m u t u a l l y  e x c l u s i v e  H I V - t r e a t m e n t  i n t e r v e n t i o n s .  T h e  c h a p t e r  b e g i n s  b y  d e s c r i b i n g  t h e  
p r o c e s s  o f  c a l c u l a t i n g  a n d  a t t a c h i n g  c o s t s  a n d  o u t c o m e s  t o  M a r k o v  s t a t e s  a n d  p r e s e n t s  t h e  
t r a n s i t i o n  p r o b a b i l i t i e s  t h a t  d e t e n n i n e  m o v e m e n t s  b e t w e e n  t h e s e  s t a t e s .  T h e  n e x t  s e c t i o n  
d e s c r i b e s  t h e  r e s u l t s  o f  a n  e x t e n s i v e  v a l i d a t i o n  o f  t h e  m o d e l s  w h i c h  i n c l u d e s  a  d e t a i l e d  r e v i e w  o f  
s i m i l a r  a n a l y s e s  i n  t h e  l i t e r a t u r e .  T h e  c h a p t e r  c o n c l u d e s  b y  p r e s e n t i n g  t h e  p a t i e n t - l e v e l  r e s u l t s  
a s s o c i a t e d  w i t h  a  n u m b e r  o f  i n t e r v e n t i o n s .  T h e  i m p l i c a t i o n s  o f  d e f i n i n g  n e e d  a s  i l l n e s s  o r  a s  
c a p a c i t y  t o  b e n e f i t  a r e  a l s o  a s s e s s e d .  
2  A t t a c h i n g  r e w a r d s  t o  M a r k o v  s t a t e s  
E a c h  M a r k o v  s t a t e  i s  a s s o c i a t e d  w i t h  c o s t s  a n d  o u t c o m e s ,  w h i c h  t o g e t h e r  a r e  k n o w n  a s  r e w a r d s .  
B e c a u s e  t h e  c h o s e n  c y c l e  l e n g t h  o f  t h e  m o d e l  i s  t h r e e  m o n t h s ,  t h e s e  r e w a r d s  n e e d  t o  r e f l e c t  e i t h e r  
t h r e e  m o n t h s  o f  c o s t s  o r  t h r e e  m o n t h s  o f  o u t c o m e s .  
2 . 1 .  C o s t  p e r  M a r k o v  s t a t e  
T h e  c o s t  p e r  M a r k o v  s t a t e  i s  a  p r o d u c t  o f  t h e  u t i l i s a t i o n  o f h e a I t h  s e r v i c e s  a n d  t h e  u n i t  c o s t s  o f  
t h a t  u t i l i s a t i o n .  G i v e n  t h a t  u n i t  c o s t s  h a v e  b e e n  p r e s e n t e d  i n  t h e  p r e v i o u s  c h a p t e r ,  t h i s  s e c t i o n  
f o c u s e s  o n  t h e  c a l c u l a t i o n  o f  u t i l i s a t i o n  a n d  t h e  c a l c u l a t i o n  o f  t h e  c o s t  p e r  M a r k o v  s t a t e .  H I V  
c l i n i c  u t i l i s a t i o n  w a s  c a l c u l a t e d  f r o m  1 , 7 2 9  p a t i e n t s  w i t h  1 , 1 4 6  N o - A R T  p a t i e n t  y e a r s  a n d  2 , 2 2 9  
A R T  p a t i e n t  y e a r s ,  o v e r  a  m e d i a n  N o - A R T  a n d  A R T  f o l l o w - u p  o f  0 . 6 3  y e a r s  ( l Q R  0 . 3 3 - 1 . 3 2 ,  
m a x  4 . 3 5 )  a n d  1 . 0 3  y e a r s  ( l Q R  0 . 6 8  - 1 . 7 0 ,  m a x  4 . 0 8 )  r e s p e c t i v e l y .  U t i l i s a t i o n  o f  t u b e r c u l o s i s  
a n d  i n p a t i e n t  c a r e  w a s  b a s e d  o n  a  s u b - s a m p l e  o f  6 7 0  p a t i e n t s ,  w i t h  5 0 1  p a t i e n t - y e a r s  f o r  N o - A R T  
a n d  6 9 3  p a t i e n t - y e a r s  f o r  A R T  p a t i e n t s .  A n  a d d i t i o n a l  s a m p l e  o f  8 3  p a t i e n t s  w a s  u s e d  t o  
c a l c u l a t e  i n p a t i e n t  u t i l i s a t i o n  p r i o r  t o  d e a t h  f o r  N o - A R T  p a t i e n t s .  T h e  s a m e  p r o c e d u r e  w a s  
f o l l o w e d  f o r  t h e  8 1  p a t i e n t s  o n  A R T  w h o  d i e d  o f  H I V - r e l a t e d  c a u s e s .  D u r i n g  t h e  f o l l o w - u p  
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period, No-ART patients had 10,892 visits, 1,342 inpatient days and 159 treated episodes of 
tuberculosis. ART patients had 39,450 visits, 840 days in hospital and 86 TB episodes. 
When specified by Markov state, results indicated that patients commencing ART with CD4<50 
cells/, .. tl had 10.5 (95% CIIO.2-10.7) clinic visits, 1.1 (\.0-1.3) days in hospital and 0.08 (0.05-
0.12) tuberculosis cases per patient in the first 3 months. Note that these clinic visits include 
patient work-up prior to ART commencement. During the same period, patients commencing 
ART with CD4 50-199 cells/ill had 9.7 (9.5-9.9) clinic visits, 0.6 (0.5-0.7) days in hospital and 
0.06 (0.04-0.1) cases of tuberculosis. All health care utilisation dropped markedly over time. 
During the third year on treatment 2.6 (2.5-2.7) clinic visits, 0.1 (0.08-0.\3) inpatient days and 
0.02 (0.0 I -0.03) tuberculosis cases occurred per patient period. Patients not accessing ART with 
CD4<50 celis/ill utilised 3.4 (3.2-3.5) clinic visits, 0.7 (0.6-0.8) inpatient days, and had 0.1 (0.07-
0.13) tuberculosis cases per quarter. AJi patients spent between 4 and 6 days in hospital prior to 
death. So as not to underestimate costs for patients lost to follow-up, it was assumed that these 
patients also incurred the inpatient utilisation associated with dying. Table 22 shows utilisation of 
health services in different Markov states per three-month period. 
Table 22: Health service utilisation in Markov states per three-month period 
Mean visits (95%CI) Mean inpatient days Mean TB cases 
Markov states: (95%CI) (95%CI) 
ART 
CD4<50 cells/lJl months 0-3 10.47 (10.21-10.74) 1.09 (0.96-1.25) 0.08 (0.05-0.12) 
CD4<50 cells/lJl months 3-6 3.67 (3.52-3.84) 0.77 (0.66-0.90) 0.04 (0.02-0.08) 
CD4 50-199 cells/lJl months 0-3 9.69 (9.51-9.88) 0.60 (0.52-0.7) 0.06 (0.04-0.1) 
CD4 50-199 cells/lJl months 3-6 3.46 (3.34-3.57) 0.12 (0.09-0.17) 0.02 (0.01-0.04) 
All patients months 6-12 3.62 (3.54-3.70) 0.21 (0 .18-024) 0.02 (0.01-0.03) 
All patients months 12-24 2.72 (2.65-2.79) 0.10 (0.08-0.13) 0.02 (0.01-0.03) 
All patients months 24-36 2.58 (2.48-2.69) 0.10 (0.08-0.13) 0.02 (0.01-0.03) 
All patients month 36 onwards 2.76 (2.56-2.97) 0.10 (0.08-0.13) 0.02 (0.01-003) 
Utilisation for patients who die I default 3.95 (1 .72-6.19) 
No-ART 
CD4 <50 cells/lJl 3.35 (3.24-3.49) 0.7 (0.64-0.75) 0.1 (0.07-0.13) 
CD4 50-199 cells/lJl 2.58 (2 .53-2.64) 0.3 (0.28-0.32) 0.D7 (0.06-0.09) 
Utilisation for patients who die I default 5.75 (351-7.98) 
The generalizability of these utilisation estimates has been assessed by comparing these results 
against those of a South African cost-effectiveness analysis based on a cohort of ART patients 
enrolled in a clinical trial and a natural history No-ART group (Badri, Cleary et al. 2006). 
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Although data are not presented in a directly comparable manner, some general conclusions can 
be made. For ART patients, quarterly utilisation of inpatient care varied between a high of 0.45 
days for patients with AIDS and CD4<200 cells/f.11 and a low of 0.04 for patients with CD4>350 
ceIls/f.11 and No-AIDS. fnpatient utilisation in Khayelitsha was higher, but this could relate to the 
lower CD4 levels of patients. Quarterly outpatient utilisation in Badri, Cleary et al. (2006) varied 
between 1.4 and 1.9 visits. Although utilisation of clinic visits in Khayelitsha may appear high 
compared to these data, this may reflect the model of care, where clinical visits were to a 
combined doctor-nurse team, with the implication that patients would not see a doctor at every 
visit. This differs from settings where visits are counted only as those in which a doctor is 
consulted. 
fn the No-ART natural history cohort (Badri, Cleary et al. 2006), quarterly inpatient utilisation 
was 4.43 days and outpatient utilisation was 1.93 visits for patients with AIDS and CD4<200 
cells/f.11. fnpatient utilisation is similar in Khayelitsha, especially if one takes utilisation at death 
into account (which would be included in the 4.43 measure from the natural history cohort) while 
outpatient visits were again considerably higher in Khayelitsha. 
To enhance the generalizability of visit utilisation, scenario analysis will consider the following 
adjustments: 
• Basing ART visits on national ART guidelines 
• Basing No-ART visits on data from Badri, Cleary et al. (2006) under the assumption that 
patients with CD4<50 cells/f.11 use the same visits as those with CD4<200 cells/f.11 and 
AIDS while patie ts with CD4 50-199 cel\s/f.11 use the same visits as those with 
CD4<200 celIs/f.11 who are in other WHO stages. While this is a crude assumption, there 
are no other data to which this comparison can currently be made. 
These utilisation estimates are presented in Table 23. 
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Table 23: Alternative estimates of visit utilisation per three-month period 
Markov states: Mean visits (95%CI) 
~RT 
CD4<50 cells/~1 months 0-3 6.00 
CD4<50 cells/~1 months 3-6 3.00 
CD4 50-199 cells/~1 months 0-3 6.00 
CD4 50-199 cells/~1 months 3-6 3.00 
All patients months 6-12 3.00 
All patients months 12-24 3.00 
All patients months 24-36 3.00 
All patients month 36 onwards 3.00 
No-ART 
CD4 <50 cells/~1 1.93 
CD4 50-199 cells/~1 1.40 
TabJe 24 illustrates the proportion of patients on different antiretroviral drugs. In the first-Jine 
regimen, all patients were assumed to receive stavudine and lamivudine in line with "National 
Antiretroviral Treatment Guidelines" (National Antiretroviral Treatment Guidelines 2004). Data 
indicated that 47 per cent (44 per cent-49 per cent) of patients received efavirenz and the 
remainder received nevirapine. All patients are assumed to receive zidovudine, didanosine, and 
lopinavir/ritonavir as the second-line. 
Table 24: Proportion of patients on each ARV 
proportion patients 
Medicine name I formulation (95%CI) 
First-line 
Stavudine (30mg) 0.50 
Stavudine (40mg) 050 
Lamivudine (150mg) 1.00 
Efavirenz (600mg) 0.47 (0.44-0.49) 
Nevirapine (200mg) 0.53 (0.51-0.56) 
Second-line 
Zidovudine J300m91 1.00 
Didanosine (250mg) 0.50 
Didanosine (400mg) 0.50 
Lopinavir/ritonavir (133.3/33.3mg) 1.00 
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Utilisation of health care services and AR Ys is multiplied by the unit cost of each to calculate the 
cost per Markov state. The following is a generic formula for calculating the cost per three-month 
period in Markov state n: 
Stage _ costn 
Where: 
Stage_costn is the total cost per three-month period in Markov state n 
ARV1 7n is the proportion of patients on each individual ARy7 in Markov state n 
c_ ARVl 7n is the three-month cost of ARyl . 7 in Markov state n 
c _labsn is the three-month cost of laboratory investigations in Markov state n 
visitn is the distribution (mean and 95 per cent confidence interval) of visits per three-month 
period in Markov state n 
c _visitn is the unit cost per visit in Markov state n 
ipn is the distribution (mean and 95 per cent confidence interval) of inpatient days in Markov state 
n 
c _ip is the unit cost per inpatient day 
tbn is the distribution (mean and 95 per cent confidence interval) ofTB incidence in Markov state 
n 
c _tb is the unit cost per TB treatment completed 
disc Jate is the discount rate per three-month period 
Table 25 summarizes utilization information and presents the cost per Markov state. Note that the 
cost per Markov state is calculated by multiplying unit costs (as presented in the previous 
chapter) by the utilization of different service categories. ART costs were highest for patients 
with CD4<50 cells/!J.l during the first three months on treatment, at US$548 excluding costs for 
patients who died. Costs remained steady at around US$180 per quarter from 12 months onwards 
while patients remained on first-line, but increased to over US$340 per quarter when second-line 
treatment was initiated. No-ART costs in the CD4<50 cells/!J.l category were US$239 per patient-
quarter excluding patients who died. Obviously, No-ART patients do not incur ARY or ARY 
7 ARYs include combinations ofstavudine, iamivudine, nevirapine, efavirenz, didanosine, zidovudine or 
iopinavir/ritonavir as appropriate to each Markov state. For No-ART states, ARy l 7" = o. 
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related costs these cat.egl[)fH;S are therefore not UIJIJ.",U A mean cost of over 
1 000 was incurred at the precedimg death. 
University of Cape Town
Table 25: Summary of service utilisation and the cost per Markov state (US$) 
Clinic visits Inpatient days Tuberculosis Safety and Additional cost for dying treatment ARVCost monitoring Cost per Ratients Health state Meal I Cost Meall/P MealJ Markov state MOi.ln IP Lh,ys Cost Cost (95% CI) laboratory (95%CI) clay:; Cost VISlls a (95%CI) caSAS (95%CI) costs (95%CI) (95%Lll (95 YoCI) (95%CI) (95%CI) (95%CI) 
ART CD4<50 ce lis IIJ I months 0-3 IO~I/O·· 199 (194- 1 ( ~ 10 177 (155- ,18,0 .. 48 (30-76) 72.7 (70.2-75.1) 52 548 (502-609) 4 () 11 '6 .; 704 (306-10 71 204) 1251 201) Lie} 1102) 
ART CD4<50 celis/lJl months 3-6 .."I "7' r:~ :: . 70 (67-73) C (0"-;' 125 (107- 00-1
,00'. 
25 (13-49) 72.7 (70.2-75.1) 0 293 (257-343) .J J I' 1-, '1 704 (306-
s 8) 
" .JO) 146) 008' 1102) 
ART CD4 50-199celis/lJl months 0-3 ~ '/9 • 184 (181- D 6,052· 98 (84-114) o uf 10 '-1- 38 (24-60) 72.7 (70.2-75.1) 52 444 (410-488) J 0 i I - •• ' ~.I 704 (306-9 n,1 188) (7) n I 1102) 
ART CD4 50-199 celis/lJl months 3-6 J 5 (J 66 (64c68) (ll II' 09 20 (14-27) C )? (I~ C' 11 (4-26) 72.7 (70.2-75.1) 0 169 (152-196) 
" 
II 1-0 ~, 704 (306-
H " 111 01'.'-' 1102) 
First-line ART months 6-12 J 6 (3 50 69 (67-70) (' I{; 18· 33 (29-39) tl I;' (0 c,,· 13 (8-21) 72.7 (70.2-75.1) 24 212 (198-229) 4(,[170. 704 (306-
Second-line ART months 6-12 3.) 02/11 (j 03) 238 28 381 (370-397) 1102) 
First-line ART months 12-24 :- (~ 6;;· 52 (50-53) () 11')08 17 (14-20) J O~,O 01 12 (8-20) 72.7 (70.2-75.1) 24 178 (167-193) 704 (306-
Second-line ART months 12-24 28) L) PI D 031 
O{l16;'1 
1102) 238 28 347 (338-360) 
First-line ART months 24-36 .1(:5- 49 (47-51) rJ III I).' 17 (14-20) 00;(001 12 (8-20) 72.7 (70.2-75.1) 24 175 (164-191) 704 (306-
Second-line ART months 24-36 ~fl IlJ I, 03,1 238 28 344 (335-358) 
.$ ) I J , ... ;; .' 
1102) 
First-line ART beyond 36 months 8 It &- 52 (49-56) IV 01;· 17 (14-20) L' 0: (e: ,- 12 (8-20) 72.7 (70.2-75 .1) 24 179 (165-196) H " ;.;, i' 704 (306-Second-line ART beyond 36 months J 0. 0131 1.0.;) 238 28 348 (337-363) 1102) 
I 
No-ART CD4 <50 celis/lJl J 1(3 ". 66 (63c68) C 1<) 0-"- 113 (104- (I , (007- 60 (46-79) N/A NlA 239 (213-269) ~ .J ·8)) 1023 (626-
• 51 ( l51 122) f1 '..)1 1422) 
No-ART CD4 50-199 celis/lJl "!' r5 r"~ I:- 51 (49-52) (l ~ ,02(;· 49 (45-52) JCIC(!6 45 (37-55) N/A N/A 145 (132-159) <; 7 135-11 II 1023 (626-~ (. I 0.1. D U9) 1422) 
IP: Inpatient care 
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2.2. Outcomes in each Markov state 
In order for the model to calculate life-years or QAL Ys, outcome rewards are attached to each 
Markov state (other than the absorbing state - death - where no outcomes are accrued). If 
outcomes are life years, the reward is the same as the Markov cycle length, which in this case is 
three months. In the case ofQAL Ys, each three-month period is multiplied by the HRQoL value 
that is appropriate to each Markov state. HRQoL has been measured in Khayelitsha on a subset of 
patients over a 12 months period using the EQ-5D instrument (Jelsma, MacLean et a!. 2005) and 
has been valued using a United Kingdom general population ITO value set (Dolan, Gudex et a\. 
1995). Results are presented in Table 26. 
Table 26: HRQoL values 
Health state Value 
ART 0-3 months 0.71 
ART 3-6 months 0.81 
ART 6-12 months 0.82 
ART >12 months 0.85 
No-ART 0.71 
3 Transition probabilities 
Table 27 contains transition probabilities and data sources for the ART and No-ART models . As 
explained in the methods, ART transition probabilities were calculated from 1,729 patients 
followed over a maximum duration of 48 months. 
Sixty-three per cent of patients initiated ART with CD4 50-199 cells/fll and the remainder with 
CD4 counts <50 cells/fl!. Deaths were concentrated in the first year. At six months on ART, 83.9 
per cent of the 643 patients initiating with a CD4 count <50 cells/fll were alive in comparison 
with 93 .9 per cent of those initiating with CD4 50-199 cells/ fl!. No patients were changed to 
second-line during the first 6 months, but by 48 months, 16 per cent of those surviving had 
switched. The product limit estimate of survival was 86.9 per cent, 83.4 per cent and 76.2 per cent 
at 12,24 and 48 months respectively. Extrapolated results indicate 71 per cent surviving at 60 
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months. These outcomes are slightly worse than results from a 7-year Senegalese cohort study 
(Etard, Ndiaye et al. 2006) which indicated 88.3 per cent, 82.6 per cent and 75.4 per cent 
surviving at 12,24 and 60 months respectively but, given the higher base case CD4 counts of the 
Senegalese patients, results are comparable. 
Local natural history data indicated that fifty per cent of No-ART patients with CD4<200 celiS/ill 
were alive at 24 months (Badri, Bekker et al. 2004). 
Table 27: Transition probabilities (per three-month period) and data sources 
Input parameters Data sources Transition probability (range) 
CD4 category at baseline for ART and No-ART 
CD4<50 cells/ml 0.372 (0.349-0 .395) 
'I CD4 50-199 eellslml 0.628 (0 .605-0.651) 
Probabilities of transitioning between alive Markov states 
First-line regimen to second-line regimen 
0-6 months NIA - no patients switched 0.000 
6-12 months 0.48% switched by 12 months 0.002 (0.001-0.006) 
12-24 months 4.66% switched by 24 months 0.011 (0.007-0.015) 
24-36 months 11 .73% switched by 36 months 0.019 (0.014-0.026) 
36-48 months 15.9% switched by 48 months 0.012 (0 .005-0.024) 
>48 months Average over 0-48 months 0.011 (0 .007-0.017) 
No-ART, CD4 50-199 eel/simi to CD4<50 eel/simi 
Calculated to ensure 50% surviving at 
all quarters 24 months 0.040 (0.026-0.043) 
Probabilities of transitionil19 to dead Markov states 
ART CD4<50 eel/simi 
0-3 months 86.9% surviving at 3 months 0.131 (0.107-0.159) 
3-6 months 83.9% surviving at 6 months 0.034 (0.031·0 .038) 
ART CD4 50-199 eel/simi 
0-3 months 95.9% surviving at 3 months 0.041 (0 .030-0.054) 
3-6 months 93.9% suriviving at 6 months 0.021 (0.019-0.024) 
AI/ patients on ART, irrespective of regimen 
6-12 months 86.9% suriviving at 12 months 0.018 (0.017-0 .020) 
12-24 months 83.4% surivivinfl at 24 months 0.010 (0.008-0.012) 
24-36 months 79 .5% surviving at 36 months 0.012 (0 .009-0.016) 
36-48 months 76 .2% surivivingat 48 months 0.010 (0.005-0 .017) 
>48 months Average over 0-48 months 0.017 (0 .013-0.021) 
No ART CD4 count <50 eel/simi 
all quarters 20% surviving at 24 months 1 0.182 (0 .147-0.227L 
No ART CD4 50-199 eel/simi 
5U"Io surviVing at £4 montns Wltn 
CD4<200 cells/ml2 divided by hazard 
all quarters rati03 0.039 (0.034-0.043) 
Sources: 
I No-ART survival with CD4<50 cellS/ill from Post, Wood et al. (2002) 
2 No-ART survival with CD4<200 cellS/ill from Badri, Bekker et al. (1996) 
3 Hazard ratio for death in CD4<50 versus 50-199 cellS/ill from Coetzee, Hildebrand et al. (2004) 
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While ART data were similar to those reported in the Senegalese cohort, generalizability has also 
been assessed by comparing 12-month clinical outcomes against ART-LINC data. These data are 
from a collaboration of ART cohorts in low income countries. A recent publication includes data 
from 4,810 patients receiving ART in Africa (including 278 Khayelitsha patients), South America 
and Asia and provides information about base case CD4 stratum, loss to follow up and deaths 
after one year of treatment (ART-LINC and ART-CC 2006). Because a number of these patients 
were enrolled in cohorts without active folIow-up, this comparison focuses on 2,725 ART-LINC 
patients who were actively followed. Results are presented in Table 28. 
Table 28: Comparison of outcomes at one-year between ART-LINC and Khayelitsba 
ARTLinc Khayelitsha 
Number of patients 2725 1729 
Proportion loss to follow-up 12% coded as deaths 
Proportion deaths 6% 13% 
Combined deaths and loss to follow-up 18% 13% 
Thirty-one per cent of patients in ART-LINC initiated ART with CD4<50 cells/!!I in comparison 
with 37 per cent in Khayelitsha. Loss to follow-up was higher in ART-LINC than in Khayelitsha, 
but the rate of death was far higher in Khayelitsha than in ART-LINC which suggests that many 
of the patients that were lost to follow-up in ART-LINC had died. The final row in the table 
therefore calculates combined deaths and loss to follow-up. When these data are compared, one 
could conclude that outcomes at one-year in Khayelitsha might be more favourable than in 
routine settings despite the higher proportion of patients initiating ART in lower CD4 strata. To 
increase the generalizability of results, death transition probabilities will be increased to match 
ART-LINC results in scenario analysis (see section 5.2). This would represent a conservative 
overestimate of mortality because patients who were lost to follow-up would not necessarily have 
died within this one-year period. 
The generalizability of No-ART outcomes has been assessed by comparing results reported in 
Table 27 against a literature review of natural history data from developed and developing 
countries (Schneider, Zwahlen et al. 2004). This indicated that patients with CD4<200 cells/!!I 
had a median survival of 11 months (ranging between 7-38 months), whereas calculations from 
secondary data for this thesis (Badri, Bekker et al. 2004) indicate a median survival of 15 months. 
Similar to ART, No-ART outcomes are therefore slightly higher than in other resource-poor 
settings. This will also be addressed in scenario analysis. 
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While Table 27 presents the probabilities of dying from HIV -related causes, one also has to 
include the probability of dying from other causes, adjusted for socioeconomic status, age and 
gender of HIV positive peopJe. These data were taken from a sample of749 patients accessing 
ART in a number of clinics in the Western Cape (Pienaar, Myer et al. 2006). Seventy-seven per 
cent of these patients were women. Men had a median age of37 as compared to 32 for women 
and an average of 33 for both genders. Socio-economic status was estimated by constructing an 
asset index using the 1998 Demographic and Health Survey adult dataset. Six socio-economic 
groups were calculated based on this asset index, and by mapping the same asset index onto 
patients in the ART sample, it was possible to estimate the socio-economic strata of these 
patients. Group 1 is the lowest socio-economic stratum. Results indicate that 33 per cent of ART 
users fell into the poorest three groups and 67 per cent were in groups 4, 5 or 6. The majority of 
the sample (32.6 per cent) fell into group 4. See Table 29. There were no major differences in 
strata between men and women. 
Table 29: Socioeconomic groupings of men and women in the ART sample 
Women % Men % All % 
~ 
Group 1 6 1.0% 0.0% 6 0.8% 
Group 2 61 10.6% 26 14.9% 87 11 .6% 
Group 3 117 20.3% 37 21 .3% 154 20.6% 
Group 4 200 34.8% 44 25.3% 244 32.6% 
Group 5 157 27.3% 54 31 .0% 211 28.2% 
Group 6 34 5.9% 13 7.5% 47 6.3% 
Total 575 I 100.0% I 174 100.0% 749 100.0% 
Armed with age, gender and socio-economic status, it is finally possible to estimate the 
probability of dying from causes other than HfV per three-month period as a function of the age 
of the cohort. This is a time dependent probability which increases from the age of entry into care 
(average of33 years) until the maximum age of 100 is reached when it is assumed that the 
probability of dying is 1. 
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4 Model validation 
This section covers validation of the model under the categories of technical, predictive, face and 
modelling process validity. In terms of technical and predictive validity, the overall objective is to 
ascertain whether the model is reproducing primary data accurately whereas face validity assesses 
whether the model produces the output that one would expect. Non-illV-related mortality 
probabilities have therefore been excluded from these sections. Modelling process validity 
ascertains whether the results in this thesis are comparable to other published cost-effectiveness 
studies. This section therefore includes non HIV -related mortality because this should be included 
in the results in the literature (Sonnenberg and Beck 1993). 
4.1. Technical validity 
Technical validity involves identifying and correcting for modelling bugs such as unexpected 
model behaviour, redundant variables, programming errors and typing errors (Sendi, Craig et al. 
1999). A useful method of debugging a model is to vary one or more parameter over its entire 
range and to examine any anomalies in model outputs. This process was done using cohort 
simulation on the following transition probabilities: 
• Probabilities of dying (ARTs and No-ART model) 
• Probabilities offailing first-line (ART model) 
In order to validate death transition probabilities (TPs), the TPs for death were doubled and 
halved, and comparison was made to base case. Figure 15 shows total outcomes in the ART and 
No-ART models when these adjustments are made. Under base case assumptions, total ART 
outcomes are 14.7; when the death TPs are doubled, total outcomes are 7.1; and when death TPs 
are halved, total outcomes are 29.2. Adjustments to the death TP will never lead to exactly the 
same adjustment in outcomes because outcomes are also a function of the number of patients 
remaining in any given state facing a particular probability of dying. However, the validation 
shows that the model is performing as expected. Similarly, No-ART outcomes are 3.0 under base 
case TPs; 1.7 when the TPs are doubled; and 4.9 when the TPs are halved. 
8 Given that the first and second-line and first-line models are structured similarly, this validation has only 
been performed on the first and second-line model. 
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Technical validity has also been established for second-line TPs. While transitions to second-line 
will have no impact on total outcomes9, there will be an impact on total costs because second-line 
drugs are more expensive. Therefore, the key purpose of the second-line TP is to ensure an 
appropriate split between first and second-line ARV regimens in order to capture cost differences. 
As before, the second-line TP was halved and doubled and results were compared to base case. 
For the purposes of technical validity, one would expect that doubling the TP would increase the 
percentage oftota] outcomes that are gained on second-line whereas halving it would do the 
opposite. While the second-line TPs function is to make cost adjustments, one can judge whether 
these are producing reasonable results by assessing the percentage of outcomes (e.g. life years) 
that are gained in first-line and second-line Markov states. Results are shown in Figure 16. Under 
the base case TP, 38 per cent of total outcomes are gained on second-line; when the second-line 
TP is doubled, 55 per cent of total outcomes are gained on second-line; and when the TP is 
halved, 23 per cent of outcomes are gained on second-line. 
9 A simplifying assumption of the model is that the probability of dying is a function of duration on 
treatment and does not vary in first or second-line specifically, although the overall chance of being on 
second-line does increase as time on treatment increases. 
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Figure 15: Modelled survival curves and outcomes for ART and No-ART under base case, halved and doubled death transition 
probabilities 
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Figure 16: Cumulative time on first and second-line under base case, halved and doubled second-line transition probabilities 
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4.2. Predictive validity 
Predictive validity of a model can be tested by comparing intermediate and final outcomes from 
the model against outcomes from primary data (Sendi, Craig et aJ. 1999) in order to assess 
whether the model is adequately reflecting the data from which it is derived. Outcomes have also 
been compared against secondary data - see section 3. Figure 17 compares the modelled survival 
curves for ART and No-ART to the primary/secondary data points from which these are 
derived 10. The figure shows that the model perfectly replicates death data thereby indicating very 
strong predictive validity. Similarly, when modelled output is compared to primary data detailing 
the proportion of patients (out of those surviving) switching on to the second-line regimen, the 
modelled output shows a highly accurate replication of the data from which it is derived. 
10 The No-ART modelled output is validated against an exponential curve fitted to a point estimate of just 
under 50% surviving with CD4<200 cells!!!l at 24 months from secondary data (Badri, Bekker et al. 2004). 
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Figure 17: Comparison of proportion surviving and proportion on second-line between primary data and modelled output 
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4.3. Face validity 
Face validity assesses whether the model produces the output that one would expect (Sendi, Craig 
et al. 1999). Expected model output could include: 
• Higher outcomes for ART than for No-ART 
• Higher outcomes for patients starting with a CD4 level between 50 and 199 cellslll versus 
CD4<50 cellslll 
• Higher lifetime costs for ART versus No-ART 
It has already been shown that patients on ART survive for longer than those receiving No-ART 
(see Figure 15) and lifetime cost results will be presented in section 5. It remains to be established 
whether outcomes are lower for patients entering care with lower CD4 levels. This is validated by 
altering the base case "seeding" of the models - in other words, the entire cohort is assumed to 
enter care with CD4 50-199 cellslll or is assumed to enter care with CD4<50 cellslll and survival 
is established. Results are presented in Figure 18. 
The figure indicates that survival is worse for patients entering care later, and this is especiaIly 
marked for the No-ART group. In the ART group, although initial survival is impacted by a lower 
CD4 level at base case, patients who survive beyond the first year tend to recover and perform 
similarly to patients entering care with higher CD4 levels. 
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Figure 18: Survival curves for patients initiating care with CD4 50-199 cells/~I or CD4<50 cells/~I 
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4.4. Modelling process validity 
The final step in model validation is establishing the modelling process validity. Here, the 
lifetime costs, outcomes and cost-effectiveness conclusions of published studies have been 
compared to the results obtained through the models in this thesis. Results include non HIV-
related mortality because one is comparing against published results that ought to include deaths 
from all causes. A published review of HIV-treatment and prevention cost-effectiveness studies 
was the primary source of published studies (Harling, Wood et aJ. 2005). A small number of 
additional studies were also identified. 
Studies were included if: 
• Total direct health care costs were calculated (studies were excluded if they only 
calculated the incremental costs of the programme under evaluation ll ) 
• Final outcomes were calculated (final outcomes could be life years or QALYs) 
• Interventions included treatment and prophylaxis l2 of opportunistic and HIV-related 
infections and/or ART for adult patients 
A total of 57 English language studies were identified based on Harling, Wood et al. (2005) and 
an additional four studies were identified that have been published more recently, leading to a 
total of61 studies. 
Of these studies: 
• Three were excluded because they focused on a subset of H IV disease (e.g. only patients 
with pneumocystis camii pneumonia) 
• Nine were excluded because they did not calculate final outcomes 
• Four were excluded that only calculated incremental costs (e.g. only isoniazid 
prophylaxis for tuberculosis was included in costs and all other HI V-related health care 
costs were excluded) 
II These studies were excluded because the overall conclusions of the study in terms of cost-effectiveness 
were not comparable. 
12 Prophylactic interventions were included in the review if the type of prophylaxis is currently 
recommended in South Africa. 
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• Seventeen were excluded because it was found that they did not include either ART or 
No-ART (for example, a number of studies evaluated AR V monotherapy or dual therapy) 
• Two were excluded because they focused on a different patient population (e.g. children) 
• Three were excluded because no journal access was available in South Africa either from 
the University of Cape Town or interlibrary loans 
After these 38 exclusions, 23 studies remained. 
Of these, only three studies explicitly compared ART to No-ART (Sendi, Bucher et al. 1999; 
Freedberg, Losina et al. 200 I; Bachman 2006) and another 3 compared the cost-effectiveness of 
starting ART within different CD4 bands and included a No-ART comparator (Schackman, 
Goldie et al. 200 I; Schackman, Freedberg et al. 2002; Badri, Cleary et al. 2006). One study 
compared monotherapy to No-ART (Moore, Hidalgo et al. 1994). Five studies compared triple 
ART to dual therapy (Moore and Bartlett 1996; Cook, Dasbach et al. 1999; Anis, Guh et al. 2000; 
Miners, Sabin et al. 200 I). Eleven studies evaluated various prophylactic agents for opportunistic 
infections versus No-ART without prophylaxis or ART in the absence of prophylaxis (Moore and 
Chaisson 1997; Bayowni and Redelmeier 1998; Freedberg, Scharfstein et al. 1998; Paltiel and 
Freedberg 1998; Goldie, Weinstein et al. 1999; Sendi, Craig et al. 1999; Paltiel, Goldie et al. 
200 I; Goldie, Kaplan et al. 2002; Yazdanpanah, Goldie et al. 2003; Hoffmann and Brunner 2004; 
Yazdanpanah, Losina et al. 2005). 
Of all studies included, only 3 were based in developing countries (Yazdanpanah, Losina et al. 
2005; Bachman 2006; Badri, Cleary et al. 2006). 
From these studies, it is only possible to draw broad conclusions about the range of plausible 
outcomes for ART and No-ART. This is partly because in order to evaluate different HIV-
treatment interventions, the studies had different assumptions about when patients would enter 
care. In addition, a number of studies only presented discounted results. Results are therefore 
discussed separately for zero and other discount rates. The majority of studies presented outcomes 
as life years, and some presented outcomes as life years and QALYs. The discussion therefore 
focuses on life years because this allows comparison across all studies with the exception of one 
that only calculated QAL Ys. However, full details of outcomes are presented in Appendix B. 
147 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
The undiscounted outcomes for No-ART 1-""''''''''-' no n"',n"MI<'v for 
infections between 0.6 life years for et aL I to 
8.2 life years for n"t.l>nt" care with CD4>350 The latter was 
most studies with patients care with CD4 350-500 calculated 
outcomes between 3.2 and 6.6 life years. This is ('{"l1mn"rn to the 2.9 years calculated in this 
thesis that paClvHC" had much lower CD4 levels. 
In studies that discounted results at 3 per cent per the calculated 
outcomes between 2 and 4 life years for care in a ofCD4 strata 
Bucher et aL 1 In this outcomes are 2.7 life years for No-ART at a 3 per cent discount 
rate. 
For ART undiscounted outcomes between 5.8 and Brunner and 18.8 life 
et al. of studies calculated outcomes between 14 years 
and 15 years. For studies that UI.,,,VCU.,,,"U at 3 per cent 
outcomes between 5.3 Losina et al. 2001) and 11A Goldie et 
al. life years, but most studies calculated lifetime outcomes that were closer to 10 years 
than to 5 years. 
Because ART is 
about the 
anew 
,,,,,,''',,,,,", t:re:edbel'g et at 
a number ."""u"",,, have tended to be conservative 
Losina et at 200 I; Goldie et al. 200 I; 
that have these U1..Uav'.Il,Y 
have calculated much hPrIPtit" from ART Bucher et aL 
et al. 
cent annual discount 
life years are 13 at a zero discount rate and 9.5 at a 3 per 
. These results are when with 
The final in u.~'''''',''. process is to compare the ICERs studies to the 
be made results in this thesis. Because costs are context will 
between this thesis and studies conducted in other countries. Based on the candidate's 
Given the low discount rate, one be the in life years from 13 to 9.5. In 
the model runs for than these years to calculate results to the of the 
survival curve that is assumed in Markov 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
own calculations 14, the two studies from developing countries had ICERs of ART versus No-
ART of US$2,486 (Sachman 2006) and US$504 (Sadri, Cleary et al. 2006) per life year gained. 
However, the former derives ARV costs from Cleary, Soulle et al. (2004) at about U$I,475 
including laboratory investigations whereas the latter used the South African government tender 
prices of US$558 per annum for first-line. This thesis calculates an ICER of US$I ,023 per life 
year gained which is higher than Sadri, Cleary et al. (2006). However, there are a number of key 
differences that would influence ICER results. In the Sadri, Cleary et al. (2006) study, the ICER 
was heavily dependent on high lifetime costs for No-ART patients (of US$7,877 versus 
US$2,966 in this thesis). This is because patients in the Badri, Cleary et al. (2006) study enter the 
model with CD4>350 cells/!-ll whereas in this thesis, they enter the model with CD4<200 cells/!-ll. 
The lifetime costs of ART in the two studies are more comparable, at approx US$13,191 in this 
thesis and US$14,230 in Sadri, Cleary et al. (2006). ICERs from developed countries are much 
higher and are not comparable given the much higher lifetime costs of treatment in these settings 
(although the outcomes have been found to be similar in the above sections). 
Across all studies, none that took a provider's perspective found ART to be cost-saving over No-
ART, but instead based their cost-effectiveness recommendations on whether the ICER was a 
good buy in the particular context. One study that took a societal perspective (including 
productivity gains) in Switzerland found ART to be cost-saving, but not from a provider's 
perspective (Sendi, Bucher et al. 1999). A recent study of the costs and benefits of HIV treatment 
to a Ugandan firm found ART in combination with cotrimoxazole to be cost saving over a 5-year 
time frame, but if costs and outcomes were calculated over a ten-year period, this result no longer 
held (Marseille, Saba et al. 2006). The latter study illustrates the difficulty of decision-making for 
HIV-treatrnent where uncertainty relating to future effectiveness requires assumptions to be made 
that can radically alter the study conclusions. 
Results of all studies included in the review are presented in Appendix B. 
14 These studies included interventions that are not comparable with this thesis. leERs were therefore re-
calculated in order to compare the incremental cost per life year gained between ART and No-ART. 
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5 Results 
Having described the process of attaching costs and outcomes to Markov states and the extensive 
validation of Markov models, this section finally presents patient-level lifetime costs, individual 
health gains and ICERs under a base case scenario, where data from the Khayelitsha pilot are 
unadjusted; a generalized scenario, where a number of adjustments are made based on secondary 
literature; and a low cost generalized scenario which explores the possibilities for additional cost 
savings. The final section considers the implications of initiating ART within different CD4 
categories. This section draws on earlier work (Badri, Cleary et al. 2006) as well as insights from 
primary data 
5.1. Base case scenario 
For the base case results, uncertainty relating to data requirements has been assessed using 
probabilistic sensitivity analysis (PSA), which propagates parameter and underlying modelling 
uncertainty through the model by means of first and second-order Monte Carlo simulation. 
Simulations have been run using 1,000 distribution values, and each distribution value has been 
sUbjected to 1,000 first-order simulations. This allows overall parameter uncertainty to be 
captured as confidence intervals around lifetime costs, outcomes and ICERs (Briggs 1995; 
O'Hagan, McCabe et al. 2005). 
Figure 19 shows scatterplots of discounted ICERs that have been generated through these 
simulations. Each of the 1,000 points (derived from second-order Monte Carlo sampling) shows 
the mean incremental costs and incremental outcomes of first-line ART over No-ART and first 
and second-line ART over first-line ART. Each of these points has been generated from 1,000 
first order simulations. 
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Figure 19: leER scatterplots (QAL Ys, discounted at 3 per cent per annum) 
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Table 30 shows the results of these simulations as 95 per cent confidence intervals around 
lifetime costs, outcomes and ICERs - these indicate, with 95 per cent probability, the range in 
which results can be expected to fall. The mean results have been calculated from cohort 
simulation as this gives expected values whereas Monte Carlo simulation gives a different result 
with every simulation. At a zero annual discount rate, the model estimated a mean survival of2.9 
years for No-ART, 8.5 life years for first-line ART and 12.9 life years for first and second-line 
ART which translates into 2. I, 7. I and 10.8 QAL Ys respectively. Discounted per patient lifetime 
costs were US$2,966 for No-ART, US$5,779 for first-line ART and US$9,435 for first and 
second-line ART. The full breakdown ofthese costs by service category and by human resource 
components (doctors and nurses) is presented in Figure 20. Sixty-five per cent of lifetime costs on 
first and second-line ART were for ARVs, laboratory investigations and other medicines while 
overhead and capital costs were the largest cost driver for No-ART at 66 per cent of lifetime 
costs. Lifetime clinical staff costs were US$5 16 for No-ART, US$93 I for first-line ART and 
US$I,305 for first and second-line ART. First-line ART had a discounted ICER of US$795 per 
QAL Y gained versus No-ART while first and second-line ART had an ICER ofUS$I,625 versus 
first-line ART. ICERs were slightly lower per L Y gained. Although not presented in the table, the 
discounted ICER for first and second-line ART versus No-ART would be approximately 
US$ I, I 02 per QAL Y gained. 
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Table 30: Base case results, including PSA 
Outcomes ICER 
Treatment option Lifetime costs (95%CI) Life Years 
(95%CI) QAL Ys (95%CI) Life Years (95%CI) QAL Ys (95%CI) 
~~ 
No-ART 2,966 (2 ,611-3,343) 2.9 (2 .6-3.3) 2.1 (1 .8-2.3) 
First-line ART 7,085 (6,099-7,988) 8.5 (7 .1-9.6) 7.1 (5 .9-8.1) 736 (663-831) 816 (726-917) 
First and second-line ART 13,191 (11,167-16,056) 12.9 (11 .1-15.2) 10.8 (9 .1-12.5) 1,388 (1 ,362-1 ,414) 1,641 (1,621-1 ,683) 
~ I 
No-ART 2,743 (2 ,414-3,057) 2.7 (2.4-3.0) 1.9 (1 .7-2.1) 
First-line ART 5,779 (5,149-8,351) 6.9 (6.0-7.6) 5.7 (5 .0-8.3) 723 (652-846) 795 (706-911) 
First and second-line ART 9~3~8 ,~4-10,891)_ _ 9.5 (8 .5-10 .7) 8.0 (7 .3-8.6) 1,365 (1,344-1,398) 1,625 (1 ,601-1,665) 
- - - - -
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Figure 20: Lifetime cost curves for first and second-line ART, first-line ART and No-ART in the base case scenario 
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5.2. Generalized scenario 
This section makes a number of adjustments to the base case scenario in order to enhance the 
generalizability of estimates. The following adjustments have been made to utilisation data: 
• ART visits are based on national ART guidelines 
• No-ART visits are based on a local natural history cohort (8adri, Cleary et al. 2006) 
under the assumption that patients with CD4<50 ce\ls/lJ.l use the same visits as those with 
CD4<200 cells/~.tl and AIDS while patients with CD4 50-199 cells/lJ.l use the same visits 
as those with CD4<200 cells/lJ.l who are in other WHO stages 
The following adjustments have been made to unit costs: 
• Inpatient care is at secondary level hospitals 
• No-ART visit costs are based on the costs from clinics and community health centres 
(costs from hospital outpatient departments have been excluded) 
Outcomes have been adjusted by increasing the death transition probabilities on ART and No-
ART such that 18 per cent of the ART cohort is dead by one year based on ART-LINC data 
(ART-LINC and ART-CC 2006) and the median No-ART survival is 11 months based on a 
review of natural history data from resource poor settings (Schneider, Zwahlen et al. 2004). These 
adjustments might make results more applicable to routine settings. 
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Table31: Generalized results 
Treatment option Lifetime costs Outcomes leER Life Years OALYs Life Years QALYs 
• 
, I~ 
Generalized No-ART 1,813 2.3 1.6 
Generalized first-line ART 5,615 69 5.7 824 919 
Generalized first and second-line ART 9,474 9.7 8.1 1,387 1,651 
• 
, . , 
Generalized No-ART 1,706 2.1 1.5 
Generalized first-line ART 4,716 5.7 4.8 835 921 
Generalized first and second-line ART 7,215 7.6 6.3 1,374 1,635 
When comparisons are made between the base case and generalized scenario, lifetime costs were 
reduced by around US$I, 150 for No-ART, US$1 ,500 for first-line ART and US$4,000 for first 
and second-line ART. No-ART life expectancy was decreased by 0.6, first-line ART life-
expectancy was decreased by 1.6 and first and second-line ART life-expectancy was decreased by 
3.2. Although costs and outcomes were reduced, note the similarity between the generalized and 
base case leERs. 
5.3. Low cost generalized scenario 
This scenario extends the generalized framework to consider the impact of additional cost saving 
assumptions: 
• No viral load laboratory investigations 
• All patients receive nevirapine (US$17 .12 per quarter) instead of efavirenz (US$ 86.14 
per quarter) in the first-line regimen 
While data are insufficient to make adjustments to clinical outcomes when efavirenz is replaced 
by nevirapine, it should be noted that outcomes might be lower because nevirapine has been 
shown to be associated with more side-effects than efavirenz. 
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Table 32: Low cost generalized results 
Treatment option Lifetime costs Outcomes leER 
Life Years QALYs Life Years QALYs 
~-! r "']' 
Low cost No-ART 1 ,813 2.3 1.6 
Low cost first-line ART 4,204 6.9 5.7 518 578 
Low cost first and second-line ART 7,841 9.7 8.1 1,307 1,556 
Ilfn ~!r:ll 
Low cost No-ART 1,706 2.1 1.5 
Low cost first-line ART 3,541 5.7 4.8 509 561 
Low cost first and second-line ART 5,895 7.6 6.3 1,294 1,541 
Table 32 indicates that additional cost savings are possible through the use of cheaper ARVs and 
by eliminating viral load tests. Cost savings are around US$3,000 and US$5,000 when the low 
cost first-line and first and second-line results are compared to the base case. The lCERs oflow 
cost options are also more favourable than the base case ICERs presented in Table 30 indicating 
that the cost-effectiveness of either ART option might be higher in routine settings if low cost 
options are pursued. 
5.4. Debating when to start ART 
ln South Africa, a patient is medically eligible for ART if she or he has an AlDS diagnosis at any 
CD4 level or a CD4 count of less than 200 cells/!J.I at any WHO stage. While these medical 
eligibility criteria are usually thought of as merely technical, in reality they reflect a trade-off 
between maximising individual patient benefits and increasing coverage. Because of this trade-
off, patients are eligible for ART at a point when their capacity to benefit is reduced owing to 
their advanced stage of illness. This section considers the impact of prioritizing patients according 
to their capacity to benefit. The discussion in this section will draw on two separate analyses. 
Firstly, data in this thesis allows an assessment of the cost-effectiveness of initiating ART with 
CD4 50-199 cellsl).d and CD4<50 cells/!J.l. Secondly, earlier work reported in Badri, Cleary et al. 
(2006) allows an assessment of the cost-effectiveness of initiating ART with CD4>350 cells/i.d, 
CD4 200-350 cel/s/!J.1 and CD4<200 cells/!J.I. 
The data in this thesis, as presented in Figure 18, have shown that survival is slightly lower for 
patients who start ART with CD4<50 cells/!J.I in comparison to those who start with CD4 50-199 
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ceJls/1l1. However, the relatively ill patients that survive the first year on ART can still attain 
substantial benefits. What this analysis did not show is that many patients would die prior to 
starting ART if therapy initiation were delayed. 
In order to provide further understanding of the implications of starting ART once severely 
immune compromised, it is necessary to assume that all enter the models with CD4 50-199 
celiS/ill, from where they are "randomised" to start ART immediately, start ART once their CD4 
has dropped below 50 celiS/ill, or to continue with the No-ART option)5. For simplicity, only the 
first and second-line ART option is modelled. Results are presented in Table 33. Discounted (at 3 
per cent annual rate) QAL Ys are 2.5, 3.3 and 8.3 and lifetime costs (US$) are 3,090, 4,364 and 
9,695 for No-ART, starting ART with CD4<50ceJls/1l1 and starting with CD4 50-1 99ceJls/1l1 
respectively. FoJlowing Siegel, Weinstein et al. (1996), ICERs have been calculated by first 
ordering interventions from the least effective to the most effective. Then the ICER of starting 
ART at CD4 50-199 celiS/ill is calculated against starting ART at CD4<50 celiS/ill which in tum 
is calculated against No-ART. However, if an option is dominated, then the ICER is calculated 
against the next un-dominated intervention. Absolute dominance is defined as the case where a 
more effective option is less costly. While there is no absolute dominance in this scenario, starting 
ART with CD4<50 celIS/ill is dominated through extended dominance. Essentially this means 
that one could maximise benefits through following a mixed strategy of starting ART with CD4 
50-199 celiS/ill and No-ART. Because starting ART with CD4<50 celiS/ill is dominated, the 
ICER for starting ART earlier is calculated against No-ART. 
The following conclusions can be drawn about starting ART in the lower CD4 stratum: 
• Outcomes are considerably lower if ART is started during late immune decline, although 
there are still benefits in comparison to No-ART 
• The majority of deaths occur prior to ART initiation (this is deduced by comparing the 
considerably higher outcomes that are calculated in Figure 18 which showed outcomes 
for patients with CD4<50 celiS/ill from the time of initiating ART) 
IS Note that the results in Table 12 differ from those in Table 9 because all patients enter care in the higher 
CD4 stratum. 
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This result has implications for prioritizing patients if one is unable to offer treatment for all 
patients presenting with CD4<200 cells/~1. If patients with CD4<50 cells/fJ.1 are prioritized, the 
outcomes of healthier patients are jeopardized. If one is concerned with maximising outcomes 
and maximising the coverage of patients in need in the short-run, then patients with higher CD4 
levels should be prioritised for treatment over sicker patients. In the long-run however starting 
ART in patients with higher capacity to benefit has a higher opportunity cost in terms of health 
care resources (i .e. higher lifetime cost) than starting in the lower stratum. 
Table 33: Implications of starting ART with CD4 50-199 cells/ftJ versus CD4<50 cells/ftl 
Treatment option Lifetime costs Outcomes ICER 
Life Years QALYs Life Years QALYs 
Wi: 1& 1J:ilt'f 
No-ART 3.401 3.8 2.7 
Start ART at CD4<50 cells/ml 6.366 5.7 4.8 dominated dominated 
Start ART at CD4 50-199 cells/ml 13,605 13.5 11.3 1,061 1,192 
l]lt~ Ll..:J 
No-ART 3,090 3.5 2.5 
Start ART at CD4<50 cells/ml 4,364 3.9 3.3 dominated dominated 
Start ART at CD4 50-199 cells/ml 9,695 9.9 8.3 1,031 1,135 
While the preceding analysis provides insight into the alternative costs and outcomes associated 
with ART in patients with CD4<200 ceJls/~I , it should be borne in mind that the medical 
eligibility criteria for ART in South Africa are relatively conservative. Badri, Cleary et al. (2006) 
have used a similar approach to that described in this thesis to assess the cost-effectiveness of 
starting ART within higher CD4 strata. In this analysis, all patients enter care with CD4>350 
cells/fJ.1 from where they start ART immediately, start ART with CD4 200-350 cells/fJ.l, start with 
CD4<200 cells/~l or to continue with the No-ART status quo. Results indicate that undiscounted 
life expectancy could be 23,21, 19 and 6 years from each of these strategies. However, earlier 
initiation was inevitably associated with higher lifetime costs given that at least 50 per cent of 
ART costs are associated with recurrent medication and laboratory investigations. The study 
found that the ICER was lowest for starting ART at CD4<200 cells/fJ.l (US$6JI per QAL Y 
gained at a zero discount rate), followed by 200-350 cells/~1 (US$915 per QAL Y gained) and 
finally> 350 cells/~1 (US$J ,236 per QAL Y gained). 
6 Summary 
159 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
This chapter has presented extensively justified patient-level lifetime costs and individual health 
gains associated with alternative HIV-treatment interventions. The building blocks of these 
estimates have included widely generalizable unit costs, estimates of the utilisation of clinic visits 
from 1,729 patients, estimates of the utilisation ofTB and inpatient services from 670 patients, 
secondary HRQoL data from a sample of patients in the same clinics (Jelsma, MacLean et al. 
2005), ART transition probabilities estimated from 1,729 patients over a maximum follow-up of 
four years, and No-ART transition probabilities from a local natural history cohort (Post, Wood et 
al. 1996; Badri, Bekker et al. 2004). These building blocks have been fed into the Markov 
models, which have been shown to perform well in terms of technical, predictive, face and 
modelling process validity. Uncertainty relating to data requirements has been assessed in 
probabilistic sensitivity analysis; the very narrow confidence intervals generated through this 
analysis suggest that one can place confidence in the results that have been produced. 
Patient-level results have been produced in four scenarios. In the base case scenario, results were 
estimated from Khayelitsha data. The generalized scenario made a number of adjustments to cost, 
utilisation and clinical outcomes based on secondary literature. While ICERs in this scenario were 
similar to base case, lifetime costs and outcomes were reduced. The low cost generalized scenario 
explored the implications of using cheaper first-line ARVs and removing viral load testing. This 
scenario indicated that cost-effectiveness could be considerably improved through these 
strategies. In each of these scenarios, it was indicated that the highest individual benefits could be 
achieved through first and second-line ART. However, if access to second-line were restricted, it 
is likely that more patients could access first-line ART. 
The final section considered the implications of starting ART in alternative CD4 strata. This 
concluded that capacity to benefit would be improved if ART were initiated at CD4 50-199 
cells/J.ll. However, defining need as capacity to benefit does not necessarily mean that the most 
effective intervention should be implemented. The opportunity cost of the additional resources 
associated with starting ART earlier would need to be considered given resource scarcity. On the 
other hand, initiating care in a state of advanced immune suppression (CD4<50 cells/J.ll) is 
dominated through extended dominance. What this means is that a health maximising strategy 
would suggest that patients who present for care with CD4 50-199 cells/J.ll should be prioritised. 
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Chapter 7: Population-level results 
1 Introduction 
This chapter extends patient-level results to the population-level. While patient-level analyses 
were concerned with calculating lifetime costs and individual health gains, at the population-level 
one is concerned with assessing the total costs and total QAL Y s that can be gained through 
delivering each intervention to a defined population in need over a given planning time frame. 
These results are fed into mathematical programming algorithms in order to estimate the 
proportion of patients receiving alternative HIV-treatment interventions, the QALYs that can be 
gained and the percentage of need that can be met in each of three different social choice rules. In 
health maximisation, technical efficiency is assessed through choosing the mutually exclusive 
HlV-treatment intervention(s) that maximises health within the budget allocated to one 
independent health care programme (HIV-treatment). In the decent minimum, health is 
maximised within the budget constraint with the proviso that all patients in need receive one of 
the mutually exclusive HIV -treatment interventions. In equal health, health is maximised within 
the budget constraint with the constraint that all patients receive the same health gain (in other 
words, they receive the same HIV-treatment intervention). By comparing the percentage of need 
that can be met and the QAL Ys that can be gained at the same budget in each social choice rule, 
the equity/efficiency trade-off is apparent. These analyses are described in detail in this chapter, 
and form a key part of the discussion in Chapter 7. 
The chapter has three parts. The first part sets the scene for subsequent sections by discussing the 
HlV-treatment scenarios that will be considered; the choice of the decision-making time frame; 
the need for HlV-treatment; the patient targets contained in the "Operational Plan for HIV and 
AIDS Care" (Department of Health 2003); and the health care budget and clinical personnel 
available for HI V-treatment. The second part of the chapter presents total costs and QALYs if 
each of the different HIV-treatment programmes were to reach 100 per cent of need over the 
decision-making period. These totals are then used in the mathematical programming algorithms 
to assess the implications of alternative social choice rules. The third part models the resources 
required to implement the targets contained in the Operational Plan and considers how the current 
programme could be offered in a more efficient or equitable manner. 
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2 Background 
2.1. Scenarios 
Total costs and QAL Ys will be calculated for three mutually exclusive HI V-treatment 
interventions grouped into two scenarios: 
Base case scenario (derived from patient-level costs and outcomes as per Khayelitsha data) 
• No-ART 
• First-line ART 
• First and second-line ART 
Generalized scenario (includes adjustments to unit costs, utilisation and outcomes to enhance 
generalizability of results) 
• No-ART 
• First-line ART 
• First and second-Hne ART 
Two scenarios from the previous chapter will be excluded from this analysis . The low cost 
generalized scenario will not be considered because while it is likely to have an impact on 
outcomes, no data exist about what this impact might be. If it were considered, it would dominate 
certain options (having lower costs but identical outcomes) which might not be realistic. 
Secondly, the impact of prioritising patients based on their capacity to benefit will not be 
considered. In order to consider this scenario, it would be necessary to calculate the numbers of 
patients in need of treatment within different CD4 strata, but current demographic models do not 
provide these data. 
2.2. Decision-making time frame 
A key choice in HI V-treatment priority setting is that of the decision-making time frame. Most 
frequently, HIV/AIDS strategic plans tend to cover a five-year time period. South Africa's first 
strategic plan covered the period 2000-2005, the Operational Plan covered 2003-2008 and a new 
strategic plan is currently being developed to cover a four-year period from 2007 to 20 II . 
However, this does not imply that these are the appropriate time frames for decision-making. 
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Patient-level models can assist in the choice of the decision-making time frame, through an 
assessment of the relationship between the marginal and average cost and the level of the leER at 
different levels of output for each mutually exclusive intervention in the base case scenario. 
Figure 21 shows the average total cost (total cost divided by total QALYs) and the marginal cost 
(the change in total costs divided by the change in QAL Ys) over an individual's lifetime. 
A verage and marginal costs are higher during the initial period on treatment and this is 
particularly marked in the two ART options. For No-ART and first-line ART, marginal cost 
approaches average cost when a very high proportion of the cohort is dead. What this means is 
that while all patients will have higher costs at the time of death (owing to the death transition 
cost), when the distribution of costs is compared across an infmite cohort, these higher costs even 
out because different patients will be dying at different points. However, for first and second-line 
ART, there is a large increase in costs as patients move on to the second-line regimen. This 
causes the marginal cost to exceed the average cost after 4 QAL Y s have been gained on 
treatment. The implication of this analysis is that limiting the time frame of analysis for first and 
second-line ART in particular will tend to overstate the cost-effectiveness of this intervention in 
comparison to first-line ART. 
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Figure 21: Average and marginal cost of interventions 
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This can be further unpacked by exploring the impact on results of the modelling time horizon. 
To do this, the base case models were run over 5 years, 10 years and until 100 per cent of the 
cohort was dead. Undiscounted per-patient lifetime costs ranged between US$2,516 and 
US$2,966 for No-ART; between US$3,473 and US$7,085 for first-line ART; and between 
US$3,860 and US$13, 191 for first and second-line ART under different modelling time horizons 
(Table 34) while undiscounted QALYs ranged between 1.7 and 2.1 for No-ART; between 3.2 and 
7.1 for first-line ART; and between 3.5 and 10.8 for first and second-line ART. Mean leERs 
(calculated for life years and QALYs) are presented in Table 34. The discounted incremental cost 
per QAL Y gained of first-line ART versus No-ART is US$636, 736 and 795 under a 5-year, 10-
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year and unlimited horizon. Conservative time horizons also tend to mask the difference in 
lifetime costs and QALYs as shown by the lower incremental costs and incremental QALYs 
under 5-year, 1 O-year and unlimited time horizons. 
Table34: Lifetime costs, effectiveness and leERs of interventions with alternative modelling 
time horizons 
Treatment option Lifetime costs Outcomes leER 
Life Years QALYs Life Years QALYs 
Illfif. • o • 
Simulation over 5 years 
No-ART 2,516 2.4 1.7 
First-line ART 3,473 3.9 3.2 638 634 
First and second-line ART 3,860 4.3 3.5 968 1,334 
Simulation over 10 years 
No-ART 2,881 2.8 2.0 
First-line ART 5,123 6.0 5.0 701 742 
First and second-line ART 6,617 7.2 6.0 1,245 1,540 
Simulation until 100% dead 
No-ART 2,966 2.9 2.1 
First-line ART 7,085 8.5 7.1 736 816 
First and second-line ART 13,191 12.9 10.8 1,388 1,641 
• . . . 
Simulation over 5 years 
No-ART 2,391 2.3 1.6 
First·line ART 3,275 3.7 3.0 631 636 
First and second·line ART 3,620 4.0 3.3 1,150 1,327 
Simulation over 10 years 
No·ART 2,686 2.6 185 
First-line ART 4,600 5.4 4 .5 684 736 
First and second·line ART 5,823 6.3 5.3 1,359 1,529 
Simulation until 100% dead 
No-ART 2,743 2.7 1.9 
First-line ART 5,779 6.9 5.7 723 795 
First and second-line ART 9,435 9.5 8.0 1,406 1,625 
The implication is that very short time horizons tend to overstate the cost-effectiveness of the two 
ART strategies, and to underestimate lifetime costs and outcomes. If HI V-treatment budgets were 
based on shorter time horizons this could result in fewer patients being treated than had been 
planned. Based on this reasoning, March 2004 has been chosen for the start of the projection 
because although the rollout of ART was announced in late 2003, service delivery mainly began 
during 2004. Given the likelihood offuture technological innovation in this field and the 
uncertain impact of the provision of ART on future incidence and prevalence of HI VIA IDS (see 
(Blower, Bodine et al. 2005» projections have been limited to ten-year duration. Any change in 
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incidence of HIV from the start of ART in the country until 2014 would not have a significant 
impact on the numbers of patients developing AIDS. This is because this projection will primarily 
be dealing with patients who are already HIV-positive as of2006. By limiting the projection to 
ten years and therefore primarily dealing with people who are already HIV-positive, this analysis 
avoids having to make assumptions about the impact of ART on HIV incidence. A potentially 
optimal strategy for strategic planning could be to continue to update HIV/AIDS strategic plans 
every five years, but to base these plans on a ten-year analysis of costs and outcomes. 
2.3. Need 
As explained in the methodology, the number of people in need of HI V-treatment is assumed to 
be equivalent to the number of new AIDS cases each year based on ASSA2003lite estimates over 
the period March 2004 until March 2014. It is worthwhile reiterating that because one is using 
new AIDS cases as the proxy for need, when one meets a certain percentage of this new need, one 
has met a lower percentage oftotal need. Figure 22 shows the number of adults newly developing 
AIDS, as calculated from ASSA2003lite. 
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Figure 22: New AIDS sick adults between 2004 and 2014 
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Source: extracted from ASSA2003lite AIDS and Demographic Model of the Actuarial Society of 
South Africa (release 24 November 2005), as downloaded in December 2005 from 
www.assa.org.za 
2.4. Treatment targets in the Operational Plan 
The government committed to the public sector rollout of ART in October 2003. By mid-
November of that year, the Operational Plan detailing the implementation of the rollout was 
released. This document contains targets for patients entering and remaining in care as detailed in 
Table 35. The plan does not contain a specific target for adults, so these have been calculated 
based on the average proportion of new adult AIDS cases out of new AIDS sick adults and 
children (94 per cent) between 2004 and 2014, from ASSA20031ite. 
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Table 35: Operational Plan targets of patients starting and remaining on ART 
Patients Adults 
New patients New adults remaining on remaining 
By end of : starting ART starting ART ART on ART 
Mar-04 53,000 49,820 53,000 49,820 
Mar-05 138,315 130,016 188,665 177,345 
Mar-06 215,689 202,748 381,177 358,306 
Mar-07 299,516 281,545 645,740 606,996 
Mar-08 411 ,889 387,176 1,001,534 941,442 
Mar-09 551,089 518,024 1,470,510 1,382,279 
Although the Operational Plan initially envisaged placing 53,000 people on ART between 
November 2003 and March 2004, in his State of the Nation Address delivered after the April 
2004 general elections, President Mbeki stated that this patient target would only be met by 
March 2005 (Mbeki 2004). The analysis of the Operational Plan in this dissertation will therefore 
assume that the targets of new adults starting ART in Table 35 are lagged by one year. 
The Operational Plan intended to provide ART to incrementally higher proportions of new AIDS 
cases until 100 per cent of need was reached after a 5-year period. A comparison between these 
lagged patient targets, new adult AIDS cases (from ASSA2003lite) and the proportion of need 
that is met is presented in Table 36. By March 20 I 0, the Operational Plan target would be 
meeting 106 per cent of need - this is because the targets were designed to meet 100 per cent of 
need by March 2009 (when need was higher) and were based on an earlier version of the ASSA 
model which produced slightly different estimates. It will therefore be assumed that the target is 
to meet 100 per cent of need by March 2010, which requires starting an additional 488,468 
patients on ART. 
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Table 36: New adults starting ART, new AIDS sick adults and the proportion of met need 
New adults NewAIDS 
By end of: starting ART sick adults Met need (%) 
Mar-05 49,820 361,866 14% 
Mar-06 130,016 406,144 32% 
Mar-07 202,748 440,803 46% 
Mar-08 281,545 465,758 60% 
Mar-09 387,176 481,351 80% 
Mar-10 518,024 488,468 106% 
When monitoring the extent to which ART patient targets are being met, the most appropriate 
standard is the target for patients entering care. However, the government only releases data on 
the number of patients remaining on ART. In order to assess whether patient targets are being 
met, one therefore has to estimate the number of patients that would be remaining in care if the 
targets for patients entering care were being met. 
One way of doing this is by using Markov modelling, and this approach was taken by the authors 
of the Operational Plan. However, their estimation of patients remaining in care assumed that 
death and drop out rates would be close to zero during the earlier periods on ART, while primary 
data suggest a higher death and drop-out rate during the first year and much lower rates during 
later years. Table 37 contains a comparison between the Operational Plan's target for patients 
remaining in care versus calculations of patients remaining in care using base case and 
generalized scenario survival functions. The proportion of patients remaining in care is calculated 
by dividing the total remaining in care in year x by the total that entered care in year x and all 
preceding years. The table indicates that the Operational Plan is intending much higher patient 
retention than has been attained in Khayelitsha. 
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Table 37: Comparison between Operational Plan target of patients remaining in care to 
calculations from the base case and generalized scenarios 
Adults Adults 
remaining in Adults remaining in 
care - Proportion remaining in Proportion care - Proportion 
Operational remaining in care - base remaining in generalized remaining in 
B'i end of: Plan care case scenario care scenario care 
Mar-05 49,820 100% 45,700 92% 44,327 89% 
Mar-06 177,345 99% 161 ,275 90% 155,073 86% 
Mar-07 358,306 94% 335,717 88% 320,145 84% 
Mar-08 606,996 91% 572,042 86% 541,748 82% 
Mar-09 941,442 90% 891,472 85% 839,514 80% 
Mar-10 1,382,279 88% 1,289,227 82% 1,207,184 77% 
The implication is that when one evaluates the progress of the rollout, it becomes relatively 
complex to ascertain whether the patient targets are being met. A paper presented at the XVI 
International AIDS Conference (Abdullah 2006) reported that 42,000 patients were on ART by 
March 2005 and 142,773 by March 2006 in South Africa. If it is assumed that 94 per cent of these 
are adults, then approximately 39,000 adults were on treatment by March 2005 and over 132,000 
by March 2006. If one compares these data to estimates using a survival function based on base 
case ART, the public sector had met 82 per cent of its patient targets by March 2006 or 86 per 
cent if the generalized ART scenario is assumed. These percentages are higher than those 
estimated using the survival function assumed by the authors ofthe Operational Plan. See Table 
38. 
Table 38: Numbers of patients receiving ART in the public sector and the proportion of the 
Operational Plan target being met 
Adults Per cent Per cent Per cent 
remaining in Operational base case generalized 
care - actual Plan target target target 
Mar-05 39,060 78% 85% 88% 1 
Mar-06 132,779 75% 82% 86% 
To summarize the discussion thus far, Table 39 presents the numbers of adults entering care 
based on the Operational Plan targets. Beyond 20 I 0, it has been assumed that ART will be 
available to all new adult AIDS cases, based on ASSA2003lite estimates (in other words, the 
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Operational Plan target for 20 lOis replaced by more recent estimates of need). Just fewer than 3 
million adults are projected to enter care over the ten-year period and 77 per cent could be alive 
and remaining in care by the end of March 2014, ifsurvival and patient retention is as assumed in 
the base case scenario. 
Table 39: Adults entering and remaining in care under Operational Plan targets 
Patients Proportion 
Adults remaining in remaining in 
entering care - care - base care - base 
By end of: target case case 
Mar-05 49,290 45,700 93% 
Mar-06 128,633 161,275 91% 
Mar-07 200,591 335,717 89% 
Mar-08 278,550 572,042 87% 
Mar-09 383,057 891,472 86% 
Mar-10 488,468 1,289,227 84% 
Mar-11 488,494 1,662,543 82% 
Mar-12 483,561 2,010,266 80% 
Mar-13 475,540 2,329,518 78% 
Mar-14 465,945 2,618,936 77% 
Total 2,976,183 2,618,936 88%' 
While the preceding table gives a picture of the patients receiving first and second-line ART and 
remaining in care, it is likely that patients who do not receive ART would receive some other 
form of care and support, Data suggest that the quality of care that patients receive in the absence 
of ART is lower than base case No-ART (Cleary, Chitha et al. 2005), In what follows, it will 
therefore be assumed that adults with AIDS who do not receive ART receive generalized No-
ART. Table 40 shows the numbers of patients receiving generalized No-ART care (the difference 
between the number developing AIDS and those who received first and second-line ART) and 
remaining in care between March 2004 and March 20 I 4. During this period, over 1.1 million 
adults in need of treatment would not be able to access ART, and 0.1 per cent would be alive and 
remaining in care by the end of March 2014. From March 2010, no new patients would be started 
on generalized No-ART as all new need would be treated with ART. However, those patients 
who were aJready on generalized No-ART would continue along this treatment path - if the target 
is to meet 100 per cent of new need, one is meeting less than 100 per cent of total need. The table 
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however indicates that if one has been meeting all new need on a continuous basis over 4 or 5 
years, meeting new need becomes very similar to meeting total need. 
Table 40: Patients receiving generalized No-ART and remaining in care 
Patients 
Patients remaining in 
receiving care - Proportion 
generalized No generalized remaining in 
Bflear ending: ART No-ART care 
Mar-05 312,046 260,074 83% 
Mar-06 276,128 388,624 66% 
Mar-07 238,055 440,584 53% 
Mar-08 184,213 432,443 43% 
Mar-09 94,175 356,403 32% 
Mar-10 - 208,711 19% 
Mar-11 - 112,968 10% 
Mar-12 - 53,898 5% 
Mar-13 
-
19,068 2% 
Mar-14 - 2,751 0% 
Total 1,104,617 2,751 0% 
To conclude, this section has presented data on the numbers of adults developing AIDS between 
March 2004 and March 2014 and has contrasted these against the ART patient targets in the 
Operational Plan. These data will form the basis for calculations of total resource needs and total 
QAL Ys from alternative HI V-treatment scenarios. 
2.5. HIV -treatment budget constraint 
The total budget available for HIV -treatment is a crucial input into an assessment of the 
affordability of alternative treatment strategies. According to Hickey (2004) the 2004/05 national 
budget was the first that specifically made provisions to support the first year of the ART rollout. 
In this year, National Treasury alIocated US$161 million to the budget of the Chief Directorate: 
HIV/AIDS and TB in the NDoH. These funds included allocations for direct spending by the 
NDoH, funds to be transferred to NGOs and funds to be transferred as conditional grants to the 
provincial health departments. The funds that are spent directly by the NDoH primarily include 
spending on public awareness and prevention programmes and condom distribution. Grants to 
NGOs include allocations for the South Africa AIDS Vaccine Initiative, HIV awareness 
campaigns and smaller amounts to provincial and national NGOs. Finally, around 55 per cent of 
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the Chief Directorate's budget is transferred to provincial health departments to finance a range of 
HIV 1 AIDS interventions including: 
• Voluntary counselling and testing 
• Community and home-based care and support 
• Prevention of mother to child transmission of HIV programmes 
• Step-down care 
• Strengthening of provincial management 
• Establishing regional training centres with academic institutions 
• Post exposure prophylaxis for rape survivors 
• Step down care 
• Sex worker programmes 
From 2004/05 , this conditional grant from National Treasury to the Chief Directorate was 
increased markedly, with the intention that the increase would cover provincial ART programmes 
and national oversight of these treatment programmes within the NDoH. These conditional grants 
are intended to finance the incremental costs of the ART programme (ARVs, laboratory tests and 
additional clinical personnel) with the implication that fixed costs such as overheads and capital 
within HIV -treatment clinics and community health centres, ongoing HIV -related inpatient care 
and HIV-related TB treatment l6 would continue to be fllanced via general provincial health care 
budgets. Thus while a large proportion of HI V-treatment costs are likely to be covered through 
provincial health care budgets, there are no specific budgetary allocations to cover these costs. 
Table 41 shows the estimated ART conditional grants and the total provincial health care budget 
for primary health care, hospital services and facility capital. The provincial estimates exclude a 
number of functional classifications that would not relate to health service delivery such as health 
sciences training and administration. Data on ART conditional grants are from Hickey (2004) and 
data on provincial health care budgets are from the National Treasury (2005). All data are 
Medium Term Expenditure Framework estimates except for the 2004/05 provincial estimates 
which are preliminary expenditure estimates. 
16 While TB treatment was initially provided through local governments, TB is becoming part ofthe 
provincial government responsibility and these costs are therefore reflected in provincial Medium Term 
Expenditure Framework (MTEF) allocations. 
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Table 41: Budget for ART and provincial health care budgets (in US$ millions and 2003/04 
prices) 
2004/05 2005/06 2006/07 2007108 
ART conditional grants for provinces 39.68 77.05 124.68 12105 
Provincial health care budget by functions 
Hospitals 3,095.79 3,047.81 3,021.46 2,960.61 
Primary health care 1,095.85 1,196.37 1,232.76 1,232.09 
Capital 284.88 368.99 408.86 396.56 
Total 4,476.52 4,613.17 4,663.08 4,589.26 
It is widely argued that the key resource constraint to successfully scaling up HTV-treatment in 
developing countries is clinical personnel (Kober and Van Damme 2004). Data extracted from the 
South African public health personnel information system (PERSAL) provide estimates of the 
health personnel working in the public health care system in 2005 and 2006. As shown in Table 
42, there were over 13,000 medical officers and 44,071 professional nurses in 2006. 
Table 42: Numbers of health professionals working in the public health care system 
I Medical doctors I, Medical I Total medical I Professional specialists officers nurses 
2005 I 8,747 'I 3,499 L 12,246 l 43,660 
2006 l 9,527l 3,695l 13,2221 44,071 
Source: PERSAL; http://www.hst.org.zaJhealthstat l index .php 
Total and clinical personnel resource estimates ofaltemative HrV-treatment interventions will be 
compared against these budget constraints in later parts of this chapter. 
3 Population-level costs and QAL Y s 
This section describes the total costs (million US$) and total QALYs (million) in the base case 
and generalized scenarios in each HI V-treatment intervention. Projections are estimated under the 
assumption that 100 per cent of patients in need of ART (developing AIDS) enter the models 
during each cycle of the planning period. Outcomes are expressed as QAL Ys and results are 
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discounted at an annual rate of three per cent. Because calculations using life years and zero 
discount rates do not change the results obtained in different social choice rules, these will not be 
presented. 
3.1. Total costs and QALYs in the base case and generalized scenarios 
Figure 23 and Figure 24 present the cumulative total costs and total QAL Ys if each of the three 
HIV-treatment interventions under consideration were implemented to all in need between 2004 
and 2014. By the end of March 2014, cumulative total costs in the first and second-line ART 
scenario would be around US$12.5 billion and total outcomes would be 12 million QAL Ys. First-
line ART would have a cumulative cost of around US$ll billion for 10.5 million QAL Ys while 
No-ART would cost just over US$7.6 billion for 5 million QALYs. In the generalized scenario, 
first and second-line ART would cost around US$11 billion for 11 million QAL Ys, first-line 
ART would cost around US$9.6 billion for 9.6 million QAL Ys and No-ART would cost around 
US$5 billion for 4 million QALYs. Clinical personnel and patient specific resources (the 
approximate incremental costs of HIV -treatment) would amount to US$8.5 billion (base case first 
and second-line ART), US$7 billion (base case first-line ART), US$7.7 billion (generalized first 
and second-line ART) and US$6.4 billion (generalized first-line ART). 
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Figure 23: Total costs (US$ million) and total QALYs (million) in base case scenario 
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Figure 24: Total costs (US$ million) and total QALYs (milJion) in generalized scenario 
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3.2. Total clinical personnel required to provide base case and 
generalized HIV-treatment programmes 
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l 
Given the importance of clinical personnel in the scale-up process, the number of medical officers 
and professional nurses required under each scenario has also been calculated. To do this, the first 
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step was to group facilities into hospitals or clinics and community health centres. The second 
step was to calculate the total expenditure and proportion of expenditure on medical officers and 
nurses in these groups. The third step was to calculate the clinical stafflifetime cost (from the 
patient-level Markov models) incurred at hospitals and clinics or community health centres. This 
cost was then apportioned to nurses or medical officers based on the proportional cost of these 
staff in hospitals or clinics, as calculated in step two. By adding the proportion spent on nurses at 
clinics to the proportion spent on nurses at hospitals, it was possible to calculate the total lifetime 
cost spent on nurses. A similar exercise was followed for doctors. Finally, it was possible to 
calculate the percentage of the clinical stafflifetime cost that was spent on medical officers or 
nurses. These calculations are shown in Table 43. 
Table 43: Breakdown of patient-level clinical staff costs (US$) in base case and generalized 
scenarios 
Lifetime Lifetime Total 
cost- cost - lifetime cost %ofcost 
clinics hospitals 
-. 
. 
No-ART 
Medical officer costs 63 201 264 51% 
Nurse costs 155 97 252 49% 
Total 218 298 516 100% 
First-line ART 
Medical officer costs 525 157 682 73% 
Nurse costs 173 76 249 27% 
Total 698 233 931 100% 
First and second-line ART 
Medical officer costs 774 186 960 74% 
Nurse costs 255 90 345 26% 
Total 1,029 276 1,305 100% 
. . . 
No-ART 
Medical officer costs 27 114 141 54% 
Nurse costs 66 55 121 46% 
Total 93 169 262 100% 
First-line ART 
Medical officer costs 438 93 531 74% 
Nurse costs 144 45 189 26% 
Total 582 138 720 100% 
First and second-line ART 
Medical officer costs 608 105 713 74% 
Nurse costs 200 51 251 26% 
Total 808 156 964 100% 
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In the social choice "tVY'"'t.>, these were used to calculate the total cost to 
nurses and doctors costs 23 and as 
indicated in Table 44. the total medical officer or nurse cost the average annual 
cost Inv",,,,nt of each it was !-'V.'.>lIL)',", to estimate the number of medical 
officers and nurses to manage each HIV treatment intervention and scenario each 
year of the These results are shown in 25. ART treatment are much 
more medical officer intensive than the No-ART V,",'''J''''. the end of March 20 
medical officers and 1 nurses would be under base case first and second-line ART 
while 737 medical officers and I nurses would be base case No-ART. In the 
medical officers and I nurses, or 382 medical officers and 868 
nurses would be in the first and second-line ART or No-ART 
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Figure 25: Number of medical officers and professional nurses required to manage HIV-
treatment programmes each year 
BASE CASE SCENARIO GENERALIZED SCENARIO 
First and second-line ART 
2003 2005 2007 2009 2011 2013 2015 2003 2005 2007 2009 2011 2013 2015 
2003 2005 2007 2009 2011 2013 2015 2005 2007 2009 2011 2013 
I No-ART I 
4,000 4,000 
3,000 3,000 
2,000 2,000 · 
1,000 1,000 
2005 2007 2009 2011 2013 2015 2005 2007 2009 2011 2013 
Number of medical officers 
-
Number of nurses D 
3.3. Validating the decision-making time frame 
There are two ways in which the time horizon has an influence on the modelling approach. In 
patient-level models, the modelling time horizon has been shown to have an impact on lifetime 
costs, outcomes and the level of the leER (see section 2.2). At the population level, a decision-
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making time horizon might also be influential because countries need to consider whether they 
can sustain HIV-treatment programmes once these have been initiated. While a ten-year time-
frame has been adopted for patients entering the projection, this time frame will not capture the 
full costs of treatment because the majority would still be alive and remaining in care (see Table 5 
for example). The further one looks into the future, the higher the potential resource-level 
required owing to increasing numbers of patients being enrolled and maintained in care, but the 
more likely that projections become irrelevant owing to changes in technology (e.g. new 
medicines or therapeutic vaccines). 
Economic thinking suggests that the chosen treatment programme should have the lowest 
marginal cost (change in cost divided by the change in QALYs). However, if the marginal cost 
differs over the time frame, then different HIV-treatment programmes might seem more cost-
effective at different points in time. To test whether this might be the case, the marginal cost of 
each programme delivered to 100 per cent of patients in need was calculated for each cycle 
(three-month period) of the projection. This involved dividing the change in total costs from one 
cycle to another by the change in total outcomes in the same period. The results are presented in 
Figure 26. In the earliest time periods, the marginal costs of the first-line ART and first and 
second-line ART options are similar. However, as time passes and more patients transition to 
second-line, the marginal cost of the two first and second-line options becomes higher than the 
two first-line options. The implication is that very short decision-making time-frames might be 
misleading. This analysis has therefore validated the choice of a ten-year decision-making time 
frame that has been proposed. 
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Figure 26: Evolution of the marginal cost (discounted at 3 per cent) over time in base case 
and generalized scenarios 
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This section compares the QAL Y s gained and percentage of need that can be reached under 
health maximisation, the decent minimum or equal health social choice rules in the base case and 
generalized scenario. Base case and generalized scenarios are not assumed to be in competition 
with each other - in other words the generalized scenario interventions are only in competition 
with each other, but not with the base case scenarios. This is because it would be unfair to design 
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policy that specifically places some patients on a generalized option and others on a base case 
option given the different quality of care. 
Social choice rule calculations are based on the total discounted costs and QALYs associated with 
each HlY-treatment intervention between March 2004 and March 2014. The health maximisation 
social choice rule chooses the scenario or combination of scenarios that produces maximum 
QALYs at a given budget constraint irrespective of the proportion of need that is met, the "decent 
minimum" maximises outcomes subject to all patients receiving some form of treatment, while 
equal health places all patients on the same treatment intervention. Table 44 shows the mix of 
treatment programmes and total QALYs that are produced at different budget constraints. For the 
two more equitable social choice rules (equal health and the decent minimum) the QALY loss 
associated with being equitable is calculated by comparing each of these against health 
maximisation. The cost of health maximisation is expressed in terms of the percentage of need 
that is unmet. Results are presented for budgets ranging from US$5 billion to US$13 biUion. The 
former is slightly higher than the cheapest treatment strategy (generalized No-ART) while the 
latter is slightly higher than the most expensive option (base case first and second-line ART). 
In the base case scenario, neither of the more equitable rules places any patients on treatment 
until the budget is approximately US$8 billion, but the health maximisation rule is able to place 
64 per cent of patients on first-line ART for a QAL Y gain of 6.8 million. At lower budgets, both 
equitable strategies place patients on No-ART, which is never a policy choice under health 
maximisation. Results from social choice rules converge as the budget increases. Once US$ll 
billion is available, 100 per cent of need is met under all social choice rules, and the decent 
minimum and health maximisation produce the same results. Similar patterns are found in the 
generalized scenario, although note that at lower budgets the generalized scenario is both more 
equitable and more technically efficient than the base case scenario. The proportion of patients on 
different HIY-treatment programmes as the budget increases is depicted in Figure 27. 
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Table 44: Total QALYs and mix of programmes at different budget constraints in the social choice rules 
EQUAL HEALTH DECENT MINIMUM HEALTH MAXIMISATION 
Budget Proportion on: Total QALY Proportion on: Total QALY Proportion on: Total (US$ 
No- First- First & QALYs cost No- First- First & QALYs cost No- First- First & QALYs Unmet million) 
ART line second- (millions) (millions) ART line second- (millions) (millions) ART line ART second- (millions) need ART line ART ART line ART line ART 
Base case scenario Baae CBse scenario Base CBse scenario 
5,000 - -4.8 - - - - -4 .8 - 46% - 4.8 54% 
6,000 - -5.8 - - - - -5.8 - 55% - 5.8 45% 
7,000 - -6.8 - - - - -6.8 - 64% - 6.8 36% 
8,000 100% 5.2 -2 .5 I 88% 12% - 5.8 -1 .9 - 74% - 7.8 26% 9,000 100% 5.2 -3 .5 58% 42% - 7.5 -1 .2 - 83% - 8.7 17% 
10,000 100% 5.2 -4.5 27% 73% - 9.1 -0.6 - 92% - 9.7 8% 
11,000 100% 10.5 -0.1 0% 92% 8% 10.6 0.0 - 92% 8% 10.6 0% 
12,000 100% 10.5 -0.8 0% 31% 69% 11.3 -0.0 - 31% 69% 11 .3 0% 
13,000 100% 11 .7 - - 0% 100% 11.7 - - 0% 100% 11 .7 -
Generalized scenario Generalized scenario Generalized scenario 
5,000 100% 4.2 -0 .8 97% 3% - 4.4 -0.6 - 52% - 5.0 48% 
6,000 100% 4.2 -1 .8 76% 24% - 5.5 -0.5 - 63% - 6.0 37% 
7,000 100% 4.2 -2.8 55% 45% - 6.7 -0.4 - 73% - 7.0 27% 
8,000 100% 4.2 -3.8 34% 66% - 7.8 -0.2 - 84% - 8.1 16% 
9,000 100% 4.2 -4.8 12% 88% - 9.0 -0.1 - 94% - 9.1 6% 
10,000 100% 9.6 -0 .3 0% 72% 28% 9.9 0.0 - 72% 28% 9.9 0% 
11,000 100% 9.6 -1.0 0% 6% 94% 10.6 - - 6% 94% 10.6 0% 
12,000 100% 10.7 - - - 100% 10.7 - - - 100% 10.7 -
13,000 100% 10.7 - - - 100% 10.7 - - - 100% 10.7 -
-
-
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Figure 27: Proportions of patients on alternative HI V-treatment programmes at different 
budget constraints 
GENERALIZED SCENARIO BASE CASE SCENARIO 
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9,000 11 ,000 13,000 
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There are a number of implications of this analysis: 
• At lower budgets, in particular in the base case scenario, the equitable social choice rules 
present a potentially unacceptable reduction in the health gains of HIV -positive people 
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because allow no access to antiretroviral treatment. the benefit of these 
solutions is that all will receive treatment for 
infections and care. 
• All social choice rules favour the use of ART but once it be 
to limit access to an additional This would be 
controversial for who fail the first-line to side-effects. 
• The scenario is both more and more than the 
base case scenario at lower constraints. 
4 
This section of ART from an and 
it has been assumed that the 
sector rollout of ART n,.r."p,~rI" to the and that the 
in need receive No-ART care. Base case first and second-line ART has been 
assumed because the Plan describes a resource intensive model of care and 
No-ART has been assumed that data show that receive a less resource 
intensive form or this care than that assumed in base case No-ART Chitha et al. 
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Figure 28: Estimated costs and QAL Ys of implementing the Operational Plan 
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incremental costs of first and second-line ART (clinical personnel and patient-specific) are 
compared against the ART conditional grants. This is because, as explained above, only these 
components are fmanced via this mechanism. The full costs of generalized No-ART and the 
overhead and capital costs of ART are compared against provincial health care budgets 
(excluding conditional grants). Costs and budgets are expressed in 2003/04 prices and discounted 
at an annual rate of three per cent. As shown in Table 45, the incremental costs of the ART 
programme would initially be covered by the conditional grants, but by 2006/07, these allocations 
become inadequate. The costs of generalized No-ART and the ART overhead and capital costs 
amount to 9 per cent of the provincial health care budget by 2007/08. If the growth of these 
budgets keeps pace with real budgetary growth rates seen in recent years 17, it is possible that 
HIV -treatment could amount to 40 per cent of combined conditional grants and provincial health 
care budgets by 2014. 
Table 45: Comparison ofHIV-treatment costs to conditional grants and health care budgets 
(US$ million) 
2004/05 2005/06 2006/07 2007108 
ART conditional grants for provinces 39.68 7705 124.68 121 .05 
ART annual clinical personnel cost 4.65 16.15 32.26 52.43 
ART annual patient-specific cost 10.61 44.64 103.14 184.79 
Total 15.26 60.79 135.40 237.22 
Proportion of ART conditional grants 38% 79% 109% 196% 
Provincial health care budget 4,476.52 4,613.17 4,663.08 4,589.26 
ART annual overhead and capital cost 12.62 43.06 84.95 137.03 
No-ART annual clinical personnel cost 15.78 35.22 42.53 42.67 
No-ART annual patient-specific cost 18.24 40.93 49.64 49.96 
No-ART annual overhead and capital cost 75.01 167.39 202.13 202.80 
Total 121.65 286.60 379.24 432.46 
Proportion of provincial health care budgets 3% 6% 8% 9% 
While total resources are clearly a constraint to scaling up HIV -treatment programmes, it is also 
argued that clinical personnel constraints might be even more important (Kober and Van Damme 
17 The recent growth in real per capita public health care budgets follows a period of stagnation at the end 
ofthe 1990s in government health care financing (Mcintyre, Gilson et al. 2006). In estimating the budget 
for 2013114, it has been assumed that the recent rate of increase would be maintained. 
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2004). The NDoH has estimated that 725 medical officers and 2,175 professional nurses would be 
required to deliver comprehensive HIY -treatment between April 2005 (lagged to April 2006) and 
April 2008 (lagged to April 2009) (Operational Plan for Comprehensive HIY and AIDS Care 
2003), each comprising 5 per cent of these cadres employed in the public sector in 2006. In 
comparison, Tab.le 46 shows estimates of clinical personnel required based on the data in this 
thesis. These indicate that 819 medical officers and 1,075 professional nurses would be required 
in the base case scenario and 607 medical officers and 660 professional nurses in the generalized 
scenario by April 2009. Estimates of medical officers in the base case scenario are higher than 
those in the Operational Plan, but estimates of professional nurses are lower in both scenarios. By 
April 2014, base case first and second-line ART and No-ART would require 10 per cent and 2 per 
cent respectively of the medical officers and professional nurses working in the public sector in 
2006. In comparison to the Operational Plan, the estimates from this thesis indicate that current 
delivery of HlY -treatment is more medical officer intensive than has been envisaged in the 
Operational Plan. 
Table 46: Clinical personnel required between April 2006 and April 2009 to deliver base 
case or generalized HIV -treatment programmes 
BASE CASE SCENARIOS GENERALIZED SCENARIOS 
Professional Professional 
Medical officers nurses Medical officers nurses 
By April 2006 
First & second-line ART 139 I 108 107 82 
No-ART 264 664 160 365 
Total 299
1 
473 107 82 1 
Per cent of 2006 workforce 2% 1% 1% 0% 
By April 2007 
First & second-line ART 245 190 198 151 
No-ART 302 762 175 399 
Total 420 589 198 151 
Per cent of 2006 workforce 3% 1% 1% 0% 
By April 2008 
First & second-line ART 386 300 319 243 
No-ART 299 755 166 377 
Total 552 677 319 243 
Per cent of 2006 workforce 4% 2% 2% 1% 
By April 2009 
First & second-line ART 568 441 476 362 
No-ART 251 634 131 297 
Total 819 1,075 607 660 
Per cent of 2006 workforce 6% 2% 5% 1% 
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While these estimates of clinical seem there are a number 
of that should be borne in mind. to a Human Sciences Research Council 
there were and 
in 2002 and Erasmus 
vacant medical officer and sector 
Ul~;""IUJl<:tI", 27.2 per cent 
HIV/AlDS is pvn,pM,>fi on 
the because in South Africa in 16.3 per cent of health 
workers were HIV-infected and because np"(,pnt"",n" 
due to HIV exposure could cause or reduce incentives for young 
career in the health sector of health 
Africa is also 
more than 500 
a 
from South 
indicate that 
nurses from South Africa rpol<:!/'r a:UHI~U"J' with the 
of issue. Data rpr,"rlrpn in Blaauw et al. 
officers and I 
United 
national level also tend to hide the the internal brain drain from 
the rural to urban areas is 
et at. Blaauw et at. 
.... ".,. ..... _" the various uncertainties inherent the need for health care workers in the 
sector in it should be noted that the estimates of clinical npr'<:Clrln 
""'''''PM'''' in Table 46 are data from the 
had 1.3 medical officers each nurse while the TC Newman 
ART programme has 3.2 medical officers to each 
more medical officer intensive. While norms of 
",."mplnt in the Western a nAtpnt,!.> 
officers and 2.1 nurses for every 1 
School of Public Health and 
nurse, that programme 
in ART sites are still under 
of 
be 0.7 medical 
Public Health 
norm, similar numbers of medical officers would be 
but far more nurses than n"p""'n,tpfi 
that exist in HIV-treatment 
treated with caution. 
18 H.v .... UH.", all nurse posts, not nurses. 
the wide range of 
the data ",,,,",,,,,,.,,, in Table 46 should be 
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this section calculates the peJrcent~lge of need that can be met 
and under different social choice rules between 2004 and 2014 at a 
which is the estimated total cost of the 
for base case first and second-line ART and as 
shown in that South is base 
case ART 
that the 
with in the social choice rule calculations it assumed 
can either a base case or a of the 
two because of considerations of fairness between Dal:JerHS. In Table in 
and/or in coverage between the base case and scenarios for each of the social 
choice rules versus the Plan is shown. I n the first of the first-line ART is 
not included as a 
ART is not a 
but this constraint is relaxed in the bottom half. Where first-line 
the social choice rule results will differ those 
prf:semeo in earlier sections. 
In Plan 17 per cent of receive No-ART and the 
remainder receive first and second-line ART. Recall that in the Plan the 
of access to first and second-line ART IUlInn,>n" over the years between 
2004 and 20 I 0, with I 00 per cent of new need met ART from this time until the end 
the in 2014. This scenario 8.4 million 
In the base case scenario costs and outcomes derived from the 
maximisation increases in to the Plan 
health 
but a 
lower level of need would be met. While the decent minimum meets 100 per cent of far 
fewer patIents receive first and second-line ART and the cost in terms of 
to the Plan is 1.23 million. If treatment scenarios are 
both health maximisation and the decent minimum 
fewer n>ltIPnt" receive first and second-line 
ITP"tmPnt which is exacerbated 
over while all other scenarios assume an instant ~<.;i:tI<;;-t.'1J 
What this means is that while 83 per cent of 
to 
fewer 
relates to 
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ART is included as a choice shown in the no social 
choice rules choose and second-line ART at a of billion. Health 
favours ART while the decent minimum proposes a combination of No-
treatment is it is to ART and first-line ART. If the set 
as many as 0.7 million the decent minimum in to the 
Plan. The comes health under the 
scenario but five per cent of need unmet. 
The choice rule proposes that all n.,t."' .... tc receive No-ART at a 
constraint Given the is 
to be considered to be too in terms of its 
In that No-ART care too motivation for 
overcome access h"r· .. ip .. ~ such as ':>",,,B'U. Thus it ironic that the most 
billion could be health maximisation which reaches 95 per cent 
first-line ART. 
health 
to 
at a 
n;>T1pnTC with 
these are accrued later in time and are discounted at a 
the other scenarios. 
rate than is the case under 
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Table 47: Comparison ofthe Operational Plan to social choice rules 
Per cent 
Per cent first and Total OALY gain 
Per cent first-line second-line OALYs Unmet or loss 
No-ART ART ART (millions) need (%) (millions) 
Operational Plan 17% - 83% 8.4 0% -
Base case scenario 
Health maximisation - - 73% 8.5 27% 0.11 
Decent minimum 70% - 30% 7.1 0% -1 .23 
Equal health I 100% 5.2 0% -3.15 
Generalized scenario 
Health maximisation - - 82% 8.7 18% 0.36 
Decent minimum 32% - 68% 8.6 0% 0.21 
Equal health 100% 4.2 0% -4.13 
IF F1RST-LiNE ART WERE A POLICY OPTION 
Base case scenario 
Health maximisation - 84% - 8.8 16% 0.42 
Decent minimum 55% 45% - 7.6 0% -0.77 
Equal health 100% 5.2 -3.15 
Generalized scenario 
Health maximisation - 95% - 9.1 5% 0.77 
Decent minimum 11% 89% - 9.1 0% 0.70 
Equal health 100% 4.2 -4.13 
The implication of this analysis is that if the country wishes to place a higher proportion of 
patients on ART and gain QAL Ys, thereby improving both equity and efficiency, consideration 
should be given to implementing less resource intensive models of ART delivery and/or limiting 
ART regimens to first-line only. This strategy is in line with the WHO's policy of a public health 
approach to scaling up ART in resource limited settings (Gilks, Crowley et al. 2006) and is 
similar to the approach adopted in Malawi's scale-up of ART (Harries, Schouten et al. 2006). 
While many would favour this strategy as it leads to higher patient coverage, others argue against 
compromising the quality of ART care (recall that the generalized scenarios assume that patients 
have no access to hospital outpatient care, to tertiary inpatient care and are followed-up less 
frequently than has been the case in Khayelitsha). Proponents of maintaining quality of care 
would probably see the current South African strategy in a favourable light. 
The assumption that the patients in need of care who are not accessing ART receive generalized 
No-ART care deserves additional scrutiny. The provision of even generalized No-ART care 
requires diagnosis and a chronic disease approach to patient management to ensure that 
appropriate prophylactic medication and treatment of acute infections is provided. Given the 
current emphasis on scaling up ART in the public health system, the development of a chronic 
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-
of No-ART care has ne!~le(~te(j.1t is also that some with HIV 
are unaware of their HIV-status - some remain while their immune 
becomes and die ;:'U~IUI;;.llly an acute ",,"v,",L'V". 
into care to be too 
be 
Thus while the current but 
in 
5 
less than 
on technical ~H'~ .. __ F'" 
and second-line ART to a n"L' ..... nrtum 
No-ART to the remainder. 
This "h<,,,t,~ .. has extended the results from ......... "'".-'''' models to ,-,,,,'v ... ,,,,, .... the costs and 
with alternative treatment interventions and those to the 
Plan's treatment and 
The scenario nprtl"lrm better than base case in terms of the ..... " ..... " .... "." that 
can be met and the amount of that can be 
it 
are available. Within 
be achieved and at the same time secures a wider of the benefits 
benefits to 
trelUment than 
ART. 
that this would 
benefits that are ""r.,.",,,thl ..... ",,,,,'o<>ti the 
of the 
This 
not be 
HIV -treatment 
be "v"vIJ'au' .... in the 
short-run numbers of f..''''''''''''' in need were reached and if a commitment were made to 
extend access to first and second-line ART over the medium term. 
taken in this is the 
considered to be into a fair process "AI'"'''''''' 
in this dissertation 
this evidence from and 
these 
HlV -treatment 
sketch the outlines of a framework for HIV -treatment 
could be 
l1a,u"I"'. The 
been orCIDo:sed in 
UVI"""""."" in order to 
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1 
This 
.. 
.. 
has advocated an aPtJrOiiCn to HlV-treatment that 
considers the costs trade-off. This has 
been data to the 
level. Once armed with the total costs and total health of alternative nte:rv~!ntlonlS, the social 
choice which acts as the set or values on which distributions are is 
to detennine the health of need that is met and the ..... "In"rti,'n of I-'Utl","'" 
alternative treatment . nH""<~'''''J at a HIV -treatment 
Because reasonable are to on the choice of the value base and the extent to 
which the health care should be allocated to _tl"f'",hTlPInt this "h"nt,~ .. considers how 
could be undertaken within what Daniels 
elements of this fair process will be discussed in section 2 of this 
there are no n/i,>npnti,p,nt criteria that that health maximisation 
... rp·t""Y'Pt1 social choice rule and 12 billion is the :.nr,ror,n 
"''''.tl"·",.",,yl,,,ntc in a way that achieves 
and 
. The 
n"'.AlP'lIP" if 
I;:;A<""~}l'" J is the 
the ;~; •• ~-.~ at a "Consultation on ethics and access to treatment and care 
for HIV / AIDS" have that access "is the ethical outcome" and 
UNAIDS 2004 p. one has to bear in mind that once some level access has been 
"n'PVF't1 ethical debate could on whether more resource intensive 
should be 
be 
whether third-line or 
to oatlents with CD4>200 
Tnp,,.,,,",,, should be offered and whether ART should 
Thus while some calculations 
presented in this thesis will become outdated as new treatment tecnnOlOigl(~S become the 
framework will continue to have relevance when these new are considered. 
that the term "universal access" is misused in this context. this means 
with a defined level of need. 
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The sections in this 
introduced in earlier and in 
III Whether a resource-intensive 
treatment should be taken 
III Whether first-line 
III Whether and/or how medical 
will revisit a number of the debates that have been 
will cover the three am~suons 
or more minimalist to 
or first and second-line should be nU"''''''r! 
for ART should be revised 
the of what health care and hence what health benefit to distribute to HIV-
adults are the central of this it is also ;rnnn,e1"<tt,t to broaden the 
discussion to consider the characteristics of who are in need of 
treatment and the broader that could accrue to The discussion will follow the 
structure of 29 which has been overleaf from 3. The views of 
process of on the 
of to whom the will determine the existence of and 
""".u", •. " of cal\s for increased HIV -treatment resources and also relate to the value base 
that is ..... "J~ ........ This in tum will determine the that HIV -treatment will have on the healtb 
the social 
what 
of tbe and associated with and 
oftbese a decision about 
or health care to could be In this manner, are "",V";:}" • ..,, ''''Y, 
and into the final decision. 
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Figure 29: A framework for considering to wbom tbe good should be distributed. Solid 
arrows sbow tbe causes of illness and consequences of bealth care. Dotted arrows show 
claims on the good. Reproduced from Chapter 3. 
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2 . J 
In an earlier it was that focuses on the fairness of the process 
which a distribution is achieved that the distribution of the 
South While there 
be no on the social choice if a fair process is 
the be fair. 
argue that are valuable for their instrumental role in 
better outcomes. to Wailoo and Anand this reflects the notion of 
in the fair division of a the "" .. ",£'orl" of the 
cake is valuable if it ensures the outcome of a close to division. On the other in pure 
while continue to 
inherent or intrinsic value. The inherent value is also su!~ge:ste:d 
advocate for a "communitarian claims" <>nr, .. r."roh where it is that the 
and Jan 1 value in the process of involved in 
Jan et al. 
Daniels argues that the central fair process are: 
can also have 
those who 
finds 
.. the process must be n""'''',p'nt and involve available rationales for 
the that are set. This has the added benefit governance. 
.. Relevance: stakeholders who are affected the decisions should agree that rest on 
reasons, view as relevant to fair decisions about ''''''1>''"'' and evidence that 
This has the added benefit stakeholders that their voice has been 
heard. 
.. and UV'J~U'" decisions can be revisited and revised in of new evidence 
and aLlIY,,",""" process nu,vl,rl"." nr,lt"'('llr1,n to those who have 
reasons for an ex'~et)tlCm to "'''''''''{1 
"5'"''''''V,''' a mechanism is in .. Enforcement or 
conditions are met. 
to ensure that the 
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The of is ambitious In most resource 
allocation and decisions are taken condition of 
resultant recommendations and any or 
related to these decisions would need to be in the that was 
been taken 
to a 
it 
audience. There are a number of intrinsic and 
to decisions that are taken 
nhf1p,,,'p in the process and the outcomes 
values to 
and 
decisions that affect their lives have been taken in the way have 
Coast et al. Daniels Wailoo and Anand a form of 
ort::ce.aerlce emerges which assists in over time. This has intrinsic value from an 
Of'lc<:n;f'('tl\lf' as it ensures that like cases are treated in a and Anand 
'''IO",''''VY also has instrumental value since the nrc·"p,rlp""p assists in future 
The relevance '-'V'''>1''V'', 
of rationales that are 
should be 
the of Ue(;ISlon·,ma over time. 
""',;1"."'"'' that there should be restrictions on the kinds 
to serve as a basis for 
stakeholders. These "reasonable 
and that these restrictions 
be set within a 
communitarian claims process, where the or rules on 
which to base social welfare function ... and hence the basis for in health care" 
M,,;,.,n,·v 1998 p. 11 In other the be about the social 
choice rule as well as the characteristics of that could serve to additional 
claims or limitations of claims on the claims 1 to 3 in The latter deals with 
issues of vertical It 
be decided that claim on health care resources 
the social context on the social fabric and the health of 
that treatment affords. Communitarian claims is not about the bureaucrat 
would a role in the value base of the health care 
instead the 
and the 
bureaucrat would have a role in to these values 
Research has shown that the finds intrinsic value in a 
voice in the to set reasonable rationales one avenue for 
this voice et al. Wailoo and Anand 
The third .iu'm,'nt for fair process and due process. A distributive decision will 
tend to be more acc:eptable if there are mechanisms which allow decisions to be and 
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reversed 
and 
and due process is 
and Anand This also allows for the 
over time as resource constraints and 
related to the condition because the ansoar'enc:y of the 
decision both in tenns of rationales and ultimate recommendations facilitates the 
identification of mistakes. It also an avenue for affected decisions to 
Even the voice to stakeholders who not have been 
included in the decision and adds to the the 
of future decision 
The final for fair process is and enforcement. A mechanism needs to be 
created to ensure that the fair process with the relevant reasons and 
'~"'V"A" and aU.JVa", .rp,mpnt", that are outlined above 
mp,lennerltatlOn of fair process would include institutional levels of 
structures to address decisions at each to 
comr,ett!nc:e in fair process, from and 
research and mechanisms for enforcement the ae1{eI4[)orne! 
of fair process should not stall the up as fair process is it could 
care 
Rather than 
have additional benefits as a model for other V"""""·,,, 
and 
as candidates for redistributive 
this aDl)ro:ach encourages active 
a benevolent state 
",-,'V""'V'1I in resource 
to hold O''''IPrYlt'n,,'ntc and allocation in health which could the of civil 
donors to account, with both instrumental and intrinsic value. 
3 
The of to whom the 
characteristics of 
claims on the as illustrated 
0W'U~'''.J transmitted U'':>'''=''-'. 
and discrimination 
should be distributed considers whether the np,,,,rol'''' 
should be a basis for additional claims or for limitations of 
claims 1-3 in 29. Because HIV a nrc'vpnt" 
have 
Brennan et aL It is 
been 
that 
to levels of 
is a tool used 
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cultures to exclude those felt to have broken the dominant of HIV-
is therefore one that casts them as immoral et al. This 
leads to discussion in 
to this COllCf~Ot, a could if the causes of her illness 
were exogenous as Anr'''~'>'' to determined behaviour Salek et aL I 
Richardson et al. as illustrated the free choice continuum in 29, The oval 
in the left-hand comer relates to no free choice in and therefore claim 
1 on the 
HIV 
relates to bad but it can also relate to COlmpen~>atllon for who 
mother to child t,.'.>n"r""~ sexual blood transfusion and accidental 
who fall into this group could be to have 
c1ain1s on the On the other of the free 
choice it is inHIV 
it is difficult to how unless someone exposes him or herself to 
HIV on a basis, It is that for HIV status is mediated 
via social context What this means is that any claim that someone is less of HIV-
treatment to HIV would to consider the social 
context within which infection occurred, the claim based on would 
the claim based on bad luck and would offset any 
reduction in claims to 
Given the 
based on n .. ,,-,,u,,, 
claim based on 
it is worthwhile 
for HIV -status, 
any reduction in claims 
of the social context 
in HIV infection in South Africa, HIV is a viral disease caused a retrovirus that attacks the 
immune Not all become to do the virus needs a niche or 
social context within which it can thrive, While HIV/AIDS does not affect the poor, n'''JPncv 
is to be the main social context Niekerk 200 the HIV 
is situated within poor countries. Sub-Saharan Africa has 
10 per cent of the world's fJ'UUUVH, but over 60 per cent of the world's mY-infected 
factors are to South 
Africa at a risk of an HIV in income and levels of 
One would be needle stick where a health herself with a 
needle that has been used on a 
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and and Schneider South Africa is an 
upper middle income rates among more 
than 50 per cent of the in the distribution of and 
and of crime and violence is 
the racial bias in these in I income of 
whites was 7.4 times than that of Africans. While 6.7 per cent of whites were 
, the was 46 per cent for Africans. real per 
on Africans was over level of social on whites 
"'llP'rn,rr,,'nt social like other 
economic and vvu",",u, power for whites 
of 
Gilson et al. 
times for 
990s this translated into infant 
for Africans than for whites and maternal 
than for white women 
rates that were 
rates that were 31 
in income and toHIV 
infection via 
information and n",'vP'nt, 
increase 
diminished access to health 
~~"~."'-' transmitted infections which 
and 
less concern about one's health and the 
and treatment of these 
to the difficulties of the 
and Budlender 
months 
malnutrition and certain 
infection 
The second factor that is 
a 2002 household survey some for this 
was 40.2 per cent for those who had a ulcer within the last 
Besides transmitted u,o>·,;;a.;:,,;;o>, it is also 
in Africa increase 
to be associated with to HIV is the 
has historical 
labour was scarcer than 
that 
to HIV 
of the 
South Africa. 
the white elite forced the IJUi,aCIVH into 
with the result that 
serfdom and other 
The use ofthe tenns "African", "coloured", "Indian" and "white" reflects the stratification of the 
in tenns ofthe fonner Act. The tenn "blacks" refers to 
While it is necessary to maintain these tenns when the 
""T'h"',£1 and resultant socioeconomic and health this does not 
these terms. 
'A".v.a,nt is ""C'nrtiina to the eX~lan(lea definition ofthe labour force outside the fonnal sector. 
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fonns of labour. In many cases, it was to labour 
the late almost all arable of their land. HnU'f>Vpr 
land in South Africa was U,A"Ul}''"'U white landowners and smaller fanns became eC()fl(lml 
unviable. For the first white landowners entered the market where were in direct 
,v" .... ".~titi"n with African labour. This situation eV(~ntlllally led to the enactment of a number of 
laws aimed at "''"''''VUlt>'> as a subservient the 
elite status of the white IJV~'U'~'" Anlnp"t of each race group 
also that while a certain of African in urban areas was desired the 
urbanisation was not. A small 
were therefore allowed to live npr'tn~InP'nt in urban areas, but the vast were confined to 
the "homeland conditions in these areas made it 
l1'o<>nT'''' necessary for to seek work in urban areas, a process which was controlled 
under a of influx laws 
that is to the discussion transmission is An 
the 
of this 
labour in the mines. Levels of HIV infection are ~U'~","",~' the in mine 
workers. For the mines "'"''''I'''' around 90 per cent of whom are 
either from the ex-homeland and rural areas in South Africa or from other countries 
such as "",-,:>v,uv, Botswana and The vast of workers are housed in 
sex hostels with up to 18 \.c(:orcjmg to infonnants in one 
and sex ",nf",<>"p(j to be some of the few activities available on a to basis that could divert 
attention from 
mines 
while 
to their homes 
communities. 
The third 
to Terreblanche 
and 
Mine workers who 
nature of work _ .... _.,.,. 
HIV and other 
in the 
transmit these infections to their wives when return 
of the social context that is 
levels of sexual and 
the between different 
to increase South Africa's risk of an HIV 
violence Maforah et aL 1 
levels of violence and crime in South Africa are rooted in the 
and chronic While levels of 
24 In terms of the 1913 "Natives Land Act" Africans were confined to in ten homelands which were 
of the total surface area of scattered South A frica. These areas less than 14 per 
South Africa. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
crime in are in South poor women and children of whom are 
vulnerable to violent crime which is often pe(1)e1tuated within households 
It is that there are at least four mechanisms which 
violence can increase exposure to HIV. Violence may increase a woman's risk infection 
forced/coercive sexual intercourse and women's to "\';~~vll.a.", the use of 
HIV ..... ,"'".,,""'" tecnfllOJogu::s such as condoms. and sexual abuse childhood has 
also been associated with 
women who are 
sexual behaviour in adolescence and adulthood. 
and disclose their status may be at increased risk of violence 
In a in an antenatal clinic in South it was found that 
violence was associated with increased odds of HI V infection 
Jewkes et ai. 
The race dimension of 
sexual violence and the need to 
Africans have 
Indians (1.0 per 
statistics from a 
far the 
and Whites 
In exposure to and 
from one's home in search of work is reflected in recent 
survey. These data indicate that 
followed coloureds per 
per Rehle et al. 
_"r·"""I",.",",,,, is over 20 per cent women who have had one lifetime sexual 
and is up to 50 per cent for women who have had three sexual 
et al. in Fassin and Schneider As Fassin and Schneider "in 
this net",..,!·", social context has a far on risk of infection than individual sexual 
behaviour", This once the in 
.. 0' ..... '0 claim 
reductions based on "pr'<nr,':' 
While HIV has clear race dimensions in South there is evidence to that 
income 
income .u'"'y .... ·"'." 
claim based on 
within the 
are 
are 
on class as to race dimensions within-race 
within the African group The 
the need for claims 
,"'':',(1V,Un'"'''f''' African group. While there are 
the poor even 
limited data 
the socioeconomic status of South one in an version of the 
above-mentioned survey t"Pr",ri,p,-l Val"""," was 13.9 per cent, 14 per cent, 6.5 per cent, and 
5.0 per cent who had "not money for food", for 
short for other", ~"'J~"',,, for most , and "some money for extras" 
and 
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The race dimension of HIV in South is further ""'.l1n".o that 
Africans are the main belletlcllU of HI V-treatment services. In Aid for 
HlV I AIDS disease man~,ement programme, a 
indicated that 97 per cent were African et al. 
sector, while data were not pn~sent(:d on race, at least 91 per cent of the ""'UV''"'~ 
of ART services in 5 clinics in the Western were as 
et al. Data on the socioeeonomic status of these 
sector 
home 
also 
indicate that the service has the nOtPn,rH. the poor. Socioeconomic 
of ART users in this instance is "",rnn,,,rF·r! of South Africa as a 
whole and the asset 'I"'"'''''''' a 
described in Palmer et al. ""uF,F,,",,n that these users of ART services have a 
status when cOlrnpare:d to the but are poor 
in ,",VJHV"U to their communities with over 50 per cent of users rer:lres;ented the PO()re:st two 
Thus while Western ART users could be "",,,,, It"'" 
these data indicate that ART services are accessible to the ",,,,",,,,,,~t 
eommunities. Whether or not this 
in these 
is a function 
is unknown. 
far numbers of poor HIV-
Socioeconomic status has been assessed tbe asset index metnC,(lOIOI1:V which bas been described in 
£'1. __ + __ 4 and used to assess non-HI V related -~ ... - ..... , 
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Figure 30: Asset quintiles of ART users in the Western Cape 
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ART users in comparison to the full DHS sample 
ART users in comparison with the "township" DHS sample 
To conclude, given that a particular social context is argued to encourage HIV-transmission and 
that this social context is argued to be the legacy of Apartheid (Terreblanche 2002), a focus on 
individual responsibility for HIV -status runs a risk of penalizing people who have become ill 
through no fault of their own. Such a stance could increase levels of stigma and discrimination 
against HIV -positive people and reduce levels of social solidarity (see additional discussion under 
claim 8 in section 6). Because HIV finds fertile soil amongst the most historically disadvantaged 
race group in South Africa one could argue that there is a social responsibility to provide 
additional access to HIV-treatment to these groups for reasons of vertical equity. According to 
Mooney (1996 p. 102): "if, as is normally the case, ill health is not randomly distributed across 
different groups in society, might that society not want to give preference, on vertical equity 
grounds, for health gains to those groups in that society who are on average in poor health?" 
Participants in a fair process might therefore be concerned that HIV-positive people be given 
preferential access to health care services (and to other social services given the relationship 
between health and other social inequalities) to counter the legacy of disadvantage that has 
potentially made them vulnerable to HIV-infection. 
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4 What health care and health benefit? 
The key contribution of this has an assessment of technical efficiency and 
in HIV -treatment at population-level - the \.IU'''''LJ'VU of what health care be 
distributed and what health could be In these the has 
taken approach health care berletlts in terms 
model. that the focus of this has one of maximisation or equalisation 
the health care constraint, it also necessary to solely on 
opportunity cost care resources. While this approach is theoretically correct, it is also 
narrow. Section 4.1 therefore weaknesses in the QAL Y approach 
benefits from health care. Section 4.2 the that have been presented the 
wnletnl~r a base case or less reSOUlrce··mlten:Sl U; .... lJ"'J, ........ "' ... 1 approach to care should 
be adopted. 4.3 discusses the three mutually exclusive HIV -treatment strategies and 
Section 4.4 revisits debate about whether medical criteria treatment 
initiation should be 
In a more practical context, the following comments might apply to the different social choice 
rules: 
• Those who favour health in HIV -treatment would 
focusing on developing the infrastructure and cap,aCftY 
areas such as rural and ex-homeland areas. 
to be in 
tracl1tl<mally poorly 
of 
• Those who favour health maximisation likely to that access to treatment 
is better in areas where existing is the and hence where the largest 
numbers of patients can be enrolled quickly into care. 
• who favour the decent minimum be to a balance between 
"'<"'''11J'5 existing capacity and actClltlO.nal caplaci'ty thereby off between 
the maximisation of outcomes and increasing geographical coverage. 
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4.1. QALYs and other health care benefits 
This has defined from the individual's of view as an absence or 
injury, through QALYapproach. approach is oelemlOO given need to 
assess opportunity costs in HIV -treatment, as reflected by health care benefits that 
are achievable, it is relevant to conlSHller Deflertts of health care that are not captured 
within the QAL Y approach. 
Ryan (J 999) has shown Ull'JU".ll the example vitro fer1:iHzaticID that the benefits of health 
care are broader health, and can include process attributes as 
the is clearly more that is generating health care than health 
gains, health (both process and out.come) will .... "",,,,,,",u,,,, on 
intervention or disease. while the individual utility (or disutility) that is gained from HIV 
(Ila.gn()sls is more to be related to the tnt,orrtlation that is received test, in the 
context ofHIV -positive people imminent it is likely that treatment is particularly 
valued in terms in morbidity and mortality. However, this dominance 
in HIV -treatment might over the ofthe lifetime. While 
initial utility largely relate to health as health improves and duration on treatment 
IIll;!["""''''''_ non-health outcomes and process might more These could 
include the attitudes care continuity of contact with the same staff given the long-
term nature autonomy access to These elements of health care 
benefit are not in the 
A shortcoming of the QAL Y approach used in this thesis is that it is asS:urriOO that a 
QAL Y has a constant value, when this is to be the case. With Up~!lU"'''''\.J'U to 
-.·_··-r .. · .. -- means that one is indifferent between 1 QAL Y on No-
ART fonowed by gained the context of more health 
on ART. To illustrate point, that a respondent has a value base that is best reflected 
by the decent minimum social choice rule and that HIV -treatment budget has an upper 
constraint ofUS$9 billion. These two choices point towards around half ofthe patients in need 
f'"",,,,ivincr No-ART and the rest receiving """'._11 .... ART. While it is possible within a 
~"""V'~~U for to about outcomes, in this case it is also 
possible dlSagl'eelnellt about outcomes could be explained by increasing value of 
health, especially in the context of interventions such as No-ART wh~re individual gains 
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are small. If the ...... ", .. "i ... ,,1 of a QAL Y on No-ART is lower than has assumed, 
this would mean .. ".1,.1'",,,1,, less while ART and first and 
more cost-effective. This shortcoming of the QAL Y approach 
would be if one were no information about the care 
interventions that were under discussion. It is important that participants in a fair 
process be information about both the individual and population health gains from 
interventions, and that any is to allow for adequate '"'u' ... ..,.,.vu 
and if necessary . 
4.2. Base case or generalized treatment 
While the base case is based on utilisation, unit cost and outcome that are derived 
from the follow-up cohort in the three .:"'llan;,ll 
- ...... un'''' where 
ART delivery was piloted prior to the initiation service in the country, the generalized 
is based on a designed to estimate the lifetime costs and 
outcomes less resource intensive aPt)rOiilCn to treatment. Three key were made. 
Firstly, ART visit utilisation was assumed to occur at the frequency recommended in the National 
Antiretroviral Treatment Guidelines (2004). This amounts to 6 of between 9 and ] 0 
pre-ART and first 3 months on treatment in Khayelitsha; 3 visits as opposed to 
4 in months 3 to 6; and 6 visits as opposed to 7.2 in months 6 to 12. Thereafter, visits are assumed 
to continue at a rate of approximately 1 per month. No-ART visits were based on a local 
natural history cohort (Badri, et aI. 2006), and were considerably reduced from 3.4 to 1.9 
in the CD4<50 ceUs/).AI group, and from 2.6 to 1.4 per quarter in the CD4 50-199 ceUs/).Al group. 
The second adjustment is to unit costs. care was restricted to and 
levels 30 per cent care was at the level in and 
No-ART outpatient care was to clinics and community health centres. This the 
type of care that exists in most of South Africa outside the larger cities. The average cost per 
inpatient day was reduced from US$161.67 to US$1 18.56 and the average No-ART visit cost was 
reduced from 9.62 to US$17.24. No were made to ARV or the 
national protocol 
these cOlltitme to reflect the rec:orrlml~ndlations in the 
2004). 
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The third adjustment, which has the impact, is to outcomes. Death transition 
U"~HH'.''''''' have all been by 40 per cent to reflect clinical outcomes at 
one year in a number country ART cohorts and ART-CC 2006) and a 
review country natural history cohorts Zwahlen et al. 2004). These 
reduced outcomes reflect the lower and more development 
resistance that could be an implication 
2004)26. 
resource-intensive models (Mugyeni 
Whereas in the case scenario, discounted lifetime costs are US$2,966 for No-ART, 
for ART and for first and ART, these are reduced by 
approximately US$I, 150 for No-ART, US$l first-line ART and US$4,000 for and 
second-line ART in the &"".,."'.' .. u .. "'"'''' scenario. Similarly, while outcomes are 2.9 life years No-
8.5 life years first-line ART 12.9 life years and second-line ART at a zero 
annual discount rate in the base case scenario (2.1, 7.1 and to.8 QALYs No-ART 
life was 0.6, ART was decreased 1.6 and 
first and second-line ART llte:-e}i:pelctalrlCy was dec:reased by 3.2 years in the generalized scenario. 
ICERs in the case and 5"",,,,,,,.,au,e,,,,u scenarios are Given that most reduction in 
111.'-"11"" costs in the 
note that the lCERs in the 
This indicates that the 
When the costs 
ct'Pl'''U'U\ is related to it is instructive to 
scenario are lower if no adjustment is made to outcomes. 
scenario is to have cost-
up are assessed, the generalized scenarIo achieves both QALYs 
and coverage than the case scenario under most social choice rules. Under health 
maximisation at budgets lower than US$ll the has 
and covers a of need than base case. For of over 11 billion, the 
base case scenario is superior owing to higher outcomes that are achieved through this 
approach. Under the decent minimum, no treatment would be in the base case if 
the budget is less than US$7 while solutions are possible in the at 
I'\,ui"",+" between and 7 billion. The continues to <::n1'1"", .. i, ..... to base 
case in terms gains and a 
26 A study on adherence in 
viral replication virus was <400 (".nnl~~fm 
"''''0,,,,,,,,,,",,,,,1,, \ '~U"'UC"'" Boune et a1. 2004). 
first-line 
proportion achieved suppression of 
70 per cent of patients at 6, 12 and 24 months 
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ART or first and second-line ART until the exceeds I billion. Under 
the generalized scenario outperforms base case """.u""""', as with the decent minimum, it offers a 
solution when the budget is between and 7 billion. For 1J"'~'F. ... ",between US$8 and 9 
base case has higher than 5"",",":UlL,,",U, which is mainly owing to the step-wise 
nature of the health social choice rule, where no 1-""'1 .... 11"" can be moved onto a more 
effective treatment strategy until sufficient 
moved simultaneously. However, the budget 
av""".u ... " .. ",,.. to allow all patients to be 
to move to a more effective strategy is 
......... 'u.n."",, ....... sooner in the generalized scenario than in base case, which means that once a budget 
billion is reached, all patients are put onto first-line ART with a QAL Y benefit of 4.4 
million in to base case. 
In many this generalized scenario could be to enhance the generalization of 
a pilot setting to the general HIV population as to being a reflection of a less 
resource intensive model of care. When the latter is oe[Iate:o in the the discussion is of a 
model of care that is far less costly than the scenario. In terms the 
debate concerns whether to a doctor can be once every three months (which is 
the norm in oe'ilell:>De:o """,,,.h-i,3,, and is recommended in South to once every six months 
or once per annum or even whether routine consultations with a are necessary, especially 
the mainnmance period on treatment (Jaffar, Govender et aI. Schouten et al. 
S:innil<.rlv it is debated whether treatment can be delivered through lower cadres of health 
orclte!,si{mals such as nurses or even community health workers the of doctors in 
many countries Leandre et al. 200 I; Calmy, Klement et at 2004; Jaffar, Govender et aI. 
Stewart and Loveday 2005; Hames, Schouten et al. 2006). 
Many countries use a fixed dose combination of stavudine, and """,T11'<l.nn,,' in 
first-line reglm~m at a cost of around US$140 per annum (MSF 2002) as OPlIOS(:d to the more 
complex non fixed-dose combinations that are used in South Africa which have an average 
annual cost that this ea~;V-l:C)-llse nr<IT.lln"" reg1m€~n has been 
lar!!!e-:scale ART programme with few resources fundamental to the de,relc.omlent 
Klement et al. 2004; "'"",,,",,,£Iini Jeannin et 2006). Although this nXj:::d-ao~.e rf:grrnen is pre-
21 Visits are to a combined doctor/nurse team in Khayelitsha - the monthly visits mentioned in an earlier 
section are therefore not doctor visits. 
28 First-line are lamivudine and nevirapine (non fixed-dose version) or ~t<""mrlii ... ", 
lamivudine and efavirenz. 
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the World Health Organisation and has been shown to have ""~.''''u'''. 
and (Laurent, Kouanfack et 2004), South Africa continues to use the less 
and more expensive non tlXie<l-illo~.e "",,,,,,,nT'" There is also debate about the 
and tre{1I1,~n(~v of laboratory investigations that are necessary Klement et at 
.n'''~n''';> .. et at 2005). WHO (2002) ART distinguish between four cat<~gOlt'leS of 
"""'l".~'U"'H", absolute minimum, basic desirable and South 
Africa's recommendations fall within the optional "'<t1"", ... ,,,,.,., Treatment initiation in Haiti was 
based on clinical criteria the 1 998 to 2002 when CD4 was not 
Leandre et al. 2001; ....... V ... llJ:;;, Leandre et al. 2004). In Malawi, where than 
10 per cent of patients initiate care based on CD4 it is argued that the introduction of 
CD4 and viral load laboratory tests could ml1if>rrnl11,f> the ART programme through the 
Schouten et al. 2006). 
Additional 341ustments to costs were therefore made in a "low cost generalized scenario". These 
included assuming that all patients would receive non fixed-dose combinations 
lamivudine and which reduces annual first-line ARV costs from US$291 to 
l'Itirhtj'"'Inl'l cost reductions ofUS$22 per annum could be achieved if the fixed-dose "'VJ,Uu'.u".n,'ll 
was It was also assumed that no viral load would be undertaken, which redlucl~s 
costs between US$60 and US$70 per . In sum, this scenario reduced undiscounted 
lifetime costs by an additional US$1,400 for ART and by US$1,600 for first and second-
line ART in comparison to the generalized sce~nrut'lo. The discounted ICER per QAL Y 
low cost ART was US$S61 in COrnp3lrl in the generalized 
"" .. nn",.i"r,., to US$1,63S. 
and 
the ICER for first and second-line ART was 
To it has been shown that the implementation less resource-intensive model 
HlV-treatment has the potential to enhance and efficiency in HIV-treatment at 
. A key argument these less resource-intensive approaches, hmJVf>lJf>r 
is that could accelerate the transmission of resistant virus strains from poorly adherent 
patients to other members ofthe which could result in a negative for 
VV.JUli1UU'11 health. This issue is explored in detail in section 5. 
l"h, .. rmnT'\l investigations are maintained to the national protocoL This means that the 
low cost approach is still more resource~intensive than many treatment programmes in other 
African countries. 
30 As if higher budgets are available then health is maximized through more resource-intensive 
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4.3. No-ART, first-line ART or first and second-line 
patients "''1'''''1'''1'110- tiitt~· .. .,.r\t treatment 
"_.t",~"",,, is a function ofthe feasible treatment SID:ltelgies, the budget constn:lint and the value 
In approach advocated in the proportion 
base. In other words, receiving alternative treatment are not 
<iAIJU'-'lUY chosen, but are instead the solution of prior choices. This is true if the set of 
'''''-''1''1\0 treatment is While the treatment to or 
exclude certain strategies would not influence overall approach decision-
"''''''''',6' the empirical would need to be recalculated. This Ul:)"'U~':)"':) the int,~ ..... la" 
between value base, constn:lint and the resultant QAL Ys that can be gained, proportion of 
that can be reached and the percentage receiving No-ART, ART and 
first and second-line ART. 
health maximisation social choice rule is No-ART tre:atnlenlt, "JI""""P;," HJ:'W ....... "'''' in 
the feasible set, would never be a policy choice. At budgets less than 1 billion, up to 92 per 
cent of patients receive ART. For between US$l1 and billion, a "tr<.t",,,,., 
first-line ART with and second-line ART maximises If the budget is 
than US$13 frrst and second-line ART is the dominant policy. Similar results are 
found in the although first and ART becomes the dominant 
str~Lte.!l~Y at a lower To summarize, a health maximisation social choice rule, No-
ART is never a policy choice and first-line ART the largest over most 
ranges, the highest budgets are available. 
Under the decent nu..n .. , ... u .. , a stn:ltegy of No-ART is combined with ART when "'''''p;,'''''' 
are between billion and US$9 billion in the generalized scenario) 
which leads to a loss of between 0.6 1.9 million in to the health 
maximisation " .... <.t"'"", Once budgets are 1 billion (or US$l 0 billion in the 
the decent minimum has the same results as health maximisation. 
health is the most austere social choice rule in tenns but has the benefit of 
"'''''''''''''''0 that all n"t-i",,,t,, receive the same fonn treatnlellit. It is associated with a 
approach to up treatment - are maintained on an treatment until 
the budget is sufficient to allow the entire group to be moved to a more effective treatment. 
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implication is that QAL Y losses in cornpaJi to health maximisation accumulate over certain 
ranges 
increases. 
mmlmmrIl, QAL Y dec:rea:se as the budget 
Current HIV -treatment includes first and ART for a n,.",T\£\rfi",n 
the population in need. Although policy states that patients who are unable to access 
ART receive No-ART care, likely uptake of this treatment is low. It was Tn"·,.",!",.,,, 
assumed for purposes the Operational Plan that No-ART care would be 
used who were not to use ART. Results indicate 8.4 could 
gained this treatment programme between March 2004 and March 2014, and that 83 per 
cent of these would be gained first and second-line ART. The total cost of the 
programme is estimated to be billion. 
If one assumes US$9 billion is the government's treatment over this 
mathematical programming can to assess wnletnl~r irnplrovemlen1ts in efficiency equity 
could attained in comparison to the government's current While the ass:uIIlptiion that 
the is US$9 billion is the general and line 
not altered by the use of a different budget, particularly if this were lower. 
If first-line ART is not a policy 
Opera1tional Plan .. n"' ...... £1 
case or 
then QAL Y s can in comparison to 
maximisation " ... ru""""l'h to treatment under either base 
l)ec:au!;e a health maxirnis:ati<In slnul~gy does not mC:lU(le No-
ART care, a proportion would be untreated. Itp>rnl'lt'ivp>llv if a less resource ntP>,n"n,p> 
approach is taken (generalized scenario), then QAL Y s can be through the 
uuu"",,".,u, but a lower per'celltai~e of patients will be able to access first and sec:onO-llme ART. 
is because the decent minimum does not mix base case and generalized while the 
(''''O'Un1p",un in costing the Plan is that No-ART care in reality would be more likely to 
resemble generalized No-ART. Implementing an 
associated with substantial losses in cornPlll'is 
health approach is unsurprisingJy 
to the Operational Plan. 
Iffirst-line ART is a option, then more are available for coverage 
of patients with ART and for gaining QAL Y s. In particular, a generalized health maximisation 
s:rnltellv gains 0.77 million QAL Ys and provides lll;)"-Uln;; ART to 95 per cent of patients in need. 
in the j', ... ", ...... 'uu,'""'" the decent minimmrn O.7miUion and provides 
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first-line ART to 89 per cent of patients. As health is associated with 
is too low for all patients to 1I'Pl':Pl"'P frrst-line ART. because the 
While adO,ptUlg a first-line only strategy South Africa on to a higher welfare contolIT, 
because the no-loser there would be likely to be some opposition to 
this in treatment policy. What means is that who have been to access 
ART to date would the clITtailment ofindividual health gains in favour more equal 
care While it is the task of participants in a process to 
consider whether a first-line strategy would be one might be tempted to concur with 
Harries, et al. (2006) who argue that when the majority of patients well on the first-
"'5"U,,,,jU, and when unmet need priority should be to the provision 
U"'.-.,U .... treatment to those who are not ART rather than offering better care for a 
are on ART. 
It is also that when government established its ART strat gic it that first 
and ""'''''UU'U-l,1l1''' ART would be effective than appears to be the case. For in the 
it was assumed that first and second-line ART would 5.5 life years (Joint 
Health and TII"'''''''''T'V task team 2003). in the costing of the World 
"3 by 5" it was assumed between 5 and 7 life years would be gained 
1''''1Jlum:5 on the level (Gutierrez, Johns et al. 2004). In contrast, 
the data from have indicated that the outcomes from first-line ART be 8.5 life 
years while first and second-line ART could be 12.9 life years under base case assumptions31 , and 
even this be conservative when to the 31.1 years in similar 
age in a hUl'OOtean HIV cohort Sighem, van de Wiel et al. The implication 
is that gmfentun,ent committed itself to th",,.,,.,,,, that is potentially far more effective than 
and therefore far more that 65 per cent of first and second-line costs are 
assocllatfX1 with the recmrent utilisation of medicines and laboratory 
range of 
bu(igelts than No-ART or first and sec:on<l-lme ART. This result is Strfmg1lhelle<l within the context 
ART is favoured more social choice over a To sunlm~U1 
of less resource intensive models of care. Limiting ART policy to first-line only would need to be 
31 In the generalized scenario, outcomes are 6.9 and 9.7 life years for first-line ART and first and second-
line ART resl,ec11velv 
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._ .... _ ... _._--- with due cOJlSl(1er:atl()fl for the South African f"nr",hhli".,nn'", commitment to the 
nrc,ar,p><:<:'IVP realisation socaoe,co][lormc rights32 • What this means is that "" ... ,i+ .... hl"" access to 
first-line ART were achieved, the next step would be to investigate extending access to second-
line. This would be<:orrle ",""~."''''HJ' sec;on(J-lllle reg,lllllens became less .... v."""",,. 
barriers to sec:ond-line ARVs include the higher cost three times more eXIJenlSiv'e 
than first-line regimens), aj)J:.rmcimately 9 pills per day as opposed to between 
5 and and refrigeration .. ",rmi" .. ",,,,,,,t,, which .... " .. ,,,>1 ....... '" a cold chain in tr:ansJ)ortatiion and 
storage (Calmy, Klement et al. 2004). If attempts are SU(~ce:sstilll to improve the ease of 
rejl:im,en:s, reconsideration first-line would become even 
more 
Before it is necessary to the use of a No-ART treatment stn:lte!l~y The costs of 
base case No-ART mc:lu(le between lO and 14 clinic, community health centre or hospital 
oUlrpauelll department per annum; between 0.3 and OA cases tuberculosis; and 
between 1.2 2.8 ongoing in hospital an additional 5.7 at the time of death. He:Sldc~s 
the use of medicines for the treatment of opportunistic infections, prophylactic medicines are also 
included. This care is with 2.9 years at a zero annual discount rate. These 
OUlcco:mes, which are similar to the outcomes from developed world cohorts during the 
era (Schneider, Zwahlen et at. 2004), have been derived from a large natural history cohort 
receiving treatment at one and one secondary in Cape Town Bekker et aI. 
2004). In contrast, world cohorts average outcomes of2.3 life years at a zero 
annual discount rate (Schneider, Zwahlen et al. 2004). The difference between the Cape Town 
cohort and other developing "n,,,,h,,,, cohorts is likely to relate to the additional access to care that 
the received. Therefore, 2.3 life years in the developing world could reflect survival in 
the absence oft:realtm,ent and prophylaxis, while the additional No-ART care described above is 
associated with a minimal survival gain of 6 months. Participants in a fair process therefore 
argue that a No-ART stn:ltejl;Y is a better reflection of "do-nothing" in terms of outcomes, while it 
is associated with fairly substantiallife:tirrle costs (un discounted) of around US$3,000 per patient. 
In addition, if the QAL Ys gained HIV -treatment are associated with ,n""",,,,,,, 
value at the po1:miiati()fl then a No-ART QAL Y has a lower value than an ART If 
f'f'f>rrfl",o to London, (2003 p. 10) realization balances the recognition ofthe limitations of 
existing resource with the on the state to over time, its and 
financial commitments to meet the socio-economic entitlements ofthe most vulnerable". 
33 If the fixed-dose combination of stavudine, lamivudine and were used in the pill 
burden would be 2 per day. 
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participants in a process decide No-ART is not a reasonable treatment because it is 
associated the provision of ineffective yet costly care, this implies that higher budgets need 
to be available before equal health or decent minimum become possible; overall 
approach to in this is however unaffected. 
To this section illustrated how the of the and the base 
determines the treatment " ... <.T",,,,,, As these choices should be iterative. If upon reflection 
the outcomes or coverage are to be inadequate, the is that the is too 
low, or that the value base adjustment If the less treatment are 
felt to be inappropriate higher budgets need to available to operationalise 
more equitable social 
t'{\..""t..,,,nt decision-making 
rules. focusing on the value base and the budget 
HN-treatment could be a far more sID'llgltltl()rnrarCl 
process. 
4.4. The when-to-start debate (claims 4-5) 
In South Afiica, a is medically ART if she or has an AIDS diagnosis at any 
CD4 level or a CD4 count than 200 cellS/ill at any WHO While medical 
eligibility criteria are usually thought of as tecitlflllcal, in reflect a trade-off 
between maximising individual patient benefits and increasing coverage. Because of this trade-
off, patients are ",Hl">'"'''' for ART at a point where their capacity to benefit is 
owing to advanced 
In the developed world, a recognition that the long-term use of ART could be associated with 
severe toxicities initially lead to a shift in clinical from a 'hit-early hit-hard' d..",tpov 
where ART was initiated at CD4 levels, to a more conservative strategy 
treatment until a CD4 count was less than 200 (Ho Lane and Neaton 
However, the case for earlier treatment has recently been (Holmberg, Palella 
et aL 2004). The CD4 count threshold at therapy initiation is an important determinant of both 
clinical benefit (Ho Hogg, Yip et al. 2001; Chaisson et at 2001; Lane and Neaton 
Phillips, et al. Palella et 2004) and of ART 
et al. 2001; Schackman, et al. 2002; Bachman 2006; Cleary 
et al. Both in developed countries (Hogg, Yip et al. 2001; Schackman, Freedberg et al. 
2002; Lane and Neaton 2003; Phillips, Lepri et al. 2003; Chaisson et at. 2003) and in 
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vlVj.lllJLI<. countries ll:Sl3.ClJimllU12006; Badrl, et al. 2006), indicate that <;1t~lrhn,O' 
ART at CD4 cell counts higher than 200 cellslJlI could impact favourably on outcomes. A recent 
review concluded that earlier initiation of ART could be associated with better ' ..... ''''"''''' 
nrovernent.less drug toxicity and reduced HIV transmission and Neaton 2003). 
nUlPV~'r current ~Ullue.Hm~s recommend initiating ART at a ofCD4 cell count thresholds 
for with viral loads AIDS Clinical HIV 
2003; WHO Yeni, Hammer et aI. 2004; of Health 2005). 
An<.lv<1 ... " of the Town AIDS Cohort have indicated that of ART is 
associated with reduced incidence of tuberculosis Wilson et aL 2002), AIDS and 
(Badri, Bekker et al. 2004) in comparison with rl",iF"'rt"'no treatment to CD4<200 
Extral:)Ol:!ltiem of available with the use of Markov modelling concluded that undiscounted 
life expectancy would be 23, 21 19 if ART were started with CD4>350 cellslJlI, CD4 200-
350 and CD4<200 cellslJlI respectively. earlier initiation was inevitably 
associated higher costs that at least 50 per cent of ART costs are associated 
with recurrent medication and laboratory The study found that the ICER was 
lowest for ART at CD4<200 ceIlsIJlI I per at a zero annual 
discount rate), followed 200-350 cellslJll 5 per QAL Y gained) and >350 
cellslJlI per gained). Whether any therapy is 
cotlSI(len~a to be technically on the available budget. In general, if lower 
budgets are available, health could be maximised by starting treatment at CD4<200 cellslJll as 
this threshold has the lowest ICER. However, ifhigher budgets are available, it would become 
more cosit-erreCtnre to start ART earlier. 
other hand, data from the Khayelitsha HIV clinics has shown that within a group of 
patients starting ART with CD4<200 ceUsIJlI, it could be less cost-effective to delay treatment to 
CD4<50 cellslJlI in to when the CD4 count is between 50 and 200 cellslJlI. If 
one were to define need as these sicker patients would be nnnn'r1<O!f'fl but if need were 
defined as cap'acity to an a for those who have enrolled 
in the programme in a timely manner would be nrp'<;1p.f"vP'(1 The ,",V1Ull'", between these two 
principles is likely to be of ongoing concern for health professionals in settings as 
Khayelitsha Hildebrand et aL 2004). 
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While the wi(\esJ)re2td Medec;ins sans ina 
that putting those with the risk is most in keeping with the notion of fairness 
by people with HIV/AIDS (Calmy. Klement et aL this needs to be 
verified and broader ':>V',''''LaJ views need to be A fair process could assist in deciding on 
the medical eligibility for ART initiation, or in different language, to what extent capacity 
to benefit be taken account 4 and 5 in 29). 
HnwP'vpr to do this the h-""m""Jur.,·V proposed in this thesis, would 
need to be that provide in different CD4 categories of in 
WHO _+_. ___ N so that it be possible to assess the costs and outcomes 
ItP1Tll'l1tiV"<: In the absence models, one might be terrlpte:<i to assume that ex1tenlding the 
to higher CD4 levels dramatically increase the patients. The 
ASSA2003lite model indicates that in 2006 there were an estimated 542,000 adult AIDS cases 
III cases. One might therefore be t", .... , .... t.,,i to assume that eXi,enalmg and 1,771,000 
eligibility to include III cases would more than triple the recurrent need. However 
this would fail to distinguish betwefmtotal current cases at a .... ""of' ...... 1 date 
the new cases (incident during a period around 80 per cent of 
the prevalent AIDS cases mid 2006 were incident cases during that year. While the ASSA 
model does not distinguish lJU:;v.:UlCiHL from incident III cases, it be the case that a 
lower nrr,nnrhrm III cases mid 2006 would be incident. This is because 
overall duration - the time that an individual can be expected to stay in Stage III 
developing AIDS or dying is higher than is the case for AIDS. 
Jmligille therefore that the medical eligibility criteria were cha:ng(~a from CD4<200 cellshtl to 
cellshd. As any that ""'''''''"'\1'''' AIDS would also be Badri, 
Cleary et al. (2006) have calculated the one-month probability of movements between various 
No-ART health states for patients who enter "care" at CD4>300 cells/JlI without AIDS. These 
can be used to estimate the monthly probability a patient becomes ART. 
criterion remains CD4<200 cells/I.ll, the probability is 0.037 while if the criterion becomes 
CD4950 the increases to 0.049. Thus while more new would 
34 Medecins sans Frontieres is an international NGO that has been critically involved in the provision of 
ART. 2004, their included treating 21,000 patients in 27 different l'rmntM."" 
patients Khayelitsha. 
35 The same is true of the models used by UNAlDS as in their annual "AIDS 
Epidemic 
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become eligible each year, the increase is to be lower than one assume by lUU'l\.U'l"- at 
total patients in group. because is when ART is initiated 
in the a far larger number of patients would be in care. 
It is therefore recommended that once a CD4-based delDo,grs:ph:IC model has been created (where 
new cases are distinguished from total cases) these data should be fed into the social choice 
models so that a thorough assessment can be made of the total costs and outcomes associated with 
inilri<>tincr ART at different CD4 levels. 
Impact on health of society (claim 7) 
An analysis of the impact of antiretroviral treatment on the health involves the 
balancing of a number forces. On the one the presence treatment 
HIV/AIDS is to have the potential to mv incidence. This is because there are 
au'"' ...... "" .. incentives for patients to be diagnosed and it is hoped that people who know their HIV 
status will take steps to either remain or to avoid infecting others if they are nnc,.tn,'I!> 
(Moatti, et a1. In addition evidence from a longitudinal cohort dataset indicates 
because ART suppresses the level of the virus in a patient's body, it can reduce per-
paJrtlll~rslllP infectivity by as much as 60 per cent Martin et aL 2004). On other 
the wl(lesl)re~1.d .. f"t",,,t.,,,,, treatment 
where a reduction in the perceived severity 
to what is known as disinhJibition 
to increased risky sexual 
behaviour. Evidence "T'~"'''lTIU HIV incidence in recent years in the gay communities of San 
Franci:sco """',"'''' ... " this hYI)otlllesis et al. 2002; Blower, Bodine 
et a1. However, a of studies on sexual risk behaviour in antiretroviral treated 
patients in the developed world showed that these patients did not exhibit increased sexual risk 
behaviour Hart et aI. 2004). One study in Uganda at 6 months after ART showed 
reduced sexual risk behaviour. When coupled with viral suppression, this study concluded that 
..... """ ... ,tir .. , progrrunmes had reduced the transmission of HI V by 98 per cent 
in these patIents (Bunnell, Ekwaru et a1. 
The other key to the health of society associated with the introduction of ART is the 
elopment and transmission resistant forms of the virus 2004). The threat of 
drug resistance in Africa has led to calls for limiting ART to the public health risk. 
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limiting ART in poor countries owing to fears of drug However, others have argued 
resistance amounts to double between the North and the South N'Doye et aL 
2003; Spire et al. 2004). A in North America has shown that the proportion of new 
HIV that involve has the 
1995 to 1998 to 12.4 per cent between 1999 and 2000 (Little, Holte et 2002). 
some studies have shown no resistance in these infection cohorts, most studies show that 
resistance is among infected (Blower, et at It is 
important to distinguish between transmitted and acquired resistance. The former to the 
level in virus with one is infected, while the latter to 
develops over time as an inevitable consequence 
treatment. It is important to maintain good adherence to ART in to maximise individual 
health and to the chance of transmitting a resistant virus in the event of 
unprotected sexual intercourse. Given the importance of adherence, it is interesting to note that 
evidence from a large meta-analysis indicates that Africans antiretrovirals achieved 
'OULU,",<:l,llL':t higher levels of adherence than North Americans adjusted of ART 
",£II,p",,,.nr·,,, in African studies in to ART in North America was 3.0 (Mills, 
Nachega et at 2006). 
Mathematical studies have attempted to estimate overall impact of these various 
factors on the health of society in San Francisco where prevalence in the gay community is 
around 30 per cent et at 2002) and in sub-Saharan 
(Blower, the San Francisco study indicate that a usage of 
ART (between 50 HIV-positive people receiving ART) would ""E>'UL""'''''U'J 
reduce the severity of the HIV epidet1nic. If this was coupled with substantial reductions in 
sexual behaviour, there would be a high chance of eradicating the HIV epidemic emlrel!Y 
However, the probability of epidemic eradication from the widespread use of ART is reduced to 
50 per cent sexual behaviour remains and if this behaviour increases, the 
Vl\J'va,,J1l1LY is further decreased. high levels of ART coverage would still have an 
overall beneficial even with increased risky sexual behaviour and high levels of ARV 
resistance. This study the:retore argues that the use of ART is recommended both as an effective 
therapeutic smltefl~ and as an ",1"1"_,,,,,, public health intervention (Velasco-
et al. 2002). 
36 Defined as level resistance to one or more 
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Because the public health impact of ART is dependent on the percentage of the population 
receives treatment, in sub-Saharan Africa, the of ART on overall societal is likely 
to be small (Blower, et al. In South Africa in only about 3 per cent of the 
over 5 million mv -positive people were receiving ART. However, if current treatment is 
could to about 27 per cent by 20 10 and 45 per cent 2014. 
Modelling predicts that if20 per cent are on trelltment n1"f"Vj;ll~n(~~ could decrease 5 to 10 per 
cent, while if 40 per cent are on tre:atrrlent, it could dec;re:ase by 15 per cent 10 years after the 
rollout has commenced. 
To conclude, data and modelling studies .""",,,,.,,1' that the ..... ,,"'''''t'\n an 
opportunity to reduce mv incidence and "'V<U"' •• "'" and that the positive public health impact of 
ART is enhanced if a high percentage ofHIV-positive people access to ART. While 
j;I~t1n.r,>rl drug is drug resistance is to remain 
low. also that Africans are not more likely to have worse adherence than North 
Americans. In sum, there could be substantial positive externalities through the provision of ART 
on the health 
6 Impact on the social fabric (claim 6) 
This section outlines the that and access to treatment is predicted to have on 
the social fabric. Social fabric, following Haacker (2004), includes social and economic 
'u",,, .... "v,,,, such as and and less tangible such 
as social solidarity. 
There is some debate about the impact that HIV I AIDS will have on economic and GDP 
per A number of studies that consider the of HIVI AIDS in South 
Africa been conducted, a variety models the Solow 
model 2005), and Lewis 2000) and a 
macro-econometric demand-side model Smit et at 2001). While all 
concur that the level of GDP will be lower than it would have been in the absence of the HIV 
epidemic, there is debate about whether the in the population AIDS related 
will on balance increase Smit et al. Young 
Ellis et at. 2006), or decrease GDP per (Arndt and Lewis 2000). One that Hl"J' ...... ~'u 
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the of the provision to 50 per cent AIDS cases concluded 
that the cost of this prOignlunrneJ would be more than offset th,.,r.no,h P.l"nt'lnl"~'('! GDP m 
comparison to a No-ART scenario (Smit, Ellis et aL 
Thus the impact ofHIV/AIDS in terms of morbidity and mortality is because this 
impact tends to be unevenly spread through the population it is less apparent at the aggregate 
A death in one could be to another household if a 
(Haacker 2004). It is therefore that the ofHIV/AIDS at the 
aggregate level provides little information about the impact on individual households. While poor 
households contribute 
accommodate to adverse 
a limited amount to overall GDP, are also less able to 
to income or expenditure which increase their level of 
vulnerability and Haacker 2004}. HIV / AIDS could therefore lead to an increase in levels 
..... ,"','''' .... '''' (Greener 2004). Those who a would me:ret,ore 
losses in life ext)ecl:anc:y have an i ....... ,"'yof·"' .. t welfare cost that is hidden 
within aggregate macroeconomic variables (Crafts and Haacker 2004). 
In contrast to the more standard macroeconomic studies, research an overlapping 
generations model to assess the impact of HI V / AIDS on the long-term formation of human 
capital to a risk eccmOlrnlC collapse within a few geller:atHms unless policy is 
imJ)leIlnented to the ,"',,, . ...,,,, ... et 2004). In 1990, 
36 per cent of 15 year old South African men and 21 per cent of 15 year old women were 
predicted to die before their sixtieth birthday. By 20] ° it is predicted that these numbers will be 
60 per cent for men and 56 per cent for women. The 500,000 maternal orphans 
under the age of 18 in 199038 were estimated to be 1.5 million 2006 (Dorrington, Johnson et 
al. to Bell, et (2004) these patterns of adult and of 
orphaned children contain a real threat of economic Because HIV / AIDS makes it 
difficult for infected adults to for their children's education or to offer them the love and 
care they to cornnlement their formal sctloolml~. the result is a generation of undereducated 
and hence underproductive youth who in turn might it difficult to provide for their children. 
This has however been ......... "'\. .... for its assumption of full emplOym,em Given that 
37 As estimated similar cost and utilization data as for this dissertation but with an alternative cost 
Erojection model- see Boulle and Cleary (2005). 
8 Matemal are reported owing to the difficulty in calculating numbers of full orphans. tiowe"er. 
given the importance of mothers in ensuring the health and well-being of children, this is nevertheless a key 
indicator. 
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HIV I AIDS is concentrated among the and unskilled sections of the labour force that can be 
replaced easily the pool of unemployed the economic 
of HI VIA IDS could be pronounced than suggested by studies that assume employment 
Ellis et 2006). 
The nature ofthe care and treatment that mY-positive people receive in South Africa has the 
potential to have an on less cOllcepts such as social ,..",1,,,,,,,,,,,.,,,..,.,, Given the scale 
of the response that is and the high proportion of the that is in there is 
a chance that mobilization around HIV I AIDS could assist South Africa to become a more 
solidaristic with positive SDln-ems for social in generaL On the other hand if the 
response is perceived to be n!>f1""""!>I,,, levels "'''''''('1'>1~'TV could decrease with a U\i;,,,,'UllJ,LUIl<, 
on the security of the country (Haacker 2004). 
An response is however on a commitment to equity, which will be 
influenced by the values of South African society and the level of compassion that South Africans 
have for the poor in and for people in South Africa's of 
group another and more recent adoption of a capitalist 
economic (Terre blanche 2002) makes it that this commitment will be 
to Coburn (2000), higher income inequality and 
lowered cOlleslon, partly thflOUjl:n undermining the welfare state. If the economy, the state 
and civil society are inextricably linked, then a neo-liberal economic system will create a more 
individualistic 2000). to (2002), in South Africa's neo-
liberal memtlers of the upper mainstream economic 
activity while the black lower classes42 are increasingly pauperized. While the political 
landscape Africa in the is far more inclusive than in the past, the 
social landscape remains unchanged. A programme of ambitious budget deficit reductions 
combined with personal income tax re(lIUC1[1011S has also constrained the extent to which the 
gmrentlm1ent can increase social SDemamg (McIntyre, et al. 2006). 
39 Approximately] 1 per cent of South Africans are 
40 Neo-Iiberalism is defined as the dominance of markets and market models in the economy, where it is 
assumed that markets are the best and most efficient allocators of resources in production and distritlUtion, 
that societies are collections of autonomous individuals motivated chiefly by economic considerations and 
that competition is the major market vehicle for innovation 2000). 
41 Approximately one third of the of 4 million blacks and 4 million whites. 
42 Approximately 50 per cent of the population. 
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If, as Mooney (2002) argues, a country's health care system is a retllectlOn of its 
citizens, then the South African health care system provides additional evidence of the 
nature In 2003/04, health care timmcmg captured by 
was an estimated 62 and 38 per cent "",,,',",,,,r·tnl,,,lv while the 
private sector served less than 20 per cent of the population (McIntyre, et al. 2006). This 
tiered care has implications for in health. A public health care 
serves the of the population will tend to of higher quality than one that mainly 
serves the poor. If the political support of the middle and upper of the public health 
is lost, {lIt'h~I"~'nr:{'" in access and quality between income groups are further reinforced 
(Gilson 1998). many SOCletlies consider South Africa's '",,,·,,,,,,,l1t''''''' in status 
and access to health care as inequitable, it is not clear that South (especially the elite) 
share this view. Instead South Africa's elite view the public provision 
the poor in terms of "we are 
service" (Mooney 2002). 
(1 argues active 
for them" as OU!IOS(~<1 to "we are for our health 
need to be taken to create the social capital 
"'-I""'""'"' to 
to 
uro·mOle equity through a broad process of social change in which all groups an active role. 
Perhaps the most critical factor is the development of an enabling state which ...... ",1''''"." and 
the interests ofthe poor. will is not civil society can 
a key role, as has been seen through Treatment Action Campaign43 (London 
2003). In this way, mv 1 AIDS could be considered to be a "resource for democracy" and 
Schneider 2003 p. Given the human ofmV/AIDS, it has the 
potential to raise awareness of health inequalities and to advance 
through the mobilization of activists and lay people. 
battle for social 
To conclude, mViAIDS has a impact on through morbidity and 
this is less apparent at the macroeconomic "."n".r:i'~lIvgiven mY/AIDS 
primarily affects the low and semi skilled sefl:me:nts of the population that can be replaced 
but 
relatively from the large of unemployed people. On the other hand, if one considers 
the impact ofmV 1 AIDS on long-term human capital formation, the affects could be far more 
43 Ae<:ordlmgto London (2003) the Treatment Action Campaign was started in 1998 as a lobbying and 
advocacy group for HIV -positive in South Africa, with the intention for greater 
access to treatment for all South by raising public awareness and about issues 
sunroUlldiIlg the availability, and use of HIV treatments. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
devastating than predicted the shorter-tenn macroeconomic forecasts. The extent to 
South Africa to the .... ",,.,,,,<> need for treatment will be detennined by values of 
South African society the level to Given the cost and the 
potential that taxation might be required to finance treatment, a commitment to treating 
HIV will require that citizens be motivated by social solidarity as opposed to sel:t:"mlterlest. 
7 Policy im plications 
The approach advocated in dissertation could be at the international by national 
C1l"'f>l'Tlmf"nt" and by provincial to increase the of HIV -treatment 
priority setting. priority is to be more equitable than implicit rationing, 
where rationing could be as the "controlled distribution goods and " .... vii'''''''' 
(tlenne:ll and Chanfreau 2005 p. 542), This section will argue with the use of two that 
the process nri.r\1"iiv setting that is currently used in many setltm~ts is more to lead to 
implicit rationing. This is because optimistic coverage targets tend to be set in one process 
C011Sl(le~atJ(m of the costs these because 
appear equitable, policymakers are able to avoid the politically sensitive and divisive process of 
detennining criteria for treatment (Bennett and Chanfreau 2005). 
In contrast to the approach in this patient and treatment interventions are nonnal1y 
set within one forum, and the costs of meeting the resulting decisions are established separately. 
For the WHO's "3 by 5" aimed to meet 50 per cent of new AIDS cases 
2005. While the costs this target were subsequently calculated (Gutierrez, Johns et al. 
2004), the feasibility these resource needs seems to have been inadequately considered 
- there appears to be an inadequate feedback between the target setting and the costing processes. 
Over (2004) has compared the projected total HIV-treatment in 2004/05 that was 
"Pllll,r,"Li to meet the "3 5" the non HIV -treatment health care expenditure in 34 
"3 by 5" countries in 2002. In out of34 the ratio ofHIV-treatment eX]Jen.onure 
to other was one-third or in 14 countries the was then nn'._Tr ... ·n and 
in 3 countries the ratio was greater than one. What this means is that projected HIV-treatment 
costs in 2005 would exceed total public health care expenditure in 2002 in these 3 countries. 
When HIV -treatment costs are the GDP per capita and the number of 
"''VI'''''', Over (2004) concludes that 21 per cent of the 3 million ART live in countries 
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facing a '''''''''LV'''' challenge, 41 per cent live in facing a substantial challenge and 38 per 
cent live in cOllfltt1es facing greatest challenge. During the period covered by the "3 by 5,,44, 
the number on ART in increased from 400,000 in December 2003 to 
approximately 1 million by June 2005. Although no final report on the "3 5" has been 
re!leasea, the June 2005 concedes that it is unlikely that target of 3 million would be 
reaChe~Cl by December of that year and WHO 2005). Thus while the aimed to 
substantially increase coverage an equity 
met. 
- it was unsurprising that these were not 
More recently, in September 2005, the United Nations General Assembly endorsed a target of as 
close as possible to access by 2010 for all in 2006). practical 
interpretation of this target is to meet 80 per cent of new AIDS cases by this date. One example of 
an att€~ml)t to countries to meet is "Five ("""nt,"" study" that WHO 
WHO AFRO and WHO offices in Mozambique, Burkina and 
Ghana initiated during 200646 . Consultants in each country were contracted to calculate costs 
using a costing model (Bollinger, Boune et al. 2006) and to assess options for the 
financing costs. An earlier """""""'" of this model was used in the "3 by 5" costing 
mentioned above. However, as before, the process is one of the as opposed to 
using opportunity cost Itp.rn,:,tivp. ap):jrOatCh(~S and the constraint to set feasible 
that are in with the The "'V"""'E, n .. ,-,,,,,;,,.,, little 
guidance as to whether the chosen strategies are eIIIClt~m. 
A number of publications have also recently that assess the cost-
effectiveness ofaltemative (Yazdanpanah, Losina et al. 2005; Bachman 2006; Badri, 
Cleary et at 2006; McIntyre et at 2006; Goldie, Yazdanpanah et at 2006). While cost-
effectiveness/utility analyses can theore:tlc:aHy assess e111cl1em:y in the cos:t-errelctnreness 
of an intervention is judged cornpllflIlg the incremental cost per to a sOC:letal 
threshold. Besides the theoretical sh()rtc:omtin~~s of this aPllro:ach and its assumption that health 
44 In addition, while the "3 by 5" clearly missed its patient targets, one cannot suggest that the 1 million 
patients who did start ART were initiated solely through "3 5" efforts as a variety of multilateral, private 
and individual country donors have also been involved in the efforts to increase access to ART this 
~eriod. 
5 The same caveats to the use ofthis term apply. 
46 The information in this section is based on personal experience in training country teams to use the 
model and providing technical assistance in this 
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maximisation is the only appropriate social rule (Birch Donaldson, Currie 
et at 2002; and Birch 2006) are additional difficulties if a country has not defined 
'th1'\p"hnlrl The result been the publications mentioned above have taken 
the advice Commission on Macroeconomics and Health (200 I) and an 
t'ltp,'nlP"nhclt'I "very cost-effective" if it has an cost per QAL Y than per 
capita gross domestic product (GDP) and if it is less than twice per GDP. 
In South Africa, where per capita GDP is US$ 3,089 (Statistics South Africa 2004), either ART 
option be very provides no 
guidance on the total budget that would be required which is particularly relevant for mv-
treatment the number patIentS in need. 
If the approach advocated in this dissertation were used, it is argued that the explicitness of HI V -
treatment would be with for both equity and 
eUlcHenc:y This is because implicit which is what uaL'''''''';:) when HIV -treatment 
are missed, is likely to be consistent and fair and is transparent and open to review than 
is the case with explicit (Bennett Chanfreau 2005). To be equitable in HIV 
treatment does not mean that access to ART for all in need is the possibility. 
resource scarcity, unequal access might be unavoidable. if the approach to priority 
, ... ",,,,.."'''' a fair process where costs and the values are 
the resultant HIV-treatment strategy would be equitable. Moreover, as Rosen, Sanne et aL (2004; 
2005) have argued, govermnents that make explicit choices and then explain and defend these 
cn()lc~~s would be more likely to sustain social cohesion and extract a ~~'''-''J U'""",,,,,V'''' return 
from the investment that is being made. 
The candidate has been involved in the development of two of the costing models that are 
by international (Boulle, Johnson et at. 2004; Boulle et at 
2006). While both use a similar (although simplified) approach to ""i:U""Uli:1~1l1~ costs as has been 
taken in this neither models currently the life years or the QAL Y s 
are associated with these costs. Both models currently calculate the costs associated with No-
ART and first and second-line ART. first-line only strategy were to be included as a policy 
choice, this would require some additional Once these to the models have 
been they could used to calculate the costs and life years or 
associated with treatment to all in over a time 
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period. results are fed into the mathematical programming algorithms, which are easy to 
provide as an models. 
On a note of caution, however, to date in training participants in use 
co~;tmlg models while these models attempt to make the process as simple as 
for users, many in appear to lack computer 
required to enter data into the models and to navigate between different sheets to read the results. 
Thus while including a measure of benefits and would not add a 
of complexity to the approach is currently taken vast majority of work would still 
relate to collecting and entering unit cost and utilisation data in the models to calculate one 
would still to contend with shortage and skills in many 
poor countries. 
8 Sunlmary 
This chapter has outlined the elements of a pr()CeIlUI 
!!rO'Ullllea in the notion 
distribution has been identified, this chapter argues that 
approach to disltributirlg the good to 
use 
definition of a just 
procedurally just approach 
I';.iU'WHJ\oU in the values can increase the legitimacy of the resultant distribution. 
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
Chapter 9: Conclusion 
This final outlines contributions, limitations, recommendations for further research 
recommendations from the work in this tii<!<!P'I'tJ'lt'10n 
1 Contributions and limitations 
This thesis makes a number of new contributions. On the conceptual a new framework for 
the been proposed, application to HIV -treatment. This Trn'mp'W01rl< 
however has relevance in health more as it could be applied to other diseases 
and interventions. The framework is built through considering the nature of the good of health 
care, and debating the pros and cons of conceiving of the good as utility, health or capabilities. 
The next step in constructing the framework involved "to whom" the should be 
distributed. This section the potential have on the good which 
InC'II''''''' notions versus morally bad luck in HIVacctuj!,iti>on, 
the social on the health of society and the on the social fabric. 
By spelling out in detail the various the framework the decision-maker to consider 
issues more holistically than if one were to consider health care 
costs and outcomes. The third step in developing the framework examined how the good should 
be distributed. This section advocated for the use of social choice rules to illustrate the 
equity/efficiency trade-off in IllV-treatment allocations and 
'''l5JlLlllll£.\;i the choice of the 
that a fair process could 
This framework is tested against empirical data and substantially revisited in Chapter 8 where 
notion of claims is in more detail. it is that 
procedural can increase legjtlInac~y in HIV -treatment U,""""""n-,u<!.,,\.l - allocations that are 
determined within a fair process will be that this process is "1'''''1>1'1.1 
This means that universal access, for example, is not nel:es:sarl the only ethical outcome; given 
resource constraints, universal access might be out of the of many poor countries. In 
addition, ifuruversal access were attained to first-line ART for example, the next 
would be to determine whether additional health care benefits were affordable. 
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On the empirical side, the data that have collected and presented are relatively given 
the and """~'V"j"'''','''' 1tlltervelltloins, and the resource-poor setting in which 
the evaluations were undertaken where data to be scarce or quality. The o"P,tlp,r.~1 
absence of electronic records in these meant that data collection took a number of years. 
While a small number ofHIV-treatment from the developing world have 
been published to date, one other has been based on of primary data 
Cleary et al. 2006) while this dissertation continues to be the only analysis that been based on 
the of services in routine as to within a clinical trial. The of data 
around HIV -treatment costs has meant that poIicymakers have on normative costing 
where a number are made about the ingredients that would be ,.""rl11i •• &»rI 
to HIV -treatment as the of different types laboratory 
investigations and medicines. This dissertation therefore makes a significant contribution to the 
about the costs and of HI V-treatment The number of 
facilities included in the assessment of unit costs, the size of the ART cohort and length of 
follow-up are additional strengths data in this thesis. 
There are however shortcomings in the costing approach. In particular it been assumed that 
the unit cost (long-run average total cost) is a proxy for the cost, which is the correct 
cost statistic to use in the average total cost that one 
assumes that either one is at the lowest on this schedule where the marginal and 
average costs coincide or there are constant returns to scale. Whether or not this is the case is an 
empirical which this thesis has not been able to assess, although uncertainty in the 
results has been assessed in 
A key analytical contribution has been made in terms of the Markov modelling process. The 
differed from the commoner in the literature which uses in the 
CD4 count over time stratified to the viral load) as an intermediate 
outcome based on which the final outcome years or QAL Ys has been modelled. In this 
thesis the longer fonow-up time has allowed survival to be estimated directly and then 
extrapolated. The CD4 has only been used at base case to differentiate between patients 
ART with very low CD4 counts because empirical data indicated that these patients had a higher 
probability during the first 6 months on treatment. 
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The modelling aPt)rmlcl1 in this thesis has placed additional emphasis on the costs 
In most developing cotmtries, there is a split between first and second-line ARV 
regimens with important cost implications while in the developed world a number of different 
drug combinations can be In the latter situation it is not necessary to assess the 
prc!balbUltv of moving from the first-line to the second I)e(:am;e cost tiittprPr\,''''''' are 
less significant. In addition, many analysts ignore the period oftreatment failure where patients 
ae\relOip opportunistic that inpatient care. This has introduced the 
technique these as transition costs incurred when a "patient" in model transitions 
to the "dead" Markov state which ensures that these costs are captured at the appropriate point in 
time. 
Further analytical in this thesis have included the validation of the models in terms of 
face and process In technical and predictive the 
objective is to assess whether the model is reproducing primary data accurately; in face validity 
one assesses whether model the that one might and in HI\,'U<OUUIl:'. 
process validity one assesses whether the results are comparable to results in the This 
process of validation has therefore thoroughly assessed any uncertainty relating to the modelling 
process and the data. 
Other forms of uncertainty were also thoroughly assessed. These included uncertainty relating to 
the data requirements of the study, choice of analytic method and generalizability of results. 
In4'Pri,.inlN N>I~tinO' to was through pr()balbllistlic ",.~n""Tn!l1V 
while uncertainty method was assessed in one-way sensitivity 
analyses where the discount rate was varied and results were presented as life years and 
tlowever. these "",.,,,1tnl1,hr <l,n<lIU'''''' have not been presented in the popUlation level results where 
mean results have been used, at 3 per cent per annum outcomes 
eX1Dresse:u as Given that the probabilistic and one-way 
analyses did not significantly alter the conclusions of the at the patient-level, and that 
additional tables of results at the population level would be potentially confusing, this was 
justified, Uncertainty relating to generalizability was assessed by comparing the results in the 
base case scenario to data, HIV ~treatment and to the cost structures that 
in other parts of South Africa there is no access to for This 
led to the construction of a "'_" ____ ' scenario took elements into account. 
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While patient-level models have been constructed, validated and used to assess uncertainty, the 
standard to decision-making in cost-effectiveness/utility at the patlenHe 
have not used in thesis. Ordinarily, a nl"\<"tn'l> leER (where a new intervention 
is both more ",u"."t."", than a comparator) then the decision of whether to 
ImlPieme:nt this ,nt"rv,f"nt.nn is a value judgment up extra costs and 
benefits under the assumption that health maximization is the appropriate social choice rule. 
u,,,.,,o.'u., a mathematical programming approach has been developed that is capable of integrating 
concerns and costs up. It is that this simplifies 
lIIV -treatment decision-making. Instead of facing a number of choices, decision-makers only 
need to explicit about the health care budget constraint and the value base. These two elements 
the that is the that is the proportion of 
patients receiving alternative treatment While a similar mathematical programming 
"' .... '1"\<><." has previously recommended in the health economics literature and Gafni 
1992; and Paltiel and the utility type of approach has tested with 
"convenience,,41 data (Anand 2003) to the best of the candidate's knowledge this has yet to be 
implemented in However, in the implementation of this one limitation has 
constant returns to scale has been assumed - the costs and effects that were in 
Khayelitsha were applied uniformly to other parts of South Africa when it is likely that costs and 
would change as the is scaled up. This limitation has 
extent through generalized "...,,,.HaJl1V. 
Outcomes have been presented as Some would the use of the approach to 
use in resource and valuing health. While one could agree that 
allocation across diseases and interventions ""'l'In'"'''' nterpe:rs(JinaJ comparability assumpti()ns that 
are unrealistic, application ofthe QAL Y to one ""''''''''''''', and hence one group of people, is less 
questionable. However, it is important with care, in particular because of 
the of constant means is that should 
consider the individual costs and benefits care intervention as well as the population 
level costs and Finally, the assessment of health care costs and health care 
benefits has been narrow, the concept of claims has been used to include other considerations that 
be relevant to participants in a process. This could be presented and 
discussed in order to inform the choice of the health care and value base. 
41 Data that are invented to illustrate the usefulness of the aDllifoa:ch. 
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2 Recommendations for further work 
While there are many 
work are: 
dissertation that could taken forward, three areas 
• Lu .... nU!~ societal T\,.".f;".""n,~ .. " reg.arding the constituents for guiding aW)CaIlOJIlS 
to mv -treatment 
• the care hudget that should be made available for HIV -treatment 
• the that are "",,,,,,,,,'11 to implement PfClCe,1ur:alb just U"'~'I''''V''-llIa.,,"l!J'a 
This has outlined a number of claims that HIV -positive people might have on the good 
"IV1"'''''''", personru char:acteristics and disadvantage, need as illness or as to the 
impact on the health of society and the on the social it is not known 
whether South African society would view these claims as relevant to decision-making. A 
potential for future research therefore in ,",U"HU1F, societal n..."tpr·"''',~",,, regarding claims on the 
A number of different could be to elicit these including 
discrete choice experiments (conjoint analysis) or contingent valuation (willingness to pay) 
surveys. Discrete choice would be helpful in the views 
the relative to each other while valuation would to 
detlerrntme whether views mv -treatment as an intervention has 
Including SOC:leual n .. "'t:.....,.",.."" regarding the importance of the claims ofmV-positive people on 
the good is an instrumentally valuable input into the procedur:ally process 
because it ensures that the value base of the participants at this level is as far as possible reflective 
value base societal also has intrinsic value because 
allows the voice of the community or society to be heard. 
A crucial input into the process advocated in this thesis has been the level of the health care 
budget allocated to HIV-treatment This, together with the value determines the pet'ceJlta~~e 
of need that can be met within each treatment and the quantity of QAL Y s that can be 
.... """'v.· .. aeclslOn·r:nru~ers are not always 1."""111r\np·rI to make the 
allocation u .... ,"" .. vu" to set budgets and as a often rely on historical budgeting 
approaches. Historical buc!gel:ing is particularly ill-suited to the context ofHIV where required 
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increases in health care budgets would the amounts that would be anocated through 
historical In historical is to lead 
suboptimal allocations because it does not adequately consider the concepts of opportunity cost 
and the margin. In an ideal situation, it would be possible to apply the mathematical programming 
approach that has been outlined in dissertation to the entire of independent 
programmes within public care sector. Given current data a more pnalgnlatllc 
alternative is programme budgeting and marginal analysis (PBMA). This approach relies upon an 
advisory that is tasked with areas where services are and areas where 
resources could be released in order to fund the areas of expansion (Mitton and Donaldson 2004). 
Finally, additional research is __ nH1ePl"1 this 
aDt)ro:acn can be This would include ".>l.nTVln,u institutional levels of decision-
making, oe'vel,opllng structures to address decisions at each training to riP.,,,''''','''' cc:>mpet,enc:e 
in fair process, learning from experience, improving the process through training and research, 
and developing for enforcement 2004). In particular, the choice of 
and to include the of the requires 
thought. 
3 Policy recommendations 
This dissertation has not aimed to conclusive recommendations regarding just allocations 
of the good to HIV -positive people, but has rather outlined a framework for decision-making. 
This section provides more concrete recommendations about how this framework could be 
ImIJlelnell1te.:1, where the aim would be to increase the explicitness of priority to mv-
treatment as one programme out number that are funded within the health 
care IJV""UH". each element in this process needs to the criteria of 
publicity, rplf~V::llnr.p appeals, and enforcement in order to ensure as far as possible that the 
resulting choices are viewed as legitimate. 
The fIrst involves identif).ring the that is available for HlV-treatment from all sources 
H''''''''''''''U" donors over a If a is not it be to 
extrapolate current Based on the evidence in this thesis, it is not recommended that 
decision-making time frame be reduced as this has the potential to mask the full cost implications 
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of illV -treatment which could lead to the rationing If current or 
budget plans are not readily available, it might be necessary to implement a PBMA-style exercise 
which means that this is far from However, the has been set there 
is a that the setting will result in the of highly optimistic 
once again resulting in implicit rationing. 
Once the has been set, the next step is to choose the set of stakeholders. The aim is to be 
representative of all interested parties while bearing in mind that reaching consensus is 
to become more difficult if the group is particularly Stakeholders also need to be able to 
commit to a number include civil groups such as 
people with illV/AIDS and other groups, clinical in illV me,OlcllDe, 
representatives from key government departments such as the National Department of Health and 
National re]:~res:enl:ati'ves from parliament and representatives from academic groups 
that are with equity issues. Many countries have a National AIDS 
Council - stakeholders can also be drawn from this group. Once tbe stakeholders have been 
identified, the aim of the first meeting would be to clearly define the aim of the priority setting 
exercise and the tenns of reference of the stakeholders. Ifpossible, an introduction to the priority 
!>nt"'l\'~l':n would be the of opportunity the and the 
lcanOllS of the social choice rules f r health or the can 
be met. There sbould also be a discussion about the value base of the group and the influence that 
on the good have on this value base. Ifsocietal claims have been 
would be a input at this as far as the values should 
detennine the values adopted by the group. 
The next step would be to present the group with patient-level results regarding each of the 
interventions under consideration. All members need to understand the implications of each 
intervention in tenns years or QAL Y s as well as the and range 
associated with these estimates. A full discussion IIn,r'.prt!>llntv would be particularly relevant 
that ,VU'''ULj,l''. has been used and it is that at least some would be 
skeptical about this "black box" approach. Stakeholders might also that certain '''V'''''''''/;5 
assumptions are changed, that certain interventions are excluded or that other interventions are 
added. For example, it be of interest to further unpack a less resource-intensive model of 
care that has reliance on nurses. There should be time between this and 
sut)se,quc~nt ""-"'''''1'>'' to allow for any reanalysis that be """,,,.i,,,,,,.-I 
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After this, population-level results each social choice rule given the health care budget 
constraint would be These results include the proportion of patients receiving each 
intervention and the QAL Ys that can be It also be necessary to these 
for a range of budgets because it is possible that the staKerlOUJer group recommend that the 
is """.",,:,,,,;;, ..... Results should also be presenlea all choice rules instead of only 
according to the value of the group because the opportunity cost of one value base over 
another in terms of health gains foregone or unmet need would not have been apparent during 
earlier discussions. The ultimate aim at this point is to reach consensus on the value base - this 
choice will determine which are If the group recommends that the 
be expanded, it would be necessary to the budget setting process. would imply 
that a decision would be deferred and the group would be expected to meet again to reach 
consensus on the choice rule once additional on the budget had been 
4 Summary 
Responding to the HIV-epidemic is among one of the many challenges currently facing the new 
South Whether this response becomes a "resource for uvlUU ... I<lIv) 
and Schneider 2003 p. 497) or whether it undermines social cohesiveness within poor 
communities and between rich and poor communities will be partially determined by the steps 
that are taken during the next ten years. Implicit rationing oftreatment, where optimistic 
treatment are set and is less equitable and less likely to a 
socially return than To aid in the a framework for 
aec~lsllon-makllng that is ".ul""~H"'Y and the costs up in a 
way that makes these trade-offs traJlsp;arellt has been proposed and applied. The final step in the 
framework involves the use of procedural justice to increase the legitimacy of the chosen 
strategies. If decision-making around HIV -treatment is undertaken within this approach, the 
resulting consequences will be equitable. 
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Appendix - WHO staging system 
Clinical 
1. 
I: 
as)'m~'tornatic infection 
2. persistent generalized lymphadenophathy 
3. acute retroviral infection 
Clinical stage II: 
1. unintentional weight loss < ] 0 per cent of body weight 
2. minor mucocutaneous manifestaticlns 
3. zoster within the 5 years 
4. recurrent upper tract Imc~cnons 
Clinical III: 
I. unintentional > J 0 per cent of body 
2. chronic diarrhoea> 1 month 
3. prolonged > 1 month 
4. oral v< ........ ~U<.L.;)." 
5. hairy leukoplakia 
6. pulmonary TB 
7. severe bacterial infections 
8. candidiasis, chronic 
Clinical stage IV (AIDS): 
I. mv wasting syndrome 
2. Pneumocystis carnii pneumonia (PCP) 
3. toxoplasmosis 
4. cryptosporidiosis with diarrhoea 
5. with diarrhoea 
6. 
7. 
co'pt()cocC()sis extrapulmonary 
disease of an organ other than or lymph node 
8. herpes simplex virus infection, mucocutaneous, (> I month) or visceral (any duration) 
9. progressive multi focal leukoencephalopathy 
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lO. any disseminated endemic mycosis 
11. candidiasis of the trachea, bronchi or 
12. ",n, .. " ... ",1 my(~Ob~lctelt10S]!S, ClI.sselTImi!l.teCl (MAl) 
13. non-typhoid salmonella septicaemia 
14. TB 
15. Iymtpn()ma 
16. Kaposi's sarcoma 
17. HIVencephalopathy 
Source: WHO (1993) 
University of Cape Town
Appendix B - summary of cost-effectiveness/utility analyses 
Table 48: Summary of cost-effectiveness/utility analyses - undiscounted 
Currency, price year and Lifetime costs 
Reference Intervention and characteristics of patients Setting discount rate In US$ Lifetime outcome 
Undllcountlld • No ART 
Moore, Hidalgo et al1994 No-ART for patients with AIDS United States of America US$, 1990, ? 31 ,300 0.64 life years 
Sendi, Bucher et al 1999 No-ART for patients representative of the Swiss HIV cohort Switzerland Swiss francs, 1997, 4% 140,065 6.64 life years 
Patients enter care with CD4=331 and receive no prophylaxis 
Yazdanpanah, Losina et al 2005 and No-ART Cote d'ivoire US$, 2000, 3% 1,260 3.2 life years 
Patients enter care with CD4=331 and receive cotrimoxazole 
Yazdanpanah, Losina et al 2005 prophylaxis and No-ART Cote d'ivoire US$, 2000, 3% 1.320 3.5 life years 
Patients enter care with CD4>350 and No-AIDS and receive 6.2 life years or 
Badri , Cleary et al2006 No-ART South Africa US$, 2004, 8% 7,877 4.3 QALYs 
Patients enter care with CD4>350 and No-AIDS and receive 
Bachman, 2005 No-ART South Africa US$, 2005, 3% 2,952 8.2 life years 
Patients enter care with CD4>350 and No-AIDS and receive 
Bachman, 2005 No-ART with cotrimoxazole prophylaxis from CD4<200 South Africa US$, 2005, 3% 3,140 8.4 life years 
Undllcaunl8d • ART 
-
Sendi, Bucher et al 1999 ART for patients representative of the Swiss HIV cohort Switzerland Swiss francs, 1997, 4% 338,544 14.85 life years 
English Pounds, 
1999/2000, 6% on costs 
Miners, Sabin et al2001 ART for patients with CD4<200 and No AIDS United Kingdom and 0% on outcomes 191,624 14.5 life years 
6.48 life years or 
Bayoumi and Redelmeier 1998 No MAC prophylaxis and ART for patients with CD4<100 North America US$, 1997,3% 233,000 4.16 QALYs 
Hoffmann and Brunner 2004 No MAC prophylaxis and ART for patients with CD4< 1 00 Berlin, Germany Euro, 1998, 0% 114,828 5.8 life years 
Patients enter care with CD4>350 and No-AIDS and start 18.8 life years or 
Badri , Cleary et al2006 ART with CD4<200 South Africa US$, 2004, 8% 14,230 14.6 QALYs 
Patients enter care with CD4>350 and No-AIDS and receive 
Bachman, 2005 ART from CD4<200 South Africa US$, 2005, 3% 19.300 14.9 life years 
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Table 49: Summary of cost-effectiveness/utility analyses - discounted 
Currency, price year and Lifetime costs 
Reference Intervention and characteristics of patients Setting dillcount rate in US$ Lifetime outcome 
DlKowded No-ART 
Freedberg , Losina et al 2001 Patients enter care with CD4<200 and receive No-ART United States of America US$, 1998, 3% 55,400 
3.33 life years or I 
2.7 QALYs 
7.02 life years or I 
Schackman, Goldie et al2001 Patients enter care with CD4 of 500 and receive No-ART United States of America US$, 1998, 3% 69,900 6.23 QALYs I 
Schackman, Freedberg et al 
2002 Patients enter care with CD4 of 350 and receive No-ART United States of America US$, 1999, 3% 61,600 4 .3 QALYs 
Women representative of US HIV-positive popUlation enter 3 .16 life years or 
Goldie, Weinstein et al1999 care and receive no papanicolaou smears and No-ART United States of America US$, 1996, 3% 75,410 2 .66 QALYs 
Women representative of US HIV-positive population enter 3.24 life years or 
Goldie, Weinstein et al1999 care and receive an annual papanicolaou smear and No-ART United States of America US$, 1996,3% 76,700 2 .73 QALYs 
Freedberg, Scharfstein et al 
1998 Patients enter care with CD4 200-300 and receive No-ART United States of America US$, 1995,3% 40,288 3 .8 life years 
Freedberg, Scharfstein et al Patients enter care with CD4 200-300 and receive No-ART 
1998 and cotrimoxazole prophylaxis is initiated at CD4<200 United States of America US$, 1995, 3% 44,786 4 .2 life years 
Paltiel and Freedberg, 1998 Patients enter care with CD4<100 and receive No-ART United States of America US$, 1991, 3% 32,100 2 .2 life years 
Dlacoun!lld ART 
5.32 life years or 
Freedberg, Losina et al2001 Patients enter care and initiate ART with CD4<200 United States of America US$, 1998,3% 88,250 4.6 QALYs 
Patients enter care with CD4 of 500 and start ART with 8.51 life years or 
Schackman, Goldie et al2001 CD4<200 United States of America US$, 1998, 3% 98,000 7.64 QALYs 
Schackman, Freedberg et al Patients enter care with CD4 of 350 and initiate ART with 
2002 CD4<200 US US$, 1999, 3% 139,700 9.31 QALYs 
10.9 life years or 
Goldie, Kaplan et al - 2002 Patients enter care and initiate ART with a CD4 of 350 US US$, 1999, 3% 144,260 9 .8 QALYs 
Sendi , Craig et al1999 Patients on ART enter care with CD4<50 and no AIDS Switzerland Swiss francs , 1997, 4% 140,804 6 .15 life years 
Patients enter care with CD4 of 370 and start HAART with 11 .2 life years or 
Yazdanpanah, Goldie et al2003 CD4<350 France Euro , 2000, 3% 171,060 9.4 QALYs 
Patients enter care with CD4 of 370 , start HAART with 11.4 life years or 
Yazdanpanah, Goldie et al 2003 CD4<350 and start cotrimoxazole prophylaxis with CD4<200 France Euro , 2000, 3% 173,180 9.5 QALYs 
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